

Summary Tables by Market Group, Health Area, Country and Product

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Market Group
1/2019 - 11/2019

| | New HIV Infections | STI Deaths | PWID Deaths | TB Deaths | CYP* | Maternal Deaths | Unintended Pregnancies | Malaria Deaths | Diarrhea Deaths | Pneumonia Deaths | Cervical Cancer Death | Sum of All Deaths |
|------------------------------------|--------------------|------------|-------------|--------------|-------------------|-----------------|------------------------|----------------|-----------------|------------------|-----------------------|-------------------|
| Acceleration Market Group | 37,199 | - | - | 2,906 | 2,466,370 | 3,975 | 1,077,960 | 1,004 | 550 | 98 | 3 | 21,712 |
| Anglophone Africa Market Group | 88,771 | 22 | - | 5 | 3,626,818 | 3,800 | 1,496,472 | 803 | 133 | - | 55 | 36,238 |
| Franco/Lusophone Africa Market Gro | 8,740 | 4 | - | - | 1,620,269 | 2,334 | 651,295 | 2,852 | 433 | - | - | 19,350 |
| Latin America & Asia Market Group | 3,995 | - | 48 | 2,001 | 3,879,647 | 1,785 | 1,481,935 | 2 | 76 | - | - | 13,158 |
| Foundation Market Group | 2,696 | 2 | - | 677 | 1,432,630 | 1,692 | 561,291 | 34,511 | 211 | 786 | 2 | 49,177 |
| Social Enterprise | 16,011 | - | - | - | 1,109,629 | 1,149 | 395,412 | - | 314 | - | - | 3,512 |
| Total | 157,413 | 28 | 48 | 5,588 | 14,135,364 | 14,734 | 5,664,365 | 39,173 | 1,718 | 884 | 59 | 143,147 |

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Market Group
Period: 11
Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|--|------------------|-------------------|-------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| GRAND TOTAL | 2,423,905 | 23,999,549 | 17,488,856 | (27%) | | 25,463,292 | 69% |
| Acceleration Market Group | 331,437 | 4,220,737 | 3,064,942 | (27%) | 100% | 4,096,068 | 75% |
| Modern Contraception | 169,980 | 1,204,919 | 1,237,342 | 3% | 40% | 1,305,027 | 95% |
| HIV & STIs | 148,611 | 2,649,675 | 1,530,528 | (42)% | 50% | 2,388,411 | 64% |
| Malaria | 129 | 116,976 | 70,397 | (40)% | 2% | 116,230 | 61% |
| Maternal, Newborn, and Child H | 2,545 | 37,184 | 45,489 | 22% | 1% | 62,513 | 73% |
| Non-communicable diseases | 4 | 64 | 71 | 11% | 0% | 73 | 98% |
| Nutrition | - | 249 | - | (100)% | 0% | - | 0% |
| Safe Abortion | 2,577 | 123,068 | 91,246 | (26)% | 3% | 119,871 | 76% |
| Tuberculosis | 6,437 | 81,148 | 78,525 | (3)% | 3% | 94,197 | 83% |
| WASH | 1,154 | 7,454 | 11,346 | 52% | 0% | 9,747 | 116% |
| Anglophone Africa Market Group | 536,193 | 8,167,452 | 6,495,249 | (20%) | 100% | 6,838,586 | 95% |
| Modern Contraception | 280,309 | 3,303,967 | 2,862,115 | (13)% | 44% | 3,168,819 | 90% |
| HIV & STIs | 209,051 | 4,601,584 | 3,544,876 | (23)% | 55% | 3,592,960 | 99% |
| Malaria | 44,842 | 225,222 | 56,590 | (75)% | 1% | 35,727 | 158% |
| Maternal, Newborn, and Child H | 28 | 6,311 | 2,055 | (67)% | 0% | 4,132 | 50% |
| Non-communicable diseases | 19 | 285 | 1,449 | 409% | 0% | 264 | 549% |
| Safe Abortion | 1,117 | 22,122 | 20,822 | (6)% | 0% | 25,618 | 81% |
| Tuberculosis | 24 | 292 | 260 | (11)% | 0% | 626 | 42% |
| WASH | 803 | 7,669 | 7,083 | (8)% | 0% | 10,440 | 68% |
| Franco/Lusophone Africa Market Group | 173,794 | 2,266,215 | 1,902,820 | (16%) | 100% | 2,699,713 | 70% |
| Modern Contraception | 124,144 | 1,099,012 | 1,270,369 | 16% | 67% | 1,242,892 | 102% |
| HIV & STIs | 36,653 | 406,583 | 355,111 | (13)% | 19% | 543,046 | 65% |
| Malaria | 6,864 | 679,694 | 222,205 | (67)% | 12% | 846,256 | 26% |
| Maternal, Newborn, and Child H | 723 | 57,384 | 19,398 | (66)% | 1% | 37,043 | 52% |
| Non-communicable diseases | - | 6 | 2 | (72)% | 0% | - | 0% |
| Nutrition | - | - | - | 0% | 0% | - | 0% |
| Safe Abortion | 4,305 | 16,686 | 22,692 | 36% | 1% | 18,447 | 123% |
| WASH | 1,105 | 6,850 | 13,043 | 90% | 1% | 12,029 | 108% |
| Latin America & Asia Market Group | 127,977 | 1,128,528 | 1,186,530 | 5% | 100% | 1,133,232 | 105% |
| Modern Contraception | 101,399 | 760,372 | 841,559 | 11% | 71% | 873,063 | 96% |
| HIV & STIs | 12,940 | 206,453 | 184,150 | (11)% | 16% | 214,953 | 86% |
| Malaria | 14 | 2,361 | 189 | (92)% | 0% | 424 | 45% |
| Maternal, Newborn, and Child H | 248 | 1,136 | 6,753 | 495% | 1% | 1,827 | 370% |
| Non-communicable diseases | - | - | - | 0% | 0% | - | 0% |
| Nutrition | 1 | - | 19 | 0% | 0% | - | 0% |
| Safe Abortion | 4,349 | 48,544 | 46,356 | (5)% | 4% | 42,896 | 108% |
| Tuberculosis | 9,025 | 109,532 | 107,461 | (2)% | 9% | 38 | 283,105% |
| WASH | - | 130 | 43 | (67)% | 0% | 30 | 141% |
| Foundation Market Group | 1,225,785 | 7,018,641 | 3,952,020 | (44%) | 100% | 9,033,832 | 44% |
| Modern Contraception | 95,522 | 796,194 | 931,527 | 17% | 24% | 949,254 | 98% |
| HIV & STIs | 7,713 | 201,525 | 138,774 | (31)% | 4% | 146,629 | 95% |
| Malaria | 1,094,622 | 5,197,541 | 2,635,517 | (49)% | 67% | 7,691,092 | 34% |
| Maternal, Newborn, and Child H | 11,309 | 664,530 | 109,838 | (83)% | 3% | 92,588 | 119% |
| Non-communicable diseases | 4 | 55 | 44 | (20)% | 0% | 210 | 21% |
| Nutrition | 15,356 | 65,977 | 83,812 | 27% | 2% | 103,209 | 81% |
| Safe Abortion | 1,162 | 9,420 | 12,419 | 32% | 0% | 14,822 | 84% |
| Tuberculosis | - | 76,671 | 38,021 | (50)% | 1% | 34,091 | 112% |
| WASH | 97 | 6,728 | 2,069 | (69)% | 0% | 1,936 | 107% |

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Market Group
Period: 11
Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|--------------------------------|-----------------|------------------|------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| Social Enterprise | 28,719 | 1,196,214 | 887,295 | (26%) | 100% | 1,661,860 | 53% |
| Modern Contraception | 6,620 | 259,614 | 190,875 | (26)% | 22% | 376,521 | 51% |
| HIV & STIs | 19,763 | 825,749 | 619,269 | (25)% | 70% | 1,103,405 | 56% |
| Maternal, Newborn, and Child H | (14) | 22,450 | 27,150 | 21% | 3% | 26,486 | 103% |
| Nutrition | 20 | 321 | 220 | (31)% | 0% | 381 | 58% |
| Safe Abortion | 2,330 | 88,080 | 49,781 | (43)% | 6% | 155,067 | 32% |
| Other | - | - | - | 0% | 0% | - | 0% |
| Inactive | - | 1,762 | 0 | (100%) | -% | - | -% |
| Modern Contraception | - | 1,520 | - | (100)% | 0% | - | 0% |
| HIV & STIs | - | 242 | - | (100)% | 0% | - | 0% |

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Health Area
Period: 11
Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|--|------------------|-------------------|-------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| GRAND TOTAL | 2,423,905 | 23,999,549 | 17,488,856 | (27)% | | 25,463,292 | 69% |
| Modern Contraception | 777,973 | 7,425,598 | 7,333,787 | (1)% | 100% | 7,915,576 | 93 % |
| Acceleration Market Group | 169,980 | 1,204,919 | 1,237,342 | 3% | 17 % | 1,305,027 | 95% |
| Anglophone Africa Market Group | 280,309 | 3,303,967 | 2,862,115 | (13)% | 39 % | 3,168,819 | 90% |
| Franco/Lusophone Africa Market Group | 124,144 | 1,099,012 | 1,270,369 | 16% | 17 % | 1,242,892 | 102% |
| Latin America & Asia Market Group | 101,399 | 760,372 | 841,559 | 11% | 11 % | 873,063 | 96% |
| Foundation Market Group | 95,522 | 796,194 | 931,527 | 17% | 13 % | 949,254 | 98% |
| Social Enterprise | 6,620 | 259,614 | 190,875 | (26)% | 3 % | 376,521 | 51% |
| Inactive | - | 1,520 | - | (100)% | 0 % | - | 0% |
| HIV & STIs | 434,732 | 8,891,812 | 6,372,709 | (28)% | 100% | 7,989,404 | 80 % |
| Acceleration Market Group | 148,611 | 2,649,675 | 1,530,528 | (42)% | 24 % | 2,388,411 | 64% |
| Anglophone Africa Market Group | 209,051 | 4,601,584 | 3,544,876 | (23)% | 56 % | 3,592,960 | 99% |
| Franco/Lusophone Africa Market Group | 36,653 | 406,583 | 355,111 | (13)% | 6 % | 543,046 | 65% |
| Latin America & Asia Market Group | 12,940 | 206,453 | 184,150 | (11)% | 3 % | 214,953 | 86% |
| Foundation Market Group | 7,713 | 201,525 | 138,774 | (31)% | 2 % | 146,629 | 95% |
| Social Enterprise | 19,763 | 825,749 | 619,269 | (25)% | 10 % | 1,103,405 | 56% |
| Inactive | - | 242 | - | (100)% | 0 % | - | 0% |
| Malaria | 1,146,472 | 6,221,794 | 2,984,897 | (52)% | 100% | 8,689,728 | 34 % |
| Acceleration Market Group | 129 | 116,976 | 70,397 | (40)% | 2 % | 116,230 | 61% |
| Anglophone Africa Market Group | 44,842 | 225,222 | 56,590 | (75)% | 2 % | 35,727 | 158% |
| Franco/Lusophone Africa Market Group | 6,864 | 679,694 | 222,205 | (67)% | 7 % | 846,256 | 26% |
| Latin America & Asia Market Group | 14 | 2,361 | 189 | (92)% | 0 % | 424 | 45% |
| Foundation Market Group | 1,094,622 | 5,197,541 | 2,635,517 | (49)% | 88 % | 7,691,092 | 34% |
| Maternal, Newborn, and Child Health | 14,839 | 788,994 | 210,681 | (73)% | 100% | 224,590 | 94 % |
| Acceleration Market Group | 2,545 | 37,184 | 45,489 | 22% | 22 % | 62,513 | 73% |
| Anglophone Africa Market Group | 28 | 6,311 | 2,055 | (67)% | 1 % | 4,132 | 50% |
| Franco/Lusophone Africa Market Group | 723 | 57,384 | 19,398 | (66)% | 9 % | 37,043 | 52% |
| Latin America & Asia Market Group | 248 | 1,136 | 6,753 | 495% | 3 % | 1,827 | 370% |
| Foundation Market Group | 11,309 | 664,530 | 109,838 | (83)% | 52 % | 92,588 | 119% |
| Social Enterprise | (14) | 22,450 | 27,150 | 21% | 13 % | 26,486 | 103% |
| Non-communicable diseases | 27 | 409 | 1,566 | 282% | 100% | 547 | 286 % |
| Acceleration Market Group | 4 | 64 | 71 | 11% | 5 % | 73 | 98% |
| Anglophone Africa Market Group | 19 | 285 | 1,449 | 409% | 93 % | 264 | 549% |
| Franco/Lusophone Africa Market Group | - | 6 | 2 | (72)% | 0 % | - | 0% |
| Latin America & Asia Market Group | - | - | - | 0% | 0 % | - | 0% |
| Foundation Market Group | 4 | 55 | 44 | (20)% | 3 % | 210 | 21% |
| Nutrition | 15,378 | 66,546 | 84,052 | 26% | 100% | 103,591 | 81 % |
| Acceleration Market Group | - | 249 | - | (100)% | 0 % | - | 0% |
| Franco/Lusophone Africa Market Group | - | - | - | 0% | 0 % | - | 0% |
| Latin America & Asia Market Group | 1 | - | 19 | 0% | 0 % | - | 0% |
| Foundation Market Group | 15,356 | 65,977 | 83,812 | 27% | 100 % | 103,209 | 81% |
| Social Enterprise | 20 | 321 | 220 | (31)% | 0 % | 381 | 58% |
| Safe Abortion | 15,841 | 307,921 | 243,315 | (21)% | 100% | 376,721 | 65 % |
| Acceleration Market Group | 2,577 | 123,068 | 91,246 | (26)% | 38 % | 119,871 | 76% |
| Anglophone Africa Market Group | 1,117 | 22,122 | 20,822 | (6)% | 9 % | 25,618 | 81% |
| Franco/Lusophone Africa Market Group | 4,305 | 16,686 | 22,692 | 36% | 9 % | 18,447 | 123% |
| Latin America & Asia Market Group | 4,349 | 48,544 | 46,356 | (5)% | 19 % | 42,896 | 108% |
| Foundation Market Group | 1,162 | 9,420 | 12,419 | 32% | 5 % | 14,822 | 84% |
| Social Enterprise | 2,330 | 88,080 | 49,781 | (43)% | 20 % | 155,067 | 32% |

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Health Area
Period: 11
Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|--------------------------------------|-----------------|------------------|------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| Tuberculosis | 15,487 | 267,642 | 224,267 | (16)% | 100% | 128,952 | 174 % |
| Acceleration Market Group | 6,437 | 81,148 | 78,525 | (3)% | 35 % | 94,197 | 83% |
| Anglophone Africa Market Group | 24 | 292 | 260 | (11)% | 0 % | 626 | 42% |
| Latin America & Asia Market Group | 9,025 | 109,532 | 107,461 | (2)% | 48 % | 38 | 283,105% |
| Foundation Market Group | - | 76,671 | 38,021 | (50)% | 17 % | 34,091 | 112% |
| WASH | 3,158 | 28,831 | 33,583 | 16% | 100% | 34,182 | 98 % |
| Acceleration Market Group | 1,154 | 7,454 | 11,346 | 52% | 34 % | 9,747 | 116% |
| Anglophone Africa Market Group | 803 | 7,669 | 7,083 | (8)% | 21 % | 10,440 | 68% |
| Franco/Lusophone Africa Market Group | 1,105 | 6,850 | 13,043 | 90% | 39 % | 12,029 | 108% |
| Latin America & Asia Market Group | - | 130 | 43 | (67)% | 0 % | 30 | 141% |
| Foundation Market Group | 97 | 6,728 | 2,069 | (69)% | 6 % | 1,936 | 107% |
| Other | - | - | - | 0% | 0% | - | 0 % |
| Social Enterprise | - | - | - | 0% | 0 % | - | 0% |

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 11
Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|---------------------------------------|------------------|-------------------|-------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| GRAND TOTAL | 2,423,905 | 23,999,549 | 17,488,856 | (27%) | | 25,463,292 | 69% |
| Acceleration Market Group | 331,437 | 4,220,737 | 3,064,942 | (27%) | 100% | 4,096,068 | 75% |
| India | 35,434 | 155,704 | 166,572 | 7 % | 5% | 151,017 | 110% |
| Modern Contraception | 34,468 | 150,768 | 158,590 | 5% | 5% | 142,343 | 111 % |
| Tuberculosis | - | - | - | 0% | 0% | 1,677 | 0 % |
| WASH | 966 | 4,936 | 7,982 | 62% | 0% | 6,997 | 114 % |
| Kenya | 156,045 | 1,767,766 | 1,418,360 | (20)% | 46% | 2,352,036 | 60% |
| Modern Contraception | 73,923 | 455,742 | 525,223 | 15% | 17% | 579,992 | 91 % |
| HIV & STIs | 81,911 | 1,204,309 | 831,492 | (31)% | 27% | 1,646,645 | 50 % |
| Malaria | 24 | 80,025 | 33,966 | (58)% | 1% | 75,807 | 45 % |
| Maternal, Newborn, and Child Health | - | 25,135 | 24,275 | (3)% | 1% | 46,781 | 52 % |
| Non-communicable diseases | - | 51 | 40 | (22)% | 0% | 63 | 63 % |
| Tuberculosis | - | - | - | 0% | 0% | - | 0 % |
| WASH | 187 | 2,503 | 3,363 | 34% | 0% | 2,750 | 122 % |
| Myanmar | 21,140 | 256,860 | 280,073 | 9 % | 9% | 317,773 | 88% |
| Modern Contraception | 6,418 | 61,614 | 67,051 | 9% | 2% | 81,594 | 82 % |
| HIV & STIs | 5,630 | 64,822 | 76,822 | 19% | 3% | 87,494 | 88 % |
| Malaria | 106 | 36,951 | 36,431 | (1)% | 1% | 40,423 | 90 % |
| Maternal, Newborn, and Child Health | 2,545 | 12,049 | 21,214 | 76% | 1% | 15,733 | 135 % |
| Non-communicable diseases | 4 | 13 | 31 | 147% | 0% | 10 | 315 % |
| Nutrition | - | 249 | - | (100)% | 0% | - | 0 % |
| Tuberculosis | 6,437 | 81,148 | 78,525 | (3)% | 3% | 92,520 | 85 % |
| WASH | - | 15 | - | (100)% | 0% | - | 0 % |
| Nigeria | 10,470 | 41,015 | 30,306 | (26)% | 1% | - | -% |
| Modern Contraception | 10,470 | 32,172 | 30,306 | (6)% | 1% | - | 0 % |
| HIV & STIs | - | 8,844 | - | (100)% | 0% | - | 0 % |
| PSI Nigeria | 47,278 | 576,042 | 547,418 | (5)% | 18% | 620,328 | 88% |
| Modern Contraception | 44,701 | 452,974 | 456,173 | 1% | 15% | 500,457 | 91 % |
| Safe Abortion | 2,577 | 123,068 | 91,246 | (26)% | 3% | 119,871 | 76 % |
| South Africa | 61,070 | 1,423,349 | 622,213 | (56)% | 20% | 654,913 | 95% |
| Modern Contraception | - | 51,649 | - | (100)% | 0% | 641 | 0 % |
| HIV & STIs | 61,070 | 1,371,700 | 622,213 | (55)% | 20% | 654,272 | 95 % |
| Anglophone Africa Market Group | 536,193 | 8,167,452 | 6,495,249 | (20)% | 100% | 6,838,586 | 95% |
| Ethiopia | 12,520 | 263,653 | 138,801 | (47)% | 2% | 144,850 | 96% |
| Modern Contraception | 3,966 | 87,922 | 44,822 | (49)% | 1% | 47,793 | 94 % |
| HIV & STIs | 7,927 | 171,995 | 88,420 | (49)% | 1% | 89,820 | 98 % |
| Malaria | - | - | 1 | 0% | 0% | - | 0 % |
| Non-communicable diseases | - | - | - | 0% | 0% | - | 0 % |
| Tuberculosis | - | - | - | 0% | 0% | - | 0 % |
| WASH | 628 | 3,736 | 5,558 | 49% | 0% | 7,237 | 77 % |
| Ghana | 2 | 165,252 | 69,948 | (58)% | 1% | 97,820 | 72% |
| Modern Contraception | - | 165,144 | 69,858 | (58)% | 1% | 95,927 | 73 % |
| HIV & STIs | - | 64 | - | (100)% | 0% | 1,792 | 0 % |
| WASH | 2 | 44 | 90 | 103% | 0% | 101 | 89 % |
| Lesotho | 5,375 | 461,154 | 55,761 | (88)% | 1% | 34,799 | 160% |
| Modern Contraception | 414 | 39,549 | 5,505 | (86)% | 0% | 3,516 | 157 % |

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 11

Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|-------------------------------------|-----------------|------------------|------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| HIV & STIs | 4,937 | 421,361 | 49,996 | (88)% | 1% | 30,657 | 163 % |
| Non-communicable diseases | - | - | - | 0% | 0% | - | 0 % |
| Tuberculosis | 24 | 244 | 260 | 7% | 0% | 626 | 42 % |
| Malawi | 132,160 | 1,129,935 | 1,118,008 | (1)% | 17% | 1,170,485 | 96% |
| Modern Contraception | 51,234 | 502,060 | 501,020 | 0% | 8% | 578,870 | 87 % |
| HIV & STIs | 80,904 | 625,425 | 612,313 | (2)% | 9% | 588,683 | 104 % |
| Malaria | 22 | 1,948 | 4,503 | 131% | 0% | 2,818 | 160 % |
| Non-communicable diseases | - | - | - | 0% | 0% | - | 0 % |
| WASH | - | 502 | 172 | (66)% | 0% | 113 | 152 % |
| Namibia | 2 | - | 2,252 | - % | -% | - | -% |
| Modern Contraception | - | - | 242 | 0% | 0% | - | 0 % |
| HIV & STIs | 2 | - | 2,011 | 0% | 0% | - | 0 % |
| PSI Uganda | 154,423 | 1,476,192 | 1,451,431 | (2)% | 22% | 1,617,541 | 90% |
| Modern Contraception | 153,264 | 1,428,939 | 1,409,283 | (1)% | 22% | 1,561,294 | 90 % |
| HIV & STIs | 674 | 27,829 | 25,957 | (7)% | 0% | 34,195 | 76 % |
| Maternal, Newborn, and Child Health | 28 | 6,133 | 2,055 | (66)% | 0% | 4,132 | 50 % |
| Non-communicable diseases | 3 | 57 | 28 | (50)% | 0% | - | 0 % |
| Safe Abortion | 453 | 13,024 | 14,007 | 8% | 0% | 17,809 | 79 % |
| WASH | - | 210 | 102 | (52)% | 0% | 111 | 91 % |
| Rwanda | 28,959 | 233,817 | 241,244 | 3 % | 4% | 272,046 | 89% |
| Modern Contraception | 7,438 | 66,221 | 66,118 | 0% | 1% | 70,959 | 93 % |
| HIV & STIs | 21,521 | 167,159 | 174,941 | 5% | 3% | 200,615 | 87 % |
| WASH | - | 437 | 184 | (58)% | 0% | 472 | 39 % |
| Swaziland | 52,234 | 744,799 | 542,430 | (27)% | 8% | 330,572 | 164% |
| Modern Contraception | 3,412 | 48,165 | 34,102 | (29)% | 1% | 18,016 | 189 % |
| HIV & STIs | 48,821 | 696,634 | 508,328 | (27)% | 8% | 312,556 | 163 % |
| Non-communicable diseases | - | - | - | 0% | 0% | - | 0 % |
| Tuberculosis | - | - | - | 0% | 0% | - | 0 % |
| Tanzania | 78,339 | 905,304 | 424,923 | (53)% | 7% | 506,709 | 84% |
| Modern Contraception | 32,681 | 597,563 | 365,556 | (39)% | 6% | 463,818 | 79 % |
| HIV & STIs | - | 74,654 | 80 | (100)% | 0% | 1,690 | 5 % |
| Malaria | 44,820 | 223,274 | 52,086 | (77)% | 1% | 32,909 | 158 % |
| Non-communicable diseases | - | - | - | 0% | 0% | - | 0 % |
| Safe Abortion | 664 | 9,395 | 6,815 | (27)% | 0% | 7,808 | 87 % |
| WASH | 174 | 418 | 386 | (8)% | 0% | 484 | 80 % |
| Uganda | 9,721 | 333,815 | 370,242 | 11 % | 6% | 285,612 | 130% |
| Modern Contraception | - | 161,093 | 75,668 | (53)% | 1% | 69,347 | 109 % |
| HIV & STIs | 9,721 | 172,812 | 294,574 | 70% | 5% | 216,265 | 136 % |
| Malaria | - | - | - | 0% | 0% | - | 0 % |
| Maternal, Newborn, and Child Health | - | 178 | - | (100)% | 0% | - | 0 % |
| Non-communicable diseases | - | 28 | - | (100)% | 0% | - | 0 % |
| Safe Abortion | - | (297) | - | (100)% | 0% | - | 0 % |
| WASH | - | - | - | (100)% | 0% | - | 0 % |
| Zambia | 31,361 | 421,601 | 437,092 | 4 % | 7% | 510,034 | 86% |
| Modern Contraception | 16,912 | 145,474 | 203,170 | 40% | 3% | 172,215 | 118 % |
| HIV & STIs | 14,449 | 274,219 | 233,330 | (15)% | 4% | 335,898 | 69 % |
| WASH | - | 1,908 | 592 | (69)% | 0% | 1,922 | 31 % |
| Zimbabwe | 31,097 | 2,031,929 | 1,643,118 | (19)% | 25% | 1,868,119 | 88% |

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 11

Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|---|-----------------|------------------|------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| Modern Contraception | 10,988 | 61,837 | 86,770 | 40% | 1% | 87,065 | 100 % |
| HIV & STIs | 20,094 | 1,969,432 | 1,554,927 | (21)% | 24% | 1,780,790 | 87 % |
| Non-communicable diseases | 15 | 199 | 1,421 | 612% | 0% | 264 | 538 % |
| Tuberculosis | - | 48 | - | (100)% | 0% | - | 0 % |
| WASH | - | 414 | - | (100)% | 0% | - | 0 % |
| Franco/Lusophone Africa Market Group | 173,794 | 2,266,215 | 1,902,820 | (16)% | 100% | 2,699,713 | 70% |
| Angola | 3,642 | 652,314 | 289,956 | (56)% | 15% | 276,666 | 105% |
| Modern Contraception | 1,085 | 116,475 | 121,712 | 4% | 6% | 142,140 | 86 % |
| HIV & STIs | 239 | 14,559 | 10,050 | (31)% | 1% | 23,605 | 43 % |
| Malaria | 105 | 516,106 | 147,045 | (72)% | 8% | 106,722 | 138 % |
| Safe Abortion | 2,191 | 3,899 | 9,856 | 153% | 1% | 2,557 | 385 % |
| WASH | 22 | 1,275 | 1,292 | 1% | 0% | 1,641 | 79 % |
| Benin | 22,177 | 283,130 | 248,885 | (12)% | 13% | 306,792 | 81% |
| Modern Contraception | 20,400 | 232,478 | 190,241 | (18)% | 10% | 245,407 | 78 % |
| HIV & STIs | 967 | 12,343 | 39,373 | 219% | 2% | 24,948 | 158 % |
| Malaria | 1 | 686 | 5 | (99)% | 0% | - | 0 % |
| Maternal, Newborn, and Child Health | 123 | 35,338 | 14,477 | (59)% | 1% | 33,329 | 43 % |
| Non-communicable diseases | - | 6 | 2 | (72)% | 0% | - | 0 % |
| Safe Abortion | 101 | 448 | 910 | 103% | 0% | - | 0 % |
| WASH | 583 | 1,831 | 3,878 | 112% | 0% | 3,108 | 125 % |
| Burundi | 7,771 | 156,407 | 144,317 | (8)% | 8% | 151,589 | 95% |
| Modern Contraception | 364 | 40,858 | 36,303 | (11)% | 2% | 42,894 | 85 % |
| HIV & STIs | 529 | 41,878 | 37,460 | (11)% | 2% | 37,486 | 100 % |
| Malaria | 6,857 | 73,510 | 70,274 | (4)% | 4% | 70,791 | 99 % |
| Safe Abortion | 21 | 161 | 280 | 74% | 0% | 418 | 67 % |
| Cameroon | 60,244 | 479,357 | 458,703 | (4)% | 24% | 900,441 | 51% |
| Modern Contraception | 37,305 | 317,120 | 331,384 | 4% | 17% | 272,311 | 122 % |
| HIV & STIs | 22,273 | 123,669 | 116,837 | (6)% | 6% | 152,624 | 77 % |
| Malaria | 65 | 11,174 | 1,817 | (84)% | 0% | 461,281 | 0 % |
| Maternal, Newborn, and Child Health | 600 | 22,046 | 4,921 | (78)% | 0% | 3,715 | 132 % |
| Nutrition | - | - | - | 0% | 0% | - | 0 % |
| Safe Abortion | 1 | 5,169 | 3,701 | (28)% | 0% | 10,508 | 35 % |
| WASH | 1 | 178 | 43 | (76)% | 0% | 2 | 2,086 % |
| Cote d'Ivoire | 11,915 | 19,117 | 131,909 | 590 % | 7% | 81,095 | 163% |
| Modern Contraception | 11,389 | 15,002 | 127,092 | 747% | 7% | 78,028 | 163 % |
| HIV & STIs | 477 | 3,805 | 3,668 | (4)% | 0% | 2,387 | 154 % |
| WASH | 50 | 311 | 1,149 | 270% | 0% | 679 | 169 % |
| Mozambique | 57,030 | 432,314 | 436,620 | 1 % | 23% | 588,280 | 74% |
| Modern Contraception | 43,395 | 250,757 | 297,005 | 18% | 16% | 317,733 | 93 % |
| HIV & STIs | 13,202 | 178,369 | 133,284 | (25)% | 7% | 264,540 | 50 % |
| Malaria | - | 95 | - | (100)% | 0% | - | 0 % |
| WASH | 434 | 3,093 | 6,331 | 105% | 0% | 6,006 | 105 % |
| Niger | 9,752 | 129,480 | 123,205 | (5)% | 6% | 270,417 | 46% |
| Modern Contraception | 9,629 | 55,127 | 115,831 | 110% | 6% | 65,342 | 177 % |
| HIV & STIs | - | 116 | 5,596 | 4,711% | 0% | 1,328 | 421 % |
| Malaria | - | 70,640 | - | (100)% | 0% | 202,854 | 0 % |
| Safe Abortion | 123 | 3,597 | 1,777 | (51)% | 0% | 893 | 199 % |

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 11
Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|--|-----------------|------------------|------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| PSI Benin | 4,442 | 43,150 | 36,952 | (14)% | 2% | 50,634 | 73% |
| Modern Contraception | 2,574 | 39,736 | 30,785 | (23)% | 2% | 46,563 | 66 % |
| Safe Abortion | 1,867 | 3,414 | 6,167 | 81% | 0% | 4,071 | 151 % |
| Senegal | (3,179) | 70,945 | 32,272 | (55)% | 2% | 73,800 | 44% |
| Modern Contraception | (1,997) | 31,457 | 20,016 | (36)% | 1% | 32,473 | 62 % |
| HIV & STIs | (1,034) | 31,843 | 8,842 | (72)% | 0% | 36,127 | 24 % |
| Malaria | (164) | 7,483 | 3,064 | (59)% | 0% | 4,608 | 66 % |
| Nutrition | - | - | - | 0% | 0% | - | 0 % |
| WASH | 15 | 163 | 350 | 115% | 0% | 593 | 59 % |
| Latin America & Asia Market Group | 127,977 | 1,128,528 | 1,186,530 | 5% | 100% | 1,133,232 | 105% |
| Cambodia | 10,605 | 209,360 | 203,369 | (3)% | 17% | 250,805 | 81% |
| Modern Contraception | 6,665 | 120,606 | 116,171 | (4)% | 10% | 142,792 | 81 % |
| HIV & STIs | 2,314 | 62,154 | 60,436 | (3)% | 5% | 77,713 | 78 % |
| Malaria | 1 | 392 | 8 | (98)% | 0% | 160 | 5 % |
| Maternal, Newborn, and Child Health | 247 | 1,125 | 6,726 | 498% | 1% | 1,752 | 384 % |
| Safe Abortion | 1,377 | 25,083 | 20,028 | (20)% | 2% | 28,390 | 71 % |
| Caribbean | - | - | - | - % | -% | - | -% |
| Non-communicable diseases | - | - | - | 0% | 0% | - | 0 % |
| Costa Rica | 141 | 2,200 | 1,924 | (13)% | -% | 2,522 | 76% |
| Modern Contraception | 18 | 279 | 244 | (13)% | 0% | 320 | 76 % |
| HIV & STIs | 123 | 1,920 | 1,679 | (13)% | 0% | 2,201 | 76 % |
| Dominican Republic | 1,005 | 15,731 | 26,220 | 67 % | 2% | 15,540 | 169% |
| Modern Contraception | 267 | 4,625 | 7,522 | 63% | 1% | 4,631 | 162 % |
| HIV & STIs | 737 | 11,105 | 18,698 | 68% | 2% | 10,909 | 171 % |
| El Salvador | 14 | 5,678 | 8,710 | 53 % | 1% | 7,134 | 122% |
| Modern Contraception | 8 | 1,556 | 2,249 | 45% | 0% | 1,794 | 125 % |
| HIV & STIs | 7 | 4,110 | 6,460 | 57% | 1% | 5,340 | 121 % |
| Maternal, Newborn, and Child Health | - | 10 | - | (100)% | 0% | - | 0 % |
| Non-communicable diseases | - | - | - | 0% | 0% | - | 0 % |
| Safe Abortion | - | 2 | - | (100)% | 0% | - | 0 % |
| El Salvador SA | 1,129 | 2,343 | 5,560 | 137 % | -% | 1,910 | 291% |
| Modern Contraception | 479 | 2,277 | 3,843 | 69% | 0% | 1,851 | 208 % |
| HIV & STIs | 649 | 41 | 1,678 | 4,036% | 0% | - | 0 % |
| Safe Abortion | 1 | 25 | 39 | 57% | 0% | 59 | 66 % |
| Guatemala | 7 | 35,721 | 14,264 | (60)% | 1% | 29,609 | 48% |
| Modern Contraception | 2 | 22,616 | 6,356 | (72)% | 1% | 13,146 | 48 % |
| HIV & STIs | 5 | 12,997 | 7,908 | (39)% | 1% | 16,463 | 48 % |
| Safe Abortion | - | 109 | - | (100)% | 0% | - | 0 % |
| Guatemala SA | 11,840 | 63,389 | 65,431 | 3 % | 6% | 10,527 | 622% |
| Modern Contraception | 9,844 | 63,171 | 60,243 | (5)% | 5% | 10,203 | 590 % |
| HIV & STIs | 1,993 | 121 | 4,719 | 3,797% | 0% | - | 0 % |
| Safe Abortion | 3 | 97 | 469 | 383% | 0% | 324 | 145 % |
| Honduras | 115 | 19,019 | 9,260 | (51)% | 1% | 19,810 | 47% |
| Modern Contraception | 107 | 3,210 | 1,875 | (42)% | 0% | 2,693 | 70 % |
| HIV & STIs | 8 | 15,810 | 7,385 | (53)% | 1% | 17,117 | 43 % |

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 11

Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|-------------------------------------|-----------------|------------------|------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| Honduras SA | 2,756 | - | 7,848 | - % | 1% | - | -% |
| Modern Contraception | 372 | - | 1,059 | 0% | 0% | - | 0 % |
| HIV & STIs | 2,384 | - | 6,789 | 0% | 1% | - | 0 % |
| Kazakhstan | 79 | 862 | 977 | 13 % | -% | 562 | 174% |
| Modern Contraception | - | 10 | 16 | 64% | 0% | 4 | 380 % |
| HIV & STIs | 79 | 853 | 961 | 13% | 0% | 558 | 172 % |
| Tuberculosis | - | - | - | 0% | 0% | - | 0 % |
| Kyrgyzstan | 82 | 563 | 670 | 19 % | -% | 457 | 147% |
| Modern Contraception | 1 | 13 | 12 | (12)% | 0% | 22 | 52 % |
| HIV & STIs | 81 | 550 | 658 | 20% | 0% | 435 | 151 % |
| Tuberculosis | - | - | - | 0% | 0% | - | 0 % |
| Laos | 1,517 | 26,927 | 21,827 | (19)% | 2% | 27,508 | 79% |
| Modern Contraception | 1,147 | 22,401 | 16,958 | (24)% | 1% | 22,913 | 74 % |
| HIV & STIs | 350 | 3,388 | 3,521 | 4% | 0% | 3,564 | 99 % |
| Malaria | 11 | 232 | 160 | (31)% | 0% | 156 | 103 % |
| Safe Abortion | - | 843 | 1,159 | 37% | 0% | 837 | 138 % |
| Tuberculosis | 9 | 64 | 29 | (54)% | 0% | 38 | 77 % |
| Nepal | 2,042 | 50,801 | 24,235 | (52)% | 2% | 30,224 | 80% |
| Modern Contraception | 168 | 36,676 | 12,497 | (66)% | 1% | 17,110 | 73 % |
| HIV & STIs | - | 5 | - | (100)% | 0% | - | 0 % |
| Safe Abortion | 1,873 | 14,120 | 11,738 | (17)% | 1% | 13,114 | 90 % |
| Nicaragua | 2,977 | 13,668 | 16,797 | 23 % | 1% | - | 3,499,359% |
| Modern Contraception | 2,212 | 8,285 | 10,668 | 29% | 1% | - | 0 % |
| HIV & STIs | 761 | 5,280 | 6,014 | 14% | 1% | - | 1,252,934 % |
| Safe Abortion | 4 | 103 | 114 | 11% | 0% | - | 0 % |
| Nicaragua SA | - | - | - | - % | -% | 16,895 | -% |
| Modern Contraception | - | - | - | 0% | 0% | 10,574 | 0 % |
| HIV & STIs | - | - | - | 0% | 0% | 6,148 | 0 % |
| Safe Abortion | - | - | - | 0% | 0% | 173 | 0 % |
| Pakistan | 43,086 | 520,328 | 532,279 | 2 % | 45% | 383,003 | 139% |
| Modern Contraception | 30,856 | 365,703 | 384,941 | 5% | 32% | 348,668 | 110 % |
| HIV & STIs | 2,122 | 36,995 | 27,079 | (27)% | 2% | 34,336 | 79 % |
| Nutrition | 1 | - | 19 | 0% | 0% | - | 0 % |
| Safe Abortion | 1,091 | 8,162 | 12,808 | 57% | 1% | - | 0 % |
| Tuberculosis | 9,016 | 109,468 | 107,432 | (2)% | 9% | - | 0 % |
| Panama | 297 | 6,345 | 4,189 | (34)% | -% | 7,260 | 58% |
| Modern Contraception | 69 | 1,491 | 972 | (35)% | 0% | 1,719 | 57 % |
| HIV & STIs | 228 | 4,855 | 3,217 | (34)% | 0% | 5,542 | 58 % |
| Papua New Guinea | 567 | 2,041 | 957 | (53)% | -% | 3,278 | 29% |
| Modern Contraception | 296 | 169 | 482 | 186% | 0% | 1,889 | 26 % |
| HIV & STIs | 271 | 154 | 444 | 189% | 0% | 1,309 | 34 % |
| Malaria | - | 1,714 | - | (100)% | 0% | - | 0 % |
| Maternal, Newborn, and Child Health | - | - | 27 | 0% | 0% | 76 | 36 % |
| WASH | - | 4 | 3 | (23)% | 0% | 4 | 88 % |
| PSI Pakistan | 48,983 | 107,898 | 225,584 | 109 % | 19% | 304,660 | 74% |
| Modern Contraception | 48,820 | 106,934 | 215,160 | 101% | 18% | 292,577 | 74 % |
| HIV & STIs | 164 | 964 | 10,424 | 981% | 1% | 12,083 | 86 % |

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 11
Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|-------------------------------------|------------------|------------------|------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| Tajikistan | 670 | 14,412 | 14,227 | (1)% | 1% | 19,404 | 73% |
| Modern Contraception | 5 | 179 | 60 | (67)% | 0% | 80 | 75 % |
| HIV & STIs | 664 | 14,233 | 14,167 | 0% | 1% | 19,324 | 73 % |
| Tuberculosis | - | - | - | 0% | 0% | - | 0 % |
| Viet Nam | 66 | 31,240 | 2,205 | (93)% | -% | 2,123 | 104% |
| Modern Contraception | 63 | 172 | 232 | 35% | 0% | 76 | 304 % |
| HIV & STIs | - | 30,920 | 1,912 | (94)% | 0% | 1,912 | 100 % |
| Malaria | 3 | 22 | 21 | (6)% | 0% | 108 | 19 % |
| Non-communicable diseases | - | - | - | 0% | 0% | - | 0 % |
| Tuberculosis | - | - | - | 0% | 0% | - | 0 % |
| WASH | - | 126 | 39 | (69)% | 0% | 26 | 148 % |
| Foundation Market Group | 1,225,785 | 7,018,641 | 3,952,020 | (44)% | 100% | 9,033,832 | 44% |
| Haiti | 8,230 | 158,728 | 116,908 | (26)% | 3% | 87,193 | 134% |
| Modern Contraception | 62 | 20,272 | 8,596 | (58)% | 0% | 9,184 | 94 % |
| HIV & STIs | 5,994 | 59,951 | 29,343 | (51)% | 1% | 12,871 | 228 % |
| Malaria | 2,168 | 1,833 | 35,550 | 1,839% | 1% | 23,585 | 151 % |
| Maternal, Newborn, and Child Health | 6 | - | 5,398 | 0% | 0% | 7,462 | 72 % |
| Non-communicable diseases | - | 1 | - | (80)% | 0% | - | 0 % |
| Tuberculosis | - | 76,671 | 38,021 | (50)% | 1% | 34,091 | 112 % |
| Liberia | 276 | 10,069 | 7,826 | (22)% | -% | 27,447 | 29% |
| Modern Contraception | 97 | 4,618 | 3,547 | (23)% | 0% | 12,602 | 28 % |
| HIV & STIs | 180 | 5,334 | 4,188 | (21)% | 0% | 14,733 | 28 % |
| WASH | - | 118 | 91 | (23)% | 0% | 112 | 81 % |
| Madagascar | 161,037 | 1,921,631 | 987,612 | (49)% | 25% | 1,094,187 | 90% |
| Modern Contraception | 36,055 | 425,813 | 456,720 | 7% | 12% | 476,130 | 96 % |
| HIV & STIs | 1,518 | 136,160 | 104,507 | (23)% | 3% | 117,859 | 89 % |
| Malaria | 119,670 | 1,285,010 | 366,028 | (72)% | 9% | 459,706 | 80 % |
| Maternal, Newborn, and Child Health | 3,257 | 65,665 | 53,242 | (19)% | 1% | 36,677 | 145 % |
| Non-communicable diseases | 1 | 21 | 8 | (61)% | 0% | - | 0 % |
| Nutrition | - | 119 | - | (100)% | 0% | - | 0 % |
| Safe Abortion | 533 | 3,543 | 5,584 | 58% | 0% | 3,618 | 154 % |
| WASH | 5 | 5,300 | 1,523 | (71)% | 0% | 197 | 771 % |
| Mali | 866,814 | 3,336,866 | 1,946,057 | (42)% | 49% | 4,563,000 | 43% |
| Modern Contraception | 57,264 | 341,572 | 457,775 | 34% | 12% | 446,445 | 103 % |
| HIV & STIs | - | 1 | 578 | 55,700% | 0% | 1,036 | 56 % |
| Malaria | 808,865 | 2,989,340 | 1,480,704 | (50)% | 37% | 4,103,046 | 36 % |
| Non-communicable diseases | 3 | 33 | 35 | 8% | 0% | 210 | 17 % |
| Safe Abortion | 630 | 5,877 | 6,835 | 16% | 0% | 11,204 | 61 % |
| WASH | 51 | 43 | 130 | 202% | 0% | 1,059 | 12 % |
| Somaliland | 25,682 | 126,580 | 141,394 | 12 % | 4% | 158,117 | 89% |
| Modern Contraception | 2,045 | 3,920 | 4,890 | 25% | 0% | 4,893 | 100 % |
| HIV & STIs | 22 | 80 | 158 | 97% | 0% | 131 | 121 % |
| Malaria | 173 | 666 | 1,012 | 52% | 0% | 866 | 117 % |
| Maternal, Newborn, and Child Health | 8,047 | 58,821 | 51,197 | (13)% | 1% | 48,449 | 106 % |
| Nutrition | 15,356 | 61,826 | 83,812 | 36% | 2% | 103,209 | 81 % |
| WASH | 41 | 1,267 | 325 | (74)% | 0% | 568 | 57 % |
| South Sudan | 163,746 | 1,464,766 | 752,222 | (49)% | 19% | 3,103,888 | 24% |

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 11
Year: 2019

| | DALY 11/2019 | YTD DALY 2018 | YTD DALY 2019 | Percentage Change | Percentage of Category | Annual DALY Target | Percentage of Target Achieved |
|-------------------------------------|-----------------|------------------|------------------|----------------------|---------------------------|--------------------------|-------------------------------------|
| Malaria | 163,746 | 920,691 | 752,222 | (18)% | 19% | 3,103,888 | 24 % |
| Maternal, Newborn, and Child Health | - | 540,043 | - | (100)% | 0% | - | 0 % |
| Nutrition | - | 4,031 | - | (100)% | 0% | - | 0 % |
| Social Enterprise | 28,719 | 1,196,214 | 887,295 | (26)% | 100% | 1,661,860 | 53% |
| India LLC | 18,921 | 496,803 | 337,902 | (32)% | 38% | 805,943 | 42% |
| Modern Contraception | 5,533 | 211,106 | 151,961 | (28)% | 17% | 312,748 | 49 % |
| HIV & STIs | 11,072 | 175,167 | 109,010 | (38)% | 12% | 311,642 | 35 % |
| Maternal, Newborn, and Child Health | (14) | 22,450 | 27,150 | 21% | 3% | 26,486 | 103 % |
| Safe Abortion | 2,330 | 88,080 | 49,781 | (43)% | 6% | 155,067 | 32 % |
| Other | - | - | - | 0% | 0% | - | 0 % |
| Paraguay | 2,650 | 24,007 | 21,794 | (9)% | 2% | 24,784 | 88% |
| Modern Contraception | 659 | 6,611 | 6,206 | (6)% | 1% | 7,205 | 86 % |
| HIV & STIs | 1,970 | 17,075 | 15,368 | (10)% | 2% | 17,198 | 89 % |
| Nutrition | 20 | 321 | 220 | (31)% | 0% | 381 | 58 % |
| PSI South Africa | 7,148 | 675,405 | 527,599 | (22)% | 59% | 831,133 | 63% |
| Modern Contraception | 427 | 41,898 | 32,707 | (22)% | 4% | 56,569 | 58 % |
| HIV & STIs | 6,721 | 633,507 | 494,892 | (22)% | 56% | 774,565 | 64 % |
| Inactive | - | 1,762 | - | (100)% | -% | - | -% |
| Guinea | - | 1,762 | - | (100)% | -% | - | -% |
| Modern Contraception | - | 1,520 | - | (100)% | 0% | - | 0 % |
| HIV & STIs | - | 242 | - | (100)% | 0% | - | 0 % |

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Acute Malnutrition Screening_CU5 | - | - | 389 | 312 | 619,573 | (100)% | 619,573 | 621,339 | 389 | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | 312 | 518 | (100)% | 518 | 1,895 | - | - | - |
| Foundation Market Group | - | - | 389 | - | 619,055 | (100)% | 619,055 | 619,444 | 389 | - | - |
| Antiretroviral Treatment | - | - | - | - | - | -% | - | 18,119 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 18,119 | - | - | - |
| Antiretroviral Treatment (Currently Enrolled) | 71,418 | 59,554 | 474,998 | 313,246 | 506,231 | (6)% | 535,855 | 1,483,195 | 39,583 | - | 85,921 |
| Acceleration Market Group | 15,234 | 15,017 | 158,492 | 170,176 | 138,790 | 14% | 152,003 | 386,976 | 13,208 | - | 31,377 |
| Anglophone Africa Market Group | 14,541 | 13,988 | 148,526 | 105,390 | 134,560 | 10% | 148,026 | 415,785 | 12,377 | - | 26,374 |
| Franco/Lusophone Africa Market Group | 6,040 | 6,411 | 55,966 | 7,723 | 16,071 | 248% | 19,016 | 81,612 | 4,664 | - | 9,368 |
| Latin America & Asia Market Group | 767 | 925 | 7,541 | - | 233 | 3,136% | 233 | 7,774 | 628 | - | 1,049 |
| Foundation Market Group | 34,836 | 23,212 | 104,473 | 29,957 | 216,577 | (52)% | 216,577 | 591,048 | 8,706 | - | 17,752 |
| Antiretroviral Treatment (Newly Enrolled) | 2,245 | 2,955 | 18,279 | 13,389 | 14,938 | 22% | 15,865 | 61,242 | 18,279 | - | - |
| Acceleration Market Group | 276 | 325 | 3,481 | 3,981 | 3,148 | 11% | 3,434 | 13,067 | 3,481 | - | - |
| Anglophone Africa Market Group | 837 | 623 | 6,648 | 4,695 | 6,309 | 5% | 6,634 | 29,513 | 6,648 | - | - |
| Franco/Lusophone Africa Market Group | 156 | 149 | 1,265 | 1,396 | 1,752 | (28)% | 1,807 | 3,486 | 1,265 | - | - |
| Latin America & Asia Market Group | 88 | 40 | 449 | - | 92 | 388% | 92 | 541 | 449 | - | - |
| Foundation Market Group | 888 | 1,818 | 6,436 | 3,317 | 3,637 | 77% | 3,898 | 14,635 | 6,436 | - | - |
| Antiretroviral Treatment (Tablet) | - | - | - | - | - | -% | - | 97,980 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 97,980 | - | - | - |
| ARV Prophylaxis 28 wks (Mother and Baby) | - | - | - | - | - | -% | - | 382 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 382 | - | - | - |
| ARV Prophylaxis 28 wks (Mother Only) | - | - | - | - | - | -% | - | 359 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 359 | - | - | - |
| Basic Care Package | - | - | - | - | 1 | (100)% | 1 | 176,452,482 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 1,064,698 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 1 | (100)% | 1 | 174,969,459 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 418,325 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 666 | (100)% | 666 | 16,834 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 4,995 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 544 | (100)% | 544 | 9,416 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | 122 | (100)% | 122 | 1,919 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 504 | - | - | - |
| Cervical Cancer-HPV DNA and Conization | 3 | 1 | 7 | - | - | -% | - | 7 | 7 | - | 3 |
| Anglophone Africa Market Group | 3 | 1 | 7 | - | - | -% | - | 7 | 7 | - | 3 |
| Cervical Cancer-HPV DNA and Cryotherapy | 1 | 2 | 6 | - | 3 | 100% | 3 | 9 | 6 | - | 3 |
| Anglophone Africa Market Group | 1 | 2 | 6 | - | 3 | 100% | 3 | 9 | 6 | - | 3 |
| Cervical Cancer-HPV DNA and Refer to any Treatment | 1 | - | 1 | - | - | -% | - | 12 | 1 | - | - |
| Anglophone Africa Market Group | 1 | - | 1 | - | - | -% | - | 12 | 1 | - | - |
| Cervical Cancer-HPV DNA and Refer to Conization | - | - | - | - | - | -% | - | 9 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 9 | - | - | - |
| Cervical Cancer-HPV DNA Screening | 615 | 700 | 3,790 | - | - | -% | - | 3,790 | 3,790 | - | - |
| Anglophone Africa Market Group | 615 | 554 | 3,013 | - | - | -% | - | 3,013 | 3,013 | - | - |
| Latin America & Asia Market Group | - | 146 | 777 | - | - | -% | - | 777 | 777 | - | - |
| Cervical Cancer-Pap and Conization | - | - | 1,753 | - | - | -% | - | 1,753 | 1,753 | - | 778 |
| Anglophone Africa Market Group | - | - | 1,753 | - | - | -% | - | 1,753 | 1,753 | - | 778 |
| Cervical Cancer-Pap and Cryotherapy | - | - | - | - | 4 | (100)% | 4 | 39 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 25 | - | - | - |
| Foundation Market Group | - | - | - | - | 4 | (100)% | 4 | 4 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 10 | - | - | - |
| Cervical Cancer-Pap and Refer to any Treatment | - | 1 | 9 | - | - | -% | - | 11 | 9 | - | 2 |
| Anglophone Africa Market Group | - | 1 | 9 | - | - | -% | - | 11 | 9 | - | 2 |
| Cervical Cancer-Pap and Refer to Conization | - | - | - | - | - | -% | - | 9 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 9 | - | - | - |
| Cervical Cancer-Pap Smear Screening | 31 | 47 | 408 | - | 92 | 343% | 92 | 7,765 | 408 | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Acceleration Market Group | - | - | - | - | - | -% | - | 6,497 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 291 | - | - | - |
| Latin America & Asia Market Group | 31 | 47 | 408 | - | 92 | 343% | 92 | 888 | 408 | - | - |
| Inactive | - | - | - | - | - | -% | - | 89 | - | - | - |
| Cervical Cancer-VIA and Conization | 20 | 18 | 234 | 290 | 98 | 139% | 126 | 538 | 234 | - | 84 |
| Anglophone Africa Market Group | 20 | 18 | 234 | 290 | 98 | 139% | 126 | 538 | 234 | - | 84 |
| Cervical Cancer-VIA and Cryotherapy | 57 | 70 | 2,052 | 1,247 | 1,091 | 88% | 1,162 | 23,491 | 2,052 | - | 677 |
| Acceleration Market Group | 18 | 27 | 300 | 240 | 264 | 14% | 286 | 11,546 | 300 | - | 71 |
| Anglophone Africa Market Group | 23 | 21 | 1,596 | 307 | 610 | 162% | 639 | 10,045 | 1,596 | - | 560 |
| Franco/Lusophone Africa Market Group | 3 | 1 | 13 | - | 46 | (72)% | 48 | 387 | 13 | - | 2 |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 8 | - | - | - |
| Foundation Market Group | 13 | 20 | 143 | 700 | 171 | (16)% | 189 | 1,485 | 143 | - | 44 |
| Inactive | - | - | - | - | - | -% | - | 20 | - | - | - |
| Cervical Cancer-VIA and Refer to any Treatment | 5 | 9 | 84 | - | 24 | 250% | 25 | 522 | 84 | - | 15 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 127 | - | - | - |
| Anglophone Africa Market Group | 5 | 9 | 84 | - | 24 | 250% | 25 | 395 | 84 | - | 15 |
| Cervical Cancer-VIA and Refer to Conization | 1 | 3 | 22 | 290 | 94 | (77)% | 102 | 2,082 | 22 | - | 4 |
| Acceleration Market Group | - | - | - | - | 1 | (100)% | 4 | 4 | - | - | - |
| Anglophone Africa Market Group | 1 | 3 | 22 | 290 | 93 | (76)% | 98 | 2,078 | 22 | - | 4 |
| Cervical Cancer-VIA and Refer to Cryotherapy | - | - | - | 150 | 32 | (100)% | 39 | 2,084 | - | - | - |
| Acceleration Market Group | - | - | - | 150 | 22 | (100)% | 29 | 913 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 10 | (100)% | 10 | 625 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 10 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 536 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | 14,678 | 13,716 | 129,546 | 145,293 | 183,295 | (29)% | 194,523 | 1,170,250 | 129,546 | - | - |
| Acceleration Market Group | 319 | 3,320 | 37,667 | 21,500 | 32,301 | 17% | 34,714 | 502,099 | 37,667 | - | - |
| Anglophone Africa Market Group | 4,986 | 3,715 | 44,125 | 88,793 | 93,489 | (53)% | 95,922 | 385,211 | 44,125 | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|------------------|------------------|
| Franco/Lusophone Africa Market Group | 4,314 | 2,680 | 25,347 | - | 45,503 | (44)% | 50,592 | 186,176 | 25,347 | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 387 | - | - | - |
| Foundation Market Group | 5,059 | 4,002 | 22,407 | 35,000 | 12,002 | 87% | 13,295 | 96,107 | 22,407 | - | - |
| Inactive | - | - | - | - | - | -% | - | 270 | - | - | - |
| Chlorhexidine | 2,411 | 8,716 | 37,758 | 25,755 | 130,235 | (71)% | 130,742 | 655,673 | 33,982 | - | 2,279 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 148,406 | - | - | - |
| Anglophone Africa Market Group | 375 | 953 | 6,327 | 16,755 | 23,115 | (73)% | 23,622 | 42,992 | 5,694 | - | 440 |
| Foundation Market Group | 2,036 | 7,763 | 31,431 | 9,000 | 107,120 | (71)% | 107,120 | 464,275 | 28,288 | - | 1,839 |
| Clean Delivery Kit | - | - | - | - | 3,449 | (100)% | 3,449 | 1,708,471 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 346,994 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 3,449 | (100)% | 3,449 | 470,003 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 710,114 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 180,586 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 774 | - | - | - |
| Condom | 29,583,900 | 35,575,835 | 372,947,013 | 553,397,069 | 431,045,734 | (13)% | 504,429,167 | 21,819,957,081 | 2,797,101 | 2,797,101 | 3,334,526 |
| Acceleration Market Group | 3,925,890 | 3,766,518 | 41,894,829 | 41,769,999 | 32,518,684 | 29% | 38,017,548 | 9,795,693,180 | 314,211 | 314,211 | 919,925 |
| Anglophone Africa Market Group | 3,485,580 | 3,770,886 | 44,140,095 | 49,703,561 | 62,498,630 | (29)% | 65,266,786 | 3,191,048,778 | 331,051 | 331,051 | 884,357 |
| Franco/Lusophone Africa Market Group | 3,930,749 | 3,103,577 | 35,274,796 | 59,938,298 | 45,226,474 | (22)% | 51,015,576 | 1,664,543,458 | 264,561 | 264,561 | 445,821 |
| Latin America & Asia Market Group | 11,658,825 | 20,653,880 | 166,126,123 | 196,479,173 | 162,702,912 | 2% | 187,072,729 | 4,018,248,586 | 1,245,946 | 1,245,946 | 358,910 |
| Foundation Market Group | 154,896 | 327,972 | 1,749,228 | 2,920,716 | 2,987,434 | (41)% | 3,347,338 | 954,246,461 | 13,119 | 13,119 | 15,642 |
| Social Enterprise | 6,427,960 | 3,953,002 | 83,761,942 | 202,585,322 | 125,111,600 | (33)% | 159,709,190 | 796,280,817 | 628,213 | 628,213 | 709,870 |
| USA | - | - | - | - | - | -% | - | 289,819 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 1,399,605,982 | - | - | - |
| Condom Provided | - | - | - | - | - | -% | - | 18,930,351 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 50,644 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 17,527,104 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 673,774 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 651,148 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 27,681 | - | - | - |
| Counseling & Tx for Moderate Acute MalnutritionCU5 | 3,347 | 1,406 | 18,707 | 20,946 | 9,126 | 105% | 20,332 | 194,194 | 18,707 | - | 58,514 |
| Franco/Lusophone Africa Market Group | - | - | - | 4 | - | -% | - | 8 | - | - | - |
| Foundation Market Group | 3,347 | 1,406 | 18,707 | 20,942 | 9,126 | 105% | 20,332 | 194,186 | 18,707 | - | 58,514 |
| Deworming Tablets | - | - | - | - | - | -% | - | 1,095,308 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 1,095,308 | - | - | - |
| Diarrhea Treatment Kit | 13,618 | 29,915 | 419,811 | 780,367 | 615,992 | (32)% | 666,448 | 20,157,284 | 377,830 | - | 26,192 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 6,854,139 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 24,379 | - | - | - |
| Franco/Lusophone Africa Market Group | 11,988 | 28,814 | 299,408 | 424,000 | 404,486 | (26)% | 431,332 | 4,432,537 | 269,467 | - | 17,537 |
| Latin America & Asia Market Group | 1,630 | 1,100 | 37,750 | 91,951 | 57,190 | (34)% | 57,190 | 986,426 | 33,975 | - | 743 |
| Foundation Market Group | - | 1 | 82,653 | 264,416 | 154,316 | (46)% | 177,926 | 5,112,857 | 74,388 | - | 7,913 |
| Inactive | - | - | - | - | - | -% | - | 2,746,946 | - | - | - |
| Diarrhea Treatment Kit Provided | - | 586 | 15,147 | 29,000 | 18,332 | (17)% | 20,038 | 84,078 | 15,147 | - | 503 |
| Acceleration Market Group | - | 586 | 15,147 | 29,000 | 16,520 | (8)% | 18,226 | 69,404 | 15,147 | - | 503 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 2,400 | - | - | - |
| Foundation Market Group | - | - | - | - | 1,812 | (100)% | 1,812 | 12,274 | - | - | - |
| Early Infant Male Circumcision | - | - | - | - | - | -% | - | 4,886 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 4,886 | - | - | - |
| Emergency Contraception | 201,609 | 330,538 | 2,821,571 | 2,499,767 | 2,685,560 | 5% | 3,049,904 | 47,410,732 | 126,971 | 126,971 | 22,898 |
| Acceleration Market Group | 65 | (8,178) | (40,654) | - | (121) | -% | (121) | 16,325,687 | (1,829) | (1,829) | (235) |
| Anglophone Africa Market Group | 24,675 | 3,024 | 103,659 | 7,000 | 168,048 | (38)% | 180,947 | 1,751,416 | 4,665 | 4,665 | 1,838 |
| Franco/Lusophone Africa Market Group | 3,173 | 1,724 | 38,848 | 255,200 | 132,415 | (71)% | 135,874 | 715,154 | 1,748 | 1,748 | 1,062 |
| Latin America & Asia Market Group | 146,757 | 294,593 | 2,291,194 | 981,837 | 1,833,387 | 25% | 2,139,235 | 23,352,980 | 103,104 | 103,104 | 17,917 |
| Foundation Market Group | (6) | (5) | 44,764 | 15,700 | 40,026 | 12% | 40,018 | 165,295 | 2,014 | 2,014 | 548 |
| Social Enterprise | 26,945 | 39,381 | 383,760 | 1,240,030 | 511,805 | (25)% | 553,951 | 3,449,863 | 17,269 | 17,269 | 1,768 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Inactive | - | - | - | - | - | -% | - | 1,650,337 | - | - | - |
| Emergency Contraception Provided | 16,533 | 14,463 | 176,018 | 1,199,860 | 25,576 | 588% | 29,591 | 240,967 | 8,801 | 8,801 | 3,062 |
| Acceleration Market Group | 9,664 | 9,300 | 55,225 | 19,800 | 3,303 | 1,572% | 4,173 | 60,826 | 2,761 | 2,761 | 423 |
| Anglophone Africa Market Group | 2,174 | 2,873 | 90,402 | 30,493 | 6,634 | 1,263% | 6,887 | 98,508 | 4,520 | 4,520 | 2,290 |
| Franco/Lusophone Africa Market Group | 284 | 306 | 3,714 | 3,000 | 2,514 | 48% | 2,877 | 8,201 | 186 | 186 | 116 |
| Latin America & Asia Market Group | 4,405 | 1,978 | 26,558 | 1,146,567 | 12,851 | 107% | 15,372 | 71,331 | 1,328 | 1,328 | 231 |
| Foundation Market Group | 6 | 5 | 119 | - | 274 | (57)% | 282 | 2,100 | 6 | 6 | 2 |
| Inactive | - | - | - | - | - | -% | - | 1 | - | - | - |
| Expanded Clean Delivery Kit | - | - | - | - | 13,160 | (100)% | 13,160 | 25,000 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 13,160 | (100)% | 13,160 | 25,000 | - | - | - |
| Expanded Clean Delivery Kit (+CHX) | 14 | 1,420 | 11,040 | 20,285 | 14,044 | (21)% | 14,531 | 26,188 | 9,936 | - | 1,615 |
| Anglophone Africa Market Group | 14 | 1,420 | 11,040 | 20,285 | 14,044 | (21)% | 14,531 | 26,188 | 9,936 | - | 1,615 |
| Family Planning Counseling | - | - | - | - | - | -% | - | 42,190 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 15,882 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 21,833 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 3,787 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 688 | - | - | - |
| Fecal Sludge Management (Households) | - | 66 | 3,800 | 750 | 1,686 | 125% | 2,071 | 7,453 | 18,942 | - | - |
| Acceleration Market Group | - | 13 | 489 | 400 | 570 | (14)% | 697 | 2,768 | 2,347 | - | - |
| Franco/Lusophone Africa Market Group | - | 53 | 3,311 | 350 | 1,116 | 197% | 1,374 | 4,685 | 16,595 | - | - |
| Fecal Sludge Management (Liters) | - | 836,000 | 13,055,000 | 15,559,190 | 7,855,000 | 66% | 9,121,000 | 29,322,200 | - | - | 1,443 |
| Acceleration Market Group | - | 63,333 | 1,914,000 | 2,000,000 | 3,376,000 | (43)% | 4,011,000 | 13,071,200 | - | - | 118 |
| Franco/Lusophone Africa Market Group | - | 772,667 | 11,141,000 | 13,559,190 | 4,479,000 | 149% | 5,110,000 | 16,251,000 | - | - | 1,325 |
| Female Condom | 326,140 | 118,083 | 1,697,260 | 1,763,132 | 1,504,160 | 13% | 1,709,647 | 87,860,124 | 12,729 | 12,729 | 21,413 |
| Acceleration Market Group | - | 967 | 85,553 | 70,000 | 65,906 | 30% | 79,641 | 10,481,146 | 642 | 642 | 461 |
| Anglophone Africa Market Group | 17,110 | 10,798 | 173,727 | 533,000 | 463,017 | (62)% | 469,229 | 48,743,554 | 1,303 | 1,303 | 5,631 |
| Franco/Lusophone Africa Market Group | 309,030 | 106,319 | 1,437,980 | 1,160,132 | 975,137 | 47% | 1,160,677 | 13,190,625 | 10,785 | 10,785 | 15,321 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Latin America & Asia Market Group | - | - | - | - | 100 | (100)% | 100 | 660,929 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 9,300,709 | - | - | - |
| Social Enterprise | - | - | - | - | - | -% | - | 985,104 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 4,498,057 | - | - | - |
| Female Condom Provided | - | - | - | - | - | -% | - | 112,394 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 87,306 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 22,060 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 1 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 3,027 | - | - | - |
| Fever Cases Attended | 72,216 | 102,242 | 873,821 | 286,938 | 815,322 | 7% | 916,338 | 7,020,056 | 873,821 | - | - |
| Acceleration Market Group | 43,613 | 49,315 | 446,149 | - | 611,247 | (27)% | 697,782 | 2,904,296 | 446,149 | - | - |
| Anglophone Africa Market Group | - | 25,845 | 171,313 | - | - | -% | - | 171,313 | 171,313 | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | 8,385 | 14,143 | (100)% | 14,143 | 26,907 | - | - | - |
| Latin America & Asia Market Group | 8,768 | 8,700 | 79,879 | 75,685 | 112,593 | (29)% | 118,263 | 359,804 | 79,879 | - | - |
| Foundation Market Group | 19,835 | 18,382 | 176,480 | 202,868 | 77,339 | 128% | 86,150 | 3,557,736 | 176,480 | - | - |
| Fever Cases Tested with Microscopy | 3,275 | 5,199 | 40,126 | 30,340 | 50,817 | (21)% | 56,797 | 479,614 | 40,126 | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 7,474 | - | - | - |
| Latin America & Asia Market Group | - | 2,246 | 6,737 | - | - | -% | - | 6,737 | 6,737 | - | - |
| Foundation Market Group | 3,275 | 2,953 | 33,389 | 30,340 | 50,817 | (34)% | 56,797 | 465,403 | 33,389 | - | - |
| Fever Cases Tested with RDTs | 82,266 | 111,534 | 979,183 | 276,374 | 987,430 | (1)% | 1,120,815 | 7,525,079 | 979,183 | - | - |
| Acceleration Market Group | 43,613 | 49,315 | 446,149 | - | 611,247 | (27)% | 697,782 | 2,896,468 | 446,149 | - | - |
| Anglophone Africa Market Group | - | 24,741 | 163,450 | - | - | -% | - | 163,450 | 163,450 | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | 8,385 | 14,143 | (100)% | 14,143 | 42,041 | - | - | - |
| Latin America & Asia Market Group | 11,898 | 11,860 | 105,090 | 95,551 | 126,427 | (17)% | 134,061 | 400,777 | 105,090 | - | - |
| Foundation Market Group | 26,755 | 25,617 | 264,494 | 172,438 | 235,613 | 12% | 274,829 | 4,022,343 | 264,494 | - | - |
| Free Condom | 5,889,630 | 10,938,843 | 93,982,795 | 109,721,482 | 166,063,127 | (43)% | 180,808,636 | 2,717,070,633 | 704,871 | 704,871 | 1,560,307 |
| Acceleration Market Group | 468 | 2,244 | 1,920,960 | 35,500,000 | 62,784,000 | (97)% | 68,170,320 | 1,487,878,858 | 14,407 | 14,407 | 56,881 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Anglophone Africa Market Group | 5,640,266 | 5,362,560 | 55,829,602 | 44,434,784 | 71,094,778 | (21)% | 77,319,731 | 785,776,253 | 418,722 | 418,722 | 1,249,956 |
| Franco/Lusophone Africa Market Group | 29,020 | 378,487 | 14,031,761 | 5,193,631 | 3,162,015 | 344% | 3,201,731 | 84,021,954 | 105,238 | 105,238 | 89,391 |
| Latin America & Asia Market Group | 124,572 | 540,270 | 3,685,316 | 3,124,160 | 2,698,447 | 37% | 3,430,359 | 61,629,481 | 27,640 | 27,640 | 7,779 |
| Foundation Market Group | 95,304 | 4,655,281 | 18,515,156 | 21,468,907 | 25,979,571 | (29)% | 28,342,179 | 179,066,408 | 138,864 | 138,864 | 156,300 |
| Inactive | - | - | - | - | 344,316 | (100)% | 344,316 | 118,697,679 | - | - | - |
| Free Female Condom | 53,048 | 393,254 | 1,501,566 | 333,000 | 1,719,844 | (13)% | 1,803,686 | 19,153,750 | 11,262 | 11,262 | 31,464 |
| Acceleration Market Group | 12,320 | 8,620 | 38,180 | - | 1,108,500 | (97)% | 1,108,500 | 6,605,941 | 286 | 286 | 206 |
| Anglophone Africa Market Group | 29,418 | 379,536 | 1,350,782 | 251,000 | 555,165 | 143% | 623,007 | 7,439,645 | 10,131 | 10,131 | 30,174 |
| Franco/Lusophone Africa Market Group | 6,000 | 1,700 | 97,100 | 52,000 | 33,536 | 190% | 49,536 | 1,151,794 | 728 | 728 | 1,010 |
| Latin America & Asia Market Group | 5,310 | 3,398 | 15,504 | 30,000 | 21,200 | (27)% | 21,200 | 369,278 | 116 | 116 | 75 |
| Foundation Market Group | - | - | - | - | 253 | (100)% | 253 | 3,329,424 | - | - | - |
| Inactive | - | - | - | - | 1,190 | (100)% | 1,190 | 257,668 | - | - | - |
| HAART (Mother and Baby) | - | - | - | - | - | -% | - | 256 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 256 | - | - | - |
| HAART (Mother Only) | - | - | - | - | - | -% | - | 239 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 239 | - | - | - |
| HIV Self-Testing Kit | 21,143 | 206,574 | 1,158,998 | 1,716,537 | 610,816 | 90% | 2,354,376 | 3,882,921 | 1,043,098 | - | - |
| Acceleration Market Group | 3,685 | 169,925 | 641,840 | 1,066,643 | - | -% | 1,357,422 | 1,999,262 | 577,656 | - | - |
| Anglophone Africa Market Group | 17,458 | 36,326 | 516,190 | 641,306 | 610,816 | (15)% | 996,954 | 1,882,691 | 464,571 | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | 1,388 | - | -% | - | - | - | - | - |
| Latin America & Asia Market Group | - | 323 | 968 | 7,200 | - | -% | - | 968 | 871 | - | - |
| HIV Testing Services | 99,708 | 161,998 | 1,252,373 | 1,174,518 | 2,138,474 | (41)% | 2,232,177 | 24,571,911 | 1,252,373 | - | 37,809 |
| Acceleration Market Group | 15,024 | 25,830 | 303,775 | 293,418 | 1,059,481 | (71)% | 1,091,132 | 7,329,811 | 303,775 | - | 11,811 |
| Anglophone Africa Market Group | 25,441 | 29,467 | 297,202 | 518,172 | 519,986 | (43)% | 541,424 | 10,745,300 | 297,202 | - | 22,207 |
| Franco/Lusophone Africa Market Group | 6,083 | 6,841 | 81,420 | 93,415 | 99,814 | (18)% | 106,415 | 3,081,992 | 81,420 | - | 623 |
| Latin America & Asia Market Group | 6,316 | 4,225 | 67,431 | 78,439 | 93,829 | (28)% | 98,169 | 439,212 | 67,431 | - | 150 |
| Foundation Market Group | 46,844 | 95,636 | 502,545 | 191,074 | 365,364 | 38% | 395,037 | 2,201,146 | 502,545 | - | 3,018 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Inactive | - | - | - | - | - | -% | - | 774,450 | - | - | - |
| Hypertension Diagnosis | 3,091 | 3,657 | 48,304 | 34,572 | 83,721 | (42)% | 84,148 | 214,113 | 48,304 | - | - |
| Acceleration Market Group | 1,057 | 1,422 | 31,449 | 20,000 | 57,365 | (45)% | 57,768 | 142,452 | 31,449 | - | - |
| Anglophone Africa Market Group | 2,034 | 2,235 | 8,894 | - | 254 | 3,402% | 278 | 11,263 | 8,894 | - | - |
| Latin America & Asia Market Group | - | - | 7,961 | 14,572 | 26,102 | (70)% | 26,102 | 60,398 | 7,961 | - | - |
| Hypertension Screening | 93,626 | 92,625 | 724,392 | 236,477 | 687,753 | 5% | 737,910 | 2,236,778 | 724,392 | - | - |
| Acceleration Market Group | 2,049 | 2,654 | 80,891 | 50,000 | 168,855 | (52)% | 176,640 | 479,130 | 80,891 | - | - |
| Anglophone Africa Market Group | 91,576 | 89,971 | 451,581 | 36,477 | 135,242 | 234% | 147,793 | 950,034 | 451,581 | - | - |
| Latin America & Asia Market Group | 1 | - | 191,920 | 150,000 | 383,656 | (50)% | 413,477 | 807,614 | 191,920 | - | - |
| Hypertension_C Controlled Condition | 784 | 1,102 | 35,095 | 13,009 | 71,764 | (51)% | 74,033 | 170,951 | 14,038 | - | - |
| Acceleration Market Group | 781 | 1,085 | 22,960 | - | 43,197 | (47)% | 43,499 | 108,106 | 9,184 | - | - |
| Anglophone Africa Market Group | 3 | 17 | 100 | - | 86 | 16% | 91 | 257 | 40 | - | - |
| Latin America & Asia Market Group | - | - | 12,035 | 13,009 | 28,481 | (58)% | 30,443 | 62,588 | 4,814 | - | - |
| Implant 3 | 11,379 | 15,157 | 89,402 | 87,804 | 22,810 | 292% | 24,695 | 1,097,300 | 80,462 | 201,155 | 185,378 |
| Acceleration Market Group | 577 | 1,240 | 9,942 | 12,600 | 1,038 | 858% | 1,528 | 828,488 | 8,948 | 22,370 | 15,327 |
| Anglophone Africa Market Group | 5,595 | 9,691 | 53,495 | 73,620 | 5,361 | 898% | 6,088 | 186,090 | 48,146 | 120,364 | 123,101 |
| Franco/Lusophone Africa Market Group | 3,094 | 2,241 | 11,670 | (4,896) | 4,481 | 160% | 7,323 | 35,194 | 10,503 | 26,258 | 22,006 |
| Latin America & Asia Market Group | 292 | 465 | 2,703 | 4,920 | 1,683 | 61% | 1,681 | 26,547 | 2,433 | 6,082 | 838 |
| Foundation Market Group | 1,821 | 1,520 | 11,592 | 1,560 | 10,247 | 13% | 8,075 | 23,246 | 10,433 | 26,082 | 24,105 |
| Inactive | - | - | - | - | - | -% | - | (2,265) | - | - | - |
| Implant 3 Insertion | 39,866 | 40,044 | 364,585 | 341,797 | 311,431 | 17% | 334,633 | 1,308,309 | 364,585 | 911,463 | 791,917 |
| Acceleration Market Group | 8,486 | 7,437 | 35,070 | 38,123 | 4,583 | 665% | 8,884 | 47,565 | 35,070 | 87,675 | 59,669 |
| Anglophone Africa Market Group | 20,024 | 20,116 | 204,633 | 201,554 | 230,323 | (11)% | 240,316 | 915,140 | 204,633 | 511,583 | 484,214 |
| Franco/Lusophone Africa Market Group | 4,981 | 6,256 | 60,458 | 27,532 | 21,376 | 183% | 24,546 | 107,161 | 60,458 | 151,145 | 143,203 |
| Latin America & Asia Market Group | 894 | 979 | 11,265 | 12,195 | 12,945 | (13)% | 12,809 | 45,517 | 11,265 | 28,163 | 6,452 |
| Foundation Market Group | 5,481 | 5,256 | 53,159 | 62,393 | 42,204 | 26% | 48,078 | 188,219 | 53,159 | 132,898 | 98,379 |
| Inactive | - | - | - | - | - | -% | - | 4,707 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Implant 4 | 670 | - | 18,799 | - | (3,422) | -% | (3,897) | 39,581 | 16,919 | 54,141 | 48,530 |
| Anglophone Africa Market Group | 671 | - | 18,895 | - | (3,411) | -% | (3,883) | 26,643 | 17,006 | 54,418 | 48,795 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 6,200 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | (700) | - | - | - |
| Foundation Market Group | (1) | - | (96) | - | (11) | -% | (14) | 7,438 | (86) | (276) | (265) |
| Implant 4 Insertion | 931 | 2,030 | 11,658 | - | 33,013 | (65)% | 34,188 | 56,031 | 11,658 | 37,306 | 34,582 |
| Acceleration Market Group | - | 487 | 1,462 | - | 288 | 408% | 288 | 1,750 | 1,462 | 4,678 | 5,298 |
| Anglophone Africa Market Group | 930 | 1,542 | 9,994 | - | 32,712 | (69)% | 33,884 | 45,478 | 9,994 | 31,981 | 28,676 |
| Franco/Lusophone Africa Market Group | - | - | 21 | - | 2 | 950% | 2 | 752 | 21 | 67 | 40 |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 5,342 | - | - | - |
| Foundation Market Group | 1 | - | 181 | - | 11 | 1,545% | 14 | 2,709 | 181 | 579 | 567 |
| Implant 5 | 7,566 | 12,457 | 94,085 | 50,794 | 65,603 | 43% | 73,825 | 838,809 | 84,677 | 321,771 | 294,095 |
| Acceleration Market Group | (40) | (1,125) | (11,741) | (7,600) | 1,051 | (1,217)% | 2,423 | 263,257 | (10,567) | (40,154) | (29,050) |
| Anglophone Africa Market Group | 3,160 | 5,158 | 47,876 | 26,000 | 13,367 | 258% | 17,510 | 228,671 | 43,088 | 163,736 | 159,205 |
| Franco/Lusophone Africa Market Group | 4,190 | 3,942 | 25,481 | 29,052 | 25,331 | 1% | 27,720 | 147,206 | 22,933 | 87,145 | 75,199 |
| Latin America & Asia Market Group | 261 | 2,089 | 12,034 | 3,342 | 20,720 | (42)% | 20,838 | 97,587 | 10,831 | 41,156 | 9,307 |
| Foundation Market Group | (5) | 2,393 | 20,435 | - | 5,134 | 298% | 5,334 | 90,453 | 18,392 | 69,888 | 79,435 |
| Inactive | - | - | - | - | - | -% | - | 11,635 | - | - | - |
| Implant 5 Insertion | 43,577 | 38,845 | 406,022 | 372,974 | 352,181 | 15% | 373,214 | 2,392,983 | 406,022 | 1,542,884 | 1,354,218 |
| Acceleration Market Group | 10,540 | 9,265 | 99,769 | 62,915 | 79,025 | 26% | 82,547 | 534,405 | 99,769 | 379,122 | 325,253 |
| Anglophone Africa Market Group | 14,185 | 16,833 | 166,972 | 175,505 | 146,790 | 14% | 154,215 | 939,706 | 166,972 | 634,494 | 570,821 |
| Franco/Lusophone Africa Market Group | 10,759 | 7,386 | 79,984 | 71,842 | 70,806 | 13% | 76,301 | 382,256 | 79,984 | 303,939 | 272,611 |
| Latin America & Asia Market Group | 1,306 | 1,731 | 19,864 | 12,712 | 21,314 | (7)% | 21,679 | 107,644 | 19,864 | 75,483 | 15,615 |
| Foundation Market Group | 6,787 | 3,631 | 39,433 | 50,000 | 34,246 | 15% | 38,472 | 365,374 | 39,433 | 149,845 | 169,919 |
| Inactive | - | - | - | - | - | -% | - | 63,598 | - | - | - |
| Infant Fortified Food | - | - | - | - | - | -% | - | 91,859 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 91,859 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Injectable 1 | 22,900 | 24,148 | 188,584 | 150,016 | 119,765 | 57% | 130,168 | 3,848,042 | 13,056 | 13,056 | 3,015 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 1,546,164 | - | - | - |
| Latin America & Asia Market Group | 22,900 | 24,148 | 188,584 | 150,016 | 119,765 | 57% | 130,168 | 2,301,869 | 13,056 | 13,056 | 3,015 |
| Inactive | - | - | - | - | - | -% | - | 9 | - | - | - |
| Injectable 1 Provided | 12,776 | 8,894 | 98,400 | 44,561 | 85,394 | 15% | 89,057 | 326,027 | 7,569 | 7,569 | 1,525 |
| Acceleration Market Group | 4 | 1 | 13 | - | - | -% | 37 | 50 | 1 | 1 | 1 |
| Anglophone Africa Market Group | - | 4 | 42 | 36 | 534 | (92)% | 537 | 1,809 | 3 | 3 | 2 |
| Latin America & Asia Market Group | 12,772 | 8,889 | 98,075 | 44,525 | 84,860 | 16% | 88,483 | 323,898 | 7,544 | 7,544 | 1,506 |
| Foundation Market Group | - | - | 270 | - | - | -% | - | 270 | 21 | 21 | 17 |
| Injectable 2 | (585) | 16,756 | 146,488 | 39,747 | 163,291 | (10)% | 188,630 | 23,434,444 | 21,973 | 21,973 | 6,028 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 15,907,000 | - | - | - |
| Franco/Lusophone Africa Market Group | (480) | 3,670 | 21,594 | 20,016 | 45,522 | (53)% | 54,602 | 315,938 | 3,239 | 3,239 | 1,728 |
| Latin America & Asia Market Group | (105) | 13,087 | 124,894 | 19,731 | 117,769 | 6% | 134,028 | 7,211,502 | 18,734 | 18,734 | 4,300 |
| Inactive | - | - | - | - | - | -% | - | 4 | - | - | - |
| Injectable 2 Provided | 8,934 | 6,349 | 72,006 | 211,422 | 93,357 | (23)% | 102,606 | 298,906 | 12,001 | 12,001 | 4,651 |
| Acceleration Market Group | 988 | 497 | 3,355 | - | - | -% | 5,875 | 9,230 | 559 | 559 | 471 |
| Anglophone Africa Market Group | 2,112 | 2,017 | 18,802 | 29,000 | 20,971 | (10)% | 22,699 | 53,149 | 3,134 | 3,134 | 2,156 |
| Franco/Lusophone Africa Market Group | 974 | 904 | 10,810 | 50,000 | 14,833 | (27)% | 15,848 | 49,560 | 1,802 | 1,802 | 968 |
| Latin America & Asia Market Group | 4,860 | 2,932 | 39,039 | 132,422 | 57,553 | (32)% | 58,184 | 186,966 | 6,507 | 6,507 | 1,056 |
| Inactive | - | - | - | - | - | -% | - | 1 | - | - | - |
| Injectable 3-IM | 221,634 | 370,247 | 3,418,216 | 3,760,923 | 4,629,135 | (26)% | 5,050,702 | 95,362,401 | 769,099 | 769,099 | 322,665 |
| Acceleration Market Group | 63,313 | 17,179 | 281,960 | 480,600 | 416,777 | (32)% | 493,679 | 32,323,921 | 63,441 | 63,441 | 8,586 |
| Anglophone Africa Market Group | 5,364 | 36,167 | 704,336 | 605,251 | 1,800,248 | (61)% | 1,797,775 | 14,789,334 | 158,476 | 158,476 | 79,998 |
| Franco/Lusophone Africa Market Group | 17,207 | 22,873 | 182,512 | 105,000 | 107,929 | 69% | 272,940 | 1,427,152 | 41,065 | 41,065 | 27,893 |
| Latin America & Asia Market Group | 9,945 | 23,738 | 310,645 | 560,836 | 636,481 | (51)% | 687,092 | 12,059,004 | 69,895 | 69,895 | 12,903 |
| Foundation Market Group | 130,078 | 270,028 | 1,908,814 | 1,988,500 | 1,553,071 | 23% | 1,669,487 | 31,055,350 | 429,483 | 429,483 | 192,158 |
| Social Enterprise | (4,273) | 262 | 29,949 | 20,736 | 114,629 | (74)% | 129,729 | 228,759 | 6,739 | 6,739 | 1,127 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Inactive | - | - | - | - | - | -% | - | 3,478,881 | - | - | - |
| Injectable 3-IM Provided | 223,112 | 143,010 | 1,551,424 | 1,613,683 | 1,438,060 | 8% | 1,573,348 | 4,689,815 | 387,856 | 387,856 | 191,067 |
| Acceleration Market Group | 48,235 | 50,432 | 326,330 | 204,422 | 153,707 | 112% | 175,770 | 697,384 | 81,583 | 81,583 | 36,479 |
| Anglophone Africa Market Group | 31,256 | 35,591 | 394,492 | 357,197 | 295,559 | 33% | 342,639 | 1,103,240 | 98,623 | 98,623 | 65,270 |
| Franco/Lusophone Africa Market Group | 31,487 | 21,915 | 275,274 | 255,395 | 255,976 | 8% | 272,082 | 903,508 | 68,819 | 68,819 | 53,670 |
| Latin America & Asia Market Group | 103,314 | 28,553 | 485,581 | 761,629 | 663,160 | (27)% | 705,711 | 1,643,588 | 121,395 | 121,395 | 23,671 |
| Foundation Market Group | 8,820 | 6,520 | 69,747 | 35,040 | 69,658 | -% | 77,146 | 342,095 | 17,437 | 17,437 | 11,977 |
| Injectable 3-SC | 17,099 | 35,498 | 812,181 | 857,082 | 581,651 | 40% | 617,820 | 2,482,745 | 182,741 | 182,741 | 98,494 |
| Acceleration Market Group | 2,359 | 1,890 | 28,127 | 32,150 | - | -% | - | 28,127 | 6,329 | 6,329 | 791 |
| Anglophone Africa Market Group | 7,909 | 11,428 | 89,087 | 53,892 | 49,900 | 79% | 55,900 | 144,987 | 20,045 | 20,045 | 14,857 |
| Franco/Lusophone Africa Market Group | 5,933 | 7,038 | 185,505 | 151,480 | 22,079 | 740% | 26,328 | 214,448 | 41,739 | 41,739 | 31,609 |
| Latin America & Asia Market Group | (102) | - | (102) | 1,400 | - | -% | - | (102) | (23) | (23) | (1) |
| Foundation Market Group | 1,000 | 15,143 | 509,564 | 618,160 | 509,672 | -% | 535,592 | 2,095,285 | 114,652 | 114,652 | 51,237 |
| Injectable 3-SC Provided | 13,387 | 14,171 | 96,100 | 44,763 | - | -% | 5,904 | 102,004 | 24,025 | 24,025 | 18,295 |
| Acceleration Market Group | 898 | 444 | 3,116 | - | - | -% | - | 3,116 | 779 | 779 | 657 |
| Anglophone Africa Market Group | 6,917 | 4,825 | 21,404 | - | - | -% | - | 21,404 | 5,351 | 5,351 | 3,958 |
| Franco/Lusophone Africa Market Group | 4,658 | 8,706 | 69,366 | 39,163 | - | -% | 5,729 | 75,095 | 17,342 | 17,342 | 13,459 |
| Latin America & Asia Market Group | 749 | 7 | 769 | 5,600 | - | -% | - | 769 | 192 | 192 | 5 |
| Foundation Market Group | 165 | 190 | 1,445 | - | - | -% | 175 | 1,620 | 361 | 361 | 216 |
| IPTp2 | 941 | 888 | 9,962 | 291,388 | 84,822 | (88)% | 85,804 | 354,413 | 9,962 | - | 798 |
| Acceleration Market Group | - | 450 | 4,249 | - | 3,470 | 22% | 3,893 | 18,546 | 4,249 | - | 159 |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 44,748 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 54 | - | - | - |
| Foundation Market Group | 941 | 439 | 5,713 | 291,388 | 81,352 | (93)% | 81,911 | 291,065 | 5,713 | - | 639 |
| Iron Folic Acid Tablet | - | - | - | 19,843 | - | -% | - | 48,283,018 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 48,283,018 | - | - | - |
| Foundation Market Group | - | - | - | 19,843 | - | -% | - | - | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| ITN | 1,260,695 | 1,603 | 1,265,503 | - | - | -% | - | 20,663,108 | 2,050,115 | - | 45,033 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 5,306,807 | - | - | - |
| Anglophone Africa Market Group | 1,260,695 | 1,603 | 1,265,503 | - | - | -% | - | 13,342,614 | 2,050,115 | - | 45,033 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 1,983,399 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 30,288 | - | - | - |
| IUD 10 | 18,912 | 17,306 | 174,539 | 227,046 | 220,793 | (21)% | 236,433 | 3,060,559 | 157,085 | 722,591 | 496,056 |
| Acceleration Market Group | - | (355) | (7,253) | (4,600) | (1,181) | -% | 684 | 1,443,005 | (6,528) | (30,027) | (21,099) |
| Anglophone Africa Market Group | 16,432 | 13,662 | 85,449 | 93,709 | 69,563 | 23% | 68,077 | 413,732 | 76,904 | 353,759 | 342,042 |
| Franco/Lusophone Africa Market Group | 919 | 1,356 | 10,895 | 28,463 | 27,654 | (61)% | 29,804 | 218,240 | 9,806 | 45,105 | 34,187 |
| Latin America & Asia Market Group | (2,303) | 1,920 | 74,176 | 102,474 | 86,707 | (14)% | 64,790 | 712,491 | 66,758 | 307,089 | 84,776 |
| Foundation Market Group | 3,884 | 722 | 11,257 | 7,000 | 7,406 | 52% | 7,568 | 91,260 | 10,131 | 46,604 | 56,136 |
| Social Enterprise | (20) | - | 15 | - | 30,644 | (100)% | 65,510 | 65,525 | 14 | 62 | 13 |
| Inactive | - | - | - | - | - | -% | - | 116,306 | - | - | - |
| IUD 10 Insertion | 65,415 | 37,475 | 427,551 | 539,581 | 545,567 | (22)% | 572,847 | 3,634,789 | 427,551 | 1,966,735 | 1,397,795 |
| Acceleration Market Group | 10,151 | 9,782 | 91,785 | 103,790 | 84,104 | 9% | 90,084 | 717,156 | 91,785 | 422,211 | 406,827 |
| Anglophone Africa Market Group | 9,745 | 11,905 | 102,236 | 188,592 | 215,831 | (53)% | 220,262 | 1,301,874 | 102,236 | 470,286 | 415,139 |
| Franco/Lusophone Africa Market Group | 5,226 | 6,803 | 72,696 | 76,812 | 69,321 | 5% | 73,738 | 332,499 | 72,696 | 334,402 | 303,866 |
| Latin America & Asia Market Group | 36,288 | 5,977 | 126,627 | 123,733 | 139,477 | (9)% | 148,352 | 885,781 | 126,627 | 582,484 | 142,762 |
| Foundation Market Group | 4,005 | 3,009 | 34,207 | 46,654 | 36,834 | (7)% | 40,411 | 383,230 | 34,207 | 157,352 | 129,201 |
| Inactive | - | - | - | - | - | -% | - | 14,249 | - | - | - |
| IUD 3 | - | (20) | 68 | - | 6,853 | (99)% | 6,953 | 7,021 | 61 | 153 | 33 |
| Social Enterprise | - | (20) | 68 | - | 6,853 | (99)% | 6,953 | 7,021 | 61 | 153 | 33 |
| IUD 5 | 9,293 | (7,892) | 66,350 | 208,394 | 95,584 | (31)% | 102,566 | 4,452,209 | 59,715 | 197,059 | 54,846 |
| Acceleration Market Group | 53 | (19,399) | (110,407) | 2,500 | 191 | (57,905)% | 472 | 1,026,114 | (99,366) | (327,909) | (74,392) |
| Anglophone Africa Market Group | - | (1) | (32) | - | (262) | -% | (263) | 14,523 | (29) | (95) | (96) |
| Latin America & Asia Market Group | 9,220 | 11,111 | 46,225 | 94,294 | 21,894 | 111% | 22,736 | 3,096,947 | 41,602 | 137,288 | 41,423 |
| Social Enterprise | 20 | 397 | 130,564 | 111,600 | 73,761 | 77% | 79,621 | 310,899 | 117,508 | 387,775 | 87,911 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Inactive | - | - | - | - | - | -% | - | 3,726 | - | - | - |
| IUD 5 Insertion | 30,202 | 33,598 | 287,445 | 131,309 | 110,515 | 160% | 115,881 | 1,443,731 | 287,445 | 948,568 | 258,790 |
| Acceleration Market Group | 17,633 | 19,580 | 135,792 | 65,000 | 46,402 | 193% | 51,661 | 316,642 | 135,792 | 448,114 | 101,862 |
| Anglophone Africa Market Group | - | 1 | 162 | - | 290 | (44)% | 345 | 28,984 | 162 | 535 | 343 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 45 | - | - | - |
| Latin America & Asia Market Group | 12,535 | 13,995 | 151,253 | 65,998 | 63,573 | 138% | 63,576 | 1,097,523 | 151,253 | 499,135 | 155,800 |
| Foundation Market Group | 34 | 23 | 238 | 311 | 250 | (5)% | 299 | 537 | 238 | 785 | 785 |
| IUS 3 | (91) | (96) | (350) | 2,500 | 99 | (454)% | 98 | (252) | (315) | (788) | (716) |
| Anglophone Africa Market Group | (95) | (73) | (314) | - | - | -% | - | (314) | (283) | (707) | (670) |
| Foundation Market Group | 4 | (23) | (36) | 2,500 | 99 | (136)% | 98 | 62 | (32) | (81) | (46) |
| IUS 3 Insertion | 220 | 203 | 1,357 | - | 116 | 1,070% | 135 | 1,492 | 1,357 | 3,393 | 2,230 |
| Anglophone Africa Market Group | 95 | 73 | 314 | - | - | -% | - | 314 | 314 | 785 | 744 |
| Foundation Market Group | 125 | 130 | 1,043 | - | 116 | 799% | 135 | 1,178 | 1,043 | 2,608 | 1,486 |
| IUS 5 | 1 | (51) | 811 | 5,128 | 95 | 754% | 126 | 1,891 | 730 | 2,409 | 1,546 |
| Anglophone Africa Market Group | (10) | (6) | 403 | (56) | 95 | 324% | 126 | 1,483 | 363 | 1,197 | 1,345 |
| Foundation Market Group | 10 | 7 | (11) | - | - | -% | - | (11) | (10) | (33) | (81) |
| Social Enterprise | 1 | (51) | 419 | 5,184 | - | -% | - | 419 | 377 | 1,244 | 282 |
| IUS 5 Insertion | 107 | 94 | 1,658 | 756 | 1,450 | 14% | 1,516 | 4,167 | 1,658 | 5,471 | 5,692 |
| Acceleration Market Group | 96 | 71 | 1,027 | - | 734 | 40% | 775 | 2,428 | 1,027 | 3,389 | 3,897 |
| Anglophone Africa Market Group | 11 | 22 | 542 | 756 | 714 | (24)% | 739 | 1,647 | 542 | 1,789 | 1,516 |
| Latin America & Asia Market Group | - | 1 | 7 | - | 2 | 250% | 2 | 10 | 7 | 23 | 4 |
| Foundation Market Group | - | - | 82 | - | - | -% | - | 82 | 82 | 271 | 276 |
| LifeStraw | - | - | - | - | - | -% | - | 15,965 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 15,320 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 645 | - | - | - |
| LLIN | 2,435,121 | 547,419 | 7,705,732 | 18,656,324 | 25,802,873 | (70)% | 31,104,885 | 366,341,131 | 12,483,286 | - | 1,958,637 |
| Acceleration Market Group | 1,119 | 97,416 | 1,082,748 | 2,049,898 | 1,990,597 | (46)% | 2,332,163 | 65,034,184 | 1,754,052 | - | 41,116 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Anglophone Africa Market Group | 349 | 970 | 213,150 | 700,054 | 4,475,373 | (95)% | 4,545,198 | 56,897,552 | 345,303 | - | 11,557 |
| Franco/Lusophone Africa Market Group | 62,866 | 69,984 | 1,071,361 | 3,964,115 | 4,308,977 | (75)% | 4,602,963 | 53,547,862 | 1,735,605 | - | 108,740 |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 5,197,868 | - | - | - |
| Foundation Market Group | 2,370,787 | 379,048 | 5,338,473 | 11,942,257 | 15,027,926 | (64)% | 19,624,561 | 181,602,546 | 8,648,326 | - | 1,797,224 |
| Inactive | - | - | - | - | - | -% | - | 4,061,119 | - | - | - |
| LLIN (Hammock net) | - | - | 781 | 1,350 | 1,259 | (38)% | 1,259 | 2,085 | 703 | - | - |
| Latin America & Asia Market Group | - | - | 781 | 1,350 | 1,259 | (38)% | 1,259 | 2,085 | 703 | - | - |
| Lubricant | 1,097,825 | 1,384,395 | 11,010,725 | 5,295,911 | 5,143,672 | 114% | 5,621,900 | 88,792,599 | - | - | - |
| Acceleration Market Group | 293,000 | 280,426 | 2,047,836 | 70,000 | 44,649 | 4,487% | 51,861 | 15,600,125 | - | - | - |
| Anglophone Africa Market Group | 660,920 | 244,762 | 2,681,257 | 1,900,761 | 2,408,656 | 11% | 2,574,286 | 11,424,439 | - | - | - |
| Franco/Lusophone Africa Market Group | - | 2,667 | 8,855 | - | 35,046 | (75)% | 45,024 | 1,530,874 | - | - | - |
| Latin America & Asia Market Group | 120,195 | 487,924 | 2,767,315 | 731,208 | 1,347,018 | 105% | 1,423,274 | 39,465,805 | - | - | - |
| Foundation Market Group | 23,710 | 368,197 | 3,479,494 | 2,500,000 | 1,008,813 | 245% | 1,223,813 | 5,725,522 | - | - | - |
| Social Enterprise | - | 420 | 25,968 | 93,942 | 33,792 | (23)% | 37,944 | 612,224 | - | - | - |
| Inactive | - | - | - | - | 265,698 | (100)% | 265,698 | 14,433,610 | - | - | - |
| Malaria PPT (ACT) | 669,269 | 373,726 | 3,421,941 | 6,562,602 | 7,253,443 | (53)% | 7,543,851 | 138,554,533 | 3,079,747 | - | 951,828 |
| Acceleration Market Group | 244 | 8,884 | 173,273 | 182,270 | 255,664 | (32)% | 256,333 | 63,891,559 | 155,946 | - | 24,308 |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 10,387,257 | - | - | - |
| Franco/Lusophone Africa Market Group | 333 | 49,582 | 408,482 | 326,390 | 288,998 | 41% | 297,014 | 2,111,290 | 367,634 | - | 113,465 |
| Latin America & Asia Market Group | (72) | (35) | (398) | - | 287 | (239)% | 147 | 2,839,332 | (358) | - | (50) |
| Foundation Market Group | 668,764 | 315,294 | 2,840,584 | 6,053,942 | 6,708,494 | (58)% | 6,990,357 | 59,325,095 | 2,556,526 | - | 814,104 |
| Malaria PPT (Non-ACT) | 20,113 | 35,363 | 216,463 | 83,621 | (1,619) | -% | (2,041) | 14,110,751 | 194,817 | - | 23,551 |
| Acceleration Market Group | 114 | 1,242 | 2,730 | 3,621 | (1,521) | -% | (1,900) | 5,116,244 | 2,457 | - | 383 |
| Latin America & Asia Market Group | (1) | (12) | (67) | - | (98) | -% | (141) | (208) | (60) | - | (10) |
| Foundation Market Group | 20,000 | 34,133 | 213,800 | 80,000 | - | -% | - | 8,994,715 | 192,420 | - | 23,177 |
| Malaria RDK | 1,542,260 | 195,108 | 2,865,305 | 4,357,458 | 12,009,956 | (76)% | 12,180,985 | 62,313,268 | 2,578,775 | - | - |
| Acceleration Market Group | - | - | - | 432,337 | 705,945 | (100)% | 743,410 | 12,836,467 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 263,260 | - | - | - |
| Franco/Lusophone Africa Market Group | 105,275 | - | 147,125 | 250,000 | 138,510 | 6% | 177,919 | 1,244,684 | 132,413 | - | - |
| Latin America & Asia Market Group | 3,810 | 3,183 | 28,380 | 25,000 | 305,159 | (91)% | 305,189 | 7,083,276 | 25,542 | - | - |
| Foundation Market Group | 1,433,175 | 191,925 | 2,689,800 | 3,650,121 | 10,860,342 | (75)% | 10,954,467 | 40,885,581 | 2,420,820 | - | - |
| Male Circumcision (HIV-Positive) | - | - | - | - | - | -% | - | 10,836 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 6,118 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 4,718 | - | - | - |
| Male Vasodilator | 20,000 | 48,133 | 1,686,180 | 3,029,400 | - | -% | - | 1,686,180 | 12,646 | - | - |
| Social Enterprise | 20,000 | 48,133 | 1,686,180 | 3,029,400 | - | -% | - | 1,686,180 | 12,646 | - | - |
| Manual Vacuum Aspiration for PAC | 6,794 | 11,889 | 113,192 | 20,937 | 63,171 | 79% | 70,499 | 272,418 | 113,192 | - | 19,466 |
| Acceleration Market Group | 745 | 739 | 7,394 | 5,220 | 18,592 | (60)% | 19,176 | 31,866 | 7,394 | - | 5,921 |
| Anglophone Africa Market Group | 526 | 664 | 6,116 | 720 | 7,047 | (13)% | 7,531 | 16,637 | 6,116 | - | 913 |
| Franco/Lusophone Africa Market Group | 1,135 | 1,361 | 12,007 | 1,918 | 1,997 | 501% | 2,579 | 16,390 | 12,007 | - | 5,497 |
| Latin America & Asia Market Group | 3,635 | 8,536 | 81,042 | 7,295 | 29,956 | 171% | 34,966 | 187,006 | 81,042 | - | 3,935 |
| Foundation Market Group | 753 | 589 | 6,633 | 5,784 | 5,579 | 19% | 6,247 | 20,519 | 6,633 | - | 3,201 |
| Manual Vacuum Aspiration for SA | 282 | 267 | 2,541 | 743 | 1,078 | 136% | 1,224 | 3,765 | 2,541 | - | 819 |
| Acceleration Market Group | - | - | - | - | - | -% | - | - | - | - | - |
| Anglophone Africa Market Group | 80 | 72 | 770 | - | 403 | 91% | 411 | 1,181 | 770 | - | 282 |
| Franco/Lusophone Africa Market Group | 141 | 135 | 1,096 | 507 | 424 | 158% | 562 | 1,658 | 1,096 | - | 437 |
| Latin America & Asia Market Group | 61 | 59 | 675 | 236 | 251 | 169% | 251 | 926 | 675 | - | 100 |
| Foundation Market Group | - | - | - | - | - | -% | - | - | - | - | - |
| Medical Abortion | 57,283 | 54,750 | 884,748 | 2,153,877 | 1,380,499 | (36)% | 1,610,639 | 6,312,288 | 796,273 | - | 86,019 |
| Acceleration Market Group | 998 | 334 | 2,000 | 9,000 | - | -% | - | 1,499,044 | 1,800 | - | 1,689 |
| Anglophone Africa Market Group | 503 | 1,517 | 10,288 | 9,331 | 13,919 | (26)% | 13,999 | 35,298 | 9,259 | - | 3,243 |
| Franco/Lusophone Africa Market Group | 420 | 97 | 2,227 | 19,550 | 22 | 10,023% | 172 | 2,234 | 2,004 | - | 779 |
| Latin America & Asia Market Group | 30,298 | 20,612 | 334,629 | 459,996 | 418,883 | (20)% | 457,334 | 2,586,038 | 301,166 | - | 30,527 |
| Social Enterprise | 25,064 | 32,190 | 535,604 | 1,656,000 | 947,675 | (43)% | 1,139,134 | 2,189,674 | 482,044 | - | 49,781 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Medical Abortion (Misoprostol) Provided | 83 | 106 | 1,550 | 1,051 | 744 | 108% | 840 | 2,390 | 1,550 | - | 512 |
| Anglophone Africa Market Group | 65 | 91 | 967 | - | 505 | 91% | 531 | 1,498 | 967 | - | 302 |
| Franco/Lusophone Africa Market Group | 18 | 16 | 583 | 1,051 | 239 | 144% | 309 | 892 | 583 | - | 210 |
| Medical Abortion Provided | 2,028 | 1,045 | 12,555 | 4,788 | 12,152 | 3% | 12,902 | 34,238 | 12,555 | - | 1,447 |
| Anglophone Africa Market Group | 72 | 72 | 750 | - | 744 | 1% | 747 | 2,118 | 750 | - | 263 |
| Franco/Lusophone Africa Market Group | 25 | 17 | 133 | - | 51 | 161% | 51 | 374 | 133 | - | 50 |
| Latin America & Asia Market Group | 1,931 | 957 | 11,672 | 4,788 | 11,357 | 3% | 12,104 | 31,746 | 11,672 | - | 1,134 |
| Micronutrient Powder | 90,290 | 3,330 | 315,411 | 35,000 | 8,625,662 | (96)% | 8,746,552 | 48,858,443 | 778 | - | - |
| Acceleration Market Group | - | - | - | - | 1,880,940 | (100)% | 2,000,000 | 9,499,690 | - | - | - |
| Franco/Lusophone Africa Market Group | 90,290 | 3,330 | 315,411 | 35,000 | 946,742 | (67)% | 948,572 | 8,286,023 | 778 | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 9,502,912 | - | - | - |
| Foundation Market Group | - | - | - | - | 5,797,980 | (100)% | 5,797,980 | 20,562,598 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 1,007,220 | - | - | - |
| Misoprostol for PAC Provided | 11,153 | 12,615 | 112,204 | 26,807 | 80,418 | 40% | 86,914 | 217,942 | 112,204 | - | 24,715 |
| Acceleration Market Group | 566 | 672 | 6,949 | 5,220 | 14,322 | (51)% | 14,855 | 21,804 | 6,949 | - | 6,590 |
| Anglophone Africa Market Group | 201 | 257 | 2,953 | - | 3,401 | (13)% | 3,631 | 7,789 | 2,953 | - | 603 |
| Franco/Lusophone Africa Market Group | 856 | 1,500 | 9,591 | 2,222 | 1,780 | 439% | 2,304 | 12,971 | 9,591 | - | 5,321 |
| Latin America & Asia Market Group | 7,919 | 8,731 | 77,803 | 3,935 | 49,293 | 58% | 53,383 | 134,910 | 77,803 | - | 4,610 |
| Foundation Market Group | 1,611 | 1,454 | 14,908 | 15,430 | 11,622 | 28% | 12,741 | 40,468 | 14,908 | - | 7,592 |
| Misoprostol for PPH | 500 | 2,667 | 15,500 | 4,500 | 27,300 | (43)% | 30,800 | 6,332,438 | 4,650 | - | 101 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 395,225 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 5,442,839 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 100,000 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 184,166 | - | - | - |
| Foundation Market Group | 500 | 2,667 | 15,500 | 4,500 | 27,300 | (43)% | 30,800 | 210,208 | 4,650 | - | 101 |
| Misoprostol for Safe Abortion | 366,044 | 456,049 | 5,283,325 | 5,447,828 | 5,690,515 | (7)% | 6,085,267 | 22,712,779 | 277,375 | - | 110,336 |
| Acceleration Market Group | 13,636 | 161,979 | 1,747,774 | 2,339,690 | 2,145,962 | (19)% | 2,321,200 | 6,053,824 | 91,758 | - | 77,046 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|------------------|------------------|
| Anglophone Africa Market Group | 93,436 | 158,229 | 1,394,426 | 1,993,550 | 1,601,272 | (13)% | 1,655,420 | 10,434,402 | 73,207 | - | 15,215 |
| Franco/Lusophone Africa Market Group | 150,530 | 41,973 | 535,403 | 424,360 | 669,359 | (20)% | 745,045 | 2,506,297 | 28,109 | - | 10,398 |
| Latin America & Asia Market Group | 106,450 | 78,547 | 1,514,126 | 320,448 | 1,238,739 | 22% | 1,282,555 | 3,562,853 | 79,492 | - | 6,050 |
| Foundation Market Group | 1,992 | 15,321 | 91,596 | 119,780 | 35,183 | 160% | 81,047 | 155,403 | 4,809 | - | 1,627 |
| Social Enterprise | - | - | - | 250,000 | - | -% | - | - | - | - | - |
| Multivitamin | 121,190 | 116,160 | 1,309,670 | 2,256,202 | 2,327,350 | (44)% | 2,424,220 | 99,664,589 | 6,548 | - | 239 |
| Acceleration Market Group | - | - | - | - | 450,010 | (100)% | 450,010 | 3,531,010 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 12,270,645 | - | - | - |
| Latin America & Asia Market Group | 1,400 | 6,340 | 20,420 | - | - | -% | - | 11,504,725 | 102 | - | 19 |
| Foundation Market Group | - | - | - | 24,202 | - | -% | - | - | - | - | - |
| Social Enterprise | 119,790 | 109,820 | 1,289,250 | 2,232,000 | 1,877,340 | (31)% | 1,974,210 | 38,298,810 | 6,446 | - | 220 |
| Inactive | - | - | - | - | - | -% | - | 34,059,399 | - | - | - |
| Naloxone | - | 167 | 1,995 | 3,089 | 2,500 | (20)% | 2,570 | 70,246 | 1,796 | - | 2,722 |
| Latin America & Asia Market Group | - | 167 | 1,995 | 3,089 | 2,500 | (20)% | 2,570 | 34,452 | 1,796 | - | 2,722 |
| Inactive | - | - | - | - | - | -% | - | 35,794 | - | - | - |
| Needle & Syringe | 43,200 | 79,100 | 1,077,000 | 1,355,860 | 5,062,315 | (79)% | 5,815,215 | 33,442,758 | 3,757 | - | 11,984 |
| Acceleration Market Group | - | 567 | 10,100 | - | - | -% | - | 2,511,988 | 35 | - | 83 |
| Latin America & Asia Market Group | 43,200 | 78,533 | 1,066,900 | 1,355,860 | 5,062,315 | (79)% | 5,815,215 | 26,847,258 | 3,722 | - | 11,901 |
| Inactive | - | - | - | - | - | -% | - | 4,083,512 | - | - | - |
| Neonates Receiving Essential Care | - | - | - | - | - | -% | - | 174 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 174 | - | - | - |
| NVP | - | - | - | - | - | -% | - | 11,442 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 235 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 11,057 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 150 | - | - | - |
| OCs | 1,869,660 | 2,094,467 | 20,872,868 | 29,124,425 | 23,590,906 | (12)% | 26,777,114 | 656,529,405 | 1,252,372 | 1,252,372 | 382,475 |
| Acceleration Market Group | 883,713 | 897,708 | 7,879,862 | 10,222,400 | 8,158,404 | (3)% | 9,492,397 | 320,393,138 | 472,792 | 472,792 | 138,478 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Anglophone Africa Market Group | 33,859 | 204,580 | 1,530,539 | 2,258,175 | 2,381,154 | (36)% | 2,600,283 | 81,485,592 | 91,832 | 91,832 | 43,937 |
| Franco/Lusophone Africa Market Group | (10,780) | 206,192 | 1,345,956 | 851,499 | 1,233,260 | 9% | 1,347,096 | 26,166,849 | 80,757 | 80,757 | 53,007 |
| Latin America & Asia Market Group | 678,156 | 565,810 | 6,830,029 | 6,917,751 | 5,921,900 | 15% | 6,484,744 | 106,282,700 | 409,802 | 409,802 | 77,236 |
| Foundation Market Group | 229,763 | 137,458 | 2,150,244 | 1,777,420 | 1,992,855 | 8% | 2,094,239 | 72,888,894 | 129,015 | 129,015 | 60,678 |
| Social Enterprise | 54,949 | 82,720 | 1,136,238 | 7,097,180 | 3,903,333 | (71)% | 4,758,355 | 17,219,638 | 68,174 | 68,174 | 9,139 |
| Inactive | - | - | - | - | - | -% | - | 32,092,594 | - | - | - |
| OCs Provided | 524,346 | 264,977 | 2,811,226 | 2,831,217 | 1,568,599 | 79% | 1,778,915 | 7,180,540 | 187,415 | 187,415 | 76,806 |
| Acceleration Market Group | 91,519 | 111,242 | 606,019 | 181,469 | 134,752 | 350% | 151,894 | 851,128 | 40,401 | 40,401 | 8,887 |
| Anglophone Africa Market Group | 37,372 | 48,543 | 505,307 | 357,372 | 288,291 | 75% | 321,499 | 1,890,053 | 33,687 | 33,687 | 20,700 |
| Franco/Lusophone Africa Market Group | 41,213 | 61,437 | 481,204 | 683,520 | 339,725 | 42% | 367,827 | 1,439,686 | 32,080 | 32,080 | 27,463 |
| Latin America & Asia Market Group | 352,689 | 42,758 | 1,207,443 | 1,601,361 | 790,594 | 53% | 921,067 | 2,839,502 | 80,496 | 80,496 | 19,240 |
| Foundation Market Group | 1,553 | 996 | 11,253 | 7,495 | 15,237 | (26)% | 16,628 | 160,167 | 750 | 750 | 517 |
| Inactive | - | - | - | - | - | -% | - | 4 | - | - | - |
| ORS | 122,384 | 193,371 | 3,017,559 | 2,220,000 | 2,828,102 | 7% | 3,408,447 | 443,453,118 | 1,357,902 | - | 59,912 |
| Acceleration Market Group | 97,044 | 131,515 | 809,024 | 600,000 | 459,503 | 76% | 514,198 | 326,772,625 | 364,061 | - | 21,214 |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 21,149,275 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 32,783,783 | - | - | - |
| Latin America & Asia Market Group | 22,800 | 39,442 | 635,337 | - | - | -% | 500,000 | 4,912,318 | 285,902 | - | 6,009 |
| Foundation Market Group | 3,240 | 33,944 | 220,122 | 300,000 | 1,249,743 | (82)% | 1,249,743 | 16,247,803 | 99,055 | - | 5,540 |
| Social Enterprise | (700) | (11,530) | 1,353,076 | 1,320,000 | 1,118,856 | 21% | 1,144,506 | 2,824,010 | 608,884 | - | 27,150 |
| Inactive | - | - | - | - | - | -% | - | 38,763,304 | - | - | - |
| ORS Provided | 3,568 | 1,323 | 27,600 | 13,914 | 12,967 | 113% | 15,726 | 108,562 | 27,600 | - | 1,365 |
| Acceleration Market Group | - | 59 | 2,043 | - | 2,025 | 1% | 2,217 | 9,430 | 2,043 | - | 33 |
| Foundation Market Group | 3,568 | 1,264 | 25,557 | 13,914 | 10,942 | 134% | 13,509 | 99,132 | 25,557 | - | 1,332 |
| Pneumonia PPT | 8,550 | 31,432 | 139,915 | 124,910 | 768,718 | (82)% | 768,635 | 7,264,573 | 125,924 | - | 51,346 |
| Acceleration Market Group | - | - | - | 28,910 | - | -% | - | 1,414,256 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 987,367 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Franco/Lusophone Africa Market Group | - | - | - | - | 30,399 | (100)% | 30,316 | 474,924 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 119,990 | - | - | - |
| Foundation Market Group | 8,550 | 31,432 | 139,915 | 96,000 | 738,319 | (81)% | 738,319 | 4,268,036 | 125,924 | - | 51,346 |
| Pneumonia PPT Provided | 2,520 | 1,909 | 31,025 | - | 29,104 | 7% | 31,754 | 186,697 | 31,025 | - | 24,167 |
| Acceleration Market Group | - | 1,245 | 17,319 | - | 19,159 | (10)% | 20,179 | 75,392 | 17,319 | - | 8,331 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 2,500 | - | - | - |
| Foundation Market Group | 2,520 | 664 | 13,706 | - | 9,945 | 38% | 11,575 | 108,805 | 13,706 | - | 15,836 |
| Positive RDTs | 4,156 | 20,414 | 142,109 | 11,333 | 49,075 | 190% | 52,281 | 2,448,449 | 142,109 | - | - |
| Acceleration Market Group | 224 | 495 | 3,960 | - | 8,667 | (54)% | 9,712 | 43,197 | 3,960 | - | - |
| Anglophone Africa Market Group | - | 17,029 | 112,752 | - | - | -% | - | 112,752 | 112,752 | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | 13,716 | (100)% | 13,716 | 40,358 | - | - | - |
| Latin America & Asia Market Group | 144 | 125 | 1,844 | 3,333 | 11,486 | (84)% | 11,799 | 40,417 | 1,844 | - | - |
| Foundation Market Group | 3,788 | 2,764 | 23,553 | 8,000 | 15,206 | 55% | 17,054 | 2,211,725 | 23,553 | - | - |
| Positive RDTs Given First Line Treatment | 325 | 16,485 | 109,642 | 2,474 | 31,398 | 249% | 32,687 | 2,254,697 | 109,642 | - | - |
| Acceleration Market Group | 224 | 492 | 3,825 | - | 7,926 | (52)% | 8,937 | 38,427 | 3,825 | - | - |
| Anglophone Africa Market Group | - | 15,902 | 104,366 | - | - | -% | - | 104,366 | 104,366 | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | 13,647 | (100)% | 13,647 | 39,926 | - | - | - |
| Latin America & Asia Market Group | 101 | 92 | 1,451 | 2,474 | 9,825 | (85)% | 10,103 | 36,999 | 1,451 | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 2,034,979 | - | - | - |
| Pregnancy Test | 19,618 | 26,762 | 292,510 | 1,188,000 | 429,045 | (32)% | 575,675 | 1,798,634 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 575,317 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 222,334 | - | - | - |
| Social Enterprise | 19,618 | 26,762 | 292,510 | 1,188,000 | 429,045 | (32)% | 575,675 | 868,185 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 132,798 | - | - | - |
| PrEP | 4,046 | 4,208 | 43,076 | 35,111 | 31,138 | 38% | 34,437 | 80,629 | 3,590 | - | 1,371 |
| Acceleration Market Group | 77 | 69 | 478 | - | - | -% | - | 478 | 40 | - | 20 |
| Anglophone Africa Market Group | 3,969 | 4,139 | 42,598 | 35,111 | 31,138 | 37% | 34,437 | 80,151 | 3,550 | - | 1,352 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| PUR | 3,196,560 | 5,963,721 | 59,714,428 | 47,273,857 | 59,569,874 | -% | 62,440,224 | 691,243,755 | 490,804 | - | 1,452 |
| Acceleration Market Group | 2,931,360 | 2,024,083 | 29,796,020 | 19,000,000 | 26,656,029 | 12% | 28,508,349 | 226,350,117 | 244,899 | - | 604 |
| Anglophone Africa Market Group | 265,200 | 3,939,638 | 29,918,408 | 28,273,857 | 32,913,845 | (9)% | 33,931,875 | 355,800,950 | 245,905 | - | 847 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 239,541 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 62,675,382 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 45,927,973 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 249,792 | - | - | - |
| QAACTs Provided after Confirmatory Diagnosis | 472 | 337 | 27,565 | 99,182 | 115,572 | (76)% | 127,263 | 2,234,058 | 27,565 | - | 4,671 |
| Acceleration Market Group | 68 | 144 | 24,782 | 95,000 | 90,811 | (73)% | 101,767 | 145,327 | 24,782 | - | 4,097 |
| Franco/Lusophone Africa Market Group | - | - | - | - | 13,647 | (100)% | 13,647 | 13,647 | - | - | - |
| Latin America & Asia Market Group | 104 | 80 | 1,122 | 2,254 | 9,743 | (88)% | 9,977 | 36,572 | 1,122 | - | 201 |
| Foundation Market Group | 300 | 113 | 1,661 | 1,928 | 1,371 | 21% | 1,872 | 2,038,512 | 1,661 | - | 373 |
| Referral to Advanced Cervical Cancer Treatment | 3 | 6 | 62 | 136 | 17 | 265% | 17 | 479 | 62 | - | - |
| Anglophone Africa Market Group | 3 | 6 | 62 | 136 | 17 | 265% | 17 | 479 | 62 | - | - |
| Referral to CD4/Clinical Staging | - | - | - | - | - | -% | - | 34,138 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 3,364 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 30,613 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 18 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 143 | - | - | - |
| Referral to Clinical Staging | - | - | - | - | - | -% | - | 18,909 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 3,364 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 15,545 | - | - | - |
| Referral to Diabetes Management (gestational) | - | - | - | - | 67 | (100)% | 67 | 67 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 67 | (100)% | 67 | 67 | - | - | - |
| Referral to Diabetes Management (non-gestational) | - | - | - | - | - | -% | - | 1 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 1 | - | - | - |
| Referral to Early Infant Male Circumcision | - | - | - | - | - | -% | - | 94 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 94 | - | - | - |
| Referral to Emergency Contraception | - | 1 | 2 | 1 | 32 | (94)% | 32 | 252 | 2 | - | - |
| Anglophone Africa Market Group | - | - | - | 1 | 1 | (100)% | 1 | 143 | - | - | - |
| Latin America & Asia Market Group | - | 1 | 2 | - | 31 | (94)% | 31 | 109 | 2 | - | - |
| Referral to HIV Testing Services | 1,889 | 535 | 55,050 | 91,736 | 1,001 | 5,400% | 24,729 | 365,510 | 55,050 | - | 1,802 |
| Acceleration Market Group | - | - | 21,265 | - | - | -% | - | 47,140 | 21,265 | - | 754 |
| Anglophone Africa Market Group | 1,889 | 534 | 33,768 | 82,130 | 986 | 3,325% | 24,714 | 232,029 | 33,768 | - | 1,049 |
| Franco/Lusophone Africa Market Group | - | - | - | 9,600 | - | -% | - | 17,256 | - | - | - |
| Latin America & Asia Market Group | - | 1 | 17 | 6 | 10 | 70% | 10 | 35,568 | 17 | - | - |
| Foundation Market Group | - | - | - | - | 5 | (100)% | 5 | 33,366 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 151 | - | - | - |
| Referral to Hypertension Management | 29 | 33 | 323 | - | 530 | (39)% | 567 | 1,453 | 323 | - | - |
| Anglophone Africa Market Group | 29 | 33 | 323 | - | 530 | (39)% | 567 | 1,453 | 323 | - | - |
| Referral to Implant 3 Insertion | 203 | 176 | 2,238 | 1,915 | 2 | 111,800% | 1,457 | 19,809 | 2,238 | 2,798 | 638 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 996 | - | - | - |
| Anglophone Africa Market Group | - | - | 293 | 1,915 | 2 | 14,550% | 2 | 8,248 | 293 | 366 | 309 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 1 | - | - | - |
| Latin America & Asia Market Group | 203 | 176 | 1,945 | - | - | -% | 1,455 | 5,712 | 1,945 | 2,431 | 329 |
| Foundation Market Group | - | - | - | - | - | -% | - | 1,674 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 3,178 | - | - | - |
| Referral to Implant 5 Insertion | 2 | 59 | 506 | 187 | 199 | 154% | 223 | 20,235 | 506 | 961 | 227 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 584 | - | - | - |
| Anglophone Africa Market Group | - | - | 11 | 187 | 2 | 450% | 2 | 3,607 | 11 | 21 | 17 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 4,681 | - | - | - |
| Latin America & Asia Market Group | 2 | 59 | 495 | - | 197 | 151% | 221 | 1,757 | 495 | 940 | 210 |
| Foundation Market Group | - | - | - | - | - | -% | - | 9,606 | - | - | - |
| Referral to Implant Insertion (duration unknown) | 7 | 2 | 20 | - | - | -% | - | 109 | 20 | 25 | 3 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 89 | - | - | - |
| Latin America & Asia Market Group | 7 | 2 | 20 | - | - | -% | - | 20 | 20 | 25 | 3 |
| Referral to Injectable (duration unknown) | - | - | - | - | - | -% | - | 773 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 110 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 663 | - | - | - |
| Referral to Injectable 1 | 13 | 1 | 25 | - | 45 | (44)% | 47 | 436 | 25 | 1 | - |
| Anglophone Africa Market Group | - | - | - | - | 36 | (100)% | 36 | 400 | - | - | - |
| Latin America & Asia Market Group | 13 | 1 | 25 | - | 9 | 178% | 11 | 36 | 25 | 1 | - |
| Referral to Injectable 2 | - | - | - | - | - | -% | - | 56 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 56 | - | - | - |
| Referral to Injectable 3 | - | 91 | 1,777 | 6,372 | 434 | 309% | 471 | 25,250 | 1,777 | 222 | 88 |
| Anglophone Africa Market Group | - | - | 887 | 6,372 | 75 | 1,083% | 75 | 7,834 | 887 | 111 | 69 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 8,596 | - | - | - |
| Latin America & Asia Market Group | - | 91 | 890 | - | 359 | 148% | 396 | 8,820 | 890 | 111 | 19 |
| Referral to IUD 10 Insertion | 209 | 223 | 2,100 | 48 | 665 | 216% | 734 | 135,363 | 2,100 | 4,830 | 851 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 8,256 | - | - | - |
| Anglophone Africa Market Group | - | - | 4 | 48 | 5 | (20)% | 5 | 24,176 | 4 | 9 | 7 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 6,239 | - | - | - |
| Latin America & Asia Market Group | 209 | 223 | 2,096 | - | 660 | 218% | 729 | 75,286 | 2,096 | 4,821 | 844 |
| Foundation Market Group | - | - | - | - | - | -% | - | 20,969 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 437 | - | - | - |
| Referral to IUD 5 Insertion | - | - | - | - | - | -% | - | 498 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 440 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 58 | - | - | - |
| Referral to IUD Insertion (duration unknown) | 4 | 2 | 19 | - | - | -% | - | 35 | 19 | 31 | 4 |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 16 | - | - | - |
| Latin America & Asia Market Group | 4 | 2 | 19 | - | - | -% | - | 19 | 19 | 31 | 4 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Referral to IUS 3 Insertion | - | - | - | - | - | -% | - | 26 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 26 | - | - | - |
| Referral to Linkage to HIV Care | 13,110 | 14,461 | 111,662 | 45,296 | 16,642 | 571% | 26,986 | 164,727 | 111,662 | - | 88,727 |
| Acceleration Market Group | - | 799 | 5,843 | 12,150 | - | -% | - | 5,843 | 5,843 | - | 2,767 |
| Anglophone Africa Market Group | 12,819 | 13,359 | 102,771 | 29,940 | 14,080 | 630% | 24,186 | 149,415 | 102,771 | - | 83,419 |
| Franco/Lusophone Africa Market Group | - | - | - | 1,279 | - | -% | - | 281 | - | - | - |
| Latin America & Asia Market Group | 291 | 303 | 3,048 | 1,627 | 2,562 | 19% | 2,800 | 9,180 | 3,048 | - | 2,541 |
| Foundation Market Group | - | - | - | 300 | - | -% | - | - | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 8 | - | - | - |
| Referral to Manual Vacuum Aspiration - PAC | - | - | - | - | - | -% | - | 46 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 46 | - | - | - |
| Referral to Medication Abortion | - | - | - | - | - | -% | - | 24 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 24 | - | - | - |
| Referral to OCs | 1 | 78 | 987 | 665 | 419 | 136% | 484 | 11,087 | 987 | 33 | 7 |
| Anglophone Africa Market Group | - | - | 84 | 665 | 93 | (10)% | 93 | 3,389 | 84 | 3 | 2 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 1,392 | - | - | - |
| Latin America & Asia Market Group | 1 | 78 | 903 | - | 326 | 177% | 391 | 6,306 | 903 | 30 | 6 |
| Referral to Opioid Treatment | 3 | 5 | 76 | 37 | 124 | (39)% | 135 | 548 | 76 | - | - |
| Latin America & Asia Market Group | 3 | 5 | 76 | 37 | 124 | (39)% | 135 | 548 | 76 | - | - |
| Referral to PAC Service (unknown) | - | - | - | - | - | -% | - | 488 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 488 | - | - | - |
| Referral to Pre-Exposure Prophylaxis (PrEP) | - | - | 3 | - | 20 | (85)% | 20 | 253 | 3 | - | - |
| Anglophone Africa Market Group | - | - | 3 | - | 20 | (85)% | 20 | 253 | 3 | - | - |
| Referral to STI Diagnosis (lab confirmed) | - | - | - | - | - | -% | - | 332 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 332 | - | - | - |
| Referral to STI Screening (syndromic) | - | - | - | 112,000 | 7 | (100)% | 7 | 14,419 | - | - | - |
| Anglophone Africa Market Group | - | - | - | 112,000 | 7 | (100)% | 7 | 14,419 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Referral to STI Treatment (unknown) | - | - | - | - | 119 | (100)% | 119 | 9,012 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 1,690 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 119 | (100)% | 119 | 4,864 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 128 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 2,330 | - | - | - |
| Referral to TB Diagnosis | - | - | - | - | 11 | (100)% | 11 | 30,963 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 3,898 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 11 | (100)% | 11 | 16,052 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 11,013 | - | - | - |
| Referral to TB DOTS (completion confirmed) | 69 | 76 | 1,032 | 2,459 | 1,225 | (16)% | 1,364 | 4,558 | 1,032 | - | 2,977 |
| Acceleration Market Group | 42 | 70 | 951 | 2,349 | 1,075 | (12)% | 1,214 | 3,797 | 951 | - | 2,949 |
| Anglophone Africa Market Group | - | - | - | - | 2 | (100)% | 2 | 19 | - | - | - |
| Latin America & Asia Market Group | 27 | 6 | 81 | 110 | 148 | (45)% | 148 | 737 | 81 | - | 28 |
| Inactive | - | - | - | - | - | -% | - | 5 | - | - | - |
| Referral to TB DOTS (completion unknown) | 64 | 100 | 1,222 | 2,374 | 1,468 | (17)% | 1,692 | 10,910 | 1,222 | - | 3,401 |
| Acceleration Market Group | 64 | 100 | 1,218 | 2,374 | 1,351 | (10)% | 1,575 | 6,274 | 1,218 | - | 3,400 |
| Anglophone Africa Market Group | - | - | - | - | 74 | (100)% | 74 | 4,388 | - | - | - |
| Latin America & Asia Market Group | - | - | 4 | - | 43 | (91)% | 43 | 248 | 4 | - | 1 |
| Referral to TB Screening | - | - | - | 5,497 | 329 | (100)% | 329 | 115,621 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 85,548 | - | - | - |
| Anglophone Africa Market Group | - | - | - | 5,497 | 308 | (100)% | 308 | 29,857 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | 21 | (100)% | 21 | 216 | - | - | - |
| Referral to Treatment for Cervicitis | - | - | - | - | 47 | (100)% | 47 | 119 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 47 | (100)% | 47 | 119 | - | - | - |
| Referral to Treatment for Genital Herpes | - | - | - | - | 3 | (100)% | 3 | 12 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 3 | (100)% | 3 | 12 | - | - | - |
| Referral to Treatment for Inguinal Bubo | - | - | - | 112 | 2 | (100)% | 2 | 136 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Anglophone Africa Market Group | - | - | - | 112 | 2 | (100)% | 2 | 136 | - | - | - |
| Referral to Treatment for Lower Abdominal Pain | - | - | - | 112 | 1 | (100)% | 1 | 137 | - | - | - |
| Anglophone Africa Market Group | - | - | - | 112 | 1 | (100)% | 1 | 137 | - | - | - |
| Referral to Treatment for Urethral Discharge (Men) | - | - | - | 336 | 53 | (100)% | 53 | 2,659 | - | - | - |
| Anglophone Africa Market Group | - | - | - | 336 | 53 | (100)% | 53 | 2,659 | - | - | - |
| Referral to Treatment for Vaginitis | - | - | 1 | - | - | -% | - | 7,248 | 1 | - | - |
| Anglophone Africa Market Group | - | - | 1 | - | - | -% | - | 7,248 | 1 | - | - |
| Referral to Tubal Ligation | - | - | - | - | 2 | (100)% | 2 | 67 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 2 | (100)% | 2 | 6 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 61 | - | - | - |
| Referral to Tx for Nonherpetic Genital Ulcer | - | - | 1 | - | 25 | (96)% | 25 | 1,100 | 1 | - | - |
| Anglophone Africa Market Group | - | - | 1 | - | 25 | (96)% | 25 | 1,100 | 1 | - | - |
| Referral to Tx for Urethral Discharge (Women) | - | - | 10 | 560 | 48 | (79)% | 48 | 2,480 | 10 | - | 1 |
| Anglophone Africa Market Group | - | - | 10 | 560 | 48 | (79)% | 48 | 2,480 | 10 | - | 1 |
| Referral to Vasectomy | - | - | 1 | - | - | -% | - | 3 | 1 | 5 | 1 |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 2 | - | - | - |
| Latin America & Asia Market Group | - | - | 1 | - | - | -% | - | 1 | 1 | 5 | 1 |
| Referral to Voluntary Medical Male Circumcision | - | - | 3 | - | 139 | (98)% | 139 | 20,730 | 3 | - | 10 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 3,382 | - | - | - |
| Anglophone Africa Market Group | - | - | 3 | - | 139 | (98)% | 139 | 17,348 | 3 | - | 10 |
| Retreatment | - | - | - | - | - | -% | - | 46,984,114 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 8,050,379 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 35,287,804 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 1,094,479 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 1,275,789 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 1,009,438 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 266,225 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Retreatment IconMaxx | - | - | - | - | - | -% | - | 4,873,846 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 2,297,300 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 2,576,546 | - | - | - |
| Retreatment KO123 | - | - | - | - | - | -% | - | 9,124,110 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 1,106,836 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 8,013,192 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 4,082 | - | - | - |
| Retreatment KO123 net | - | - | - | - | - | -% | - | 10,259,477 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 2,151,532 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 8,107,945 | - | - | - |
| Safe Injection Kit | - | - | - | - | - | -% | - | 5 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 5 | - | - | - |
| Safe Water Solution | 259,163 | 256,104 | 4,190,488 | 4,507,380 | 5,189,455 | (19)% | 5,579,483 | 167,532,753 | 3,493,629 | - | 13,101 |
| Acceleration Market Group | 63,072 | 95,113 | 1,346,558 | 1,160,000 | 964,120 | 40% | 1,114,276 | 34,336,202 | 1,106,760 | - | 2,731 |
| Anglophone Africa Market Group | 94,919 | 80,397 | 997,927 | 1,915,700 | 2,207,153 | (55)% | 2,248,493 | 83,350,399 | 744,986 | - | 2,588 |
| Franco/Lusophone Africa Market Group | 101,172 | 70,976 | 1,475,634 | 1,400,000 | 720,831 | 105% | 870,831 | 14,204,755 | 1,212,850 | - | 6,331 |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 2,259,684 | - | - | - |
| Foundation Market Group | - | 9,618 | 370,369 | 31,680 | 1,297,351 | (71)% | 1,345,883 | 28,782,720 | 429,034 | - | 1,452 |
| Inactive | - | - | - | - | - | -% | - | 4,598,993 | - | - | - |
| SD NVP w/o Baby ARV Prophylaxis | - | - | - | - | - | -% | - | 271 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 271 | - | - | - |
| SD NVP with Baby ARV Prophylaxis | - | - | - | - | - | -% | - | 235 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 235 | - | - | - |
| SDM (Cycle Beads) | (16) | 431 | 1,278 | 306 | 6,598 | (81)% | 6,654 | 628,883 | 1,150 | 1,725 | 1,354 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 201,447 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 8,591 | - | - | - |
| Franco/Lusophone Africa Market Group | (2) | 446 | 1,459 | 306 | 1,454 | -% | 1,533 | 49,488 | 1,313 | 1,970 | 1,510 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 2,494 | - | - | - |
| Foundation Market Group | (14) | (14) | (181) | - | 5,144 | (104)% | 5,121 | 351,105 | (163) | (244) | (156) |
| Inactive | - | - | - | - | - | -% | - | 15,758 | - | - | - |
| SDM (Cycle Beads) Provided | 1,143 | 1,411 | 5,679 | 2,550 | 559 | 916% | 609 | 18,344 | 5,679 | 8,519 | 6,644 |
| Acceleration Market Group | 1,124 | 1,384 | 5,354 | - | - | -% | 3 | 5,357 | 5,354 | 8,031 | 6,283 |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 10 | - | - | - |
| Franco/Lusophone Africa Market Group | 2 | 7 | 100 | 2,550 | 83 | 20% | 96 | 497 | 100 | 150 | 115 |
| Latin America & Asia Market Group | - | - | 4 | - | 7 | (43)% | 7 | 130 | 4 | 6 | 1 |
| Foundation Market Group | 17 | 21 | 221 | - | 469 | (53)% | 503 | 12,350 | 221 | 332 | 245 |
| Seasonal Malaria Chemoprevention | - | - | - | 6,375,721 | 2,009,973 | (100)% | 2,009,973 | 4,420,982 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | 990,000 | 344,748 | (100)% | 344,748 | 344,748 | - | - | - |
| Foundation Market Group | - | - | - | 5,385,721 | 1,665,225 | (100)% | 1,665,225 | 4,076,234 | - | - | - |
| Skilled Birth Attendance | 3,206 | 3,283 | 36,892 | 66,196 | 41,266 | (11)% | 45,970 | 192,658 | 36,892 | - | 41,342 |
| Acceleration Market Group | - | 2,078 | 18,514 | 40,000 | 18,400 | 1% | 20,115 | 80,683 | 18,514 | - | 15,389 |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 50,567 | - | - | - |
| Franco/Lusophone Africa Market Group | 95 | 97 | 1,469 | 9,000 | 9,095 | (84)% | 9,160 | 27,804 | 1,469 | - | 1,861 |
| Foundation Market Group | 3,111 | 1,108 | 16,909 | 17,196 | 13,771 | 23% | 16,695 | 33,604 | 16,909 | - | 24,092 |
| STI Kit | - | - | - | - | - | -% | - | 691,263 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 240,890 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 438,695 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 329 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 9,882 | - | - | - |
| Inactive | - | - | - | - | - | -% | - | 1,467 | - | - | - |
| STI Kit (Non-Ulcerative) | 1,117 | 187 | 4,732 | 1,869 | 5,855 | (19)% | 6,655 | 4,022,900 | 4,259 | - | 304 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 742,374 | - | - | - |
| Anglophone Africa Market Group | 1,117 | 187 | 4,732 | 1,869 | 5,855 | (19)% | 6,655 | 870,733 | 4,259 | - | 304 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 7,704 | - | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Latin America & Asia Market Group | - | - | - | - | - | -% | - | 348,335 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 2,053,754 | - | - | - |
| STI Kit (Ulcerative) | 257 | 19 | 1,588 | 231 | - | -% | - | 1,855,742 | 1,429 | - | 305 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 60,473 | - | - | - |
| Anglophone Africa Market Group | 257 | 19 | 1,588 | 231 | - | -% | - | 74,280 | 1,429 | - | 305 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 480 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 1,720,509 | - | - | - |
| STI Screening | 11,668 | 11,647 | 143,812 | 227,782 | 246,379 | (42)% | 254,307 | 1,430,200 | 143,812 | - | - |
| Acceleration Market Group | 1,051 | 1,110 | 15,751 | - | 25,310 | (38)% | 27,221 | 89,667 | 15,751 | - | - |
| Anglophone Africa Market Group | 9,033 | 9,198 | 110,529 | 144,457 | 72,747 | 52% | 75,388 | 673,445 | 110,529 | - | - |
| Franco/Lusophone Africa Market Group | 616 | 640 | 8,831 | - | 8,194 | 8% | 8,747 | 39,817 | 8,831 | - | - |
| Latin America & Asia Market Group | 17 | 42 | 242 | - | 99 | 144% | 99 | 4,232 | 242 | - | - |
| Foundation Market Group | 951 | 656 | 8,459 | 83,325 | 140,029 | (94)% | 142,852 | 622,541 | 8,459 | - | - |
| Inactive | - | - | - | - | - | -% | - | 498 | - | - | - |
| TB Diagnosis | 3,987 | 3,762 | 48,797 | 28,643 | 58,822 | (17)% | 62,691 | 272,654 | 48,797 | - | - |
| Acceleration Market Group | 1,404 | 1,243 | 12,128 | 16,181 | 12,735 | (5)% | 14,315 | 99,523 | 12,128 | - | - |
| Anglophone Africa Market Group | 30 | 14 | 213 | 77 | 274 | (22)% | 283 | 1,690 | 213 | - | - |
| Latin America & Asia Market Group | 2,553 | 2,505 | 26,341 | 385 | 27,573 | (4)% | 29,853 | 111,977 | 26,341 | - | - |
| Foundation Market Group | - | - | 10,115 | 12,000 | 18,240 | (45)% | 18,240 | 49,245 | 10,115 | - | - |
| Inactive | - | - | - | - | - | -% | - | 10,219 | - | - | - |
| TB DOTS | 2,961 | 3,373 | 46,251 | 23,210 | 58,291 | (21)% | 61,338 | 430,817 | 46,251 | - | 217,888 |
| Acceleration Market Group | 988 | 1,200 | 11,636 | 13,173 | 11,937 | (3)% | 12,891 | 233,497 | 11,636 | - | 72,176 |
| Anglophone Africa Market Group | 3 | 3 | 32 | 77 | 34 | (6)% | 35 | 133 | 32 | - | 260 |
| Latin America & Asia Market Group | 1,970 | 2,170 | 23,475 | - | 23,920 | (2)% | 26,012 | 137,282 | 23,475 | - | 107,432 |
| Foundation Market Group | - | - | 11,108 | 9,960 | 22,400 | (50)% | 22,400 | 54,142 | 11,108 | - | 38,021 |
| Inactive | - | - | - | - | - | -% | - | 5,763 | - | - | - |
| TB Screening | 33,012 | 36,732 | 429,169 | 202,098 | 441,457 | (3)% | 478,931 | 2,609,449 | 429,169 | - | - |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Acceleration Market Group | 7,236 | 11,934 | 110,568 | 149,616 | 86,207 | 28% | 103,950 | 590,967 | 110,568 | - | - |
| Anglophone Africa Market Group | 19,359 | 19,684 | 223,513 | 34,396 | 210,708 | 6% | 225,880 | 1,674,538 | 223,513 | - | - |
| Latin America & Asia Market Group | 6,417 | 5,114 | 56,228 | 4,086 | 67,874 | (17)% | 72,433 | 197,744 | 56,228 | - | - |
| Foundation Market Group | - | - | 38,860 | 14,000 | 76,668 | (49)% | 76,668 | 139,061 | 38,860 | - | - |
| Inactive | - | - | - | - | - | -% | - | 7,139 | - | - | - |
| Toilets Constructed | - | - | - | - | - | -% | - | 16,479 | - | - | - |
| Acceleration Market Group | - | - | - | - | - | -% | - | 12,802 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 5 | - | - | - |
| Foundation Market Group | - | - | - | - | - | -% | - | 3,672 | - | - | - |
| Toilets Sold | 13,160 | 10,774 | 101,686 | 98,457 | 52,980 | 92% | 64,462 | 370,198 | 493,991 | - | 14,018 |
| Acceleration Market Group | 8,435 | 6,931 | 68,647 | 60,000 | 41,273 | 66% | 50,363 | 314,891 | 329,506 | - | 7,865 |
| Anglophone Africa Market Group | 1,915 | 2,301 | 18,432 | 25,600 | 4,824 | 282% | 5,651 | 24,082 | 84,050 | - | 3,244 |
| Franco/Lusophone Africa Market Group | 2,805 | 1,365 | 13,408 | 8,107 | 3,283 | 308% | 4,017 | 17,424 | 75,268 | - | 2,851 |
| Latin America & Asia Market Group | - | 175 | 1,113 | 750 | 3,573 | (69)% | 4,405 | 7,416 | 4,675 | - | 39 |
| Foundation Market Group | 5 | 2 | 86 | 4,000 | 27 | 216% | 27 | 6,384 | 493 | - | 19 |
| Toilets Sold - All | 13,919 | 12,677 | 116,352 | - | 56,074 | 107% | 69,029 | 185,381 | 559,924 | - | - |
| Acceleration Market Group | 8,435 | 6,931 | 68,647 | - | 41,273 | 66% | 50,363 | 119,010 | 329,506 | - | - |
| Anglophone Africa Market Group | 2,093 | 3,375 | 25,064 | - | 5,936 | 322% | 7,266 | 32,330 | 107,925 | - | - |
| Franco/Lusophone Africa Market Group | 3,288 | 2,137 | 19,747 | - | 4,023 | 391% | 5,726 | 25,473 | 107,666 | - | - |
| Latin America & Asia Market Group | - | 175 | 1,113 | - | 3,327 | (67)% | 4,159 | 5,272 | 4,675 | - | - |
| Foundation Market Group | 103 | 59 | 1,781 | - | 1,515 | 18% | 1,515 | 3,296 | 10,152 | - | - |
| Treatment for Cervicitis | 17 | 37 | 294 | - | 86 | 242% | 101 | 713 | 294 | - | 14 |
| Anglophone Africa Market Group | 13 | 22 | 181 | - | 58 | 212% | 73 | 544 | 181 | - | 14 |
| Franco/Lusophone Africa Market Group | 1 | 2 | 24 | - | - | -% | - | 37 | 24 | - | - |
| Latin America & Asia Market Group | 3 | 13 | 89 | - | 28 | 218% | 28 | 132 | 89 | - | - |
| Treatment for Genital Herpes | 61 | 50 | 578 | 17 | 52 | 1,012% | 70 | 749 | 578 | - | 11 |
| Anglophone Africa Market Group | 32 | 22 | 124 | 17 | 26 | 377% | 28 | 223 | 124 | - | 4 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Franco/Lusophone Africa Market Group | 29 | 28 | 453 | - | 26 | 1,642% | 42 | 517 | 453 | - | 7 |
| Latin America & Asia Market Group | - | - | 1 | - | - | -% | - | 9 | 1 | - | - |
| Treatment for Inguinal Bubo | 7 | 4 | 93 | - | 72 | 29% | 89 | 313 | 93 | - | - |
| Anglophone Africa Market Group | - | - | 17 | - | 2 | 750% | 3 | 34 | 17 | - | - |
| Franco/Lusophone Africa Market Group | 5 | 3 | 51 | - | 28 | 82% | 33 | 118 | 51 | - | - |
| Foundation Market Group | 2 | 1 | 25 | - | 42 | (40)% | 53 | 161 | 25 | - | - |
| Treatment for Lower Abdominal Pain | 172 | 216 | 1,841 | 54 | 1,399 | 32% | 1,571 | 5,218 | 1,841 | - | - |
| Anglophone Africa Market Group | 71 | 81 | 432 | 54 | 76 | 468% | 78 | 645 | 432 | - | - |
| Franco/Lusophone Africa Market Group | 62 | 96 | 943 | - | 626 | 51% | 693 | 2,010 | 943 | - | - |
| Latin America & Asia Market Group | - | 2 | 7 | - | - | -% | - | 7 | 7 | - | - |
| Foundation Market Group | 39 | 38 | 459 | - | 697 | (34)% | 800 | 2,556 | 459 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 196 | 210 | 2,262 | 94 | 6,548 | (65)% | 6,745 | 18,789 | 2,262 | - | 392 |
| Anglophone Africa Market Group | 44 | 59 | 623 | 94 | 518 | 20% | 546 | 1,769 | 623 | - | 192 |
| Franco/Lusophone Africa Market Group | 98 | 98 | 998 | - | 933 | 7% | 1,027 | 2,787 | 998 | - | 128 |
| Latin America & Asia Market Group | - | 1 | 2 | - | - | -% | - | 4 | 2 | - | - |
| Foundation Market Group | 54 | 53 | 639 | - | 5,097 | (87)% | 5,172 | 14,229 | 639 | - | 72 |
| Treatment for Pre-Eclampsia (with MgSO4) | 63 | 27 | 345 | 413 | 336 | 3% | 392 | 858 | 345 | - | 1,141 |
| Acceleration Market Group | - | 6 | 22 | 60 | 49 | (55)% | 49 | 192 | 22 | - | 20 |
| Foundation Market Group | 63 | 21 | 323 | 353 | 287 | 13% | 343 | 666 | 323 | - | 1,121 |
| Treatment for Severe Acute Malnutrition | 1,282 | 464 | 6,637 | 9,896 | 12,024 | (45)% | 12,893 | 61,180 | 6,637 | - | 25,299 |
| Franco/Lusophone Africa Market Group | - | - | - | 8 | - | -% | - | 4 | - | - | - |
| Foundation Market Group | 1,282 | 464 | 6,637 | 9,888 | 12,024 | (45)% | 12,893 | 61,176 | 6,637 | - | 25,299 |
| Treatment for Urethral Discharge (Men) | 532 | 485 | 5,838 | 195 | 7,010 | (17)% | 7,519 | 22,913 | 11,571 | - | 115 |
| Anglophone Africa Market Group | 78 | 66 | 680 | 195 | 277 | 145% | 292 | 1,582 | 1,255 | - | 74 |
| Franco/Lusophone Africa Market Group | 164 | 149 | 1,854 | - | 1,517 | 22% | 1,631 | 4,810 | 3,708 | - | 22 |
| Foundation Market Group | 290 | 270 | 3,304 | - | 5,216 | (37)% | 5,596 | 16,521 | 6,608 | - | 19 |
| Treatment for Urethral Discharge (Women) | 366 | 347 | 4,114 | 2 | 2,358 | 74% | 2,577 | 9,185 | 4,114 | - | 229 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Anglophone Africa Market Group | 121 | 98 | 1,037 | 2 | 471 | 120% | 507 | 2,560 | 1,037 | - | 153 |
| Franco/Lusophone Africa Market Group | 245 | 249 | 3,076 | - | 1,886 | 63% | 2,054 | 6,601 | 3,076 | - | 77 |
| Latin America & Asia Market Group | - | - | 1 | - | 1 | -% | 1 | 9 | 1 | - | - |
| Foundation Market Group | - | - | - | - | - | -% | 15 | 15 | - | - | - |
| Treatment for Vaginitis | 306 | 336 | 3,679 | 380 | 5,183 | (29)% | 5,511 | 17,959 | 3,679 | - | 88 |
| Anglophone Africa Market Group | 15 | 28 | 329 | 380 | 498 | (34)% | 506 | 2,541 | 329 | - | 61 |
| Franco/Lusophone Africa Market Group | 1 | - | 150 | - | 2 | 7,400% | 2 | 157 | 150 | - | - |
| Latin America & Asia Market Group | 14 | 27 | 199 | - | 25 | 696% | 25 | 227 | 199 | - | - |
| Foundation Market Group | 276 | 281 | 3,001 | - | 4,658 | (36)% | 4,978 | 15,034 | 3,001 | - | 26 |
| Tubal Ligation | 7,468 | 5,888 | 55,196 | 42,589 | 60,909 | (9)% | 67,507 | 426,752 | 55,196 | 659,942 | 228,199 |
| Acceleration Market Group | 5,558 | 3,383 | 36,549 | 25,000 | 32,967 | 11% | 38,957 | 118,764 | 36,549 | 473,472 | 128,515 |
| Anglophone Africa Market Group | 1,224 | 1,403 | 10,046 | 17,589 | 15,901 | (37)% | 16,391 | 45,860 | 10,046 | 100,460 | 79,142 |
| Franco/Lusophone Africa Market Group | - | - | - | - | 102 | (100)% | 204 | 204 | - | - | - |
| Latin America & Asia Market Group | 683 | 1,097 | 8,571 | - | 11,899 | (28)% | 11,913 | 261,778 | 8,571 | 85,710 | 20,405 |
| Foundation Market Group | 3 | 5 | 30 | - | 40 | (25)% | 42 | 146 | 30 | 300 | 137 |
| Type 2 Diabetes Diagnosis | - | - | 1 | - | 4 | (75)% | 4 | 1,436 | 1 | - | - |
| Anglophone Africa Market Group | - | - | - | - | 3 | (100)% | 3 | 1,434 | - | - | - |
| Latin America & Asia Market Group | - | - | 1 | - | 1 | -% | 1 | 2 | 1 | - | - |
| Type 2 Diabetes Screening | 853 | 1,509 | 22,563 | 33,797 | 6,141 | 267% | 6,712 | 39,156 | 22,563 | - | - |
| Anglophone Africa Market Group | 853 | 1,508 | 22,560 | 33,797 | 6,140 | 267% | 6,711 | 39,150 | 22,560 | - | - |
| Latin America & Asia Market Group | - | - | 3 | - | 1 | 200% | 1 | 6 | 3 | - | - |
| Type 2 Diabetes Controlled Condition | - | - | 2 | - | 6 | (67)% | 6 | 14 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | 6 | (100)% | 6 | 12 | - | - | - |
| Latin America & Asia Market Group | - | - | 2 | - | - | -% | - | 2 | - | - | - |
| Vaginal Wash | - | 1,005 | 18,664 | 71,280 | - | -% | - | 18,664 | - | - | - |
| Social Enterprise | - | 1,005 | 18,664 | 71,280 | - | -% | - | 18,664 | - | - | - |
| Vasectomy | 301 | 325 | 1,772 | 1,029 | 640 | 177% | 709 | 6,773 | 1,772 | 22,106 | 6,004 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Acceleration Market Group | 294 | 289 | 1,465 | 1,000 | 269 | 445% | 287 | 5,421 | 1,465 | 19,036 | 5,153 |
| Anglophone Africa Market Group | 6 | 4 | 17 | 29 | - | -% | - | 57 | 17 | 170 | 148 |
| Franco/Lusophone Africa Market Group | - | - | - | - | 53 | (100)% | 104 | 104 | - | - | - |
| Latin America & Asia Market Group | 1 | 33 | 290 | - | 318 | (9)% | 318 | 1,191 | 290 | 2,900 | 704 |
| Vivax Treatment after Confirmatory Diagnosis | 124 | 260 | 2,068 | 248 | 2,970 | (30)% | 3,400 | 11,439 | 2,068 | - | 380 |
| Acceleration Market Group | 95 | 203 | 1,822 | - | 2,858 | (36)% | 3,244 | 11,028 | 1,822 | - | 334 |
| Latin America & Asia Market Group | 29 | 57 | 246 | 248 | 112 | 120% | 156 | 411 | 246 | - | 46 |
| Voluntary Medical Male Circumcision | 13,551 | 37,244 | 337,067 | 396,145 | 407,059 | (17)% | 424,870 | 2,829,836 | 337,067 | - | 2,226,945 |
| Acceleration Market Group | 8,670 | 6,996 | 87,389 | 90,000 | 76,854 | 14% | 78,885 | 395,164 | 87,389 | - | 615,503 |
| Anglophone Africa Market Group | 4,881 | 30,247 | 249,678 | 306,145 | 330,205 | (24)% | 345,985 | 2,373,407 | 249,678 | - | 1,611,442 |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 61,265 | - | - | - |
| Water Treatment Tablets | 3,067,030 | 2,270,653 | 29,947,062 | 35,643,920 | 36,431,652 | (18)% | 38,726,042 | 848,735,378 | 492,280 | - | 3,570 |
| Acceleration Market Group | - | 9,360 | 697,680 | 300,000 | 486,000 | 44% | 501,290 | 6,638,047 | 11,469 | - | 28 |
| Anglophone Africa Market Group | 2,591,500 | 674,707 | 6,213,110 | 8,068,408 | 6,922,542 | (10)% | 6,957,142 | 364,397,620 | 102,133 | - | 404 |
| Franco/Lusophone Africa Market Group | (99,820) | 1,239,040 | 18,155,420 | 20,485,262 | 18,869,870 | (4)% | 20,217,570 | 182,401,320 | 298,445 | - | 2,536 |
| Latin America & Asia Market Group | 2,750 | 500 | 70,110 | 80,000 | 91,160 | (23)% | 91,160 | 10,823,093 | 1,152 | - | 3 |
| Foundation Market Group | 572,600 | 347,047 | 4,810,742 | 6,710,250 | 10,062,080 | (52)% | 10,958,880 | 284,475,298 | 79,081 | - | 598 |
| Woman Condom | - | - | 1,920 | - | 95,160 | (98)% | 97,728 | 141,480 | 14 | 14 | 40 |
| Anglophone Africa Market Group | - | - | 1,920 | - | 95,160 | (98)% | 97,728 | 141,480 | 14 | 14 | 40 |
| Zika Prevention Kit | - | - | - | - | 714 | (100)% | 725 | 114,581 | - | - | - |
| Latin America & Asia Market Group | - | - | - | - | 714 | (100)% | 725 | 114,581 | - | - | - |
| Zinc | 2,620 | - | 2,822 | - | 512,836 | (99)% | 512,836 | 7,212,221 | 2,540 | - | 62 |
| Acceleration Market Group | - | - | - | - | - | -% | - | 953,402 | - | - | - |
| Anglophone Africa Market Group | - | - | - | - | - | -% | - | 1,034,758 | - | - | - |
| Franco/Lusophone Africa Market Group | - | - | - | - | - | -% | - | 669,429 | - | - | - |
| Latin America & Asia Market Group | 70 | - | 132 | - | - | -% | - | 481,381 | 119 | - | 1 |
| Foundation Market Group | 2,550 | - | 2,690 | - | 512,836 | (99)% | 512,836 | 4,073,251 | 2,421 | - | 61 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Product

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | YTD USERS REACHED 2019 ^(a) | YTD CYP 2019 | YTD DALY 2019 |
|-------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|----------------------------|---|-----------------|------------------|
| Zinc Provided | 3,573 | 1,260 | 25,038 | 12,189 | 9,296 | 169% | 11,834 | 69,947 | 25,038 | - | 656 |
| Foundation Market Group | 3,573 | 1,260 | 25,038 | 12,189 | 9,296 | 169% | 11,834 | 69,947 | 25,038 | - | 656 |

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

Acceleration Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 11/2019

| | New HIV Infections | STI Deaths | PWID Deaths | TB Deaths | CYP* | Maternal Deaths | Unintended Pregnancies | Malaria Deaths | Diarrhea Deaths | Pneumonia Deaths | Cervical Cancer Death | Sum of All Deaths |
|---------------------------|--------------------|------------|-------------|-----------|-----------|-----------------|------------------------|----------------|-----------------|------------------|-----------------------|-------------------|
| Acceleration Market Group | 37,199 | - | - | 2,906 | 2,466,370 | 3,975 | 1,077,960 | 1,004 | 550 | 98 | 3 | 21,712 |
| India | - | - | - | - | 615,484 | 166 | 345,014 | - | 257 | - | - | 2,178 |
| Kenya | 19,032 | - | - | - | 876,819 | 1,043 | 342,403 | 471 | 58 | 98 | 1 | 7,327 |
| Myanmar | 1,777 | - | - | 2,906 | 530,570 | 124 | 187,712 | 533 | 235 | - | 1 | 4,508 |
| Nigeria | - | - | - | - | 27,321 | 64 | 12,612 | - | - | - | - | 379 |
| PSI Nigeria | - | - | - | - | 416,176 | 2,579 | 190,219 | - | - | - | - | 7,321 |
| South Africa | 16,390 | - | - | - | - | - | - | - | - | - | - | - |

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 11
 Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|------------------|------------------|
| Acceleration Market Group | | | | | | | | | | 2,466,370 | 3,064,942 |
| Antiretroviral Treatment (Currently Enrolled) | 15,234 | 15,017 | 158,492 | 170,176 | 138,790 | 14% | 152,003 | 386,976 | 13,208 | - | 31,377 |
| Antiretroviral Treatment (Newly Enrolled) | 276 | 325 | 3,481 | 3,981 | 3,148 | 11% | 3,434 | 13,067 | 3,481 | - | - |
| Cervical Cancer-VIA and Cryotherapy | 18 | 27 | 300 | 240 | 264 | 14% | 286 | 4,573 | 300 | - | 71 |
| Cervical Cancer-VIA and Refer to Conization | - | - | - | - | 1 | (100)% | 4 | 4 | - | - | - |
| Cervical Cancer-VIA and Refer to Cryotherapy | - | - | - | 150 | 22 | (100)% | 29 | 48 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | 319 | 3,320 | 37,667 | 21,500 | 32,301 | 17% | 34,714 | 325,396 | 37,667 | - | - |
| Condom | 3,925,890 | 3,766,518 | 41,894,829 | 41,769,999 | 32,518,684 | 29% | 38,017,548 | 1,017,398,877 | 314,211 | 314,211 | 919,925 |
| Diarrhea Treatment Kit Provided | - | 586 | 15,147 | 29,000 | 16,520 | (8)% | 18,226 | 69,404 | 15,147 | - | 503 |
| Emergency Contraception | 65 | (8,178) | (40,654) | - | 5 | 813,180)% | 5 | 137,215 | (1,829) | (1,829) | (235) |
| Emergency Contraception Provided | 9,664 | 9,300 | 55,225 | 19,800 | 3,303 | 1,572% | 4,173 | 60,826 | 2,761 | 2,761 | 423 |
| Fecal Sludge Management (Households) | - | 13 | 489 | 400 | 570 | (14)% | 697 | 2,768 | 2,347 | - | - |
| Fecal Sludge Management (Liters) | - | 63,333 | 1,914,000 | 2,000,000 | 3,376,000 | (43)% | 4,011,000 | 13,071,200 | - | - | 118 |
| Female Condom | - | 967 | 85,553 | 70,000 | 65,906 | 30% | 79,641 | 1,556,019 | 642 | 642 | 461 |
| Fever Cases Attended | 43,613 | 49,315 | 446,149 | - | 611,247 | (27)% | 697,782 | 2,877,317 | 446,149 | - | - |
| Fever Cases Tested with RDTs | 43,613 | 49,315 | 446,149 | - | 611,247 | (27)% | 697,782 | 2,877,317 | 446,149 | - | - |
| Free Condom | 468 | 2,244 | 1,920,960 | 35,500,000 | 62,784,000 | (97)% | 68,170,320 | 1,177,078,157 | 14,407 | 14,407 | 56,881 |
| Free Female Condom | 12,320 | 8,620 | 38,180 | - | 1,108,500 | (97)% | 1,108,500 | 5,068,780 | 286 | 286 | 206 |
| HIV Self-Testing Kit | 3,685 | 169,925 | 641,840 | 1,066,643 | - | -% | 1,357,422 | 1,999,262 | 577,656 | - | - |
| HIV Testing Services | 15,024 | 25,830 | 303,775 | 293,418 | 1,059,481 | (71)% | 1,091,132 | 6,361,738 | 303,775 | - | 11,811 |
| Hypertension Diagnosis | 1,057 | 1,422 | 31,449 | 20,000 | 57,365 | (45)% | 57,768 | 105,258 | 31,449 | - | - |
| Hypertension Screening | 2,049 | 2,654 | 80,891 | 50,000 | 168,855 | (52)% | 176,640 | 292,045 | 80,891 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|-----------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Hypertension_Controlled Condition | 781 | 1,085 | 22,960 | - | 43,197 | (47)% | 43,499 | 78,769 | 9,184 | - | - |
| Implant 3 | 577 | 1,240 | 9,942 | 12,600 | 1,038 | 858% | 1,528 | 828,618 | 8,948 | 22,370 | 15,327 |
| Implant 3 Insertion | 8,486 | 7,437 | 35,070 | 38,123 | 4,583 | 665% | 8,884 | 47,435 | 35,070 | 87,675 | 59,669 |
| Implant 4 Insertion | - | 487 | 1,462 | - | 288 | 408% | 288 | 1,750 | 1,462 | 4,678 | 5,298 |
| Implant 5 | (40) | (1,125) | (11,741) | (7,600) | 1,051 | (1,217)% | 2,423 | 42,249 | (10,567) | (40,154) | (29,050) |
| Implant 5 Insertion | 10,540 | 9,265 | 99,769 | 62,915 | 79,025 | 26% | 82,547 | 514,470 | 99,769 | 379,122 | 325,253 |
| Injectable 1 Provided | 4 | 1 | 13 | - | - | -% | 37 | 50 | 1 | 1 | 1 |
| Injectable 2 Provided | 988 | 497 | 3,355 | - | - | -% | 5,875 | 9,230 | 559 | 559 | 471 |
| Injectable 3-IM | 63,313 | 17,179 | 281,960 | 480,600 | 416,777 | (32)% | 493,679 | 15,734,521 | 63,441 | 63,441 | 8,586 |
| Injectable 3-IM Provided | 48,235 | 50,432 | 326,330 | 204,422 | 153,707 | 112% | 175,770 | 697,384 | 81,583 | 81,583 | 36,479 |
| Injectable 3-SC | 2,359 | 1,890 | 28,127 | 32,150 | - | -% | - | 28,127 | 6,329 | 6,329 | 791 |
| Injectable 3-SC Provided | 898 | 444 | 3,116 | - | - | -% | - | 3,116 | 779 | 779 | 657 |
| IPTp2 | - | 450 | 4,249 | - | 3,470 | 22% | 3,893 | 18,546 | 4,249 | - | 159 |
| IUD 10 | - | (355) | (7,253) | (4,600) | (1,181) | -% | 684 | 6,093 | (6,528) | (30,027) | (21,099) |
| IUD 10 Insertion | 10,151 | 9,782 | 91,785 | 103,790 | 84,104 | 9% | 90,084 | 621,313 | 91,785 | 422,211 | 406,827 |
| IUD 5 | 53 | (19,399) | (110,407) | 2,500 | 191 | (57,905)% | 472 | 27,589 | (99,366) | (327,909) | (74,392) |
| IUD 5 Insertion | 17,633 | 19,580 | 135,792 | 65,000 | 46,402 | 193% | 51,661 | 313,721 | 135,792 | 448,114 | 101,862 |
| IUS 5 Insertion | 96 | 71 | 1,027 | - | 734 | 40% | 775 | 2,428 | 1,027 | 3,389 | 3,897 |
| LLIN | 1,119 | 97,416 | 1,082,748 | 2,049,898 | 1,990,597 | (46)% | 2,332,163 | 24,765,475 | 1,754,052 | - | 41,116 |
| Lubricant | 293,000 | 280,426 | 2,047,836 | 70,000 | 44,649 | 4,487% | 51,861 | 7,280,522 | - | - | - |
| Malaria PPT (ACT) | 244 | 8,884 | 173,273 | 182,270 | 255,664 | (32)% | 256,333 | 3,362,169 | 155,946 | - | 24,308 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Malaria PPT (Non-ACT) | 114 | 1,242 | 2,730 | 3,621 | (1,521) | -% | (1,900) | 107,056 | 2,457 | - | 383 |
| Malaria RDK | - | - | - | 432,337 | 705,945 | (100)% | 743,410 | 4,731,974 | - | - | - |
| Manual Vacuum Aspiration for PAC | 745 | 739 | 7,394 | 5,220 | 18,592 | (60)% | 19,176 | 26,570 | 7,394 | - | 5,921 |
| Medical Abortion | 998 | 334 | 2,000 | 9,000 | - | -% | - | 2,000 | 1,800 | - | 1,689 |
| Micronutrient Powder | - | - | - | - | 1,880,940 | (100)% | 2,000,000 | 9,499,690 | - | - | - |
| Misoprostol for PAC Provided | 566 | 672 | 6,949 | 5,220 | 14,322 | (51)% | 14,855 | 21,804 | 6,949 | - | 6,590 |
| Misoprostol for Safe Abortion | 13,636 | 161,979 | 1,747,774 | 2,339,690 | 2,145,962 | (19)% | 2,321,200 | 4,068,974 | 91,758 | - | 77,046 |
| Multivitamin | - | - | - | - | 450,010 | (100)% | 450,010 | 883,520 | - | - | - |
| Needle & Syringe | - | 567 | 10,100 | - | - | -% | - | 1,956,069 | 35 | - | 83 |
| OCs | 883,713 | 897,708 | 7,879,862 | 10,222,400 | 8,158,404 | (3)% | 9,492,397 | 73,680,217 | 472,792 | 472,792 | 138,478 |
| OCs Provided | 91,519 | 111,242 | 606,019 | 181,469 | 134,752 | 350% | 151,894 | 851,128 | 40,401 | 40,401 | 8,887 |
| ORS | 97,044 | 131,515 | 809,024 | 600,000 | 459,503 | 76% | 514,198 | 2,039,878 | 364,061 | - | 21,214 |
| ORS Provided | - | 59 | 2,043 | - | 2,025 | 1% | 2,217 | 9,430 | 2,043 | - | 33 |
| Pneumonia PPT | - | - | - | 28,910 | - | -% | - | - | - | - | - |
| Pneumonia PPT Provided | - | 1,245 | 17,319 | - | 19,159 | (10)% | 20,179 | 75,392 | 17,319 | - | 8,331 |
| Positive RDTs | 224 | 495 | 3,960 | - | 8,667 | (54)% | 9,712 | 39,431 | 3,960 | - | - |
| Positive RDTs Given First Line Treatment | 224 | 492 | 3,825 | - | 7,926 | (52)% | 8,937 | 34,828 | 3,825 | - | - |
| PrEP | 77 | 69 | 478 | - | - | -% | - | 478 | 40 | - | 20 |
| PUR | 2,931,360 | 2,024,083 | 29,796,020 | 19,000,000 | 26,656,029 | 12% | 28,508,349 | 210,575,946 | 244,899 | - | 604 |
| QAACts Provided after Confirmatory Diagnosis | 68 | 144 | 24,782 | 95,000 | 90,811 | (73)% | 101,767 | 145,327 | 24,782 | - | 4,097 |
| Referral to HIV Testing Services | - | - | 21,265 | - | - | -% | - | 21,265 | 21,265 | - | 754 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Referral to Linkage to HIV Care | - | 799 | 5,843 | 12,150 | - | -% | - | 5,843 | 5,843 | - | 2,767 |
| Referral to TB DOTS (completion confirmed) | 42 | 70 | 951 | 2,349 | 1,075 | (12)% | 1,214 | 2,458 | 951 | - | 2,949 |
| Referral to TB DOTS (completion unknown) | 64 | 100 | 1,218 | 2,374 | 1,351 | (10)% | 1,575 | 2,793 | 1,218 | - | 3,400 |
| Safe Water Solution | 63,072 | 95,113 | 1,346,558 | 1,160,000 | 964,120 | 40% | 1,114,276 | 22,820,458 | 1,106,760 | - | 2,731 |
| SDM (Cycle Beads) Provided | 1,124 | 1,384 | 5,354 | - | - | -% | 3 | 5,357 | 5,354 | 8,031 | 6,283 |
| Skilled Birth Attendance | - | 2,078 | 18,514 | 40,000 | 18,400 | 1% | 20,115 | 80,683 | 18,514 | - | 15,389 |
| STI Screening | 1,051 | 1,110 | 15,751 | - | 25,310 | (38)% | 27,221 | 76,260 | 15,751 | - | - |
| TB Diagnosis | 1,404 | 1,243 | 12,128 | 16,181 | 12,735 | (5)% | 14,315 | 71,732 | 12,128 | - | - |
| TB DOTS | 988 | 1,200 | 11,636 | 13,173 | 11,937 | (3)% | 12,891 | 229,087 | 11,636 | - | 72,176 |
| TB Screening | 7,236 | 11,934 | 110,568 | 149,616 | 86,207 | 28% | 103,950 | 482,775 | 110,568 | - | - |
| Toilets Sold | 8,435 | 6,931 | 68,647 | 60,000 | 41,273 | 66% | 50,363 | 119,010 | 329,506 | - | 7,865 |
| Toilets Sold - All | 8,435 | 6,931 | 68,647 | - | 41,273 | 66% | 50,363 | 119,010 | 329,506 | - | - |
| Treatment for Pre-Eclampsia (with MgSO4) | - | 6 | 22 | 60 | 49 | (55)% | 49 | 192 | 22 | - | 20 |
| Tubal Ligation | 5,558 | 3,383 | 36,549 | 25,000 | 32,967 | 11% | 38,957 | 118,752 | 36,549 | 473,472 | 128,515 |
| Vasectomy | 294 | 289 | 1,465 | 1,000 | 269 | 445% | 287 | 5,420 | 1,465 | 19,036 | 5,153 |
| Vivax Treatment after Confirmatory Diagnosis | 95 | 203 | 1,822 | - | 2,858 | (36)% | 3,244 | 11,028 | 1,822 | - | 334 |
| Voluntary Medical Male Circumcision | 8,670 | 6,996 | 87,389 | 90,000 | 76,854 | 14% | 78,885 | 239,616 | 87,389 | - | 615,503 |
| Water Treatment Tablets | - | 9,360 | 697,680 | 300,000 | 486,000 | 44% | 501,290 | 6,634,880 | 11,469 | - | 28 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|------------------|------------------|
| Acceleration Market Group | | | | | | | | | | | 2,466,370 | 3,064,942 |
| India | | | | | | | | | | | 615,484 | 166,572 |
| Emergency Contraception | - | (8,489) | (41,654) | - | - | | 0% | - | (41,654) | (1,874) | (1,874) | (239) |
| (b)PSI Emergency Contraception Distributed Provided | - | (8,489) | (41,654) | - | - | | -% | - | (41,654) | (1,874) | (1,874) | (239) |
| Emergency Contraception Provided | 8,719 | 8,489 | 50,373 | 18,000 | 1,951 | | 2482% | 2,574 | 52,947 | 2,519 | 2,519 | 321 |
| Non-PSI Emergency Contraception Provided | 8,719 | - | 8,719 | 18,000 | 1,951 | | 347% | 2,574 | 11,293 | 436 | 436 | 56 |
| PSI Emergency Contraception Provided | - | 8,489 | 41,654 | - | - | | -% | - | 41,654 | 2,083 | 2,083 | 265 |
| Fecal Sludge Management (Households) | - | 13 | 489 | 400 | 570 | | (14)% | 697 | 2,768 | 2,347 | - | - |
| Fecal Sludge Management (Households) | - | 13 | 489 | 400 | 570 | | (14)% | 697 | 2,768 | 2,347 | - | - |
| Fecal Sludge Management (Liters) | - | 63,333 | 1,914,000 | 2,000,000 | 3,376,000 | | (43)% | 4,011,000 | 13,071,200 | - | - | 118 |
| Fecal Sludge Management (Liters) | - | 63,333 | 1,914,000 | 2,000,000 | 3,376,000 | | (43)% | 4,011,000 | 13,071,200 | - | - | 118 |
| Injectable 3-IM | - | (11,962) | (75,440) | - | - | | 0% | - | (75,440) | (16,974) | (16,974) | (2,840) |
| (b)PSI Injectable 3 IM Distributed Provided | - | (11,962) | (75,440) | - | - | | -% | - | (75,440) | (16,974) | (16,974) | (2,840) |
| Injectable 3-IM Provided | 9,539 | 11,962 | 84,979 | 35,000 | 13,231 | | 542% | 16,479 | 136,408 | 21,245 | 21,245 | 3,554 |
| Non-PSI Injectable 3 IM Provided | 9,539 | - | 9,539 | 35,000 | 13,231 | | (28)% | 16,479 | 60,968 | 2,385 | 2,385 | 399 |
| PSI Injectable 3 IM Provided | - | 11,962 | 75,440 | - | - | | -% | - | 75,440 | 18,860 | 18,860 | 3,155 |
| IUD 10 Insertion | - | - | - | - | 41 | | (100)% | 41 | 2,526 | - | - | - |
| Non-PSI IUD 10 Inserted | - | - | - | - | 41 | | (100)% | 41 | 2,526 | - | - | - |
| IUD 5 | - | (19,427) | (110,721) | - | - | | 0% | - | (114,127) | (99,649) | (328,841) | (74,550) |
| (b)PSI IUD 5 Distributed Inserted | - | (19,427) | (110,721) | - | - | | -% | - | (114,127) | (99,649) | (328,841) | (74,550) |
| IUD 5 Insertion | 17,553 | 19,427 | 134,533 | 65,000 | 44,907 | | 200% | 49,622 | 253,726 | 134,533 | 443,959 | 100,648 |
| Non-PSI IUD 5 Inserted | 17,553 | - | 23,812 | 65,000 | 44,907 | | (47)% | 49,622 | 139,599 | 23,812 | 78,580 | 17,814 |
| PSI IUD 5 Inserted | - | 19,427 | 110,721 | - | - | | -% | - | 114,127 | 110,721 | 365,379 | 82,834 |
| OCs | - | (102,224) | (463,593) | - | - | | 0% | - | (463,593) | (27,816) | (27,816) | (4,909) |
| (b)PSI OCs Distributed Provided | - | (102,224) | (463,593) | - | - | | -% | - | (463,593) | (27,816) | (27,816) | (4,909) |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| OCs Provided | 81,497 | 102,224 | 545,090 | 150,000 | 91,886 | | 493% | 100,521 | 709,747 | 36,339 | 36,339 | 6,414 |
| Non-PSI OCs Provided | 81,497 | - | 81,497 | 150,000 | 91,886 | | (11)% | 100,521 | 246,154 | 5,433 | 5,433 | 959 |
| PSI OCs Provided | - | 102,224 | 463,593 | - | - | | -% | - | 463,593 | 30,906 | 30,906 | 5,455 |
| TB Diagnosis | - | - | - | 400 | - | | 0% | - | - | - | - | - |
| TB Diagnosis | - | - | - | 400 | - | | -% | - | - | - | - | - |
| TB DOTS | - | - | - | 500 | - | | 0% | - | - | - | - | - |
| TB DOTS | - | - | - | 500 | - | | -% | - | - | - | - | - |
| TB Screening | - | - | - | 100,000 | - | | 0% | - | - | - | - | - |
| TB Screening | - | - | - | 100,000 | - | | -% | - | - | - | - | - |
| Toilets Sold | 8,435 | 6,931 | 68,647 | 60,000 | 41,273 | | 66% | 50,363 | 119,010 | 329,506 | - | 7,865 |
| Toilets Sold | 8,435 | 6,931 | 68,647 | 60,000 | 41,273 | | 66% | 50,363 | 119,010 | 329,506 | - | 7,865 |
| Toilets Sold - All | 8,435 | 6,931 | 68,647 | - | 41,273 | | 66% | 50,363 | 119,010 | 329,506 | - | - |
| Toilets Sold - All | 8,435 | 6,931 | 68,647 | - | 41,273 | | 66% | 50,363 | 119,010 | 329,506 | - | - |
| Tubal Ligation | 5,440 | 3,237 | 35,994 | 25,000 | 32,967 | | 9% | 38,957 | 118,197 | 35,994 | 467,922 | 125,057 |
| Tubal Ligation | 5,440 | 3,237 | 35,994 | 25,000 | 32,967 | | 9% | 38,957 | 118,197 | 35,994 | 467,922 | 125,057 |
| Vasectomy | 291 | 289 | 1,462 | 1,000 | 269 | | 443% | 287 | 5,417 | 1,462 | 19,006 | 5,134 |
| Vasectomy | 291 | 289 | 1,462 | 1,000 | 269 | | 443% | 287 | 5,417 | 1,462 | 19,006 | 5,134 |
| Kenya | | | | | | | | | | | 876,819 | 1,418,360 |
| Antiretroviral Treatment (Currently Enrolled) | 8,010 | 8,005 | 86,070 | 92,100 | 78,099 | | 10% | 85,622 | 200,522 | 7,172 | - | 18,725 |
| Antiretroviral Treatment (Currently Enrolled) | 8,010 | 8,005 | 86,070 | 92,100 | 78,099 | | 10% | 85,622 | 200,522 | 7,172 | - | 18,725 |
| Antiretroviral Treatment (Newly Enrolled) | 138 | 126 | 1,303 | 1,754 | 1,111 | | 17% | 1,227 | 4,723 | 1,303 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 138 | 126 | 1,303 | 1,754 | 1,111 | | 17% | 1,227 | 4,723 | 1,303 | - | - |
| Cervical Cancer-VIA and Cryotherapy | - | 10 | 174 | 200 | 213 | | (18)% | 227 | 3,490 | 174 | - | 40 |
| Cervical Cancer-VIA and Cryotherapy | - | 10 | 174 | 200 | 213 | 7/13 | (18)% | 227 | 3,490 | 174 | - | 40 |
| Cervical Cancer-VIA and Refer to Conization | - | - | - | - | 1 | | (100)% | 4 | 4 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Cervical Cancer-VIA and Refer to Conization | - | - | - | - | 1 | | (100)% | 4 | 4 | - | - | - |
| Cervical Cancer-VIA and Refer to Cryotherapy | - | - | - | 150 | 22 | | (100)% | 29 | 48 | - | - | - |
| Cervical Cancer-VIA and Refer to Cryotherapy | - | - | - | 150 | 22 | 12/14 | (100)% | 29 | 48 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | - | 2,958 | 34,361 | 18,000 | 29,872 | | 15% | 31,803 | 314,735 | 34,361 | - | - |
| Cervical Cancer-VIA/VILI Screening | - | 2,958 | 34,361 | 18,000 | 29,872 | | 15% | 31,803 | 314,735 | 34,361 | - | - |
| Condom | 3,017,088 | 2,137,897 | 28,497,387 | 26,249,999 | 21,138,538 | | 35% | 25,124,074 | 591,300,704 | 213,730 | 213,730 | 846,413 |
| Trust | 2,581,632 | 1,698,744 | 23,098,633 | 20,922,493 | 16,537,429 | 10/93 | 40% | 19,627,309 | 525,326,881 | 173,240 | 173,240 | 686,063 |
| Trust Ribbed | 48,384 | 44,496 | 662,593 | 591,117 | 561,957 | 5/14 | 18% | 701,493 | 4,355,456 | 4,969 | 4,969 | 19,680 |
| Trust Scented | - | - | 216 | - | 60,552 | 5/14 | (100)% | 60,552 | 3,301,903 | 2 | 2 | 6 |
| Trust Studded | 387,072 | 394,656 | 4,735,945 | 4,736,389 | 3,978,600 | 1/08 | 19% | 4,734,720 | 58,316,464 | 35,520 | 35,520 | 140,664 |
| Diarrhea Treatment Kit Provided | - | 586 | 15,147 | 29,000 | 16,520 | | (8)% | 18,226 | 69,404 | 15,147 | - | 503 |
| Non-PSI Diarrhea Treatment Kit Provided | - | 586 | 15,147 | 29,000 | 16,520 | | (8)% | 18,226 | 69,404 | 15,147 | - | 503 |
| Emergency Contraception | - | - | - | - | (126) | | 0% | (126) | (1,554) | - | - | - |
| (b)PSI Emergency Contraception Distributed Provided | - | - | - | - | (126) | | -% | (126) | (1,554) | - | - | - |
| Emergency Contraception Provided | 929 | 749 | 4,641 | 1,800 | 1,328 | | 249% | 1,539 | 7,608 | 232 | 232 | 95 |
| Non-PSI Emergency Contraception Provided | 929 | 749 | 4,641 | 1,800 | 1,202 | | 286% | 1,413 | 6,054 | 232 | 232 | 95 |
| PSI Emergency Contraception Provided | - | - | - | - | 126 | | (100)% | 126 | 1,554 | - | - | - |
| Free Condom | - | - | 1,913,760 | 35,000,000 | 23,464,800 | | (92)% | 28,851,120 | 92,411,197 | 14,353 | 14,353 | 56,841 |
| Free Male Condom - NASCOP | - | - | 1,913,760 | 35,000,000 | 23,464,800 | 5/11 | (92)% | 28,851,120 | 92,411,197 | 14,353 | 14,353 | 56,841 |
| HIV Self-Testing Kit | 3,685 | 3,853 | 43,162 | 37,343 | - | | 0% | 69,171 | 112,333 | 38,846 | - | - |
| INSTI HIVST (Blood based) | 1,280 | 866 | 3,878 | 25,000 | - | | -% | 40,000 | 43,878 | 3,490 | - | - |
| INSTI-ORAQUICK HIVST BUNDLE | - | - | - | - | - | | -% | 1,000 | 1,000 | - | - | - |
| ORAQUICK HIV Self-Testing Kit (Saliva based) | 2,405 | 2,987 | 39,284 | 12,343 | - | | -% | 28,171 | 67,455 | 35,356 | - | - |
| HIV Testing Services | 9,119 | 13,106 | 200,668 | 165,478 | 187,386 | | 7% | 212,997 | 1,388,230 | 200,668 | - | 8,382 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| VCT Individual (HIV-Negative) | 8,926 | 12,884 | 197,330 | 161,373 | 184,560 | 9/11 | 7% | 209,785 | 1,350,550 | 197,330 | - | 8,243 |
| VCT Individual (HIV-Positive) | 193 | 221 | 3,338 | 4,105 | 2,826 | 9/11 | 18% | 3,212 | 37,680 | 3,338 | - | 139 |
| Implant 3 | 500 | 1,167 | 9,100 | 6,000 | 1 | | 909900% | 1 | 816,093 | 8,190 | 20,475 | 15,005 |
| Implanon | 500 | 1,167 | 9,100 | 6,000 | 1 | 3/14 | 909,900% | 1 | 816,093 | 8,190 | 20,475 | 15,005 |
| Implant 3 Insertion | 6,682 | 6,511 | 26,215 | 38,123 | - | | 0% | - | 26,215 | 26,215 | 65,538 | 48,030 |
| Non-PSI Implant 3 Inserted | 6,682 | 6,511 | 26,215 | 38,123 | - | | -% | - | 26,215 | 26,215 | 65,538 | 48,030 |
| Implant 5 | (40) | (1,125) | (11,834) | (7,600) | 1,051 | | (1226)% | 2,423 | 42,049 | (10,651) | (40,472) | (29,103) |
| Jadelle | - | 2,570 | 17,991 | 2,400 | 20,870 | 1/09 | (14)% | 23,710 | 202,919 | 16,192 | 61,529 | 44,245 |
| (b)PSI Implant 5 Distributed Inserted | (40) | (3,695) | (29,825) | (10,000) | (19,819) | | -% | (21,287) | (160,870) | (26,843) | (102,001) | (73,349) |
| Implant 5 Insertion | 5,955 | 6,074 | 66,070 | 35,000 | 46,208 | | 43% | 50,514 | 357,869 | 66,070 | 251,066 | 180,540 |
| Non-PSI Implant 5 Inserted | 5,915 | 2,379 | 36,245 | 25,000 | 26,389 | | 37% | 29,227 | 196,999 | 36,245 | 137,731 | 99,042 |
| PSI Implant 5 Inserted | 40 | 3,695 | 29,825 | 10,000 | 19,819 | | 50% | 21,287 | 160,870 | 29,825 | 113,335 | 81,499 |
| Injectable 3-IM | 33,264 | (4,072) | 14,678 | 79,400 | 94,471 | | (84)% | 117,204 | 5,731,872 | 3,303 | 3,303 | 1,783 |
| Femiplan Injectable | 33,264 | 62 | 113,430 | 79,400 | 232,098 | 3/00 | (51)% | 267,954 | 6,141,708 | 25,522 | 25,522 | 13,776 |
| (b)PSI Injectable 3 IM Distributed Provided | - | (4,134) | (98,752) | - | (137,627) | | -% | (150,750) | (409,836) | (22,219) | (22,219) | (11,993) |
| Injectable 3-IM Provided | 36,963 | 37,776 | 236,639 | 169,422 | 137,627 | | 72% | 150,750 | 547,723 | 59,160 | 59,160 | 31,932 |
| Non-PSI Injectable 3 IM Provided | 36,963 | 33,641 | 137,887 | 169,422 | - | | -% | - | 137,887 | 34,472 | 34,472 | 18,606 |
| PSI Injectable 3 IM Provided | - | 4,134 | 98,752 | - | 137,627 | | (28)% | 150,750 | 409,836 | 24,688 | 24,688 | 13,326 |
| IPTp2 | - | 450 | 4,249 | - | 3,470 | | 22% | 3,893 | 18,546 | 4,249 | - | 159 |
| IPTp2 | - | 450 | 4,249 | - | 3,470 | | 22% | 3,893 | 18,546 | 4,249 | - | 159 |
| IUD 10 | - | (360) | (7,480) | (4,600) | (1,260) | | 0% | 605 | 2,547 | (6,732) | (30,967) | (21,249) |
| CU 380A (Copper T) | - | 63 | 190 | 2,400 | 8,191 | 3/09 | (98)% | 10,551 | 99,414 | 171 | 787 | 540 |
| (b)PSI IUD 10 Distributed Inserted | - | (423) | (7,670) | (7,000) | (9,451) | | -% | (9,946) | (96,867) | (6,903) | (31,754) | (21,788) |
| IUD 10 Insertion | 4,009 | 3,811 | 27,521 | 27,350 | 16,130 | | 71% | 17,347 | 206,775 | 27,521 | 126,597 | 86,866 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Non-PSI IUD 10 Inserted | 4,009 | 3,388 | 19,851 | 20,350 | 6,679 | | 197% | 7,401 | 109,908 | 19,851 | 91,315 | 62,657 |
| PSI IUD 10 Inserted | - | 423 | 7,670 | 7,000 | 9,451 | | (19)% | 9,946 | 96,867 | 7,670 | 35,282 | 24,209 |
| LLIN | 719 | 94,433 | 906,690 | 1,824,672 | 1,990,597 | | (54)% | 2,332,163 | 24,551,337 | 1,468,838 | - | 29,903 |
| ANC LLIN | - | - | - | 1,800,000 | - | 7/08 | -% | - | 19,189,925 | - | - | - |
| Supanet Conical | 312 | 415 | 7,942 | 8,578 | 6,118 | 10/16 | 30% | 8,447 | 23,570 | 12,866 | - | 262 |
| Supanet Rectangular | 407 | 370 | 6,917 | 16,094 | 12,900 | 10/16 | (46)% | 13,913 | 25,540 | 11,206 | - | 228 |
| Supanet XtraPower BL PNET USAID | - | 93,648 | 891,831 | - | 1,971,579 | 3/14 | (55)% | 2,309,803 | 5,312,302 | 1,444,766 | - | 29,413 |
| OCs | 315,720 | 272,712 | 2,946,593 | 3,418,400 | 3,003,944 | | (2)% | 3,635,514 | 41,593,366 | 176,796 | 176,796 | 100,670 |
| Famipill | - | - | 9,000 | - | 3,828 | 5/18 | 135% | 140,628 | 149,628 | 540 | 540 | 307 |
| Femi Girl Oral Pills | - | 632 | 4,792 | 15,900 | 162,192 | 11/16 | (97)% | 162,192 | 176,728 | 288 | 288 | 164 |
| Femiplan Pill | 315,720 | 272,870 | 2,953,888 | 3,402,500 | 2,878,638 | 3/00 | 3% | 3,376,158 | 41,360,640 | 177,233 | 177,233 | 100,919 |
| (b)PSI OCs Distributed Provided | - | (790) | (21,087) | - | (40,714) | | -% | (43,464) | (93,630) | (1,265) | (1,265) | (720) |
| OCs Provided | 8,533 | 8,216 | 53,418 | 31,469 | 41,242 | | 30% | 44,411 | 126,908 | 3,561 | 3,561 | 2,028 |
| Non-PSI OCs Provided | 8,533 | 7,427 | 32,331 | 31,469 | 528 | | 6,023% | 947 | 33,278 | 2,155 | 2,155 | 1,227 |
| PSI OCs Provided | - | 790 | 21,087 | - | 40,714 | | (48)% | 43,464 | 93,630 | 1,406 | 1,406 | 800 |
| ORS Provided | - | 59 | 2,043 | - | 2,025 | | 1% | 2,217 | 9,430 | 2,043 | - | 33 |
| Non-PSI ORS Provided | - | 59 | 2,043 | - | 2,025 | | 1% | 2,217 | 9,430 | 2,043 | - | 33 |
| Pneumonia PPT | - | - | - | 28,910 | - | | 0% | - | - | - | - | - |
| 5 & A Pneumonia Pack-Child | - | - | - | 28,910 | - | | -% | - | - | - | - | - |
| Pneumonia PPT Provided | - | 1,245 | 17,319 | - | 19,159 | | (10)% | 20,179 | 75,392 | 17,319 | - | 8,331 |
| Non-PSI Pneumonia PPT Provided | - | 1,245 | 17,319 | - | 19,159 | | (10)% | 20,179 | 75,392 | 17,319 | - | 8,331 |
| PrEP | 77 | 69 | 478 | - | - | | 0% | - | 478 | 40 | - | 20 |
| PrEP | 77 | 69 | 478 | - | - | | -% | - | 478 | 40 | - | 20 |
| PUR | 2,931,360 | 2,024,083 | 29,796,020 | 19,000,000 | 26,022,720 | | 15% | 27,875,040 | 194,718,156 | 244,899 | - | 604 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| PuR | 2,931,360 | 2,024,083 | 29,796,020 | 19,000,000 | 26,022,720 | 2/06 | 15% | 27,875,040 | 194,718,156 | 244,899 | - | 604 |
| QAACTs Provided after Confirmatory Diagnosis | - | - | 23,733 | 95,000 | 86,593 | | (73)% | 96,981 | 124,639 | 23,733 | - | 3,904 |
| Non-PSI QAACTs Provided after Confirmed Diagnosis | - | - | 23,733 | 95,000 | 86,593 | | (73)% | 96,981 | 124,639 | 23,733 | - | 3,904 |
| Safe Water Solution | 63,072 | 95,113 | 1,346,558 | 1,160,000 | 964,120 | | 40% | 1,114,276 | 22,820,458 | 1,106,760 | - | 2,731 |
| WaterGuard | 63,072 | 95,113 | 1,346,558 | 1,160,000 | 964,120 | 5/03 | 40% | 1,114,276 | 22,820,458 | 1,106,760 | - | 2,731 |
| SDM (Cycle Beads) Provided | 1,111 | 1,378 | 5,246 | - | - | | 0% | - | 5,246 | 5,246 | 7,869 | 6,086 |
| Non-PSI SDM (Cycle Beads) Provided | 1,111 | 1,378 | 5,246 | - | - | | -% | - | 5,246 | 5,246 | 7,869 | 6,086 |
| Skilled Birth Attendance | - | 2,078 | 18,514 | 40,000 | 18,400 | | 1% | 20,115 | 80,683 | 18,514 | - | 15,389 |
| Skilled Birth Attendance | - | 2,078 | 18,514 | 40,000 | 18,400 | | 1% | 20,115 | 80,683 | 18,514 | - | 15,389 |
| TB Diagnosis | - | 36 | 349 | 281 | - | | 0% | 56 | 1,020 | 349 | - | - |
| TB Diagnosis | - | 36 | 349 | 281 | - | | -% | 56 | 1,020 | 349 | - | - |
| TB Screening | - | 4,687 | 40,435 | 7,816 | - | | 0% | 6,339 | 120,813 | 40,435 | - | - |
| TB Screening | - | 4,687 | 40,435 | 7,816 | - | | -% | 6,339 | 120,813 | 40,435 | - | - |
| Treatment for Pre-Eclampsia (with MgSO4) | - | 6 | 22 | 60 | 49 | | (55)% | 49 | 192 | 22 | - | 20 |
| Treatment for Pre-Eclampsia (with MgSO4) | - | 6 | 22 | 60 | 49 | | (55)% | 49 | 192 | 22 | - | 20 |
| Tubal Ligation | 118 | 146 | 555 | - | - | | 0% | - | 555 | 555 | 5,550 | 3,458 |
| Tubal Ligation | 118 | 146 | 555 | - | - | | -% | - | 555 | 555 | 5,550 | 3,458 |
| Vasectomy | 3 | - | 3 | - | - | | 0% | - | 3 | 3 | 30 | 19 |
| Vasectomy | 3 | - | 3 | - | - | | -% | - | 3 | 3 | 30 | 19 |
| Voluntary Medical Male Circumcision | - | - | 31 | - | - | | 0% | - | 31 | 31 | - | 173 |
| Voluntary Medical Male Circumcision | - | - | 31 | - | - | | -% | - | 31 | 31 | - | 173 |
| Water Treatment Tablets | - | 9,360 | 697,680 | 300,000 | 486,000 | | 44% | 501,290 | 6,634,880 | 11,469 | - | 28 |
| Aquatab | - | 9,360 | 697,680 | 300,000 | 486,000 | 3/09 | 44% | 501,290 | 6,634,880 | 11,469 | - | 28 |
| Myanmar | | | | | | | | | | | 530,570 | 280,073 |
| Antiretroviral Treatment (Currently Enrolled) | 7,224 | 7,012 | 72,422 | 78,076 | 60,691 | | 19% | 66,381 | 186,454 | 6,035 | - | 12,652 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Antiretroviral Treatment (Currently Enrolled) | 7,224 | 7,012 | 72,422 | 78,076 | 60,691 | | 19% | 66,381 | 186,454 | 6,035 | - | 12,652 |
| Antiretroviral Treatment (Newly Enrolled) | 138 | 199 | 2,178 | 2,227 | 2,037 | | 7% | 2,207 | 8,344 | 2,178 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 138 | 199 | 2,178 | 2,227 | 2,037 | | 7% | 2,207 | 8,344 | 2,178 | - | - |
| Cervical Cancer-VIA and Cryotherapy | 18 | 17 | 126 | 40 | 51 | | 147% | 59 | 1,083 | 126 | - | 31 |
| Cervical Cancer-VIA and Cryotherapy | 18 | 17 | 126 | 40 | 51 | 11/12 | 147% | 59 | 1,083 | 126 | - | 31 |
| Cervical Cancer-VIA/VILI Screening | 319 | 362 | 3,306 | 3,500 | 2,429 | | 36% | 2,911 | 10,661 | 3,306 | - | - |
| Cervical Cancer-VIA/VILI Screening | 319 | 362 | 3,306 | 3,500 | 2,429 | | 36% | 2,911 | 10,661 | 3,306 | - | - |
| Condom | 908,802 | 1,628,621 | 13,397,442 | 15,520,000 | 11,380,146 | | 18% | 12,893,474 | 426,098,173 | 100,481 | 100,481 | 73,512 |
| Aphaw | 249,420 | 327,687 | 3,730,894 | - | 1,915,040 | 7/96 | 95% | 2,515,280 | 194,996,573 | 27,982 | 27,982 | 20,471 |
| Aphaw - Natural Touch | 104,337 | 196,410 | 1,064,013 | 1,953,000 | 1,038,437 | 8/12 | 2% | 1,039,098 | 15,841,686 | 7,980 | 7,980 | 5,838 |
| Aphaw Deluxe GL (3x1) | - | - | - | 3,515,400 | - | | -% | - | - | - | - | - |
| Aphaw Flavors | 546,744 | 601,500 | 4,442,844 | 5,208,000 | 5,471,704 | 10/01 | (19)% | 5,926,276 | 181,263,535 | 33,321 | 33,321 | 24,378 |
| Aphaw Studded | 5,301 | 252,758 | 1,612,617 | 2,343,600 | 930,515 | 7/12 | 73% | 1,050,858 | 20,061,162 | 12,095 | 12,095 | 8,848 |
| Generic Male Condom | 3,000 | 250,267 | 2,541,500 | 2,500,000 | 1,943,400 | 1/08 | 31% | 2,270,400 | 8,700,429 | 19,061 | 19,061 | 13,945 |
| OK Condom | - | - | 5,574 | - | 81,050 | 5/03 | (93)% | 91,562 | 5,234,788 | 42 | 42 | 31 |
| Emergency Contraception | 65 | 312 | 1,000 | - | 5 | | 19900% | 5 | 178,869 | 45 | 45 | 4 |
| Levonorgestrel 1.5 mg Tablet | 65 | 312 | 1,000 | - | - | | -% | - | 1,000 | 45 | 45 | 4 |
| OK EC | - | - | - | - | 5 | 8/07 | (100)% | 5 | 177,869 | - | - | - |
| Female Condom | - | 967 | 85,553 | 70,000 | 65,906 | | 30% | 79,641 | 1,556,019 | 642 | 642 | 461 |
| Generic Female Condom | - | 967 | 85,553 | 70,000 | 65,906 | 5/08 | 30% | 79,641 | 1,556,019 | 642 | 642 | 461 |
| Fever Cases Attended | 43,613 | 49,315 | 446,149 | - | 611,247 | | (27)% | 697,782 | 2,877,317 | 446,149 | - | - |
| Fever Cases Attended | 43,613 | 49,315 | 446,149 | - | 611,247 | | (27)% | 697,782 | 2,877,317 | 446,149 | - | - |
| Fever Cases Tested with RDTs | 43,613 | 49,315 | 446,149 | - | 611,247 | | (27)% | 697,782 | 2,877,317 | 446,149 | - | - |
| Fever Cases Tested with RDTs | 43,613 | 49,315 | 446,149 | - | 611,247 | | (27)% | 697,782 | 2,877,317 | 446,149 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Free Condom | 468 | 2,244 | 7,200 | - | - | | 0% | - | 7,200 | 54 | 54 | 40 |
| Free Male Condoms | 468 | 2,244 | 7,200 | - | - | | -% | - | 7,200 | 54 | 54 | 40 |
| Free Female Condom | 12,320 | 8,620 | 38,180 | - | - | | 0% | - | 38,180 | 286 | 286 | 206 |
| FC2 Female Condom | 12,320 | 8,620 | 38,180 | - | - | 11/16 | -% | - | 38,180 | 286 | 286 | 206 |
| HIV Testing Services | 5,905 | 5,428 | 55,663 | 64,440 | 44,615 | | 25% | 48,784 | 450,457 | 55,663 | - | 67 |
| VCT Individual (HIV-Negative) | 5,698 | 5,179 | 53,084 | 59,647 | 41,732 | 12/09 | 27% | 45,712 | 420,041 | 53,084 | - | 64 |
| VCT Individual (HIV-Positive) | 207 | 249 | 2,579 | 4,793 | 2,883 | 12/09 | (11)% | 3,072 | 30,416 | 2,579 | - | 3 |
| Hypertension Diagnosis | 1,057 | 1,422 | 31,449 | 20,000 | 57,365 | | (45)% | 57,768 | 105,258 | 31,449 | - | - |
| Hypertension Diagnosis | 1,057 | 1,422 | 31,449 | 20,000 | 57,365 | | (45)% | 57,768 | 105,258 | 31,449 | - | - |
| Hypertension Screening | 2,049 | 2,654 | 80,891 | 50,000 | 168,855 | | (52)% | 176,640 | 292,045 | 80,891 | - | - |
| Hypertension Screening | 2,049 | 2,654 | 80,891 | 50,000 | 168,855 | | (52)% | 176,640 | 292,045 | 80,891 | - | - |
| Hypertension_Controlled Condition | 781 | 1,085 | 22,960 | - | 43,197 | | (47)% | 43,499 | 78,769 | 9,184 | - | - |
| Hypertension_Controlled Condition | 781 | 1,085 | 22,960 | - | 43,197 | | (47)% | 43,499 | 78,769 | 9,184 | - | - |
| Implant 3 | 77 | 73 | 842 | 6,600 | 1,037 | | (19)% | 1,527 | 12,525 | 758 | 1,895 | 322 |
| Implanon NXT | 581 | 590 | 6,477 | 6,600 | 5,248 | 12/15 | 23% | 6,278 | 26,392 | 5,829 | 14,573 | 2,478 |
| (b)PSI Implant 3 Distributed Inserted | (504) | (517) | (5,635) | - | (4,211) | | -% | (4,751) | (13,867) | (5,072) | (12,679) | (2,156) |
| Implant 3 Insertion | 504 | 517 | 5,635 | - | 4,211 | | 34% | 4,751 | 13,867 | 5,635 | 14,088 | 2,395 |
| PSI Implant 3 Inserted | 504 | 517 | 5,635 | - | 4,211 | | 34% | 4,751 | 13,867 | 5,635 | 14,088 | 2,395 |
| Implant 5 | - | - | 93 | - | - | | 0% | - | 200 | 84 | 318 | 53 |
| Jadelle | - | - | 93 | - | - | 5/16 | -% | - | 200 | 84 | 318 | 53 |
| Injectable 3-IM | 30,049 | 33,213 | 342,722 | 401,200 | 322,306 | | 6% | 376,475 | 10,078,089 | 77,112 | 77,112 | 9,643 |
| OK-3 Injection | 30,049 | 33,213 | 342,722 | 401,200 | 322,306 | 9/01 | 6% | 376,475 | 10,078,089 | 77,112 | 77,112 | 9,643 |
| Injectable 3-SC | 2,359 | 1,890 | 28,127 | 32,150 | - | | 0% | - | 28,127 | 6,329 | 6,329 | 791 |
| Sayana Press | 2,359 | 1,890 | 28,127 | 32,150 | - | | -% | - | 28,127 | 6,329 | 6,329 | 791 |
| IUD 10 | - | 5 | 227 | - | 79 | | 187% | 79 | 3,546 | 204 | 940 | 150 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| OK IUD (Copper T Cu 380A) | - | 5 | 227 | - | 79 | 10/14 | 187% | 79 | 3,546 | 204 | 940 | 150 |
| IUD 5 | 53 | 28 | 314 | 2,500 | 191 | | 64% | 472 | 141,716 | 283 | 933 | 159 |
| OK IUD | - | - | - | 2,500 | 1,206 | 5/03 | (100)% | 1,206 | 198,833 | - | - | - |
| OK IUD (Inara Cu 375 Sleek) | 133 | 128 | 1,416 | - | 375 | | 278% | 768 | 2,184 | 1,274 | 4,206 | 715 |
| (b)PSI IUD 5 Distributed Inserted | (80) | (100) | (1,102) | - | (1,390) | | -% | (1,502) | (59,301) | (992) | (3,273) | (557) |
| IUD 5 Insertion | 80 | 100 | 1,102 | - | 1,390 | | (21)% | 1,502 | 59,301 | 1,102 | 3,637 | 618 |
| PSI IUD 5 Inserted | 80 | 100 | 1,102 | - | 1,390 | | (21)% | 1,502 | 59,301 | 1,102 | 3,637 | 618 |
| LLIN | 400 | 2,984 | 176,058 | 225,226 | - | | 0% | - | 214,138 | 285,214 | - | 11,213 |
| LLIN | 400 | 2,984 | 176,058 | 225,226 | - | 11/16 | -% | - | 214,138 | 285,214 | - | 11,213 |
| Lubricant | 293,000 | 280,426 | 2,047,836 | 70,000 | 44,649 | | 4487% | 51,861 | 7,280,522 | - | - | - |
| Aphaw Gel - Sachet | 293,000 | 280,317 | 2,015,002 | 40,000 | 250 | 10/06 | 805,901% | 250 | 6,443,310 | - | - | - |
| Aphaw Gel - Tube 20 cc | - | - | 12,378 | 30,000 | 44,399 | 10/06 | (72)% | 51,611 | 694,058 | - | - | - |
| Aphaw Gel - Tube 20 cc - Flavors | - | 109 | 20,456 | - | - | 10/14 | -% | - | 143,154 | - | - | - |
| Malaria PPT (ACT) | 244 | 8,884 | 173,273 | 182,270 | 255,664 | | (32)% | 256,333 | 3,362,169 | 155,946 | - | 24,308 |
| AL 1 | 47 | 89 | 2,599 | 126 | 3,388 | 7/12 | (23)% | 3,413 | 19,601 | 2,339 | - | 365 |
| AL 2 | 46 | 84 | 2,656 | 126 | 3,363 | 7/12 | (21)% | 3,390 | 20,409 | 2,390 | - | 373 |
| AL 3 | 51 | 94 | 2,991 | 379 | 3,410 | 1/11 | (12)% | 3,470 | 55,385 | 2,692 | - | 420 |
| AL 4 | 102 | 297 | 5,136 | 5,689 | 12,539 | 1/11 | (59)% | 13,664 | 281,558 | 4,622 | - | 721 |
| Arte+1 | 15 | 5 | 753 | 2,500 | - | 8/14 | -% | - | 23,032 | 678 | - | 106 |
| Arte+2 | 15 | 5 | 752 | 2,500 | - | 8/14 | -% | - | 23,930 | 677 | - | 105 |
| Arte+3 | 15 | 405 | 1,953 | 3,000 | - | 8/14 | -% | - | 28,495 | 1,758 | - | 274 |
| Arte+4 | 21 | 3,243 | 74,550 | 79,975 | 114,680 | 8/14 | (35)% | 114,680 | 655,918 | 67,095 | - | 10,459 |
| (b)PSI QAACTs Distributed Provided after Diagnosis | (68) | (144) | (1,049) | - | (4,218) | | -% | (4,786) | (20,688) | (944) | - | (147) |
| Supa Arte 1 | - | - | 1,503 | 2,500 | - | 9/12 | -% | - | 122,214 | 1,353 | - | 211 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Supa Arte 2 | - | - | 1,503 | 2,500 | - | 9/12 | -% | - | 118,055 | 1,353 | - | 211 |
| Supa Arte 3 | - | - | 1,503 | 3,000 | - | 9/12 | -% | - | 197,962 | 1,353 | - | 211 |
| Supa Arte 4 | - | 4,807 | 78,423 | 79,975 | 122,502 | 9/12 | (36)% | 122,502 | 1,836,298 | 70,581 | - | 11,002 |
| Malaria PPT (Non-ACT) | 114 | 1,242 | 2,730 | 3,621 | (1,521) | | 0% | (1,900) | 107,056 | 2,457 | - | 383 |
| Chloroquine 10's | 209 | 1,445 | 4,543 | - | - | | -% | - | 4,543 | 4,089 | - | 637 |
| (b)PSI Vivax Tx Distributed Provided after Diagnosis | (95) | (203) | (1,822) | - | (2,858) | | -% | (3,244) | (11,028) | (1,640) | - | (256) |
| Vivax Treatment Kit | - | - | 9 | 3,621 | 1,337 | 6/11 | (99)% | 1,344 | 113,541 | 8 | - | 1 |
| Malaria RDK | - | - | - | 432,337 | 705,945 | | (100)% | 743,410 | 4,731,974 | - | - | - |
| Malaria RDT (Diagnosis) | - | - | - | 432,337 | 705,945 | 3/11 | (100)% | 743,410 | 4,731,974 | - | - | - |
| Micronutrient Powder | - | - | - | - | 1,880,940 | | (100)% | 2,000,000 | 9,499,690 | - | - | - |
| Happy Kid (Micronutrient powder) | - | - | - | - | 1,880,940 | 9/16 | (100)% | 2,000,000 | 9,499,690 | - | - | - |
| Multivitamin | - | - | - | - | 450,010 | | (100)% | 450,010 | 883,520 | - | - | - |
| May May Vita Plus | - | - | - | - | 450,010 | 6/17 | (100)% | 450,010 | 883,520 | - | - | - |
| Needle & Syringe | - | 567 | 10,100 | - | - | | 0% | - | 1,956,069 | 35 | - | 83 |
| Needle & Syringe (LDS) | - | 567 | 10,100 | - | - | 10/15 | -% | - | 1,956,069 | 35 | - | 83 |
| OCs | 567,993 | 727,220 | 5,396,862 | 6,804,000 | 5,154,460 | | 5% | 5,856,883 | 32,550,444 | 323,812 | 323,812 | 42,717 |
| OK Pills | 567,828 | 725,853 | 5,383,579 | 6,804,000 | 5,130,932 | 9/01 | 5% | 5,831,882 | 32,500,539 | 323,015 | 323,015 | 42,612 |
| OK Pills (Zinnia F) | 165 | 1,367 | 13,283 | - | 23,528 | 11/16 | (44)% | 25,001 | 49,905 | 797 | 797 | 105 |
| ORS | 97,044 | 131,515 | 809,024 | 600,000 | 459,503 | | 76% | 514,198 | 2,039,878 | 364,061 | - | 21,214 |
| ORS | 97,044 | 131,515 | 809,024 | 600,000 | 459,503 | 1/08 | 76% | 514,198 | 2,039,878 | 364,061 | - | 21,214 |
| Positive RDTs | 224 | 495 | 3,960 | - | 8,667 | | (54)% | 9,712 | 39,431 | 3,960 | - | - |
| Positive RDTs | 224 | 495 | 3,960 | - | 8,667 | | (54)% | 9,712 | 39,431 | 3,960 | - | - |
| Positive RDTs Given First Line Treatment | 224 | 492 | 3,825 | - | 7,926 | | (52)% | 8,937 | 34,828 | 3,825 | - | - |
| Positive RDTs Given First Line Treatment | 224 | 492 | 3,825 | - | 7,926 | | (52)% | 8,937 | 34,828 | 3,825 | - | - |
| PUR | - | - | - | - | 633,309 | | (100)% | 633,309 | 15,857,790 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Purifier of Water | - | - | - | - | 633,309 | 4/14 | (100)% | 633,309 | 15,857,790 | - | - | - |
| QAACs Provided after Confirmatory Diagnosis | 68 | 144 | 1,049 | - | 4,218 | | (75)% | 4,786 | 20,688 | 1,049 | - | 192 |
| PSI QAACs Provided after Confirmed Diagnosis | 68 | 144 | 1,049 | - | 4,218 | | (75)% | 4,786 | 20,688 | 1,049 | - | 192 |
| Referral to TB DOTS (completion confirmed) | 42 | 70 | 951 | 2,349 | 1,075 | | (12)% | 1,214 | 2,458 | 951 | - | 2,949 |
| Referral to TB DOTS (completion confirmed) | 42 | 70 | 951 | 2,349 | 1,075 | | (12)% | 1,214 | 2,458 | 951 | - | 2,949 |
| Referral to TB DOTS (completion unknown) | 64 | 100 | 1,218 | 2,374 | 1,351 | | (10)% | 1,575 | 2,793 | 1,218 | - | 3,400 |
| Referral to TB DOTS (completion unknown) | 64 | 100 | 1,218 | 2,374 | 1,351 | | (10)% | 1,575 | 2,793 | 1,218 | - | 3,400 |
| STI Screening | 1,051 | 1,110 | 15,751 | - | 25,310 | | (38)% | 27,221 | 76,260 | 15,751 | - | - |
| STI Screening | 1,051 | 1,110 | 15,751 | - | 25,310 | | (38)% | 27,221 | 76,260 | 15,751 | - | - |
| TB Diagnosis | 1,404 | 1,206 | 11,779 | 15,500 | 12,735 | | (8)% | 14,259 | 70,712 | 11,779 | - | - |
| TB Diagnosis | 1,404 | 1,206 | 11,779 | 15,500 | 12,735 | | (8)% | 14,259 | 70,712 | 11,779 | - | - |
| TB DOTS | 988 | 1,200 | 11,636 | 12,673 | 11,937 | | (3)% | 12,891 | 229,087 | 11,636 | - | 72,176 |
| TB DOTS | 988 | 1,200 | 11,636 | 12,673 | 11,937 | 12/04 | (3)% | 12,891 | 229,087 | 11,636 | - | 72,176 |
| TB Screening | 7,236 | 7,247 | 70,133 | 41,800 | 86,207 | | (19)% | 97,611 | 361,962 | 70,133 | - | - |
| TB Screening | 7,236 | 7,247 | 70,133 | 41,800 | 86,207 | | (19)% | 97,611 | 361,962 | 70,133 | - | - |
| Vivax Treatment after Confirmatory Diagnosis | 95 | 203 | 1,822 | - | 2,858 | | (36)% | 3,244 | 11,028 | 1,822 | - | 334 |
| PSI Vivax Treatment after Confirmed Diagnosis | 95 | 203 | 1,822 | - | 2,858 | | (36)% | 3,244 | 11,028 | 1,822 | - | 334 |
| Nigeria | | | | | | | | | | | 27,321 | 30,306 |
| Emergency Contraception Provided | - | 53 | 164 | - | 24 | | 583% | 60 | 224 | 8 | 8 | 5 |
| Non-PSI Emergency Contraception Provided | - | 53 | 164 | - | 24 | | 583% | 60 | 224 | 8 | 8 | 5 |
| HIV Testing Services | - | - | - | - | 609,489 | | (100)% | 609,489 | 2,485,606 | - | - | - |
| VCT Individual (HIV-Negative) | - | - | - | - | 604,543 | 12/09 | (100)% | 604,543 | 2,342,815 | - | - | - |
| VCT Individual (HIV-Positive) | - | - | - | - | 4,946 | 12/09 | (100)% | 4,946 | 142,791 | - | - | - |
| Implant 3 Insertion | 1,300 | 409 | 3,220 | - | 372 | | 766% | 4,133 | 7,353 | 3,220 | 8,050 | 9,244 |
| Non-PSI Implant 3 Inserted | 1,300 | 409 | 3,220 | - | 372 | | 766% | 4,133 | 7,353 | 3,220 | 8,050 | 9,244 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Implant 4 Insertion | - | 487 | 1,462 | - | 288 | | 408% | 288 | 1,750 | 1,462 | 4,678 | 5,298 |
| Non-PSI Implant 4 Inserted | - | 487 | 1,462 | - | 288 | | 408% | 288 | 1,750 | 1,462 | 4,678 | 5,298 |
| Implant 5 Insertion | 1,140 | - | 1,835 | - | 5,948 | | (69)% | 2,833 | 95,537 | 1,835 | 6,973 | 7,880 |
| Non-PSI Implant 5 Inserted | 1,140 | - | 1,835 | - | 5,948 | 3/16 | (69)% | 2,833 | 95,537 | 1,835 | 6,973 | 7,880 |
| Injectable 1 Provided | 4 | 1 | 13 | - | - | | 0% | 37 | 50 | 1 | 1 | 1 |
| Non-PSI Injectable 1 Provided | 4 | 1 | 13 | - | - | | -% | 37 | 50 | 1 | 1 | 1 |
| Injectable 2 Provided | 988 | 497 | 3,355 | - | - | | 0% | 5,875 | 9,230 | 559 | 559 | 471 |
| Non-PSI Injectable 2 Provided | 988 | 497 | 3,355 | - | - | | -% | 5,875 | 9,230 | 559 | 559 | 471 |
| Injectable 3-IM Provided | 1,728 | 691 | 4,536 | - | 426 | | 965% | 6,118 | 10,654 | 1,134 | 1,134 | 956 |
| Non-PSI Injectable 3 IM Provided | 1,728 | 691 | 4,536 | - | 426 | | 965% | 6,118 | 10,654 | 1,134 | 1,134 | 956 |
| Injectable 3-SC Provided | 898 | 444 | 3,116 | - | - | | 0% | - | 3,116 | 779 | 779 | 657 |
| Non-PSI Injectable 3 SC Provided | 898 | 444 | 3,116 | - | - | | -% | - | 3,116 | 779 | 779 | 657 |
| IUD 10 Insertion | 147 | - | 232 | - | 336 | | (31)% | - | 275,284 | 232 | 1,067 | 1,155 |
| Non-PSI IUD 10 Inserted | 147 | - | 232 | - | 336 | 3/16 | (31)% | - | 275,284 | 232 | 1,067 | 1,155 |
| IUD 5 Insertion | - | 52 | 157 | - | 47 | | 234% | 479 | 636 | 157 | 518 | 596 |
| Non-PSI IUD 5 Inserted | - | 52 | 157 | - | 47 | | 234% | 479 | 636 | 157 | 518 | 596 |
| IUS 5 Insertion | 96 | 71 | 1,027 | - | 675 | | 52% | 716 | 2,369 | 1,027 | 3,389 | 3,897 |
| Non-PSI IUS 5 Inserted | 96 | 71 | 1,027 | - | 675 | | 52% | 716 | 2,369 | 1,027 | 3,389 | 3,897 |
| OCs Provided | 917 | 307 | 2,453 | - | 248 | | 889% | 5,586 | 8,039 | 164 | 164 | 145 |
| Non-PSI OCs Provided | 917 | 307 | 2,453 | - | 248 | | 889% | 5,586 | 8,039 | 164 | 164 | 145 |
| SDM (Cycle Beads) Provided | - | - | - | - | - | | 0% | 3 | 3 | - | - | - |
| Non-PSI SDM (Cycle Beads) Provided | - | - | - | - | - | | -% | 3 | 3 | - | - | - |
| PSI Nigeria | | | | | | | | | | | 416,176 | 547,418 |
| Emergency Contraception Provided | 16 | 8 | 47 | - | - | | 0% | - | 47 | 2 | 2 | 2 |
| Non-PSI Emergency Contraception Provided | 16 | 8 | 47 | - | - | | -% | - | 47 | 2 | 2 | 2 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Implant 5 Insertion | 3,445 | 3,190 | 31,864 | 27,915 | 26,869 | | 19% | 29,200 | 61,064 | 31,864 | 121,083 | 136,833 |
| Non-PSI Implant 5 Inserted | 3,445 | 3,190 | 31,864 | 27,915 | 26,869 | | 19% | 29,200 | 61,064 | 31,864 | 121,083 | 136,833 |
| Injectable 3-IM Provided | 5 | 3 | 176 | - | 2,423 | | (93)% | 2,423 | 2,599 | 44 | 44 | 37 |
| Non-PSI Injectable 3 IM Provided | 5 | 3 | 176 | - | 2,423 | | (93)% | 2,423 | 2,599 | 44 | 44 | 37 |
| IUD 10 Insertion | 5,995 | 5,971 | 64,032 | 76,440 | 67,597 | | (5)% | 72,696 | 136,728 | 64,032 | 294,547 | 318,805 |
| Non-PSI IUD 10 Inserted | 5,995 | 5,971 | 64,032 | 76,440 | 67,597 | | (5)% | 72,696 | 136,728 | 64,032 | 294,547 | 318,805 |
| IUD 5 Insertion | - | - | - | - | 58 | | (100)% | 58 | 58 | - | - | - |
| Non-PSI IUD 5 Inserted | - | - | - | - | 58 | | (100)% | 58 | 58 | - | - | - |
| IUS 5 Insertion | - | - | - | - | 59 | | (100)% | 59 | 59 | - | - | - |
| Non-PSI IUS 5 Inserted | - | - | - | - | 59 | | (100)% | 59 | 59 | - | - | - |
| Manual Vacuum Aspiration for PAC | 745 | 739 | 7,394 | 5,220 | 18,592 | | (60)% | 19,176 | 26,570 | 7,394 | - | 5,921 |
| MVA for PAC | 745 | 739 | 7,394 | 5,220 | 18,592 | | (60)% | 19,176 | 26,570 | 7,394 | - | 5,921 |
| Medical Abortion | 998 | 334 | 2,000 | 9,000 | - | | 0% | - | 2,000 | 1,800 | - | 1,689 |
| Combipack | - | - | - | 9,000 | - | | -% | - | - | - | - | - |
| Mariprist | 998 | 334 | 2,000 | - | - | | -% | - | 2,000 | 1,800 | - | 1,689 |
| Misoprostol for PAC Provided | 566 | 672 | 6,949 | 5,220 | 14,322 | | (51)% | 14,855 | 21,804 | 6,949 | - | 6,590 |
| PSI Misoprostol for PAC Provided | 566 | 672 | 6,949 | 5,220 | 14,322 | | (51)% | 14,855 | 21,804 | 6,949 | - | 6,590 |
| Misoprostol for Safe Abortion | 13,636 | 161,979 | 1,747,774 | 2,339,690 | 2,145,962 | | (19)% | 2,321,200 | 4,068,974 | 91,758 | - | 77,046 |
| Misoclear | 15,900 | 164,667 | 1,775,570 | 2,360,570 | 2,203,250 | 3/18 | (19)% | 2,380,620 | 4,156,190 | 93,217 | - | 78,272 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (2,264) | (2,688) | (27,796) | (20,880) | (57,288) | | -% | (59,420) | (87,216) | (1,459) | - | (1,225) |
| OCs Provided | 572 | 495 | 5,058 | - | 1,376 | | 268% | 1,376 | 6,434 | 337 | 337 | 300 |
| Non-PSI OCs Provided | 572 | 495 | 5,058 | - | 1,376 | | 268% | 1,376 | 6,434 | 337 | 337 | 300 |
| SDM (Cycle Beads) Provided | 13 | 6 | 108 | - | - | | 0% | - | 108 | 108 | 162 | 196 |
| Non-PSI SDM (Cycle Beads) Provided | 13 | 6 | 108 | - | - | | -% | - | 108 | 108 | 162 | 196 |
| South Africa | | | | | | | | | | | - | 622,213 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Free Condom | - | - | - | 500,000 | 39,319,200 | | (100)% | 39,319,200 | 1,084,659,760 | - | - | - |
| Public Distribution | - | - | - | 500,000 | 39,319,200 | 1/04 | (100)% | 39,319,200 | 1,084,659,760 | - | - | - |
| Free Female Condom | - | - | - | - | 1,108,500 | | (100)% | 1,108,500 | 5,030,600 | - | - | - |
| Female Condom GOSA | - | - | - | - | 1,108,500 | 10/13 | (100)% | 1,108,500 | 5,030,600 | - | - | - |
| HIV Self-Testing Kit | - | 166,072 | 598,678 | 1,029,300 | - | | 0% | 1,288,251 | 1,886,929 | 538,810 | - | - |
| ORAQUICK HIV Self-Testing Kit (Pouch) | - | 166,072 | 598,678 | 1,029,300 | - | | -% | 1,288,251 | 1,886,929 | 538,810 | - | - |
| HIV Testing Services | - | 7,296 | 47,444 | 63,500 | 217,991 | | (78)% | 219,862 | 2,037,445 | 47,444 | - | 3,362 |
| VCT Individual (HIV-Negative) | - | 6,453 | 39,651 | 50,000 | 205,287 | 12/09 | (81)% | 206,993 | 1,869,831 | 39,651 | - | 2,810 |
| VCT Individual (HIV-Positive) | - | 844 | 7,793 | 13,500 | 12,704 | 12/09 | (39)% | 12,869 | 167,614 | 7,793 | - | 552 |
| Referral to HIV Testing Services | - | - | 21,265 | - | - | | 0% | - | 21,265 | 21,265 | - | 754 |
| Referral to HIV Testing Services | - | - | 21,265 | - | - | | -% | - | 21,265 | 21,265 | - | 754 |
| Referral to Linkage to HIV Care | - | 799 | 5,843 | 12,150 | - | | 0% | - | 5,843 | 5,843 | - | 2,767 |
| Referral to Linkage to HIV Care | - | 799 | 5,843 | 12,150 | - | | -% | - | 5,843 | 5,843 | - | 2,767 |
| Voluntary Medical Male Circumcision | 8,670 | 6,996 | 87,358 | 90,000 | 76,854 | | 14% | 78,885 | 239,585 | 87,358 | - | 615,331 |
| Voluntary Medical Male Circumcision | 8,670 | 6,996 | 87,358 | 90,000 | 76,854 | | 14% | 78,885 | 239,585 | 87,358 | - | 615,331 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Anglophone Africa Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 11/2019

| | New HIV Infections | STI Deaths | PWID Deaths | TB Deaths | CYP* | Maternal Deaths | Unintended Pregnancies | Malaria Deaths | Diarrhea Deaths | Pneumonia Deaths | Cervical Cancer Death | Sum of All Deaths |
|--------------------------------|--------------------|------------|-------------|-----------|-----------|-----------------|------------------------|----------------|-----------------|------------------|-----------------------|-------------------|
| Anglophone Africa Market Group | 88,771 | 22 | - | 5 | 3,626,818 | 3,800 | 1,496,472 | 803 | 133 | - | 55 | 36,238 |
| Ethiopia | 2,237 | 13 | - | - | 89,228 | 38 | 25,190 | - | 109 | - | - | 664 |
| Ghana | - | - | - | - | 174,384 | 134 | 62,417 | - | 2 | - | - | 863 |
| Lesotho | 1,220 | - | - | 5 | 13,471 | 11 | 4,265 | - | - | - | - | 73 |
| Malawi | 15,444 | - | - | - | 673,734 | 1,169 | 263,356 | 64 | 3 | - | - | 6,361 |
| Namibia | 53 | - | - | - | 1,160 | - | 326 | - | - | - | - | 3 |
| PSI Uganda | 618 | - | - | - | 1,458,159 | 1,416 | 666,747 | - | 2 | - | 1 | 17,227 |
| Rwanda | 4,575 | - | - | - | 123,184 | 55 | 35,953 | - | 3 | - | - | 802 |
| Swaziland | 12,505 | 3 | - | - | 86,300 | 52 | 24,294 | - | - | - | - | 419 |
| Tanzania | 2 | - | - | - | 444,300 | 496 | 205,512 | 739 | 6 | - | - | 5,306 |
| Uganda | 6,628 | - | - | - | 126,368 | 70 | 35,579 | - | - | - | - | 912 |
| Zambia | 5,618 | - | - | - | 220,090 | 123 | 96,197 | - | 9 | - | - | 2,446 |
| Zimbabwe | 39,873 | 7 | - | - | 216,441 | 236 | 76,636 | - | - | - | 54 | 1,161 |

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|------------------|------------------|
| Anglophone Africa Market Group | | | | | | | | | | 3,626,818 | 6,495,249 |
| Antiretroviral Treatment (Currently Enrolled) | 14,541 | 13,988 | 148,526 | 105,390 | 134,560 | 10% | 148,026 | 415,785 | 12,377 | - | 26,374 |
| Antiretroviral Treatment (Newly Enrolled) | 837 | 623 | 6,648 | 4,695 | 6,309 | 5% | 6,634 | 29,513 | 6,648 | - | - |
| Basic Care Package | - | - | - | - | 1 | (100)% | 1 | 1 | - | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 544 | (100)% | 544 | 9,414 | - | - | - |
| Cervical Cancer-HPV DNA and Conization | 3 | 1 | 7 | - | - | -% | - | 7 | 7 | - | 3 |
| Cervical Cancer-HPV DNA and Cryotherapy | 1 | 2 | 6 | - | 3 | 100% | 3 | 9 | 6 | - | 3 |
| Cervical Cancer-HPV DNA and Refer to any Treat | 1 | - | 1 | - | - | -% | - | 12 | 1 | - | - |
| Cervical Cancer-HPV DNA Screening | 615 | 554 | 3,013 | - | - | -% | - | 3,013 | 3,013 | - | - |
| Cervical Cancer-Pap and Conization | - | - | 1,753 | - | - | -% | - | 1,753 | 1,753 | - | 778 |
| Cervical Cancer-Pap and Refer to any Treatment | - | 1 | 9 | - | - | -% | - | 10 | 9 | - | 2 |
| Cervical Cancer-VIA and Conization | 20 | 18 | 234 | 290 | 98 | 139% | 126 | 538 | 234 | - | 84 |
| Cervical Cancer-VIA and Cryotherapy | 23 | 21 | 1,596 | 307 | 610 | 162% | 639 | 8,076 | 1,596 | - | 560 |
| Cervical Cancer-VIA and Refer to any Treatment | 5 | 9 | 84 | - | 24 | 250% | 25 | 395 | 84 | - | 15 |
| Cervical Cancer-VIA and Refer to Conization | 1 | 3 | 22 | 290 | 93 | (76)% | 98 | 2,056 | 22 | - | 4 |
| Cervical Cancer-VIA and Refer to Cryotherapy | - | - | - | - | 10 | (100)% | 10 | 459 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | 4,986 | 3,715 | 44,125 | 88,793 | 93,489 | (53)% | 95,922 | 385,211 | 44,125 | - | - |
| Chlorhexidine | 375 | 953 | 6,327 | 16,755 | 23,115 | (73)% | 23,622 | 42,992 | 5,694 | - | 440 |
| Clean Delivery Kit | - | - | - | - | 3,449 | (100)% | 3,449 | 181,765 | - | - | - |
| Condom | 3,485,580 | 3,770,886 | 44,140,095 | 49,703,561 | 62,498,630 | (29)% | 65,266,786 | 1,485,991,910 | 331,051 | 331,051 | 884,357 |
| Emergency Contraception | 24,675 | 3,024 | 103,659 | 7,000 | 168,048 | (38)% | 180,947 | 1,166,829 | 4,665 | 4,665 | 1,838 |
| Emergency Contraception Provided | 2,174 | 2,873 | 90,402 | 30,493 | 6,634 | 1,263% | 6,887 | 98,454 | 4,520 | 4,520 | 2,290 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Expanded Clean Delivery Kit | - | - | - | - | 13,160 | (100)% | 13,160 | 13,160 | - | - | - |
| Expanded Clean Delivery Kit (+CHX) | 14 | 1,420 | 11,040 | 20,285 | 14,044 | (21)% | 14,531 | 26,188 | 9,936 | - | 1,615 |
| Female Condom | 17,110 | 10,798 | 173,727 | 533,000 | 463,017 | (62)% | 469,229 | 28,558,053 | 1,303 | 1,303 | 5,631 |
| Fever Cases Attended | - | 25,845 | 171,313 | - | - | -% | - | 171,313 | 171,313 | - | - |
| Fever Cases Tested with RDTs | - | 24,741 | 163,450 | - | - | -% | - | 163,450 | 163,450 | - | - |
| Free Condom | 5,640,266 | 5,362,560 | 55,829,602 | 44,434,784 | 71,094,778 | (21)% | 77,319,731 | 458,146,802 | 418,722 | 418,722 | 1,249,956 |
| Free Female Condom | 29,418 | 379,536 | 1,350,782 | 251,000 | 555,165 | 143% | 623,007 | 6,232,608 | 10,131 | 10,131 | 30,174 |
| HIV Self-Testing Kit | 17,458 | 36,326 | 516,190 | 641,306 | 610,816 | (15)% | 996,954 | 1,882,691 | 464,571 | - | - |
| HIV Testing Services | 25,441 | 29,467 | 297,202 | 518,172 | 519,986 | (43)% | 541,424 | 6,118,218 | 297,202 | - | 22,207 |
| Hypertension Diagnosis | 2,034 | 2,235 | 8,894 | - | 254 | 3,402% | 278 | 9,452 | 8,894 | - | - |
| Hypertension Screening | 91,576 | 89,971 | 451,581 | 36,477 | 135,242 | 234% | 147,793 | 950,034 | 451,581 | - | - |
| Hypertension_Controlled Condition | 3 | 17 | 100 | - | 86 | 16% | 91 | 257 | 40 | - | - |
| Implant 3 | 5,595 | 9,691 | 53,495 | 73,620 | 12,071 | 343% | 12,798 | 207,021 | 48,146 | 120,364 | 123,101 |
| Implant 3 Insertion | 20,024 | 20,116 | 204,633 | 201,554 | 230,323 | (11)% | 240,316 | 914,832 | 204,633 | 511,583 | 484,214 |
| Implant 4 | 671 | - | 18,895 | - | (3,411) | -% | (3,883) | 15,012 | 17,006 | 54,418 | 48,795 |
| Implant 4 Insertion | 930 | 1,542 | 9,994 | - | 32,712 | (69)% | 33,884 | 43,994 | 9,994 | 31,981 | 28,676 |
| Implant 5 | 3,160 | 5,158 | 47,876 | 26,000 | 18,667 | 156% | 22,810 | 251,895 | 43,088 | 163,736 | 159,205 |
| Implant 5 Insertion | 14,185 | 16,833 | 166,972 | 175,505 | 146,790 | 14% | 154,215 | 761,232 | 166,972 | 634,494 | 570,821 |
| Injectable 1 Provided | - | 4 | 42 | 36 | 534 | (92)% | 537 | 1,809 | 3 | 3 | 2 |
| Injectable 2 Provided | 2,112 | 2,017 | 18,802 | 29,000 | 20,971 | (10)% | 22,699 | 53,145 | 3,134 | 3,134 | 2,156 |
| Injectable 3-IM | 5,364 | 36,167 | 704,336 | 605,251 | 1,800,648 | (61)% | 1,798,175 | 8,881,445 | 158,476 | 158,476 | 79,998 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Injectable 3-IM Provided | 31,256 | 35,591 | 394,492 | 357,197 | 295,559 | 33% | 342,639 | 1,086,715 | 98,623 | 98,623 | 65,270 |
| Injectable 3-SC | 7,909 | 11,428 | 89,087 | 53,892 | 49,900 | 79% | 55,900 | 144,987 | 20,045 | 20,045 | 14,857 |
| Injectable 3-SC Provided | 6,917 | 4,825 | 21,404 | - | - | -% | - | 21,404 | 5,351 | 5,351 | 3,958 |
| ITN | 1,260,695 | 1,603 | 1,265,503 | - | - | -% | - | 1,265,503 | 2,050,115 | - | 45,033 |
| IUD 10 | 16,432 | 13,662 | 85,449 | 93,709 | 86,760 | (2)% | 85,274 | 324,818 | 76,904 | 353,759 | 342,042 |
| IUD 10 Insertion | 9,745 | 11,905 | 102,236 | 188,592 | 215,831 | (53)% | 220,262 | 1,223,677 | 102,236 | 470,286 | 415,139 |
| IUD 5 | - | (1) | (32) | - | (133) | -% | (134) | (166) | (29) | (95) | (96) |
| IUD 5 Insertion | - | 1 | 162 | - | 290 | (44)% | 345 | 28,727 | 162 | 535 | 343 |
| IUS 3 | (95) | (73) | (314) | - | - | -% | - | (314) | (283) | (707) | (670) |
| IUS 3 Insertion | 95 | 73 | 314 | - | - | -% | - | 314 | 314 | 785 | 744 |
| IUS 5 | (10) | (6) | 403 | (56) | 95 | 324% | 126 | 1,483 | 363 | 1,197 | 1,345 |
| IUS 5 Insertion | 11 | 22 | 542 | 756 | 714 | (24)% | 739 | 1,647 | 542 | 1,789 | 1,516 |
| LLIN | 349 | 970 | 213,150 | 700,054 | 4,475,373 | (95)% | 4,545,198 | 12,902,397 | 345,303 | - | 11,557 |
| Lubricant | 660,920 | 244,762 | 2,681,257 | 1,900,761 | 2,408,656 | 11% | 2,574,286 | 8,389,552 | - | - | - |
| Manual Vacuum Aspiration for PAC | 526 | 664 | 6,116 | 720 | 7,047 | (13)% | 7,531 | 16,637 | 6,116 | - | 913 |
| Manual Vacuum Aspiration for SA | 80 | 72 | 770 | - | 403 | 91% | 411 | 2,379 | 770 | - | 282 |
| Medical Abortion | 503 | 1,517 | 10,288 | 9,331 | 16,455 | (37)% | 16,535 | 26,823 | 9,259 | - | 3,243 |
| Medical Abortion (Misoprostol) Provided | 65 | 91 | 967 | - | 505 | 91% | 531 | 1,498 | 967 | - | 302 |
| Medical Abortion Provided | 72 | 72 | 750 | - | 744 | 1% | 747 | 2,118 | 750 | - | 263 |
| Misoprostol for PAC Provided | 201 | 257 | 2,953 | - | 3,401 | (13)% | 3,631 | 7,789 | 2,953 | - | 603 |
| Misoprostol for Safe Abortion | 93,436 | 158,229 | 1,394,426 | 1,993,550 | 1,605,124 | (13)% | 1,659,272 | 8,008,498 | 73,207 | - | 15,215 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| OCs | 33,859 | 204,580 | 1,530,539 | 2,258,175 | 2,381,220 | (36)% | 2,600,349 | 17,737,057 | 91,832 | 91,832 | 43,937 |
| OCs Provided | 37,372 | 48,543 | 505,307 | 357,372 | 288,291 | 75% | 321,499 | 1,849,541 | 33,687 | 33,687 | 20,700 |
| Positive RDTs | - | 17,029 | 112,752 | - | - | -% | - | 112,752 | 112,752 | - | - |
| Positive RDTs Given First Line Treatment | - | 15,902 | 104,366 | - | - | -% | - | 104,366 | 104,366 | - | - |
| PrEP | 3,969 | 4,139 | 42,598 | 35,111 | 31,138 | 37% | 34,437 | 80,151 | 3,550 | - | 1,352 |
| PUR | 265,200 | 3,939,638 | 29,918,408 | 28,273,857 | 32,913,845 | (9)% | 33,931,875 | 234,577,407 | 245,905 | - | 847 |
| Referral to Advanced Cervical Cancer Treatment | 3 | 6 | 62 | 136 | 17 | 265% | 17 | 479 | 62 | - | - |
| Referral to Diabetes Management (gestational) | - | - | - | - | 67 | (100)% | 67 | 67 | - | - | - |
| Referral to Emergency Contraception | - | - | - | 1 | 1 | (100)% | 1 | 134 | - | - | - |
| Referral to HIV Testing Services | 1,889 | 534 | 33,768 | 82,130 | 986 | 3,325% | 24,714 | 203,576 | 33,768 | - | 1,049 |
| Referral to Hypertension Management | 29 | 33 | 323 | - | 530 | (39)% | 567 | 1,453 | 323 | - | - |
| Referral to Implant 3 Insertion | - | - | 293 | 1,915 | 2 | 14,550% | 2 | 1,441 | 293 | 366 | 309 |
| Referral to Implant 5 Insertion | - | - | 11 | 187 | 2 | 450% | 2 | 1,307 | 11 | 21 | 17 |
| Referral to Injectable 1 | - | - | - | - | 36 | (100)% | 36 | 384 | - | - | - |
| Referral to Injectable 3 | - | - | 887 | 6,372 | 75 | 1,083% | 75 | 4,717 | 887 | 111 | 69 |
| Referral to IUD 10 Insertion | - | - | 4 | 48 | 5 | (20)% | 5 | 352 | 4 | 9 | 7 |
| Referral to Linkage to HIV Care | 12,819 | 13,359 | 102,771 | 29,940 | 14,080 | 630% | 24,186 | 149,415 | 102,771 | - | 83,419 |
| Referral to OCs | - | - | 84 | 665 | 93 | (10)% | 93 | 2,389 | 84 | 3 | 2 |
| Referral to Pre-Exposure Prophylaxis (PrEP) | - | - | 3 | - | 20 | (85)% | 20 | 253 | 3 | - | - |
| Referral to STI Screening (syndromic) | - | - | - | 112,000 | 7 | (100)% | 7 | 14,416 | - | - | - |
| Referral to STI Treatment (unknown) | - | - | - | - | 119 | (100)% | 119 | 2,584 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 11
 Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Referral to TB Diagnosis | - | - | - | - | 11 | (100)% | 11 | 255 | - | - | - |
| Referral to TB DOTS (completion confirmed) | - | - | - | - | 2 | (100)% | 2 | 19 | - | - | - |
| Referral to TB DOTS (completion unknown) | - | - | - | - | 74 | (100)% | 74 | 2,704 | - | - | - |
| Referral to TB Screening | - | - | - | 5,497 | 308 | (100)% | 308 | 29,857 | - | - | - |
| Referral to Treatment for Cervicitis | - | - | - | - | 47 | (100)% | 47 | 116 | - | - | - |
| Referral to Treatment for Genital Herpes | - | - | - | - | 3 | (100)% | 3 | 6 | - | - | - |
| Referral to Treatment for Inguinal Bubo | - | - | - | 112 | 2 | (100)% | 2 | 2 | - | - | - |
| Referral to Treatment for Lower Abdominal Pain | - | - | - | 112 | 1 | (100)% | 1 | 28 | - | - | - |
| Referral to Treatment for Urethral Discharge (Mer | - | - | - | 336 | 53 | (100)% | 53 | 113 | - | - | - |
| Referral to Treatment for Vaginitis | - | - | 1 | - | - | -% | - | 9 | 1 | - | - |
| Referral to Tubal Ligation | - | - | - | - | 2 | (100)% | 2 | 3 | - | - | - |
| Referral to Tx for Nonherpetic Genital Ulcer | - | - | 1 | - | 25 | (96)% | 25 | 73 | 1 | - | - |
| Referral to Tx for Urethral Discharge (Women) | - | - | 10 | 560 | 48 | (79)% | 48 | 557 | 10 | - | 1 |
| Referral to Voluntary Medical Male Circumcision | - | - | 3 | - | 139 | (98)% | 139 | 15,555 | 3 | - | 10 |
| Safe Water Solution | 94,919 | 80,397 | 997,927 | 1,915,700 | 2,207,153 | (55)% | 2,248,493 | 74,709,050 | 744,986 | - | 2,588 |
| STI Kit (Non-Ulcerative) | 1,117 | 187 | 4,732 | 1,869 | 5,855 | (19)% | 6,655 | 836,263 | 4,259 | - | 304 |
| STI Kit (Ulcerative) | 257 | 19 | 1,588 | 231 | - | -% | - | 73,816 | 1,429 | - | 305 |
| STI Screening | 9,033 | 9,198 | 110,529 | 144,457 | 72,747 | 52% | 75,388 | 673,445 | 110,529 | - | - |
| TB Diagnosis | 30 | 14 | 213 | 77 | 274 | (22)% | 283 | 1,690 | 213 | - | - |
| TB DOTS | 3 | 3 | 32 | 77 | 34 | (6)% | 35 | 133 | 32 | - | 260 |
| TB Screening | 19,359 | 19,684 | 223,513 | 34,396 | 210,708 | 6% | 225,880 | 1,674,538 | 223,513 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Toilets Sold | 1,915 | 2,301 | 18,432 | 25,600 | 4,824 | 282% | 5,651 | 24,082 | 84,050 | - | 3,244 |
| Toilets Sold - All | 2,093 | 3,375 | 25,064 | - | 5,936 | 322% | 7,266 | 32,330 | 107,925 | - | - |
| Treatment for Cervicitis | 13 | 22 | 181 | - | 58 | 212% | 73 | 544 | 181 | - | 14 |
| Treatment for Genital Herpes | 32 | 22 | 124 | 17 | 26 | 377% | 28 | 204 | 124 | - | 4 |
| Treatment for Inguinal Bubo | - | - | 17 | - | 2 | 750% | 3 | 34 | 17 | - | - |
| Treatment for Lower Abdominal Pain | 71 | 81 | 432 | 54 | 76 | 468% | 78 | 645 | 432 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 44 | 59 | 623 | 94 | 518 | 20% | 546 | 1,769 | 623 | - | 192 |
| Treatment for Urethral Discharge (Men) | 78 | 66 | 680 | 195 | 277 | 145% | 292 | 1,582 | 1,255 | - | 74 |
| Treatment for Urethral Discharge (Women) | 121 | 98 | 1,037 | 2 | 471 | 120% | 507 | 2,560 | 1,037 | - | 153 |
| Treatment for Vaginitis | 15 | 28 | 329 | 380 | 498 | (34)% | 506 | 2,541 | 329 | - | 61 |
| Tubal Ligation | 1,224 | 1,403 | 10,046 | 17,589 | 15,901 | (37)% | 16,391 | 45,860 | 10,046 | 100,460 | 79,142 |
| Type 2 Diabetes Diagnosis | - | - | - | - | 3 | (100)% | 3 | 8 | - | - | - |
| Type 2 Diabetes Screening | 853 | 1,508 | 22,560 | 33,797 | 6,140 | 267% | 6,711 | 39,150 | 22,560 | - | - |
| Type 2 Diabetes_Controlled Condition | - | - | - | - | 6 | (100)% | 6 | 12 | - | - | - |
| Vasectomy | 6 | 4 | 17 | 29 | - | -% | - | 17 | 17 | 170 | 148 |
| Voluntary Medical Male Circumcision | 4,881 | 30,247 | 249,678 | 306,145 | 330,205 | (24)% | 345,985 | 963,700 | 249,678 | - | 1,611,442 |
| Water Treatment Tablets | 2,591,500 | 674,707 | 6,213,110 | 8,068,408 | 6,922,542 | (10)% | 6,957,142 | 126,557,461 | 102,133 | - | 404 |
| Woman Condom | - | - | 1,920 | - | 95,160 | (98)% | 97,728 | 141,480 | 14 | 14 | 40 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|------------------|------------------|
| Anglophone Africa Market Group | | | | | | | | | | | 3,626,818 | 6,495,249 |
| Ethiopia | | | | | | | | | | | 89,228 | 138,801 |
| Antiretroviral Treatment (Currently Enrolled) | 916 | 1,162 | 12,429 | 18,804 | 15,805 | | (21)% | 16,938 | 39,679 | 1,036 | - | 1,989 |
| Antiretroviral Treatment (Newly Enrolled) | 45 | 59 | 476 | 1,155 | 1,090 | | (56)% | 1,115 | 3,046 | 476 | - | - |
| Free Condom | 1,042,000 | 308,467 | 11,740,300 | 11,820,960 | 23,271,707 | | (50)% | 23,871,707 | 176,303,745 | 88,052 | 88,052 | 128,326 |
| No Logo Condom | 1,042,000 | 308,467 | 10,461,600 | 11,820,960 | 5,869,000 | 8/09 | 78% | 5,869,000 | 20,446,600 | 78,462 | 78,462 | 114,349 |
| Protector Plus | - | - | 1,278,700 | - | 17,402,707 | 12/12 | (93)% | 18,002,707 | 155,857,145 | 9,590 | 9,590 | 13,977 |
| Free Female Condom | 15,000 | 14,480 | 88,731 | 138,000 | 138,000 | | (36)% | 138,000 | 987,820 | 665 | 665 | 926 |
| HIV Self-Testing Kit | - | 319 | 958 | 3,000 | 14,948 | | (94)% | 14,958 | 15,916 | 862 | - | - |
| HIV Testing Services | 2,209 | 3,898 | 35,429 | 31,606 | 216,747 | | (84)% | 219,864 | 1,224,643 | 35,429 | - | 188 |
| Hypertension Diagnosis | 2,006 | 2,212 | 8,643 | - | - | | 0% | - | 8,643 | 8,643 | - | - |
| Hypertension Screening | 81,339 | 80,368 | 322,442 | - | - | | 0% | - | 322,442 | 322,442 | - | - |
| LLIN | - | 5 | 14 | - | - | | 0% | - | 305,347 | 23 | - | 1 |
| Lubricant | 4,464 | 3,340 | 15,209 | 761 | 62,347 | | (76)% | 62,647 | 77,856 | - | - | - |
| PrEP | 237 | 303 | 2,200 | - | - | | 0% | - | 2,200 | 183 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| PrEP | 237 | 303 | 2,200 | - | - | | -% | - | 2,200 | 183 | - | - |
| PUR | 264,960 | 3,452,604 | 18,886,246 | 19,333,057 | 19,428,654 | | (3)% | 20,446,684 | 103,598,651 | 155,229 | - | 557 |
| P&G Purifier of Water | 264,960 | 3,452,604 | 18,886,246 | 19,333,057 | 19,428,654 | 11/15 | (3)% | 20,446,684 | 103,598,651 | 155,229 | - | 557 |
| Referral to Emergency Contraception | - | - | - | 1 | 1 | | (100)% | 1 | 134 | - | - | - |
| Referral to Emergency Contraception | - | - | - | 1 | 1 | 2/15 | (100)% | 1 | 134 | - | - | - |
| Referral to HIV Testing Services | - | - | - | 30,390 | 9 | | (100)% | 9 | 119,940 | - | - | - |
| Referral to HIV Testing Services | - | - | - | 30,390 | 9 | 12/13 | (100)% | 9 | 119,940 | - | - | - |
| Referral to Implant 3 Insertion | - | - | 293 | 1,915 | - | | 0% | - | 1,430 | 293 | 366 | 309 |
| Referral to Implant 3 Insertion | - | - | 293 | 1,915 | - | 12/14 | -% | - | 1,430 | 293 | 366 | 309 |
| Referral to Implant 5 Insertion | - | - | 11 | 187 | - | | 0% | - | 315 | 11 | 21 | 17 |
| Referral to Implant 5 Insertion | - | - | 11 | 187 | - | 12/14 | -% | - | 315 | 11 | 21 | 17 |
| Referral to Injectable 3 | - | - | 887 | 6,372 | - | | 0% | - | 3,301 | 887 | 111 | 69 |
| Referral to Injectable 3 | - | - | 887 | 6,372 | - | 1/15 | -% | - | 3,301 | 887 | 111 | 69 |
| Referral to IUD 10 Insertion | - | - | 4 | 48 | - | | 0% | - | 143 | 4 | 9 | 7 |
| Referral to IUD 10 Insertion | - | - | 4 | 48 | - | 12/14 | -% | - | 143 | 4 | 9 | 7 |
| Referral to Linkage to HIV Care | 134 | 116 | 1,567 | 1,216 | 33 | | 4648% | 33 | 4,400 | 1,567 | - | 796 |
| Referral to Linkage to HIV Care | 134 | 116 | 1,567 | 1,216 | 33 | | 4,648% | 33 | 4,400 | 1,567 | - | 796 |
| Referral to OCs | - | - | 84 | 665 | - | | 0% | - | 974 | 84 | 3 | 2 |
| Referral to OCs | - | - | 84 | 665 | - | 1/15 | -% | - | 974 | 84 | 3 | 2 |
| Referral to STI Screening (syndromic) | - | - | - | 112,000 | 4 | | (100)% | 4 | 14,311 | - | - | - |
| Referrals to STI Screening (syndromic) | - | - | - | 112,000 | 4 | | (100)% | 4 | 14,311 | - | - | - |
| Referral to TB Screening | - | - | - | 319 | 4 | | (100)% | 4 | 13,488 | - | - | - |
| Referrals to TB Screening | - | - | - | 319 | 4 | | (100)% | 4 | 13,488 | - | - | - |
| Referral to Treatment for Inguinal Bubo | - | - | - | 112 | - | | 0% | - | - | - | - | - |
| Referral to Treatment for Inguinal Bubo | - | - | - | 112 | - | 12/14 | -% | - | - | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Referral to Treatment for Lower Abdominal Pain | - | - | - | 112 | - | | 0% | - | - | - | - | - |
| Referral to Treatment for Lower Abdominal Pain | - | - | - | 112 | - | 12/14 | -% | - | - | - | - | - |
| Referral to Treatment for Urethral Discharge (Men) | - | - | - | 336 | - | | 0% | - | - | - | - | - |
| Referral to Treatment for Urethral Discharge (Men) | - | - | - | 336 | - | 12/14 | -% | - | - | - | - | - |
| Referral to Tx for Urethral Discharge (Women) | - | - | - | 560 | - | | 0% | - | - | - | - | - |
| Referral to Tx for Urethral Discharge (Women) | - | - | - | 560 | - | 12/14 | -% | - | - | - | - | - |
| Safe Water Solution | 94,919 | 75,120 | 619,831 | 740,700 | 786,668 | | (21)% | 791,708 | 25,193,722 | 509,450 | - | 1,828 |
| Wuha Agar | 94,919 | 75,120 | 619,831 | 740,700 | 786,668 | 2/06 | (21)% | 791,708 | 25,193,722 | 509,450 | - | 1,828 |
| STI Kit (Non-Ulcerative) | 1,117 | 187 | 4,732 | 1,869 | 5,855 | | (19)% | 6,655 | 836,263 | 4,259 | - | 304 |
| STI kit for Urethral Discharge | 690 | 108 | 2,542 | 882 | 1,797 | 11/10 | 41% | 2,397 | 452,641 | 2,288 | - | 140 |
| STI Kit for Vaginal Discharge | 427 | 78 | 2,190 | 987 | 4,058 | 11/10 | (46)% | 4,258 | 383,622 | 1,971 | - | 165 |
| STI Kit (Ulcerative) | 257 | 19 | 1,588 | 231 | - | | 0% | - | 73,816 | 1,429 | - | 305 |
| STI Kit for Genital Ulcer | 257 | 19 | 1,588 | 231 | - | 11/10 | -% | - | 73,816 | 1,429 | - | 305 |
| STI Screening | 2,129 | 3,464 | 25,450 | 112,000 | 33,336 | | (24)% | 33,336 | 465,500 | 25,450 | - | - |
| STI Screening | 2,129 | 3,464 | 25,450 | 112,000 | 33,336 | | (24)% | 33,336 | 465,500 | 25,450 | - | - |
| TB Screening | 2,316 | 3,783 | 29,161 | 31,910 | 31,664 | | (8)% | 31,664 | 447,903 | 29,161 | - | - |
| TB Screening | 2,316 | 3,783 | 29,161 | 31,910 | 31,664 | | (8)% | 31,664 | 447,903 | 29,161 | - | - |
| Toilets Sold | 1,895 | 2,182 | 17,695 | 25,000 | 4,700 | | 276% | 5,471 | 23,166 | 81,397 | - | 3,172 |
| Toilets Sold | 1,895 | 2,182 | 17,695 | 25,000 | 4,700 | | 276% | 5,471 | 23,166 | 81,397 | - | 3,172 |
| Toilets Sold - All | 1,895 | 2,182 | 17,695 | - | 4,700 | | 276% | 5,471 | 23,166 | 81,397 | - | - |
| Toilets Sold - All | 1,895 | 2,182 | 17,695 | - | 4,700 | | 276% | 5,471 | 23,166 | 81,397 | - | - |
| Treatment for Inguinal Bubo | - | - | 1 | - | - | | 0% | - | 1 | 1 | - | - |
| Treatment for Inguinal Bubo | - | - | 1 | - | - | | -% | - | 1 | 1 | - | - |
| Treatment for Lower Abdominal Pain | 2 | - | 3 | - | 4 | | (25)% | 4 | 70 | 3 | - | - |
| Treatment for Lower Abdominal Pain | 2 | - | 3 | - | 4 | | (25)% | 4 | 70 | 3 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Treatment for Nonherpetic Genital Ulcer | 1 | - | 8 | - | 16 | | (50)% | 16 | 79 | 8 | - | 1 |
| Treatment for Nonherpetic Genital Ulcer | 1 | - | 8 | - | 16 | | (50)% | 16 | 79 | 8 | - | 1 |
| Treatment for Urethral Discharge (Men) | 4 | 1 | 18 | - | 5 | | 260% | 5 | 163 | 36 | - | - |
| Treatment for Urethral Discharge (Men) | 4 | 1 | 18 | - | 5 | | 260% | 5 | 163 | 36 | - | - |
| Treatment for Urethral Discharge (Women) | - | - | - | - | 12 | | (100)% | 12 | 76 | - | - | - |
| Treatment for Urethral Discharge (Women) | - | - | - | - | 12 | | (100)% | 12 | 76 | - | - | - |
| Treatment for Vaginitis | 15 | 10 | 105 | - | 116 | | (9)% | 116 | 1,340 | 105 | - | 2 |
| Treatment for Vaginitis | 15 | 10 | 105 | - | 116 | | (9)% | 116 | 1,340 | 105 | - | 2 |
| Ghana | | | | | | | | | | | 174,384 | 69,948 |
| Condom | - | - | - | 412,211 | 14,700 | | (100)% | 14,700 | 799,268 | - | - | - |
| Protector | - | - | - | 412,211 | 14,700 | | (100)% | 14,700 | 799,268 | - | - | - |
| Injectable 3-IM | - | 7,400 | 455,554 | 495,534 | 1,372,981 | | (67)% | 1,376,081 | 3,596,197 | 102,500 | 102,500 | 40,152 |
| Famplan | - | 7,400 | 455,554 | 495,534 | 1,373,381 | | (67)% | 1,376,481 | 3,596,597 | 102,500 | 102,500 | 40,152 |
| (b)PSI Injectable 3 IM Distributed Provided | - | - | - | - | (400) | | -% | (400) | (400) | - | - | - |
| Injectable 3-IM Provided | - | - | - | - | 400 | | (100)% | 400 | 400 | - | - | - |
| PSI Injectable 3 IM Provided | - | - | - | - | 400 | | (100)% | 400 | 400 | - | - | - |
| OCs | - | 154,980 | 1,198,080 | 2,068,038 | 1,776,834 | | (33)% | 1,969,134 | 5,590,439 | 71,885 | 71,885 | 29,706 |
| (b)PSI OCs Distributed Provided | - | - | - | - | (66) | | -% | (66) | (66) | - | - | - |
| Secure | - | 154,980 | 1,198,080 | 2,068,038 | 1,776,900 | | (33)% | 1,969,200 | 5,590,505 | 71,885 | 71,885 | 29,706 |
| OCs Provided | - | - | - | - | 66 | | (100)% | 66 | 66 | - | - | - |
| PSI OCs Provided | - | - | - | - | 66 | | (100)% | 66 | 66 | - | - | - |
| Toilets Sold | 20 | 119 | 737 | 600 | 124 | | 496% | 180 | 916 | 2,653 | - | 72 |
| Toilets Sold | 20 | 119 | 737 | 600 | 124 | | 496% | 180 | 916 | 2,653 | - | 72 |
| Toilets Sold - All | 198 | 1,193 | 7,369 | - | 1,236 | | 496% | 1,795 | 9,164 | 26,528 | - | - |
| Toilets Sold - All | 198 | 1,193 | 7,369 | - | 1,236 | | 496% | 1,795 | 9,164 | 26,528 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Water Treatment Tablets | - | 19,067 | 461,800 | 1,066,668 | 810,300 | | (43)% | 844,900 | 1,400,100 | 7,591 | - | 18 |
| Aquatabs 67 mg (20 L) | - | 19,067 | 461,800 | 1,066,668 | 810,300 | 7/17 | (43)% | 844,900 | 1,400,100 | 7,591 | - | 18 |
| Lesotho | | | | | | | | | | | 13,471 | 55,761 |
| Antiretroviral Treatment (Currently Enrolled) | 1,366 | 1,356 | 14,723 | 1,443 | 17,166 | | (14)% | 18,922 | 53,202 | 1,227 | - | 2,787 |
| Antiretroviral Treatment (Currently Enrolled) | 1,366 | 1,356 | 14,723 | 1,443 | 17,166 | | (14)% | 18,922 | 53,202 | 1,227 | - | 2,787 |
| Antiretroviral Treatment (Newly Enrolled) | 9 | 9 | 92 | 169 | 104 | | (12)% | 110 | 320 | 92 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 9 | 9 | 92 | 169 | 104 | | (12)% | 110 | 320 | 92 | - | - |
| Emergency Contraception Provided | 11 | 33 | 163 | 25 | 17 | | 859% | 20 | 334 | 8 | 8 | 3 |
| Non-PSI Emergency Contraception Provided | 11 | 33 | 163 | 25 | 17 | | 859% | 20 | 334 | 8 | 8 | 3 |
| Female Condom | 245 | 142 | 1,486 | 3,000 | 96,545 | | (98)% | 96,546 | 2,512,568 | 11 | 11 | 43 |
| Generic | 245 | 142 | 1,486 | 3,000 | 96,545 | 1/08 | (98)% | 96,546 | 2,512,568 | 11 | 11 | 43 |
| Free Condom | 52,000 | 141,610 | 940,500 | 193,872 | 13,695,656 | | (93)% | 13,845,256 | 33,148,882 | 7,054 | 7,054 | 27,368 |
| Camouflage Free | - | - | 56,900 | 13,872 | 669,600 | 1/16 | (92)% | 747,700 | 3,015,000 | 427 | 427 | 1,656 |
| Vibe Condom | 52,000 | 141,610 | 883,600 | 180,000 | 13,026,056 | 9/14 | (93)% | 13,097,556 | 30,133,882 | 6,627 | 6,627 | 25,712 |
| HIV Self-Testing Kit | 9,251 | 18,134 | 102,747 | 111,335 | - | | 0% | 56,275 | 159,022 | 92,472 | - | - |
| ORAQUICK HIV Self-Testing Kit (Pouch) | 9,251 | 18,134 | 102,747 | 111,335 | - | | -% | 56,275 | 159,022 | 92,472 | - | - |
| HIV Testing Services | 7,229 | 8,821 | 107,974 | 137,092 | 147,125 | | (27)% | 158,712 | 1,210,735 | 107,974 | - | 11,312 |
| VCT Individual (HIV-Negative) | 6,727 | 8,286 | 102,525 | 129,331 | 142,291 | 12/09 | (28)% | 153,406 | 1,139,707 | 102,525 | - | 10,741 |
| VCT Individual (HIV-Positive) | 502 | 535 | 5,449 | 7,761 | 4,834 | 12/09 | 13% | 5,306 | 71,028 | 5,449 | - | 571 |
| Hypertension Screening | 16 | 93 | 737 | 4,020 | 2,431 | | (70)% | 2,494 | 14,433 | 737 | - | - |
| Hypertension Screening | 16 | 93 | 737 | 4,020 | 2,431 | | (70)% | 2,494 | 14,433 | 737 | - | - |
| Implant 3 Insertion | - | - | 10 | 10 | 6 | | 67% | 6 | 850 | 10 | 25 | 15 |
| Non-PSI Implant 3 Inserted | - | - | 10 | 10 | 6 | | 67% | 6 | 850 | 10 | 25 | 15 |
| Implant 5 Insertion | - | - | 8 | 20 | 11 | | (27)% | 12 | 135 | 8 | 30 | 18 |
| Non-PSI Implant 5 Inserted | - | - | 8 | 20 | 11 | | (27)% | 12 | 135 | 8 | 30 | 18 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|-------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Injectable 1 Provided | - | - | 1 | - | - | | 0% | - | 9 | - | - | - |
| Non-PSI Injectable 1 Provided | - | - | 1 | - | - | | -% | - | 9 | - | - | - |
| Injectable 2 Provided | 787 | 736 | 3,443 | 1,000 | 2,864 | | 20% | 2,864 | 8,365 | 574 | 574 | 259 |
| Non-PSI Injectable 2 Provided | 787 | 736 | 3,443 | 1,000 | 2,864 | | 20% | 2,864 | 8,365 | 574 | 574 | 259 |
| Injectable 3-IM Provided | 1,657 | 1,708 | 17,419 | 19,508 | 11,027 | | 58% | 12,574 | 42,128 | 4,355 | 4,355 | 1,967 |
| Non-PSI Injectable 3 IM Provided | 1,657 | 1,708 | 17,419 | 19,508 | 11,027 | | 58% | 12,574 | 42,128 | 4,355 | 4,355 | 1,967 |
| OCs Provided | 772 | 1,435 | 21,210 | 20,147 | 15,176 | | 40% | 17,197 | 65,465 | 1,414 | 1,414 | 674 |
| Non-PSI OCs Provided | 772 | 1,435 | 21,210 | 20,147 | 15,176 | | 40% | 17,197 | 65,465 | 1,414 | 1,414 | 674 |
| PrEP | 70 | 66 | 617 | 84 | 14 | | 4307% | 14 | 631 | 51 | - | 51 |
| PrEP | 70 | 66 | 617 | 84 | 14 | | 4,307% | 14 | 631 | 51 | - | 51 |
| Referral to HIV Testing Services | - | - | - | 1,740 | 977 | | (100)% | 1,299 | 26,462 | - | - | - |
| Referral to HIV Testing Services | - | - | - | 1,740 | 977 | 3/16 | (100)% | 1,299 | 26,462 | - | - | - |
| Referral to Linkage to HIV Care | 353 | 382 | 3,960 | 6,985 | 3,328 | | 19% | 3,328 | 14,708 | 3,960 | - | 2,381 |
| Referral to Linkage to HIV Care | 353 | 382 | 3,960 | 6,985 | 3,328 | | 19% | 3,328 | 14,708 | 3,960 | - | 2,381 |
| TB Diagnosis | 2 | 2 | 29 | 77 | 37 | | (22)% | 41 | 115 | 29 | - | - |
| TB Diagnosis | 2 | 2 | 29 | 77 | 37 | | (22)% | 41 | 115 | 29 | - | - |
| TB DOTS | 3 | 3 | 32 | 77 | 30 | | 7% | 31 | 79 | 32 | - | 260 |
| TB DOTS | 3 | 3 | 32 | 77 | 30 | | 7% | 31 | 79 | 32 | - | 260 |
| TB Screening | 1,261 | 1,479 | 17,623 | 1,443 | 19,169 | | (8)% | 21,329 | 45,651 | 17,623 | - | - |
| TB Screening | 1,261 | 1,479 | 17,623 | 1,443 | 19,169 | | (8)% | 21,329 | 45,651 | 17,623 | - | - |
| Type 2 Diabetes Screening | 1 | - | 30 | 1,340 | 395 | | (92)% | 395 | 3,969 | 30 | - | - |
| Type 2 Diabetes Screening | 1 | - | 30 | 1,340 | 395 | | (92)% | 395 | 3,969 | 30 | - | - |
| Voluntary Medical Male Circumcision | 178 | 120 | 660 | 500 | 2,825 | | (77)% | 2,962 | 4,291 | 660 | - | 8,622 |
| Voluntary Medical Male Circumcision | 178 | 120 | 660 | 500 | 2,825 | | (77)% | 2,962 | 4,291 | 660 | - | 8,622 |
| Malawi | | | | | | | | | | | 673,734 | 1,118,008 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Cervical Cancer-VIA/VILI Screening | 2,007 | 1,508 | 13,728 | 10,000 | 18,980 | | (28)% | 19,630 | 33,358 | 13,728 | - | - |
| Cervical Cancer-VIA/VILI Screening | 2,007 | 1,508 | 13,728 | 10,000 | 18,980 | | (28)% | 19,630 | 33,358 | 13,728 | - | - |
| Condom | 877,104 | 1,210,728 | 13,409,452 | 12,000,000 | 16,281,256 | | (18)% | 17,252,824 | 238,874,378 | 100,571 | 100,571 | 275,635 |
| Chishango | 877,104 | 1,210,728 | 13,409,452 | 12,000,000 | 16,281,256 | 10/94 | (18)% | 17,252,824 | 238,874,378 | 100,571 | 100,571 | 275,635 |
| Emergency Contraception | 15,405 | 152 | 46,956 | 7,000 | 10,906 | | 331% | 11,120 | 155,296 | 2,113 | 2,113 | 1,072 |
| Levonorgestrel Tablet 0.75 mg x 2's | 17,505 | 2,908 | 135,796 | - | 1,265 | | 10,635% | 1,545 | 137,341 | 6,111 | 6,111 | 3,100 |
| NORLEVO (Norlevo 1.5mg) | - | - | - | 35,000 | 13,994 | 2/14 | (100)% | 13,994 | 111,455 | - | - | - |
| (b)PSI Emergency Contraception Distributed Provided | (2,100) | (2,756) | (88,840) | (28,000) | (4,353) | | -% | (4,419) | (93,500) | (3,998) | (3,998) | (2,028) |
| Emergency Contraception Provided | 2,100 | 2,784 | 88,930 | 28,000 | 4,353 | | 1943% | 4,419 | 93,590 | 4,447 | 4,447 | 2,256 |
| Non-PSI Emergency Contraception Provided | - | 27 | 90 | - | - | | -% | - | 90 | 5 | 5 | 2 |
| PSI Emergency Contraception Provided | 2,100 | 2,756 | 88,840 | 28,000 | 4,353 | | 1,941% | 4,419 | 93,500 | 4,442 | 4,442 | 2,254 |
| Female Condom | 865 | 989 | 78,041 | 90,000 | 79,992 | | (2)% | 86,203 | 870,524 | 585 | 585 | 1,563 |
| Care | 865 | 989 | 78,041 | 90,000 | 79,992 | 1/08 | (2)% | 86,203 | 870,524 | 585 | 585 | 1,563 |
| Free Condom | 3,409,218 | 1,522,139 | 14,785,938 | 11,069,952 | 9,552,947 | | 55% | 10,466,262 | 44,365,817 | 110,895 | 110,895 | 303,930 |
| Blue Gold Condoms | - | - | - | - | 590,724 | 8/17 | (100)% | 590,724 | 1,856,634 | - | - | - |
| Free Male Condoms | 17,280 | 111,836 | 1,000,080 | - | - | 2/14 | -% | - | 2,659,852 | 7,501 | 7,501 | 20,557 |
| Generic Male Condom | - | - | - | 395,000 | - | | -% | - | - | - | - | - |
| Key Population Male Condom | 3,391,938 | 1,410,303 | 13,785,858 | 10,000,000 | 8,218,426 | 7/16 | 68% | 9,131,741 | 34,054,731 | 103,394 | 103,394 | 283,373 |
| One Community Male Condom | - | - | - | - | 743,797 | 7/16 | (100)% | 743,797 | 5,247,751 | - | - | - |
| VMMC Male Condom | - | - | - | 674,952 | - | 1/15 | -% | - | 546,849 | - | - | - |
| Free Female Condom | 8,013 | 8,157 | 48,683 | - | 150,200 | | (68)% | 151,992 | 456,524 | 365 | 365 | 975 |
| Free Female Condoms | 8,013 | 8,157 | 48,683 | - | 66,927 | 2/14 | (27)% | 68,719 | 356,589 | 365 | 365 | 975 |
| Key Population Female Condom | - | - | - | - | 83,273 | 12/17 | (100)% | 83,273 | 99,935 | - | - | - |
| HIV Self-Testing Kit | 2,752 | 4,567 | 178,054 | 173,086 | 239,618 | | (26)% | 258,868 | 525,919 | 160,249 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| INSTI HIVST (Blood based) | 2,750 | 1,892 | 8,626 | - | - | | -% | - | 8,626 | 7,763 | - | - |
| ORAQUICK HIV Self-Testing Kit (Pouch) | 2 | 2,675 | 169,078 | 173,086 | 239,618 | 8/17 | (29)% | 258,868 | 516,943 | 152,170 | - | - |
| Sure Check HIV Self-Test | - | - | 350 | - | - | | -% | - | 350 | 315 | - | - |
| HIV Testing Services | 7,489 | 10,506 | 72,364 | 35,408 | 76,101 | | (5)% | 76,101 | 314,313 | 72,364 | - | 3,078 |
| VCT Individual (HIV-Negative) | 7,228 | 10,267 | 70,328 | 34,571 | 72,736 | 12/14 | (3)% | 72,736 | 305,868 | 70,328 | - | 2,992 |
| VCT Individual (HIV-Positive) | 261 | 239 | 2,036 | 837 | 3,365 | 12/14 | (39)% | 3,365 | 8,445 | 2,036 | - | 87 |
| Implant 3 | (997) | 53 | (1,516) | 1,000 | (11,492) | | 0% | (11,432) | 5,166 | (1,364) | (3,411) | (3,099) |
| Implanon | - | - | - | 1,000 | 18,883 | 10/12 | (100)% | 18,883 | 84,144 | - | - | - |
| Implanon NXT | 1,336 | 2,318 | 23,344 | - | 1,686 | | 1,285% | 2,901 | 26,245 | 21,010 | 52,524 | 47,715 |
| (b)PSI Implant 3 Distributed Inserted | (2,333) | (2,265) | (24,860) | - | (32,061) | | -% | (33,216) | (105,223) | (22,374) | (55,935) | (50,814) |
| Implant 3 Insertion | 3,269 | 3,242 | 30,853 | 49,000 | 32,117 | | (4)% | 33,272 | 111,272 | 30,853 | 77,133 | 70,071 |
| Non-PSI Implant 3 Inserted | 936 | 977 | 5,993 | 49,000 | 56 | | 10,602% | 56 | 6,049 | 5,993 | 14,983 | 13,611 |
| PSI Implant 3 Inserted | 2,333 | 2,265 | 24,860 | - | 32,061 | | (22)% | 33,216 | 105,223 | 24,860 | 62,150 | 56,460 |
| Implant 4 | 671 | - | 18,895 | - | (3,411) | | 0% | (3,883) | 15,012 | 17,006 | 54,418 | 48,795 |
| Levoplant | 1,153 | 480 | 25,253 | - | 29,300 | | (14)% | 30,000 | 55,253 | 22,728 | 72,729 | 65,214 |
| (b)PSI Implant 4 Distributed Inserted | (482) | (480) | (6,358) | - | (32,711) | | -% | (33,883) | (40,241) | (5,722) | (18,311) | (16,419) |
| Implant 4 Insertion | 930 | 1,542 | 9,994 | - | 32,711 | | (69)% | 33,883 | 43,877 | 9,994 | 31,981 | 28,676 |
| Non-PSI Implant 4 Inserted | 448 | 1,063 | 3,636 | - | - | | -% | - | 3,636 | 3,636 | 11,635 | 10,433 |
| PSI Implant 4 Inserted | 482 | 480 | 6,358 | - | 32,711 | | (81)% | 33,883 | 40,241 | 6,358 | 20,346 | 18,243 |
| Implant 5 | (1,043) | 488 | 2,317 | 1,000 | (9,074) | | 0% | (9,003) | 12,888 | 2,085 | 7,924 | 7,095 |
| Jadelle | 1,757 | 3,009 | 25,276 | 1,000 | 26,622 | 10/12 | (5)% | 27,995 | 146,666 | 22,748 | 86,444 | 77,398 |
| (b)PSI Implant 5 Distributed Inserted | (2,800) | (2,521) | (22,959) | - | (35,696) | 3/16 | -% | (36,998) | (133,778) | (20,663) | (78,520) | (70,303) |
| Implant 5 Insertion | 3,485 | 3,319 | 27,922 | 55,000 | 35,800 | | (22)% | 37,102 | 138,845 | 27,922 | 106,104 | 95,001 |
| Non-PSI Implant 5 Inserted | 685 | 798 | 4,963 | 55,000 | 104 | | 4,672% | 104 | 5,067 | 4,963 | 18,859 | 16,886 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| PSI Implant 5 Inserted | 2,800 | 2,521 | 22,959 | - | 35,696 | 3/16 | (36)% | 36,998 | 133,778 | 22,959 | 87,244 | 78,115 |
| Injectable 3-IM | 5,242 | 3,506 | 82,411 | 35,000 | 52,651 | | 57% | 60,576 | 1,911,248 | 18,542 | 18,542 | 12,347 |
| Depo-Provera | 14,010 | 10,923 | 160,317 | - | - | | -% | 9,721 | 170,038 | 36,071 | 36,071 | 24,018 |
| (b)PSI Injectable 3 IM Distributed Provided | (8,768) | (7,417) | (77,906) | - | (64,644) | | -% | (66,440) | (151,686) | (17,529) | (17,529) | (11,672) |
| SafePlan Inj3 | - | - | - | 35,000 | 117,295 | 1/08 | (100)% | 117,295 | 1,892,896 | - | - | - |
| Injectable 3-IM Provided | 10,596 | 9,725 | 87,816 | 84,000 | 65,669 | | 34% | 67,465 | 162,621 | 21,954 | 21,954 | 14,618 |
| Non-PSI Injectable 3 IM Provided | 1,828 | 2,308 | 9,910 | 84,000 | 1,025 | | 867% | 1,025 | 10,935 | 2,478 | 2,478 | 1,650 |
| PSI Injectable 3 IM Provided | 8,768 | 7,417 | 77,906 | - | 64,644 | | 21% | 66,440 | 151,686 | 19,477 | 19,477 | 12,969 |
| Injectable 3-SC | 909 | 624 | 3,587 | - | - | | 0% | - | 3,587 | 807 | 807 | 537 |
| (b)PSI Injectable 3 SC Distributed Provided | (160) | (32) | (266) | - | - | | -% | - | (266) | (60) | (60) | (40) |
| Sayana Press | 1,069 | 655 | 3,853 | - | - | | -% | - | 3,853 | 867 | 867 | 577 |
| Injectable 3-SC Provided | 191 | 42 | 329 | - | - | | 0% | - | 329 | 82 | 82 | 55 |
| Non-PSI Injectable 3 SC Provided | 31 | 11 | 63 | - | - | | -% | - | 63 | 16 | 16 | 10 |
| PSI Injectable 3 SC Provided | 160 | 32 | 266 | - | - | | -% | - | 266 | 67 | 67 | 44 |
| ITN | - | 1,603 | 4,808 | - | - | | 0% | - | 4,808 | 7,789 | - | 212 |
| PBO Net | - | 1,603 | 4,808 | - | - | | -% | - | 4,808 | 7,789 | - | 212 |
| IUD 10 | 148 | 74 | 1,510 | 500 | (735) | | 0% | (818) | 6,762 | 1,359 | 6,251 | 5,371 |
| IUD Copper T 380A | 430 | 285 | 4,775 | 500 | 4,925 | 10/12 | (3)% | 5,154 | 21,924 | 4,298 | 19,768 | 16,983 |
| (b)PSI IUD 10 Distributed Inserted | (282) | (211) | (3,265) | - | (5,660) | 3/16 | -% | (5,972) | (15,162) | (2,939) | (13,517) | (11,613) |
| IUD 10 Insertion | 455 | 406 | 4,067 | 5,136 | 5,660 | | (28)% | 5,972 | 15,964 | 4,067 | 18,708 | 16,072 |
| Non-PSI IUD 10 Inserted | 173 | 196 | 802 | 5,136 | - | | -% | - | 802 | 802 | 3,689 | 3,169 |
| PSI IUD 10 Inserted | 282 | 211 | 3,265 | - | 5,660 | 3/16 | (42)% | 5,972 | 15,162 | 3,265 | 15,019 | 12,903 |
| LLIN | 349 | 965 | 68,506 | 45,000 | 31,104 | | 120% | 34,209 | 500,549 | 110,980 | - | 4,290 |
| Super Chitetezo Net | 349 | 965 | 68,506 | 45,000 | 31,104 | 2/11 | 120% | 34,209 | 500,549 | 110,980 | - | 4,290 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Lubricant | 466,756 | 98,028 | 1,395,066 | 1,300,000 | 994,309 | | 40% | 1,071,889 | 4,473,414 | - | - | - |
| Personal Lubricant Water 4.5 g | 466,756 | 98,028 | 1,395,066 | 1,300,000 | 994,309 | 12/12 | 40% | 1,071,889 | 4,473,414 | - | - | - |
| OCs | 16,430 | 14,977 | 125,431 | 65,000 | 123,368 | | 2% | 164,930 | 942,389 | 7,526 | 7,526 | 5,286 |
| Microgynon | 2,703 | 3,532 | 36,996 | - | 149,275 | 11/11 | (75)% | 150,604 | 842,736 | 2,220 | 2,220 | 1,559 |
| Microgynon combination 3 | 17,644 | 15,936 | 208,233 | 65,000 | 4,280 | | 4,765% | 13,640 | 221,873 | 12,494 | 12,494 | 8,776 |
| Microlut | - | - | - | - | 16,900 | 8/17 | (100)% | 47,803 | 58,879 | - | - | - |
| (b)PSI OCs Distributed Provided | (3,917) | (4,491) | (119,798) | - | (47,087) | | -% | (47,117) | (181,099) | (7,188) | (7,188) | (5,049) |
| OCs Provided | 5,356 | 6,851 | 133,940 | 35,000 | 57,602 | | 133% | 58,051 | 206,175 | 8,929 | 8,929 | 6,272 |
| Non-PSI OCs Provided | 1,439 | 2,360 | 14,142 | 35,000 | 10,515 | | 34% | 10,934 | 25,076 | 943 | 943 | 662 |
| PSI OCs Provided | 3,917 | 4,491 | 119,798 | - | 47,087 | | 154% | 47,117 | 181,099 | 7,987 | 7,987 | 5,610 |
| PUR | - | - | 6,811,200 | 4,540,800 | 5,781,185 | | 18% | 5,781,185 | 66,919,640 | 55,982 | - | 170 |
| PuR WaterGuard Waufa | - | - | 6,811,200 | 4,540,800 | 5,781,185 | 3/06 | 18% | 5,781,185 | 66,919,640 | 55,982 | - | 170 |
| Safe Water Solution | - | - | 716 | - | 143,085 | | (99)% | 143,085 | 8,496,271 | 588 | - | 2 |
| WaterGuard | - | - | 716 | - | 143,085 | 12/02 | (99)% | 143,085 | 8,496,271 | 588 | - | 2 |
| STI Screening | 478 | 398 | 2,917 | - | 2,548 | | 14% | 2,620 | 5,537 | 2,917 | - | - |
| STI Screening | 478 | 398 | 2,917 | - | 2,548 | | 14% | 2,620 | 5,537 | 2,917 | - | - |
| Treatment for Cervicitis | - | 10 | 32 | - | - | | 0% | - | 32 | 32 | - | - |
| Treatment for Cervicitis | - | 10 | 32 | - | - | | -% | - | 32 | 32 | - | - |
| Treatment for Genital Herpes | 1 | 1 | 6 | - | - | | 0% | - | 6 | 6 | - | - |
| Treatment for Genital Herpes | 1 | 1 | 6 | - | - | | -% | - | 6 | 6 | - | - |
| Treatment for Lower Abdominal Pain | 65 | 72 | 336 | - | - | | 0% | - | 336 | 336 | - | - |
| Treatment for Lower Abdominal Pain | 65 | 72 | 336 | - | - | | -% | - | 336 | 336 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 7 | 26 | 88 | - | - | | 0% | - | 88 | 88 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 7 | 26 | 88 | - | - | | -% | - | 88 | 88 | - | - |
| Treatment for Urethral Discharge (Men) | 21 | 20 | 105 | - | - | | 0% | - | 105 | 105 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|------------------|------------------|
| Treatment for Urethral Discharge (Men) | 21 | 20 | 105 | - | - | | -% | - | 105 | 105 | - | - |
| Treatment for Urethral Discharge (Women) | 42 | 24 | 209 | - | - | | 0% | - | 209 | 209 | - | - |
| Treatment for Urethral Discharge (Women) | 42 | 24 | 209 | - | - | | -% | - | 209 | 209 | - | - |
| Tubal Ligation | 1,163 | 1,378 | 9,781 | 17,281 | 15,539 | | (37)% | 16,027 | 44,947 | 9,781 | 97,810 | 76,851 |
| Tubal Ligation | 1,163 | 1,378 | 9,781 | 17,281 | 15,539 | 1/15 | (37)% | 16,027 | 44,947 | 9,781 | 97,810 | 76,851 |
| Voluntary Medical Male Circumcision | 2,651 | 6,999 | 39,082 | 56,645 | 53,033 | | (26)% | 53,033 | 132,542 | 39,082 | - | 140,876 |
| Voluntary Medical Male Circumcision | 2,651 | 6,999 | 39,082 | 56,645 | 53,033 | | (26)% | 53,033 | 132,542 | 39,082 | - | 140,876 |
| Namibia | | | | | | | | | | | 1,160 | 2,252 |
| Free Condom | 48 | 50,544 | 151,681 | - | - | | 0% | - | 16,697,726 | 1,138 | 1,138 | 2,209 |
| Smile | 48 | 50,544 | 151,681 | - | - | 1/08 | -% | - | 16,697,726 | 1,138 | 1,138 | 2,209 |
| Free Female Condom | 105 | 967 | 3,005 | - | - | | 0% | - | 513,071 | 23 | 23 | 43 |
| Femidom Free | 105 | 967 | 3,005 | - | - | 2/07 | -% | - | 513,071 | 23 | 23 | 43 |
| HIV Self-Testing Kit | 148 | 5,745 | 17,384 | - | - | | 0% | - | 17,384 | 15,646 | - | - |
| ORAQUICK HIV Self-Testing Kit (Pouch) | 148 | 5,745 | 17,384 | - | - | 1/18 | -% | - | 17,384 | 15,646 | - | - |
| Lubricant | 58,200 | 27,594 | 140,982 | - | - | | 0% | - | 140,982 | - | - | - |
| Personal Lubricant 4.5 g | 58,200 | 27,594 | 140,982 | - | - | 1/18 | -% | - | 140,982 | - | - | - |
| PSI Uganda | | | | | | | | | | | 1,458,159 | 1,451,431 |
| Basic Care Package | - | - | - | - | 1 | | (100)% | 1 | 1 | - | - | - |
| PLP Kit - NFB (with WaterGuard Tab) | - | - | - | - | 1 | | (100)% | 1 | 1 | - | - | - |
| Cervical Cancer-VIA and Cryotherapy | 9 | 8 | 74 | - | 149 | | (50)% | 150 | 224 | 74 | - | 28 |
| Cervical Cancer-VIA and Cryotherapy | 9 | 8 | 74 | - | 149 | | (50)% | 150 | 224 | 74 | - | 28 |
| Cervical Cancer-VIA/VILI Screening | 2,259 | 1,389 | 15,275 | 60,000 | 38,610 | | (60)% | 38,866 | 54,141 | 15,275 | - | - |
| Cervical Cancer-VIA/VILI Screening | 2,259 | 1,389 | 15,275 | 60,000 | 38,610 | | (60)% | 38,866 | 54,141 | 15,275 | - | - |
| Chlorhexidine | 375 | 953 | 6,327 | 16,755 | 22,704 | | (72)% | 23,211 | 29,538 | 5,694 | - | 440 |
| Chlorhexidine Gel, 5 g tube | 375 | 953 | 6,327 | 16,755 | 22,704 | | (72)% | 23,211 | 29,538 | 5,694 | - | 440 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Clean Delivery Kit | - | - | - | - | 2,840 | | (100)% | 2,840 | 2,840 | - | - | - |
| Maama Kit | - | - | - | - | 572 | | (100)% | 572 | 572 | - | - | - |
| Maama Kit Extra Clean Delivery | - | - | - | - | 2,268 | | (100)% | 2,268 | 2,268 | - | - | - |
| Condom | 51,912 | 160,392 | 1,999,296 | 2,633,850 | 1,567,440 | | 28% | 1,604,736 | 3,604,032 | 14,995 | 14,995 | 34,938 |
| Trust | 12,600 | 40,584 | 621,648 | 675,000 | 620,568 | | -% | 630,504 | 1,252,152 | 4,662 | 4,662 | 10,863 |
| Trust Ribbed | 12,096 | 42,336 | 475,344 | 665,550 | 87,120 | | 446% | 87,408 | 562,752 | 3,565 | 3,565 | 8,307 |
| Trust Scented | 15,408 | 36,576 | 466,488 | 652,050 | 335,016 | | 39% | 349,272 | 815,760 | 3,499 | 3,499 | 8,152 |
| Trust Studded | 11,808 | 40,896 | 435,816 | 641,250 | 524,736 | | (17)% | 537,552 | 973,368 | 3,269 | 3,269 | 7,616 |
| Emergency Contraception | (8) | (6) | (60) | - | - | | 0% | (107) | (167) | (3) | (3) | (2) |
| (b)PSI Emergency Contraception Distributed Provided | (8) | (6) | (60) | - | - | | -% | (107) | (167) | (3) | (3) | (2) |
| Emergency Contraception Provided | 14 | 14 | 102 | - | - | | 0% | 109 | 211 | 5 | 5 | 3 |
| Non-PSI Emergency Contraception Provided | 6 | 8 | 42 | - | - | | -% | 2 | 44 | 2 | 2 | 1 |
| PSI Emergency Contraception Provided | 8 | 6 | 60 | - | - | | -% | 107 | 167 | 3 | 3 | 2 |
| Expanded Clean Delivery Kit | - | - | - | - | 13,160 | | (100)% | 13,160 | 13,160 | - | - | - |
| Mama Kit Expanded(Chlorhexidine 400gm&Misoprostol) | - | - | - | - | 13,160 | | (100)% | 13,160 | 13,160 | - | - | - |
| Expanded Clean Delivery Kit (+CHX) | 14 | 1,420 | 11,040 | 20,285 | 13,350 | | (17)% | 13,837 | 24,877 | 9,936 | - | 1,615 |
| Mama Kit with Chlorhexidine | 14 | 1,420 | 11,040 | 20,285 | 13,350 | | (17)% | 13,837 | 24,877 | 9,936 | - | 1,615 |
| Free Condom | - | - | - | - | 576,000 | | (100)% | 576,000 | 576,000 | - | - | - |
| Generic Male Condom | - | - | - | - | 576,000 | | (100)% | 576,000 | 576,000 | - | - | - |
| Implant 3 | 6,596 | 9,649 | 56,578 | 72,620 | 33,358 | | 70% | 34,268 | 90,846 | 50,920 | 127,301 | 128,898 |
| Implanon | 6,082 | 5,664 | 55,194 | 92,900 | 53,670 | | 3% | 55,110 | 110,304 | 49,675 | 124,187 | 125,745 |
| Levoplant | 2,790 | 6,153 | 21,250 | - | - | | -% | - | 21,250 | 19,125 | 47,813 | 48,412 |
| (b)PSI Implant 3 Distributed Inserted | (2,276) | (2,168) | (19,866) | (20,280) | (20,312) | | -% | (20,842) | (40,708) | (17,879) | (44,699) | (45,259) |
| Implant 3 Insertion | 10,692 | 10,593 | 105,697 | 100,280 | 93,319 | | 13% | 99,913 | 205,610 | 105,697 | 264,243 | 267,558 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Non-PSI Implant 3 Inserted | 8,416 | 8,424 | 85,831 | 80,000 | 73,007 | | 18% | 79,071 | 164,902 | 85,831 | 214,578 | 217,270 |
| PSI Implant 3 Inserted | 2,276 | 2,168 | 19,866 | 20,280 | 20,312 | | (2)% | 20,842 | 40,708 | 19,866 | 49,665 | 50,288 |
| Implant 5 | 1,251 | 4,226 | 45,049 | 25,000 | 40,585 | | 11% | 41,363 | 86,412 | 40,544 | 154,068 | 153,333 |
| Jadelle | 2,400 | 5,300 | 54,630 | 40,000 | 52,150 | | 5% | 53,160 | 107,790 | 49,167 | 186,835 | 185,943 |
| (b)PSI Implant 5 Distributed Inserted | (1,149) | (1,074) | (9,581) | (15,000) | (11,565) | | -% | (11,797) | (21,378) | (8,623) | (32,767) | (32,611) |
| Implant 5 Insertion | 3,951 | 4,776 | 54,084 | 45,160 | 30,121 | | 80% | 33,335 | 87,419 | 54,084 | 205,519 | 204,539 |
| Non-PSI Implant 5 Inserted | 2,802 | 3,702 | 44,503 | 30,160 | 18,556 | | 140% | 21,538 | 66,041 | 44,503 | 169,111 | 168,305 |
| PSI Implant 5 Inserted | 1,149 | 1,074 | 9,581 | 15,000 | 11,565 | | (17)% | 11,797 | 21,378 | 9,581 | 36,408 | 36,234 |
| Injectable 3-IM | 122 | 25,389 | 143,570 | 48,097 | 72,175 | | 99% | 59,649 | 203,219 | 32,303 | 32,303 | 24,046 |
| Depo-Provera | 2,625 | 28,092 | 167,900 | 68,097 | 72,175 | | 133% | 82,175 | 250,075 | 37,778 | 37,778 | 28,121 |
| (b)PSI Injectable 3 IM Distributed Provided | (2,503) | (2,703) | (24,330) | (20,000) | - | | -% | (22,526) | (46,856) | (5,474) | (5,474) | (4,075) |
| Injectable 3-IM Provided | 2,545 | 2,774 | 25,155 | 21,700 | - | | 0% | 24,298 | 49,453 | 6,289 | 6,289 | 4,681 |
| Non-PSI Injectable 3 IM Provided | 42 | 71 | 825 | 1,700 | - | | -% | 1,772 | 2,597 | 206 | 206 | 154 |
| PSI Injectable 3 IM Provided | 2,503 | 2,703 | 24,330 | 20,000 | - | | -% | 22,526 | 46,856 | 6,083 | 6,083 | 4,528 |
| Injectable 3-SC | 7,000 | 10,804 | 85,500 | 53,892 | 49,900 | | 71% | 55,900 | 141,400 | 19,238 | 19,238 | 14,320 |
| Sayana Press | 7,000 | 10,804 | 85,500 | 53,892 | 49,900 | | 71% | 55,900 | 141,400 | 19,238 | 19,238 | 14,320 |
| IUD 10 | 16,295 | 13,237 | 91,413 | 90,759 | 113,319 | | (19)% | 112,806 | 204,219 | 82,272 | 378,450 | 360,165 |
| Copper T 380 | 15,900 | 9,585 | 83,755 | 87,000 | 110,545 | | (24)% | 110,545 | 194,300 | 75,380 | 346,746 | 329,993 |
| IUD PACK CU T380A | 3,241 | 6,370 | 28,401 | 60,000 | 43,467 | | (35)% | 43,587 | 71,988 | 25,561 | 117,580 | 111,899 |
| PPIUD Cu T380A | 209 | 17 | 2,025 | 1,359 | 2,675 | | (24)% | 2,675 | 4,700 | 1,823 | 8,383 | 7,978 |
| (b)PSI IUD 10 Distributed Inserted | (3,055) | (2,735) | (22,768) | (57,600) | (43,368) | | -% | (44,001) | (66,769) | (20,491) | (94,260) | (89,705) |
| IUD 10 Insertion | 5,861 | 6,983 | 54,700 | 112,680 | 88,071 | | (38)% | 89,907 | 144,607 | 54,700 | 251,620 | 239,463 |
| Non-PSI IUD 10 Inserted | 2,806 | 4,249 | 31,932 | 55,080 | 44,703 | | (29)% | 45,906 | 77,838 | 31,932 | 146,887 | 139,791 |
| PSI IUD 10 Inserted | 3,055 | 2,735 | 22,768 | 57,600 | 43,368 | | (48)% | 44,001 | 66,769 | 22,768 | 104,733 | 99,673 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| IUD 5 | - | (1) | (32) | - | (133) | | 0% | (134) | (166) | (29) | (95) | (96) |
| (b)PSI IUD 5 Distributed Inserted | - | (1) | (32) | - | (133) | | -% | (134) | (166) | (29) | (95) | (96) |
| IUD 5 Insertion | - | 1 | 34 | - | 134 | | (75)% | 135 | 169 | 34 | 112 | 114 |
| Non-PSI IUD 5 Inserted | - | - | 2 | - | 1 | | 100% | 1 | 3 | 2 | 7 | 7 |
| PSI IUD 5 Inserted | - | 1 | 32 | - | 133 | | (76)% | 134 | 166 | 32 | 106 | 107 |
| Manual Vacuum Aspiration for PAC | 29 | 78 | 852 | 720 | 455 | | 87% | 469 | 1,321 | 852 | - | 250 |
| MVA for PAC | 29 | 78 | 852 | 720 | 455 | | 87% | 469 | 1,321 | 852 | - | 250 |
| Manual Vacuum Aspiration for SA | 80 | 72 | 770 | - | 253 | | 204% | 261 | 1,031 | 770 | - | 282 |
| Manual Vacuum Aspiration for SA | 80 | 72 | 770 | - | 253 | | 204% | 261 | 1,031 | 770 | - | 282 |
| Medical Abortion | 503 | 1,517 | 10,288 | 9,331 | 16,455 | | (37)% | 16,535 | 26,823 | 9,259 | - | 3,243 |
| Divabo - Combipack (1+4's) | 575 | 1,588 | 11,038 | 9,331 | 16,721 | | (34)% | 16,804 | 27,842 | 9,934 | - | 3,480 |
| (b)PSI Medical Abortion Distributed Provided | (72) | (72) | (750) | - | (266) | | -% | (269) | (1,019) | (675) | - | (236) |
| Medical Abortion (Misoprostol) Provided | 65 | 91 | 967 | - | 318 | | 204% | 344 | 1,311 | 967 | - | 302 |
| PSI Medical Abortion (Misoprostol) Provided | 65 | 91 | 967 | - | 318 | | 204% | 344 | 1,311 | 967 | - | 302 |
| Medical Abortion Provided | 72 | 72 | 750 | - | 266 | | 182% | 269 | 1,019 | 750 | - | 263 |
| PSI Medical Abortion Provided | 72 | 72 | 750 | - | 266 | | 182% | 269 | 1,019 | 750 | - | 263 |
| Misoprostol for PAC Provided | 34 | 66 | 853 | - | 576 | | 48% | 586 | 1,439 | 853 | - | 292 |
| PSI Misoprostol for PAC Provided | 34 | 66 | 853 | - | 576 | | 48% | 586 | 1,439 | 853 | - | 292 |
| Misoprostol for Safe Abortion | 12,184 | 77,980 | 571,514 | 893,550 | 440,220 | | 30% | 452,048 | 1,023,562 | 30,004 | - | 9,374 |
| Misoprostol 200 mcg Tablet | 13,100 | 79,333 | 424,430 | - | - | | -% | - | 424,430 | 22,283 | - | 6,962 |
| Misoprostol for Safe Abortion | - | - | 162,100 | 893,550 | 446,340 | | (64)% | 458,520 | 620,620 | 8,510 | - | 2,659 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (916) | (1,353) | (15,016) | - | (6,120) | | -% | (6,472) | (21,488) | (788) | - | (246) |
| OCs | 2,999 | 4,833 | 54,808 | 45,277 | 44,974 | | 22% | 43,581 | 98,389 | 3,288 | 3,288 | 2,582 |
| Combination 3 | - | 167 | 3,100 | - | 7,900 | | (61)% | 7,900 | 11,000 | 186 | 186 | 146 |
| Family Planning Pills | - | - | - | 26,280 | 28,590 | | (100)% | 28,590 | 28,590 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|----------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Microlut - Oral Contraceptive | 2,775 | 736 | 6,764 | 2,000 | 201 | | 3,265% | 699 | 7,463 | 406 | 406 | 319 |
| (b)PSI OCs Distributed Provided | (336) | (314) | (2,666) | (3,003) | - | | -% | (2,890) | (5,556) | (160) | (160) | (126) |
| Zinnia | 560 | 4,245 | 47,610 | 20,000 | 8,283 | | 475% | 9,282 | 56,892 | 2,857 | 2,857 | 2,243 |
| OCs Provided | 342 | 327 | 2,805 | 3,103 | - | | 0% | 3,066 | 5,871 | 187 | 187 | 147 |
| Non-PSI OCs Provided | 6 | 13 | 139 | 100 | - | | -% | 176 | 315 | 9 | 9 | 7 |
| PSI OCs Provided | 336 | 314 | 2,666 | 3,003 | - | | -% | 2,890 | 5,556 | 178 | 178 | 140 |
| PUR | - | 326,860 | 3,099,421 | 3,400,000 | 6,413,745 | | (52)% | 6,413,745 | 9,513,166 | 25,475 | - | 102 |
| PuR | - | 326,860 | 3,099,421 | 3,400,000 | 6,413,745 | | (52)% | 6,413,745 | 9,513,166 | 25,475 | - | 102 |
| Referral to HIV Testing Services | - | - | - | - | - | | 0% | 11,703 | 11,703 | - | - | - |
| Referral to HIV Testing Services | - | - | - | - | - | | -% | 11,703 | 11,703 | - | - | - |
| Referral to Linkage to HIV Care | - | - | - | - | - | | 0% | 4,614 | 4,614 | - | - | - |
| Referral to Linkage to HIV Care | - | - | - | - | - | | -% | 4,614 | 4,614 | - | - | - |
| Tubal Ligation | - | 2 | 47 | - | 46 | | 2% | 46 | 93 | 47 | 470 | 404 |
| Tubal Ligation | - | 2 | 47 | - | 46 | | 2% | 46 | 93 | 47 | 470 | 404 |
| Vasectomy | 6 | 4 | 17 | - | - | | 0% | - | 17 | 17 | 170 | 148 |
| Vasectomy | 6 | 4 | 17 | - | - | | -% | - | 17 | 17 | 170 | 148 |
| Rwanda | | | | | | | | | | | 123,184 | 241,244 |
| Condom | 1,763,369 | 1,352,743 | 14,333,649 | 16,437,500 | 13,673,659 | | 5% | 13,673,659 | 215,238,535 | 107,502 | 107,502 | 230,616 |
| Plaisir | 272,280 | 301,460 | 3,061,140 | 2,000,000 | 1,688,521 | 2/13 | 81% | 1,688,521 | 19,641,160 | 22,959 | 22,959 | 49,251 |
| Prudence Plus | 1,491,089 | 1,051,283 | 11,272,509 | 14,437,500 | 11,985,138 | 2/13 | (6)% | 11,985,138 | 195,597,375 | 84,544 | 84,544 | 181,365 |
| Free Condom | - | 40 | 255 | - | 22,662 | | (99)% | 22,662 | 2,390,663 | 2 | 2 | 4 |
| Military Condom | - | 40 | 255 | - | 22,662 | 4/14 | (99)% | 22,662 | 2,390,663 | 2 | 2 | 4 |
| Injectable 3-IM | - | - | 26,132 | 26,620 | 42,020 | | (38)% | 42,020 | 107,744 | 5,880 | 5,880 | 3,784 |
| Confiance Depo-Provera | - | - | 26,132 | 26,620 | 42,020 | 2/13 | (38)% | 42,020 | 107,744 | 5,880 | 5,880 | 3,784 |
| OCs | 14,430 | 30,320 | 163,339 | 79,860 | 170,171 | | (4)% | 170,171 | 530,142 | 9,800 | 9,800 | 6,655 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Microgynon | 14,430 | 30,320 | 163,339 | 79,860 | 170,171 | 6/15 | (4)% | 170,171 | 530,142 | 9,800 | 9,800 | 6,655 |
| PUR | 240 | 160,173 | 1,121,541 | 1,000,000 | 1,286,421 | | (13)% | 1,286,421 | 13,982,170 | 9,218 | - | 19 |
| PuR | 240 | 160,173 | 1,121,541 | 1,000,000 | 1,286,421 | 2/13 | (13)% | 1,286,421 | 13,982,170 | 9,218 | - | 19 |
| Safe Water Solution | - | 5,093 | 100,024 | 275,000 | 250,823 | | (60)% | 250,823 | 4,165,607 | 82,212 | - | 166 |
| Sur Eau | - | 5,093 | 100,024 | 275,000 | 250,823 | 2/13 | (60)% | 250,823 | 4,165,607 | 82,212 | - | 166 |
| Swaziland | | | | | | | | | | | 86,300 | 542,430 |
| Antiretroviral Treatment (Currently Enrolled) | 1,715 | 1,462 | 14,215 | 19,040 | 7,989 | | 78% | 9,037 | 25,125 | 1,185 | - | 2,924 |
| Antiretroviral Treatment (Currently Enrolled) | 1,715 | 1,462 | 14,215 | 19,040 | 7,989 | | 78% | 9,037 | 25,125 | 1,185 | - | 2,924 |
| Antiretroviral Treatment (Newly Enrolled) | 45 | 64 | 701 | 359 | 563 | | 25% | 593 | 1,863 | 701 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 45 | 64 | 701 | 359 | 563 | | 25% | 593 | 1,863 | 701 | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 101 | | (100)% | 101 | 1,499 | - | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 101 | | (100)% | 101 | 1,499 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | 37 | 13 | 77 | - | - | | 0% | - | 78 | 77 | - | - |
| Cervical Cancer-VIA/VILI Screening | 37 | 13 | 77 | - | - | | -% | - | 78 | 77 | - | - |
| Condom | - | - | - | - | 5,072,763 | | (100)% | 5,072,763 | 24,040,979 | - | - | - |
| Lovers Plus | - | - | - | - | 288 | 2/01 | (100)% | 288 | 1,271,986 | - | - | - |
| Lovers Plus C&F | - | - | - | - | 253 | 1/05 | (100)% | 253 | 188,237 | - | - | - |
| Lovers Plus R&S | - | - | - | - | 80 | 5/10 | (100)% | 80 | 111,824 | - | - | - |
| Trust Regular BGF | - | - | - | - | 234 | 7/08 | (100)% | 234 | 74,421 | - | - | - |
| Trust Studded | - | - | - | - | 1,908 | 1/05 | (100)% | 1,908 | 5,550,730 | - | - | - |
| Trust Workplace | - | - | - | - | 5,070,000 | 2/06 | (100)% | 5,070,000 | 16,843,781 | - | - | - |
| Emergency Contraception Provided | - | - | 3 | - | 2 | | 50% | 2 | 10 | - | - | - |
| Non-PSI Emergency Contraception Provided | - | - | 3 | - | 2 | | 50% | 2 | 10 | - | - | - |
| Female Condom | 16,000 | 9,667 | 93,000 | 60,000 | 116,500 | | (20)% | 116,500 | 1,125,727 | 697 | 697 | 3,997 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Female Condom | 16,000 | 9,667 | 93,000 | 60,000 | 116,500 | 7/06 | (20)% | 116,500 | 1,125,727 | 697 | 697 | 3,997 |
| Free Condom | 1,137,000 | 1,326,000 | 11,400,000 | 6,000,000 | 10,911,690 | | 4% | 11,994,690 | 84,641,108 | 85,500 | 85,500 | 494,345 |
| Generic | 876,000 | 1,124,000 | 8,310,000 | 3,750,000 | 10,398,000 | 4/05 | (20)% | 11,283,000 | 70,448,544 | 62,325 | 62,325 | 360,352 |
| Vanilla & Strawberry | 261,000 | 202,000 | 3,090,000 | 2,250,000 | 513,000 | | 502% | 711,000 | 3,801,000 | 23,175 | 23,175 | 133,994 |
| Workplace | - | - | - | - | 690 | 10/01 | (100)% | 690 | 10,391,564 | - | - | - |
| HIV Self-Testing Kit | 5,307 | 4,876 | 24,601 | 27,000 | - | | 0% | 36,575 | 61,176 | 22,141 | - | - |
| ORAQUICK HIV Self-Testing Kit (Pouch) | 5,307 | 4,876 | 24,601 | 27,000 | - | | -% | 36,575 | 61,176 | 22,141 | - | - |
| HIV Testing Services | 1,431 | 1,924 | 32,197 | 32,457 | 35,330 | | (9)% | 37,788 | 652,168 | 32,197 | - | 4,378 |
| VCT Individual (HIV-Negative) | 1,156 | 1,520 | 27,785 | 27,006 | 30,495 | 12/09 | (9)% | 32,716 | 595,582 | 27,785 | - | 3,778 |
| VCT Individual (HIV-Positive) | 275 | 404 | 4,412 | 5,451 | 4,835 | 12/09 | (9)% | 5,072 | 56,586 | 4,412 | - | 600 |
| Hypertension Screening | 861 | 692 | 5,992 | 32,457 | 3,013 | | 99% | 3,270 | 14,496 | 5,992 | - | - |
| Hypertension Screening | 861 | 692 | 5,992 | 32,457 | 3,013 | | 99% | 3,270 | 14,496 | 5,992 | - | - |
| Implant 3 Insertion | - | 1 | 25 | 33 | 165 | | (85)% | 170 | 197 | 25 | 63 | 42 |
| Non-PSI Implant 3 Inserted | - | 1 | 25 | 33 | 165 | | (85)% | 170 | 197 | 25 | 63 | 42 |
| Injectable 1 Provided | - | 3 | 41 | 36 | 534 | | (92)% | 537 | 1,800 | 3 | 3 | 2 |
| Non-PSI Injectable 1 Provided | - | 3 | 41 | 36 | 534 | | (92)% | 537 | 1,800 | 3 | 3 | 2 |
| Injectable 3-IM Provided | - | 3 | 121 | 102 | 1,178 | | (90)% | 1,194 | 2,954 | 30 | 30 | 15 |
| Non-PSI Injectable 3 IM Provided | - | 3 | 121 | 102 | 1,178 | | (90)% | 1,194 | 2,954 | 30 | 30 | 15 |
| Lubricant | 115,000 | 82,667 | 742,000 | 600,000 | 1,302,000 | | (43)% | 1,342,000 | 2,757,000 | - | - | - |
| Lifestyles Liquid Personal Lubricant (4.5 g) | 115,000 | 82,667 | 742,000 | 600,000 | 1,302,000 | 8/11 | (43)% | 1,342,000 | 2,757,000 | - | - | - |
| OCs Provided | - | 5 | 97 | 70 | 681 | | (86)% | 692 | 2,308 | 6 | 6 | 3 |
| Non-PSI OCs Provided | - | 5 | 97 | 70 | 681 | | (86)% | 692 | 2,308 | 6 | 6 | 3 |
| PrEP | 11 | 16 | 164 | - | 71 | | 131% | 78 | 242 | 14 | - | 9 |
| PrEP | 11 | 16 | 164 | - | 71 | | 131% | 78 | 242 | 14 | - | 9 |
| Referral to Hypertension Management | - | - | 1 | - | 3 | | (67)% | 3 | 46 | 1 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Referral to Hypertension Management | - | - | 1 | - | 3 | | (67)% | 3 | 46 | 1 | - | - |
| Referral to Injectable 1 | - | - | - | - | 36 | | (100)% | 36 | 384 | - | - | - |
| Referral to Injectable 1 | - | - | - | - | 36 | | (100)% | 36 | 384 | - | - | - |
| Referral to Injectable 3 | - | - | - | - | 55 | | (100)% | 55 | 646 | - | - | - |
| Referral to Injectable 3 | - | - | - | - | 55 | | (100)% | 55 | 646 | - | - | - |
| Referral to Linkage to HIV Care | 132 | 211 | 2,306 | 5,178 | 2,427 | | (5)% | 2,541 | 8,909 | 2,306 | - | 1,506 |
| Referral to Linkage to HIV Care | 132 | 211 | 2,306 | 5,178 | 2,427 | | (5)% | 2,541 | 8,909 | 2,306 | - | 1,506 |
| Referral to OCs | - | - | - | - | 76 | | (100)% | 76 | 547 | - | - | - |
| Referral to OCs | - | - | - | - | 76 | | (100)% | 76 | 547 | - | - | - |
| Referral to STI Treatment (unknown) | - | - | - | - | 26 | | (100)% | 26 | 247 | - | - | - |
| Referral to STI Treatment (unknown) | - | - | - | - | 26 | 12/14 | (100)% | 26 | 247 | - | - | - |
| Referral to TB Screening | - | - | - | 5,178 | 303 | | (100)% | 303 | 4,032 | - | - | - |
| Referrals to TB Screening | - | - | - | 5,178 | 303 | | (100)% | 303 | 4,032 | - | - | - |
| Referral to Voluntary Medical Male Circumcision | - | - | - | - | 19 | | (100)% | 19 | 4,737 | - | - | - |
| Referral to Voluntary Medical Male Circumcision | - | - | - | - | 19 | 12/14 | (100)% | 19 | 4,737 | - | - | - |
| STI Screening | 1,464 | 1,960 | 32,611 | 32,457 | 35,505 | | (8)% | 37,972 | 142,059 | 32,611 | - | - |
| STI Screening | 1,464 | 1,960 | 32,611 | 32,457 | 35,505 | | (8)% | 37,972 | 142,059 | 32,611 | - | - |
| TB Screening | 1,834 | 1,926 | 32,607 | 1,043 | 35,452 | | (8)% | 37,910 | 132,904 | 32,607 | - | - |
| TB Screening | 1,834 | 1,926 | 32,607 | 1,043 | 35,452 | | (8)% | 37,910 | 132,904 | 32,607 | - | - |
| Treatment for Genital Herpes | 4 | 2 | 23 | 17 | 16 | | 44% | 17 | 67 | 23 | - | 1 |
| Treatment for Genital Herpes | 4 | 2 | 23 | 17 | 16 | | 44% | 17 | 67 | 23 | - | 1 |
| Treatment for Inguinal Bubo | - | - | - | - | 1 | | (100)% | 1 | 5 | - | - | - |
| Treatment for Inguinal Bubo | - | - | - | - | 1 | | (100)% | 1 | 5 | - | - | - |
| Treatment for Lower Abdominal Pain | - | 6 | 64 | 54 | 52 | | 23% | 54 | 173 | 64 | - | - |
| Treatment for Lower Abdominal Pain | - | 6 | 64 | 54 | 52 | | 23% | 54 | 173 | 64 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Treatment for Nonherpetic Genital Ulcer | - | 7 | 80 | 94 | 90 | | (11)% | 94 | 319 | 80 | - | 31 |
| Treatment for Nonherpetic Genital Ulcer | - | 7 | 80 | 94 | 90 | | (11)% | 94 | 319 | 80 | - | 31 |
| Treatment for Urethral Discharge (Men) | 9 | 14 | 264 | 195 | 190 | | 39% | 195 | 678 | 528 | - | 37 |
| Treatment for Urethral Discharge (Men) | 9 | 14 | 264 | 195 | 190 | | 39% | 195 | 678 | 528 | - | 37 |
| Treatment for Urethral Discharge (Women) | - | - | 3 | 2 | 2 | | 50% | 2 | 7 | 3 | - | 1 |
| Treatment for Urethral Discharge (Women) | - | - | 3 | 2 | 2 | | 50% | 2 | 7 | 3 | - | 1 |
| Treatment for Vaginitis | - | 18 | 216 | 380 | 372 | | (42)% | 380 | 1,182 | 216 | - | 57 |
| Treatment for Vaginitis | - | 18 | 216 | 380 | 372 | | (42)% | 380 | 1,182 | 216 | - | 57 |
| Type 2 Diabetes Screening | 803 | 1,478 | 22,221 | 32,457 | 607 | | 3561% | 658 | 23,138 | 22,221 | - | - |
| Type 2 Diabetes Screening | 803 | 1,478 | 22,221 | 32,457 | 607 | | 3,561% | 658 | 23,138 | 22,221 | - | - |
| Voluntary Medical Male Circumcision | 115 | 171 | 2,512 | 4,000 | 2,710 | | (7)% | 2,766 | 9,379 | 2,512 | - | 35,081 |
| Voluntary Medical Male Circumcision | 115 | 171 | 2,512 | 4,000 | 2,710 | | (7)% | 2,766 | 9,379 | 2,512 | - | 35,081 |
| Tanzania | | | | | | | | | | | 444,300 | 424,923 |
| Cervical Cancer-VIA/VILI Screening | - | - | - | - | 39 | | (100)% | 39 | 19,810 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | - | - | - | - | 39 | | (100)% | 39 | 19,810 | - | - | - |
| Condom | - | 1,440 | 10,368 | 220,000 | 9,718,704 | | (100)% | 9,719,136 | 614,748,380 | 78 | 78 | 119 |
| Salama Halisi | - | 432 | 1,296 | - | 4,191,696 | 2/11 | (100)% | 4,191,696 | 345,729,800 | 10 | 10 | 15 |
| Salama Scented | - | - | - | 220,000 | 4,398,192 | 8/06 | (100)% | 4,398,624 | 136,918,956 | - | - | - |
| Salama Studded | - | 1,008 | 9,072 | - | 1,128,816 | 6/04 | (99)% | 1,128,816 | 132,099,624 | 68 | 68 | 104 |
| Emergency Contraception | - | - | (484) | - | (738) | | 0% | (779) | (1,312) | (22) | (22) | (10) |
| (b)PSI Emergency Contraception Distributed Provided | - | - | (484) | - | (738) | | -% | (779) | (1,312) | (22) | (22) | (10) |
| Emergency Contraception Provided | 32 | 37 | 1,110 | 2,468 | 2,193 | | (49)% | 2,258 | 3,508 | 56 | 56 | 27 |
| Non-PSI Emergency Contraception Provided | 32 | 37 | 626 | 2,468 | 1,455 | | (57)% | 1,479 | 2,196 | 31 | 31 | 15 |
| PSI Emergency Contraception Provided | - | - | 484 | - | 738 | | (34)% | 779 | 1,312 | 24 | 24 | 12 |
| Implant 3 | - | - | (1,126) | - | (10,386) | | 0% | (10,487) | (78,360) | (1,013) | (2,534) | (2,162) |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| (b)PSI Implant 3 Distributed Inserted | - | - | (1,126) | - | (10,386) | | -% | (10,487) | (78,360) | (1,013) | (2,534) | (2,162) |
| Implant 3 Insertion | 4,558 | 5,032 | 55,057 | 49,779 | 72,127 | | (24)% | 73,748 | 276,217 | 55,057 | 137,643 | 117,434 |
| Non-PSI Implant 3 Inserted | 4,558 | 5,032 | 53,931 | 49,779 | 61,741 | | (13)% | 63,261 | 197,857 | 53,931 | 134,828 | 115,033 |
| PSI Implant 3 Inserted | - | - | 1,126 | - | 10,386 | | (89)% | 10,487 | 78,360 | 1,126 | 2,815 | 2,402 |
| Implant 5 | - | - | (2,067) | - | (11,883) | | 0% | (12,107) | (109,883) | (1,860) | (7,069) | (5,918) |
| (b)PSI Implant 5 Distributed Inserted | - | - | (2,067) | - | (11,883) | | -% | (12,107) | (109,883) | (1,860) | (7,069) | (5,918) |
| Implant 5 Insertion | 3,738 | 4,934 | 42,311 | 32,829 | 44,807 | | (6)% | 45,509 | 239,450 | 42,311 | 160,782 | 134,601 |
| Non-PSI Implant 5 Inserted | 3,738 | 4,934 | 40,244 | 32,829 | 32,924 | | 22% | 33,402 | 129,567 | 40,244 | 152,927 | 128,025 |
| PSI Implant 5 Inserted | - | - | 2,067 | - | 11,883 | | (83)% | 12,107 | 109,883 | 2,067 | 7,855 | 6,576 |
| Injectable 3-IM | - | - | (650) | - | 242,170 | | (100)% | 241,911 | 1,900,188 | (146) | (146) | (92) |
| Familia Injectable 3 Kit | - | - | - | - | 246,600 | 1/10 | (100)% | 246,600 | 1,913,951 | - | - | - |
| (b)PSI Injectable 3 IM Distributed Provided | - | - | (650) | - | (4,430) | | -% | (4,689) | (13,763) | (146) | (146) | (92) |
| Injectable 3-IM Provided | 3,737 | 4,507 | 41,709 | 7,419 | 35,669 | | 17% | 37,606 | 148,146 | 10,427 | 10,427 | 6,552 |
| Non-PSI Injectable 3 IM Provided | 3,737 | 4,507 | 41,059 | 7,419 | 31,239 | | 31% | 32,917 | 134,383 | 10,265 | 10,265 | 6,450 |
| PSI Injectable 3 IM Provided | - | - | 650 | - | 4,430 | | (85)% | 4,689 | 13,763 | 163 | 163 | 102 |
| ITN | 1,260,695 | - | 1,260,695 | - | - | | 0% | - | 1,260,695 | 2,042,326 | - | 44,820 |
| PBO Net | 1,260,695 | - | 1,260,695 | - | - | | -% | - | 1,260,695 | 2,042,326 | - | 44,820 |
| IUD 10 | - | 413 | (6,447) | 2,450 | (25,650) | | 0% | (26,670) | (124,989) | (5,802) | (26,691) | (21,321) |
| Familia IUD Kit | - | 413 | 2,340 | 2,450 | 12,420 | 11/09 | (81)% | 12,820 | 255,969 | 2,106 | 9,688 | 7,739 |
| (b)PSI IUD 10 Distributed Inserted | - | - | (8,787) | - | (38,070) | | -% | (39,490) | (380,958) | (7,908) | (36,378) | (29,060) |
| IUD 10 Insertion | 2,740 | 3,637 | 36,040 | 66,000 | 94,853 | | (62)% | 96,804 | 615,644 | 36,040 | 165,784 | 132,434 |
| Non-PSI IUD 10 Inserted | 2,740 | 3,637 | 27,253 | 66,000 | 56,783 | | (52)% | 57,314 | 234,686 | 27,253 | 125,364 | 100,145 |
| PSI IUD 10 Inserted | - | - | 8,787 | - | 38,070 | | (77)% | 39,490 | 380,958 | 8,787 | 40,420 | 32,289 |
| LLIN | - | - | 144,630 | 655,054 | 4,444,269 | | (97)% | 4,510,989 | 12,096,501 | 234,301 | - | 7,266 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| "New Brand" (School Net Program) | - | - | - | - | 97,352 | | (100)% | 97,352 | 1,255,210 | - | - | - |
| Olyset Nets Health Facility | - | - | 59,760 | - | 434,880 | | (86)% | 486,680 | 546,440 | 96,811 | - | 3,002 |
| Permanet (180x160x180 CM) SI | - | - | - | - | 978,840 | 2/16 | (100)% | 978,840 | 7,261,864 | - | - | - |
| Permanet Health Facility | - | - | 84,496 | 655,054 | 76,928 | | 10% | 91,648 | 176,144 | 136,884 | - | 4,245 |
| Permanet Nets School | - | - | 374 | - | 2,856,269 | | (100)% | 2,856,469 | 2,856,843 | 606 | - | 19 |
| Manual Vacuum Aspiration for PAC | 497 | 586 | 5,264 | - | 6,204 | | (15)% | 6,674 | 13,012 | 5,264 | - | 663 |
| MVA for PAC | 497 | 586 | 5,264 | - | 6,204 | | (15)% | 6,674 | 13,012 | 5,264 | - | 663 |
| Misoprostol for PAC Provided | 167 | 191 | 2,100 | - | 2,327 | | (10)% | 2,547 | 4,698 | 2,100 | - | 311 |
| PSI Misoprostol for PAC Provided | 167 | 191 | 2,100 | - | 2,327 | | (10)% | 2,547 | 4,698 | 2,100 | - | 311 |
| Misoprostol for Safe Abortion | 81,252 | 80,249 | 822,912 | 1,100,000 | 1,164,904 | | (29)% | 1,207,224 | 6,984,936 | 43,203 | - | 5,841 |
| Misoprostol Cipla 200 mcg | 81,920 | 81,013 | 831,312 | 1,100,000 | 733,576 | | 13% | 776,776 | 1,608,088 | 43,644 | - | 5,901 |
| Misoprostol for Safe Abortion | - | - | - | - | 440,636 | 3/18 | (100)% | 440,636 | 5,395,640 | - | - | - |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (668) | (764) | (8,400) | - | (9,308) | | -% | (10,188) | (18,792) | (441) | - | (60) |
| OCs | - | - | (969) | - | 287,193 | | (100)% | 287,100 | 10,206,220 | (58) | (58) | (39) |
| Familia [OC] | - | - | - | - | 295,056 | 2/08 | (100)% | 295,056 | 10,228,009 | - | - | - |
| (b)PSI OCs Distributed Provided | - | - | (969) | - | (7,863) | | -% | (7,956) | (21,789) | (58) | (58) | (39) |
| OCs Provided | 9,309 | 12,748 | 90,754 | 11,708 | 73,754 | | 23% | 75,344 | 211,019 | 6,050 | 6,050 | 4,011 |
| Non-PSI OCs Provided | 9,309 | 12,748 | 89,785 | 11,708 | 65,891 | | 36% | 67,388 | 189,230 | 5,986 | 5,986 | 3,968 |
| PSI OCs Provided | - | - | 969 | - | 7,863 | | (88)% | 7,956 | 21,789 | 65 | 65 | 43 |
| Water Treatment Tablets | 2,591,500 | 655,640 | 5,751,310 | 7,001,740 | 6,112,242 | | (6)% | 6,112,242 | 125,157,361 | 94,542 | - | 386 |
| Aquatab Tubs 8.68g | - | - | - | 1,740 | 960 | 3/16 | (100)% | 960 | 446,520 | - | - | - |
| WaterGuard Tablet ENF | - | - | 1,166,640 | 7,000,000 | 6,111,282 | 7/12 | (81)% | 6,111,282 | 52,372,322 | 19,178 | - | 78 |
| WaterGuard Tablets | 2,591,500 | 655,640 | 4,584,670 | - | - | 11/05 | -% | - | 72,338,519 | 75,364 | - | 307 |

Uganda 126,368 370,242

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|-------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Cervical Cancer-VIA and Cryotherapy | - | - | - | - | 74 | | (100)% | 74 | 2,360 | - | - | - |
| Cervical Cancer-VIA and Cryotherapy | - | - | - | - | 74 | 11/13 | (100)% | 74 | 2,360 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | - | - | - | - | 18,884 | | (100)% | 18,884 | 176,960 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | - | - | - | - | 18,884 | | (100)% | 18,884 | 176,960 | - | - | - |
| Chlorhexidine | - | - | - | - | 411 | | (100)% | 411 | 13,454 | - | - | - |
| Chlorhexidine Gel, 5 g tube | - | - | - | - | 411 | 11/16 | (100)% | 411 | 13,454 | - | - | - |
| Clean Delivery Kit | - | - | - | - | 609 | | (100)% | 609 | 178,925 | - | - | - |
| Maama Kit Extra Clean Delivery | - | - | - | - | 609 | 8/10 | (100)% | 609 | 178,925 | - | - | - |
| Condom | - | - | - | - | 180,648 | | (100)% | 180,648 | 46,911,638 | - | - | - |
| Trust | - | - | - | - | 49,392 | 6/06 | (100)% | 49,392 | 44,987,870 | - | - | - |
| Trust Ribbed | - | - | - | - | 39,528 | 11/15 | (100)% | 39,528 | 610,632 | - | - | - |
| Trust Scented | - | - | - | - | 42,408 | 11/15 | (100)% | 42,408 | 649,224 | - | - | - |
| Trust Studded | - | - | - | - | 49,320 | 11/15 | (100)% | 49,320 | 663,912 | - | - | - |
| Expanded Clean Delivery Kit (+CHX) | - | - | - | - | 694 | | (100)% | 694 | 1,311 | - | - | - |
| Mama Kit with Chlorhexidine | - | - | - | - | 694 | 11/17 | (100)% | 694 | 1,311 | - | - | - |
| Fever Cases Attended | - | 25,845 | 171,313 | - | - | | 0% | - | 171,313 | 171,313 | - | - |
| Fever Cases Attended | - | 25,845 | 171,313 | - | - | | -% | - | 171,313 | 171,313 | - | - |
| Fever Cases Tested with RDTs | - | 24,741 | 163,450 | - | - | | 0% | - | 163,450 | 163,450 | - | - |
| Fever Cases Tested with RDTs | - | 24,741 | 163,450 | - | - | | -% | - | 163,450 | 163,450 | - | - |
| Free Condom | - | 2,013,761 | 16,810,928 | 15,350,000 | 13,064,116 | | 29% | 16,543,154 | 100,022,861 | 126,082 | 126,082 | 293,774 |
| Generic | - | 1,572,161 | 11,138,768 | 10,350,000 | 11,094,196 | 1/99 | -% | 13,304,596 | 91,112,143 | 83,541 | 83,541 | 194,652 |
| Ulinzi Condoms | - | 441,600 | 5,672,160 | 5,000,000 | 1,969,920 | | 188% | 3,238,558 | 8,910,718 | 42,541 | 42,541 | 99,122 |
| Free Female Condom | - | 4,350 | 38,080 | 100,000 | 66,000 | | (42)% | 105,995 | 2,348,710 | 286 | 286 | 643 |
| Female Condom Free | - | 4,350 | 38,080 | 100,000 | 66,000 | 11/09 | (42)% | 105,995 | 2,348,710 | 286 | 286 | 643 |
| HIV Testing Services | - | 1,010 | 3,031 | - | - | | 0% | - | 130,754 | 3,031 | - | 188 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| VCT Individual (HIV-Negative) | - | 996 | 2,987 | - | - | 8/13 | -% | - | 126,391 | 2,987 | - | 186 |
| VCT Individual (HIV-Positive) | - | 15 | 44 | - | - | 8/13 | -% | - | 4,363 | 44 | - | 3 |
| Implant 3 | - | - | - | - | (5,778) | | 0% | (5,778) | 105,174 | - | - | - |
| Implanon | - | - | - | - | 932 | 12/08 | (100)% | 932 | 192,634 | - | - | - |
| (b)PSI Implant 3 Distributed Inserted | - | - | - | - | (6,710) | | -% | (6,710) | (87,460) | - | - | - |
| Implant 3 Insertion | - | - | - | - | 27,489 | | (100)% | 27,489 | 292,024 | - | - | - |
| Non-PSI Implant 3 Inserted | - | - | - | - | 20,779 | | (100)% | 20,779 | 204,564 | - | - | - |
| PSI Implant 3 Inserted | - | - | - | - | 6,710 | | (100)% | 6,710 | 87,460 | - | - | - |
| Implant 5 | - | - | - | - | (4,540) | | 0% | (4,540) | 95,981 | - | - | - |
| Jadelle | - | - | - | - | 760 | 12/08 | (100)% | 760 | 181,319 | - | - | - |
| (b)PSI Implant 5 Distributed Inserted | - | - | - | - | (5,300) | | -% | (5,300) | (85,338) | - | - | - |
| Implant 5 Insertion | - | - | - | - | 5,464 | | (100)% | 5,464 | 114,325 | - | - | - |
| Non-PSI Implant 5 Inserted | - | - | - | - | 164 | | (100)% | 164 | 28,987 | - | - | - |
| PSI Implant 5 Inserted | - | - | - | - | 5,300 | | (100)% | 5,300 | 85,338 | - | - | - |
| Injectable 3-IM | - | - | - | - | 3,950 | | (100)% | 3,950 | 263,573 | - | - | - |
| Depo-Provera | - | - | - | - | 3,950 | 11/11 | (100)% | 3,950 | 263,573 | - | - | - |
| IUD 10 | - | - | - | - | (16,307) | | 0% | (16,307) | 1,791 | - | - | - |
| IUD PACK CU T380A | - | - | - | - | 890 | 4/11 | (100)% | 890 | 238,341 | - | - | - |
| (b)PSI IUD 10 Distributed Inserted | - | - | - | - | (17,197) | | -% | (17,197) | (236,550) | - | - | - |
| IUD 10 Insertion | - | - | - | - | 23,549 | | (100)% | 23,549 | 426,314 | - | - | - |
| Non-PSI IUD 10 Inserted | - | - | - | - | 6,352 | | (100)% | 6,352 | 189,765 | - | - | - |
| PSI IUD 10 Inserted | - | - | - | - | 17,197 | | (100)% | 17,197 | 236,550 | - | - | - |
| IUD 5 | - | - | - | - | (129) | | 0% | (129) | (17,342) | - | - | - |
| (b)PSI IUD 5 Distributed Inserted | - | - | - | - | (129) | | -% | (129) | (17,342) | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| IUD 5 Insertion | - | - | - | - | 130 | | (100)% | 130 | 28,350 | - | - | - |
| Non-PSI IUD 5 Inserted | - | - | - | - | 1 | | (100)% | 1 | 11,007 | - | - | - |
| PSI IUD 5 Inserted | - | - | - | - | 129 | | (100)% | 129 | 17,342 | - | - | - |
| Manual Vacuum Aspiration for PAC | - | - | - | - | 388 | | (100)% | 388 | 2,304 | - | - | - |
| MVA for PAC | - | - | - | - | 388 | 3/16 | (100)% | 388 | 2,304 | - | - | - |
| Manual Vacuum Aspiration for SA | - | - | - | - | 150 | | (100)% | 150 | 1,348 | - | - | - |
| Manual Vacuum Aspiration for SA | - | - | - | - | 150 | | (100)% | 150 | 1,348 | - | - | - |
| Medical Abortion | - | - | - | - | (2,536) | | 0% | (2,536) | 8,475 | - | - | - |
| Divabo - Combipack (1+4's) | - | - | - | - | (2,058) | 5/17 | -% | (2,058) | 9,574 | - | - | - |
| (b)PSI Medical Abortion Distributed Provided | - | - | - | - | (478) | | -% | (478) | (1,099) | - | - | - |
| Medical Abortion (Misoprostol) Provided | - | - | - | - | 187 | | (100)% | 187 | 187 | - | - | - |
| Non-PSI Medical Abortion (Misoprostol) Provided | - | - | - | - | 26 | | (100)% | 26 | 26 | - | - | - |
| PSI Medical Abortion (Misoprostol) Provided | - | - | - | - | 161 | | (100)% | 161 | 161 | - | - | - |
| Medical Abortion Provided | - | - | - | - | 478 | | (100)% | 478 | 1,099 | - | - | - |
| PSI Medical Abortion Provided | - | - | - | - | 478 | | (100)% | 478 | 1,099 | - | - | - |
| Misoprostol for PAC Provided | - | - | - | - | 498 | | (100)% | 498 | 1,652 | - | - | - |
| Non-PSI Misoprostol for PAC Provided | - | - | - | - | 18 | | (100)% | 18 | 36 | - | - | - |
| PSI Misoprostol for PAC Provided | - | - | - | - | 480 | | (100)% | 480 | 1,616 | - | - | - |
| Misoprostol for Safe Abortion | - | - | - | - | (3,852) | | 0% | (3,852) | (8,396) | - | - | - |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | - | - | - | - | (3,852) | | -% | (3,852) | (8,396) | - | - | - |
| OCs | - | - | - | - | 1,425 | | (100)% | 1,425 | 394,086 | - | - | - |
| Family Planning Pills | - | - | - | - | 1,425 | 11/11 | (100)% | 1,425 | 394,086 | - | - | - |
| Positive RDTs | - | 17,029 | 112,752 | - | - | | 0% | - | 112,752 | 112,752 | - | - |
| Positive RDTs | - | 17,029 | 112,752 | - | - | | -% | - | 112,752 | 112,752 | - | - |
| Positive RDTs Given First Line Treatment | - | 15,902 | 104,366 | - | - | | 0% | - | 104,366 | 104,366 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Positive RDTs Given First Line Treatment | - | 15,902 | 104,366 | - | - | | -% | - | 104,366 | 104,366 | - | - |
| PUR | - | - | - | - | 3,840 | | (100)% | 3,840 | 40,563,780 | - | - | - |
| PuR | - | - | - | - | 3,840 | 10/04 | (100)% | 3,840 | 40,563,780 | - | - | - |
| Referral to HIV Testing Services | 1,889 | 534 | 33,768 | 50,000 | - | | 0% | 11,703 | 45,471 | 33,768 | - | 1,049 |
| Referral to HIV Testing Services | 1,889 | 534 | 33,768 | 50,000 | - | | -% | 11,703 | 45,471 | 33,768 | - | 1,049 |
| Referral to Linkage to HIV Care | 11,328 | 11,935 | 87,443 | 16,561 | - | | 0% | 4,614 | 92,057 | 87,443 | - | 74,587 |
| Referral to Linkage to HIV Care | 11,328 | 11,935 | 87,443 | 16,561 | - | | -% | 4,614 | 92,057 | 87,443 | - | 74,587 |
| Tubal Ligation | - | - | - | - | 10 | | (100)% | 10 | 123 | - | - | - |
| Tubal Ligation | - | - | - | - | 10 | | (100)% | 10 | 123 | - | - | - |
| Zambia | | | | | | | | | | | 220,090 | 437,092 |
| Emergency Contraception Provided | - | - | 1 | - | 1 | | 0% | 1 | 2 | - | - | - |
| Non-PSI Emergency Contraception Provided | - | - | 1 | - | 1 | | -% | 1 | 2 | - | - | - |
| Free Female Condom | - | - | - | 13,000 | 3,020 | | (100)% | 3,020 | 192,200 | - | - | - |
| Free Female Condoms | - | - | - | 13,000 | 3,020 | 1/12 | (100)% | 3,020 | 192,200 | - | - | - |
| HIV Self-Testing Kit | - | 2,683 | 135,950 | 326,885 | 356,250 | | (62)% | 394,250 | 810,750 | 122,355 | - | - |
| HIV Self Testing Kits-Blood based | - | 1,500 | 4,500 | - | - | | -% | - | 4,500 | 4,050 | - | - |
| ORAQUICK HIV Self-Testing Kit (Pouch) | - | 1,183 | 131,450 | 326,885 | 356,250 | 5/16 | (63)% | 394,250 | 806,250 | 118,305 | - | - |
| Implant 3 Insertion | 1,418 | 1,088 | 9,846 | - | 4,301 | | 129% | 4,567 | 15,310 | 9,846 | 24,615 | 24,844 |
| Non-PSI Implant 3 Inserted | 1,418 | 1,088 | 9,846 | - | 4,301 | | 129% | 4,567 | 15,310 | 9,846 | 24,615 | 24,844 |
| Implant 4 Insertion | - | - | - | - | 1 | | (100)% | 1 | 117 | - | - | - |
| Non-PSI Implant 4 Inserted | - | - | - | - | 1 | | (100)% | 1 | 117 | - | - | - |
| Implant 5 Insertion | 1,824 | 2,616 | 28,747 | 30,000 | 23,457 | | 23% | 24,703 | 76,590 | 28,747 | 109,239 | 108,522 |
| Non-PSI Implant 5 Inserted | 1,824 | 2,616 | 28,747 | 30,000 | 23,457 | | 23% | 24,703 | 76,590 | 28,747 | 109,239 | 108,522 |
| Injectable 2 Provided | 1,325 | 1,280 | 15,359 | 28,000 | 18,107 | | (15)% | 19,835 | 44,780 | 2,560 | 2,560 | 1,896 |
| Non-PSI Injectable 2 Provided | 1,325 | 1,280 | 15,359 | 28,000 | 18,107 | | (15)% | 19,835 | 44,780 | 2,560 | 2,560 | 1,896 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|-------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Injectable 3-IM Provided | 9,993 | 13,631 | 178,954 | 172,000 | 144,358 | | 24% | 157,477 | 419,865 | 44,739 | 44,739 | 33,144 |
| Non-PSI Injectable 3 IM Provided | 9,993 | 13,631 | 178,954 | 172,000 | 144,358 | | 24% | 157,477 | 419,865 | 44,739 | 44,739 | 33,144 |
| Injectable 3-SC Provided | 6,726 | 4,783 | 21,075 | - | - | | 0% | - | 21,075 | 5,269 | 5,269 | 3,903 |
| Non-PSI Injectable 3 SC Provided | 6,726 | 4,783 | 21,075 | - | - | | -% | - | 21,075 | 5,269 | 5,269 | 3,903 |
| IUD 10 Insertion | 479 | 692 | 4,788 | 3,000 | 2,075 | | 131% | 2,175 | 8,906 | 4,788 | 22,025 | 20,960 |
| Non-PSI IUD 10 Inserted | 479 | 692 | 4,788 | 3,000 | 2,075 | | 131% | 2,175 | 8,906 | 4,788 | 22,025 | 20,960 |
| IUS 3 | (95) | (73) | (314) | - | - | | 0% | - | (314) | (283) | (707) | (670) |
| (b)PSI IUS 3 Distributed Inserted | (95) | (73) | (314) | - | - | | -% | - | (314) | (283) | (707) | (670) |
| IUS 3 Insertion | 95 | 73 | 314 | - | - | | 0% | - | 314 | 314 | 785 | 744 |
| PSI IUS 3 Inserted | 95 | 73 | 314 | - | - | | -% | - | 314 | 314 | 785 | 744 |
| IUS 5 | - | - | 500 | - | - | | 0% | - | 1,300 | 450 | 1,485 | 1,501 |
| LNG-IUS | - | - | 500 | - | - | | -% | - | 1,300 | 450 | 1,485 | 1,501 |
| IUS 5 Insertion | - | - | 353 | 700 | 579 | | (39)% | 595 | 1,126 | 353 | 1,165 | 1,178 |
| Non-PSI IUS 5 Inserted | - | - | 353 | 700 | 579 | | (39)% | 595 | 1,126 | 353 | 1,165 | 1,178 |
| OCs Provided | 10,376 | 11,777 | 100,820 | 100,000 | 58,508 | | 72% | 64,379 | 198,613 | 6,721 | 6,721 | 5,253 |
| Non-PSI OCs Provided | 10,376 | 11,777 | 100,820 | 100,000 | 58,508 | | 72% | 64,379 | 198,613 | 6,721 | 6,721 | 5,253 |
| Safe Water Solution | - | 184 | 277,356 | 900,000 | 893,772 | | (69)% | 930,072 | 36,072,791 | 152,736 | - | 592 |
| Clorin | - | 184 | 277,356 | 900,000 | 893,772 | 11/98 | (69)% | 930,072 | 36,072,791 | 152,736 | - | 592 |
| Tubal Ligation | 61 | 23 | 218 | 308 | 306 | | (29)% | 308 | 697 | 218 | 2,180 | 1,887 |
| Tubal Ligation | 61 | 23 | 218 | 308 | 306 | | (29)% | 308 | 697 | 218 | 2,180 | 1,887 |
| Vasectomy | - | - | - | 29 | - | | 0% | - | - | - | - | - |
| Vasectomy | - | - | - | 29 | - | | -% | - | - | - | - | - |
| Voluntary Medical Male Circumcision | 1,937 | 1,486 | 31,275 | 45,000 | 36,540 | | (14)% | 43,253 | 178,674 | 31,275 | - | 233,297 |
| Voluntary Medical Male Circumcision | 1,937 | 1,486 | 31,275 | 45,000 | 36,540 | | (14)% | 43,253 | 178,674 | 31,275 | - | 233,297 |
| Woman Condom | - | - | 1,920 | - | 95,160 | | (98)% | 97,728 | 141,480 | 14 | 14 | 40 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| MAXIMUM DIVA | - | - | 1,920 | - | 95,160 | 4/16 | (98)% | 97,728 | 141,480 | 14 | 14 | 40 |
| Zimbabwe | | | | | | | | | | | 216,441 | 1,643,118 |
| Antiretroviral Treatment (Currently Enrolled) | 10,544 | 10,008 | 107,159 | 66,103 | 93,600 | | 14% | 103,129 | 297,779 | 8,930 | - | 18,674 |
| Antiretroviral Treatment (Currently Enrolled) | 10,544 | 10,008 | 107,159 | 66,103 | 93,600 | | 14% | 103,129 | 297,779 | 8,930 | - | 18,674 |
| Antiretroviral Treatment (Newly Enrolled) | 738 | 491 | 5,379 | 3,012 | 4,552 | | 18% | 4,816 | 24,284 | 5,379 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 738 | 491 | 5,379 | 3,012 | 4,552 | | 18% | 4,816 | 24,284 | 5,379 | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 443 | | (100)% | 443 | 7,915 | - | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 443 | | (100)% | 443 | 7,915 | - | - | - |
| Cervical Cancer-HPV DNA and Conization | 3 | 1 | 7 | - | - | | 0% | - | 7 | 7 | - | 3 |
| Cervical Cancer-HPV DNA and Conization | 3 | 1 | 7 | - | - | | -% | - | 7 | 7 | - | 3 |
| Cervical Cancer-HPV DNA and Cryotherapy | 1 | 2 | 6 | - | 3 | | 100% | 3 | 9 | 6 | - | 3 |
| Cervical Cancer-HPV DNA and Cryotherapy | 1 | 2 | 6 | - | 3 | | 100% | 3 | 9 | 6 | - | 3 |
| Cervical Cancer-HPV DNA and Refer to any Treatment | 1 | - | 1 | - | - | | 0% | - | 12 | 1 | - | - |
| Cervical Cancer-HPV DNA and Refer to any Treatment | 1 | - | 1 | - | - | | -% | - | 12 | 1 | - | - |
| Cervical Cancer-HPV DNA Screening | 615 | 554 | 3,013 | - | - | | 0% | - | 3,013 | 3,013 | - | - |
| Cervical Cancer-HPV DNA Screening | 615 | 554 | 3,013 | - | - | | -% | - | 3,013 | 3,013 | - | - |
| Cervical Cancer-Pap and Conization | - | - | 1,753 | - | - | | 0% | - | 1,753 | 1,753 | - | 778 |
| Cervical Cancer-Pap and Conization | - | - | 1,753 | - | - | | -% | - | 1,753 | 1,753 | - | 778 |
| Cervical Cancer-Pap and Refer to any Treatment | - | 1 | 9 | - | - | | 0% | - | 10 | 9 | - | 2 |
| Cervical Cancer-Pap and Refer to any Treatment | - | 1 | 9 | - | - | | -% | - | 10 | 9 | - | 2 |
| Cervical Cancer-VIA and Conization | 20 | 18 | 234 | 290 | 98 | | 139% | 126 | 538 | 234 | - | 84 |
| Cervical Cancer-VIA and Conization | 20 | 18 | 234 | 290 | 98 | | 139% | 126 | 538 | 234 | - | 84 |
| Cervical Cancer-VIA and Cryotherapy | 14 | 13 | 1,522 | 307 | 387 | | 293% | 415 | 5,492 | 1,522 | - | 532 |
| Cervical Cancer-VIA and Cryotherapy | 14 | 13 | 1,522 | 307 | 387 | 11/13 | 293% | 415 | 5,492 | 1,522 | - | 532 |
| Cervical Cancer-VIA and Refer to any Treatment | 5 | 9 | 84 | - | 24 | | 250% | 25 | 395 | 84 | - | 15 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Cervical Cancer-VIA and Refer to any Treatment | 5 | 9 | 84 | - | 24 | 1/15 | 250% | 25 | 395 | 84 | - | 15 |
| Cervical Cancer-VIA and Refer to Conization | 1 | 3 | 22 | 290 | 93 | | (76)% | 98 | 2,056 | 22 | - | 4 |
| Cervical Cancer-VIA and Refer to Conization | 1 | 3 | 22 | 290 | 93 | 12/14 | (76)% | 98 | 2,056 | 22 | - | 4 |
| Cervical Cancer-VIA and Refer to Cryotherapy | - | - | - | - | 10 | | (100)% | 10 | 459 | - | - | - |
| Cervical Cancer-VIA and Refer to Cryotherapy | - | - | - | - | 10 | 12/14 | (100)% | 10 | 459 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | 683 | 805 | 15,045 | 18,793 | 16,976 | | (11)% | 18,503 | 100,864 | 15,045 | - | - |
| Cervical Cancer-VIA/VILI Screening | 683 | 805 | 15,045 | 18,793 | 16,976 | | (11)% | 18,503 | 100,864 | 15,045 | - | - |
| Condom | 793,195 | 1,045,583 | 14,387,330 | 18,000,000 | 15,989,460 | | (10)% | 17,748,320 | 341,774,700 | 107,905 | 107,905 | 343,048 |
| Protector Plus | 153,400 | 208,958 | 2,748,000 | 3,600,000 | 3,123,740 | 1/08 | (12)% | 3,626,960 | 279,443,850 | 20,610 | 20,610 | 65,523 |
| Protector Plus Flavors | 639,795 | 836,625 | 11,639,330 | 14,400,000 | 12,865,720 | 3/14 | (10)% | 14,121,360 | 62,330,850 | 87,295 | 87,295 | 277,526 |
| Emergency Contraception | 9,278 | 2,878 | 57,247 | - | 157,880 | | (64)% | 170,713 | 1,013,012 | 2,576 | 2,576 | 778 |
| Pregnon | - | - | 37,805 | - | 147,931 | 9/10 | (74)% | 160,767 | 900,767 | 1,701 | 1,701 | 514 |
| (b)PSI Emergency Contraception Distributed Provided | (17) | (5) | (87) | - | (50) | | -% | (54) | (584) | (4) | (4) | (1) |
| Revoke-72 | 9,295 | 2,883 | 19,529 | - | 9,999 | 12/15 | 95% | 10,000 | 112,829 | 879 | 879 | 265 |
| Emergency Contraception Provided | 17 | 5 | 93 | - | 68 | | 37% | 78 | 799 | 5 | 5 | 1 |
| Non-PSI Emergency Contraception Provided | - | - | 6 | - | 18 | | (67)% | 24 | 215 | - | - | - |
| PSI Emergency Contraception Provided | 17 | 5 | 87 | - | 50 | | 74% | 54 | 584 | 4 | 4 | 1 |
| Female Condom | - | - | 1,200 | 380,000 | 169,980 | | (99)% | 169,980 | 24,049,234 | 9 | 9 | 28 |
| Care | - | - | 1,200 | 380,000 | 169,980 | 6/97 | (99)% | 169,980 | 24,049,234 | 9 | 9 | 28 |
| Free Female Condom | 6,300 | 351,583 | 1,172,283 | - | 197,945 | | 492% | 224,000 | 1,734,283 | 8,792 | 8,792 | 27,586 |
| Care (Free Distribution) | 6,300 | 351,583 | 1,172,283 | - | 197,945 | 12/11 | 492% | 224,000 | 1,734,283 | 8,792 | 8,792 | 27,586 |
| HIV Self-Testing Kit | - | - | 56,496 | - | - | | 0% | 236,028 | 292,524 | 50,846 | - | - |
| ORAQUICK HIV Self-Testing Kit (Pouch) | - | - | 56,496 | - | - | | -% | 236,028 | 292,524 | 50,846 | - | - |
| HIV Testing Services | 7,083 | 3,307 | 46,207 | 281,609 | 44,683 | | 3% | 48,959 | 2,585,605 | 46,207 | - | 3,063 |
| VCT Individual (HIV-Negative) | 5,393 | 2,145 | 32,600 | 264,340 | 28,850 | 12/09 | 13% | 31,915 | 2,279,770 | 32,600 | - | 2,161 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| VCT Individual (HIV-Positive) | 1,690 | 1,162 | 13,607 | 17,269 | 15,833 | 12/09 | (14)% | 17,044 | 305,835 | 13,607 | - | 902 |
| Hypertension Diagnosis | 28 | 23 | 251 | - | 254 | | (1)% | 278 | 809 | 251 | - | - |
| Hypertension Screening | 9,360 | 8,819 | 122,410 | - | 129,798 | | (6)% | 142,029 | 598,663 | 122,410 | - | - |
| Hypertension_Screening | 9,360 | 8,819 | 122,410 | - | 129,798 | | (6)% | 142,029 | 598,663 | 122,410 | - | - |
| Hypertension_Controlled Condition | 3 | 17 | 100 | - | 86 | | 16% | 91 | 257 | 40 | - | - |
| Hypertension_Controlled Condition | 3 | 17 | 100 | - | 86 | | 16% | 91 | 257 | 40 | - | - |
| Implant 3 | (4) | (10) | (441) | - | (341) | | 0% | (483) | (3,265) | (397) | (992) | (536) |
| (b)PSI Implant 3 Distributed Inserted | (4) | (10) | (441) | - | (341) | | -% | (483) | (3,265) | (397) | (992) | (536) |
| Implant 3 Insertion | 87 | 159 | 3,145 | 2,452 | 799 | | 294% | 1,151 | 13,352 | 3,145 | 7,863 | 4,251 |
| Non-PSI Implant 3 Inserted | 83 | 149 | 2,704 | 2,452 | 458 | 3/16 | 490% | 668 | 10,087 | 2,704 | 6,760 | 3,655 |
| PSI Implant 3 Inserted | 4 | 10 | 441 | - | 341 | | 29% | 483 | 3,265 | 441 | 1,103 | 596 |
| Implant 5 | 2,952 | 443 | 2,577 | - | (1,721) | | 0% | 1,797 | 81,159 | 2,319 | 8,813 | 4,695 |
| Jadelle | 3,000 | 500 | 6,000 | - | 2,500 | 9/09 | 140% | 6,500 | 118,708 | 5,400 | 20,520 | 10,932 |
| (b)PSI Implant 5 Distributed Inserted | (48) | (57) | (3,423) | - | (4,221) | | -% | (4,703) | (37,549) | (3,081) | (11,707) | (6,237) |
| Implant 5 Insertion | 1,187 | 1,188 | 13,900 | 12,496 | 7,130 | | 95% | 8,090 | 104,468 | 13,900 | 52,820 | 28,140 |
| Non-PSI Implant 5 Inserted | 1,139 | 1,132 | 10,477 | 12,496 | 2,909 | 1/14 | 260% | 3,387 | 66,919 | 10,477 | 39,813 | 21,211 |
| PSI Implant 5 Inserted | 48 | 57 | 3,423 | - | 4,221 | | (19)% | 4,703 | 37,549 | 3,423 | 13,007 | 6,930 |
| Injectable 3-IM | - | (128) | (2,681) | - | 14,301 | | (119)% | 13,588 | 898,876 | (603) | (603) | (239) |
| Depo-Provera | - | - | - | - | 26,562 | 9/00 | (100)% | 26,562 | 724,283 | - | - | - |
| Petogen | - | - | - | - | 700 | 9/09 | (100)% | 700 | 230,835 | - | - | - |
| (b)PSI Injectable 3 IM Distributed Provided | - | (128) | (2,681) | - | (12,961) | | -% | (13,674) | (56,242) | (603) | (603) | (239) |
| Injectable 3-IM Provided | 2,728 | 3,243 | 43,318 | 52,468 | 37,258 | | 16% | 41,625 | 261,148 | 10,830 | 10,830 | 4,292 |
| Non-PSI Injectable 3 IM Provided | 2,728 | 3,114 | 40,637 | 52,468 | 24,297 | | 67% | 27,951 | 204,906 | 10,159 | 10,159 | 4,027 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| PSI Injectable 3 IM Provided | - | 128 | 2,681 | - | 12,961 | | (79)% | 13,674 | 56,242 | 670 | 670 | 266 |
| IUD 10 | (11) | (62) | (1,027) | - | (1,064) | | 0% | (934) | 485 | (924) | (4,252) | (2,173) |
| (b)PSI IUD 10 Distributed Inserted | (11) | (62) | (1,027) | - | (1,514) | 3/16 | -% | (1,684) | (10,256) | (924) | (4,252) | (2,173) |
| TCU 380A IUCD Copper T | - | - | - | - | 450 | 4/12 | (100)% | 750 | 10,741 | - | - | - |
| IUD 10 Insertion | 210 | 186 | 2,641 | 1,776 | 1,623 | | 63% | 1,855 | 12,242 | 2,641 | 12,149 | 6,209 |
| Non-PSI IUD 10 Inserted | 199 | 124 | 1,614 | 1,776 | 109 | | 1,381% | 171 | 1,986 | 1,614 | 7,424 | 3,794 |
| PSI IUD 10 Inserted | 11 | 62 | 1,027 | - | 1,514 | 3/16 | (32)% | 1,684 | 10,256 | 1,027 | 4,724 | 2,414 |
| IUD 5 Insertion | - | - | 128 | - | 26 | | 392% | 80 | 208 | 128 | 422 | 229 |
| Non-PSI IUD 5 Inserted | - | - | 128 | - | 26 | | 392% | 80 | 208 | 128 | 422 | 229 |
| IUS 5 | (10) | (6) | (97) | (56) | 95 | | (202)% | 126 | 183 | (87) | (288) | (156) |
| LNG-IUS | - | 10 | 60 | - | 230 | | (74)% | 270 | 655 | 54 | 178 | 97 |
| (b)PSI IUS 5 Distributed Inserted | (10) | (16) | (157) | (56) | (135) | | -% | (144) | (472) | (141) | (466) | (253) |
| IUS 5 Insertion | 11 | 22 | 189 | 56 | 135 | | 40% | 144 | 521 | 189 | 624 | 338 |
| Non-PSI IUS 5 Inserted | 1 | 6 | 32 | - | - | | -% | - | 49 | 32 | 106 | 57 |
| PSI IUS 5 Inserted | 10 | 16 | 157 | 56 | 135 | | 16% | 144 | 472 | 157 | 518 | 281 |
| Lubricant | 16,500 | 33,133 | 388,000 | - | 50,000 | | 676% | 97,750 | 940,300 | - | - | - |
| Personal lubricants water based 4.5 g | 16,500 | 33,133 | 388,000 | - | 50,000 | 2/17 | 676% | 97,750 | 940,300 | - | - | - |
| OCs | - | (530) | (10,150) | - | (22,811) | | 0% | (36,058) | (24,674) | (609) | (609) | (255) |
| (b)PSI OCs Distributed Provided | - | (530) | (10,150) | - | (30,011) | | -% | (43,258) | (285,823) | (609) | (609) | (255) |
| Secure POP | - | - | - | - | 7,200 | 4/12 | (100)% | 7,200 | 261,149 | - | - | - |
| OCs Provided | 11,217 | 15,400 | 155,681 | 187,344 | 82,504 | | 89% | 102,704 | 1,160,024 | 10,379 | 10,379 | 4,340 |
| Non-PSI OCs Provided | 11,217 | 14,870 | 145,531 | 187,344 | 52,493 | | 177% | 59,446 | 874,201 | 9,702 | 9,702 | 4,057 |
| PSI OCs Provided | - | 530 | 10,150 | - | 30,011 | | (66)% | 43,258 | 285,823 | 677 | 677 | 283 |
| PrEP | 3,651 | 3,753 | 39,617 | 35,027 | 31,053 | | 28% | 34,345 | 77,078 | 3,301 | - | 1,291 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| PrEP | 3,651 | 3,753 | 39,617 | 35,027 | 31,053 | | 28% | 34,345 | 77,078 | 3,301 | - | 1,291 |
| Referral to Advanced Cervical Cancer Treatment | 3 | 6 | 62 | 136 | 17 | | 265% | 17 | 479 | 62 | - | - |
| Referral to Advanced Cervical Cancer Treatment | 3 | 6 | 62 | 136 | 17 | 12/14 | 265% | 17 | 479 | 62 | - | - |
| Referral to Diabetes Management (gestational) | - | - | - | - | 67 | | (100)% | 67 | 67 | - | - | - |
| Referral to Diabetes Management (gestational) | - | - | - | - | 67 | | (100)% | 67 | 67 | - | - | - |
| Referral to Hypertension Management | 29 | 33 | 322 | - | 527 | | (39)% | 564 | 1,407 | 322 | - | - |
| Referral to Hypertension Management | 29 | 33 | 322 | - | 527 | | (39)% | 564 | 1,407 | 322 | - | - |
| Referral to Implant 3 Insertion | - | - | - | - | 2 | | (100)% | 2 | 11 | - | - | - |
| Referral to Implant 3 Insertion | - | - | - | - | 2 | | (100)% | 2 | 11 | - | - | - |
| Referral to Implant 5 Insertion | - | - | - | - | 2 | | (100)% | 2 | 992 | - | - | - |
| Referral to Implant 5 Insertion | - | - | - | - | 2 | 12/13 | (100)% | 2 | 992 | - | - | - |
| Referral to Injectable 3 | - | - | - | - | 20 | | (100)% | 20 | 770 | - | - | - |
| Referral to Injectable 3 | - | - | - | - | 20 | | (100)% | 20 | 770 | - | - | - |
| Referral to IUD 10 Insertion | - | - | - | - | 5 | | (100)% | 5 | 209 | - | - | - |
| Referral to IUD 10 Insertion | - | - | - | - | 5 | 12/13 | (100)% | 5 | 209 | - | - | - |
| Referral to Linkage to HIV Care | 872 | 714 | 7,495 | - | 8,292 | | (10)% | 9,056 | 24,727 | 7,495 | - | 4,148 |
| Referral to Linkage to HIV Care | 872 | 714 | 7,495 | - | 8,292 | | (10)% | 9,056 | 24,727 | 7,495 | - | 4,148 |
| Referral to OCs | - | - | - | - | 17 | | (100)% | 17 | 868 | - | - | - |
| Referral to OCs | - | - | - | - | 17 | 1/15 | (100)% | 17 | 868 | - | - | - |
| Referral to Pre-Exposure Prophylaxis (PrEP) | - | - | 3 | - | 20 | | (85)% | 20 | 253 | 3 | - | - |
| Referral to Pre-Exposure Prophylaxis (PrEP) | - | - | 3 | - | 20 | | (85)% | 20 | 253 | 3 | - | - |
| Referral to STI Screening (syndromic) | - | - | - | - | 3 | | (100)% | 3 | 105 | - | - | - |
| Referrals to STI Screening (syndromic) | - | - | - | - | 3 | | (100)% | 3 | 105 | - | - | - |
| Referral to STI Treatment (unknown) | - | - | - | - | 93 | | (100)% | 93 | 2,337 | - | - | - |
| Referral to STI Treatment (unknown) | - | - | - | - | 93 | 1/15 | (100)% | 93 | 2,337 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Referral to TB Diagnosis | - | - | - | - | 11 | | (100)% | 11 | 255 | - | - | - |
| Referral to TB Diagnosis | - | - | - | - | 11 | | (100)% | 11 | 255 | - | - | - |
| Referral to TB DOTS (completion confirmed) | - | - | - | - | 2 | | (100)% | 2 | 19 | - | - | - |
| Referral to TB DOTS (completion confirmed) | - | - | - | - | 2 | | (100)% | 2 | 19 | - | - | - |
| Referral to TB DOTS (completion unknown) | - | - | - | - | 74 | | (100)% | 74 | 2,704 | - | - | - |
| Referral to TB DOTS (completion unknown) | - | - | - | - | 74 | 12/13 | (100)% | 74 | 2,704 | - | - | - |
| Referral to TB Screening | - | - | - | - | 1 | | (100)% | 1 | 12,337 | - | - | - |
| Referrals to TB Screening | - | - | - | - | 1 | | (100)% | 1 | 12,337 | - | - | - |
| Referral to Treatment for Cervicitis | - | - | - | - | 47 | | (100)% | 47 | 116 | - | - | - |
| Referral to Treatment for Cervicitis | - | - | - | - | 47 | 1/15 | (100)% | 47 | 116 | - | - | - |
| Referral to Treatment for Genital Herpes | - | - | - | - | 3 | | (100)% | 3 | 6 | - | - | - |
| Referral to Treatment for Genital Herpes | - | - | - | - | 3 | | (100)% | 3 | 6 | - | - | - |
| Referral to Treatment for Inguinal Bubo | - | - | - | - | 2 | | (100)% | 2 | 2 | - | - | - |
| Referral to Treatment for Inguinal Bubo | - | - | - | - | 2 | | (100)% | 2 | 2 | - | - | - |
| Referral to Treatment for Lower Abdominal Pain | - | - | - | - | 1 | | (100)% | 1 | 28 | - | - | - |
| Referral to Treatment for Lower Abdominal Pain | - | - | - | - | 1 | | (100)% | 1 | 28 | - | - | - |
| Referral to Treatment for Urethral Discharge (Men) | - | - | - | - | 53 | | (100)% | 53 | 113 | - | - | - |
| Referral to Treatment for Urethral Discharge (Men) | - | - | - | - | 53 | | (100)% | 53 | 113 | - | - | - |
| Referral to Treatment for Vaginitis | - | - | 1 | - | - | | 0% | - | 9 | 1 | - | - |
| Referral to Treatment for Vaginitis | - | - | 1 | - | - | 1/15 | -% | - | 9 | 1 | - | - |
| Referral to Tubal Ligation | - | - | - | - | 2 | | (100)% | 2 | 3 | - | - | - |
| Referral to Tubal Ligation | - | - | - | - | 2 | | (100)% | 2 | 3 | - | - | - |
| Referral to Tx for Nonherpetic Genital Ulcer | - | - | 1 | - | 25 | | (96)% | 25 | 73 | 1 | - | - |
| Referral to Tx for Nonherpetic Genital Ulcer | - | - | 1 | - | 25 | | (96)% | 25 | 73 | 1 | - | - |
| Referral to Tx for Urethral Discharge (Women) | - | - | 10 | - | 48 | | (79)% | 48 | 557 | 10 | - | 1 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Referral to Tx for Urethral Discharge (Women) | - | - | 10 | - | 48 | | (79)% | 48 | 557 | 10 | - | 1 |
| Referral to Voluntary Medical Male Circumcision | - | - | 3 | - | 120 | | (98)% | 120 | 10,818 | 3 | - | 10 |
| Referral to Voluntary Medical Male Circumcision | - | - | 3 | - | 120 | 12/14 | (98)% | 120 | 10,818 | 3 | - | 10 |
| Safe Water Solution | - | - | - | - | 132,805 | | (100)% | 132,805 | 780,659 | - | - | - |
| WaterGuard Solution 150mL SI | - | - | - | - | 132,805 | 4/14 | (100)% | 132,805 | 780,659 | - | - | - |
| STI Screening | 4,962 | 3,376 | 49,551 | - | 1,358 | | 3549% | 1,460 | 60,349 | 49,551 | - | - |
| STI Screening | 4,962 | 3,376 | 49,551 | - | 1,358 | | 3,549% | 1,460 | 60,349 | 49,551 | - | - |
| TB Diagnosis | 28 | 12 | 184 | - | 237 | | (22)% | 242 | 1,575 | 184 | - | - |
| TB Diagnosis | 28 | 12 | 184 | - | 237 | | (22)% | 242 | 1,575 | 184 | - | - |
| TB DOTS | - | - | - | - | 4 | | (100)% | 4 | 54 | - | - | - |
| TB DOTS | - | - | - | - | 4 | 7/14 | (100)% | 4 | 54 | - | - | - |
| TB Screening | 13,948 | 12,496 | 144,122 | - | 124,423 | | 16% | 134,977 | 1,048,080 | 144,122 | - | - |
| TB Screening | 13,948 | 12,496 | 144,122 | - | 124,423 | | 16% | 134,977 | 1,048,080 | 144,122 | - | - |
| Treatment for Cervicitis | 13 | 12 | 149 | - | 58 | | 157% | 73 | 512 | 149 | - | 14 |
| Treatment for Cervicitis | 13 | 12 | 149 | - | 58 | | 157% | 73 | 512 | 149 | - | 14 |
| Treatment for Genital Herpes | 27 | 19 | 95 | - | 10 | | 850% | 11 | 131 | 95 | - | 2 |
| Treatment for Genital Herpes | 27 | 19 | 95 | - | 10 | | 850% | 11 | 131 | 95 | - | 2 |
| Treatment for Inguinal Bubo | - | - | 16 | - | 1 | | 1500% | 2 | 28 | 16 | - | - |
| Treatment for Inguinal Bubo | - | - | 16 | - | 1 | | 1,500% | 2 | 28 | 16 | - | - |
| Treatment for Lower Abdominal Pain | 4 | 2 | 29 | - | 20 | | 45% | 20 | 66 | 29 | - | - |
| Treatment for Lower Abdominal Pain | 4 | 2 | 29 | - | 20 | | 45% | 20 | 66 | 29 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 36 | 25 | 447 | - | 412 | | 8% | 436 | 1,283 | 447 | - | 160 |
| Treatment for Nonherpetic Genital Ulcer | 36 | 25 | 447 | - | 412 | | 8% | 436 | 1,283 | 447 | - | 160 |
| Treatment for Urethral Discharge (Men) | 44 | 31 | 293 | - | 82 | | 257% | 92 | 636 | 586 | - | 37 |
| Treatment for Urethral Discharge (Men) | 44 | 31 | 293 | - | 82 | | 257% | 92 | 636 | 586 | - | 37 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Treatment for Urethral Discharge (Women) | 79 | 74 | 825 | - | 457 | | 81% | 493 | 2,268 | 825 | - | 152 |
| Treatment for Urethral Discharge (Women) | 79 | 74 | 825 | - | 457 | | 81% | 493 | 2,268 | 825 | - | 152 |
| Treatment for Vaginitis | - | - | 8 | - | 10 | | (20)% | 10 | 19 | 8 | - | 2 |
| Treatment for Vaginitis | - | - | 8 | - | 10 | | (20)% | 10 | 19 | 8 | - | 2 |
| Type 2 Diabetes Diagnosis | - | - | - | - | 3 | | (100)% | 3 | 8 | - | - | - |
| Type 2 Diabetes Diagnosis | - | - | - | - | 3 | | (100)% | 3 | 8 | - | - | - |
| Type 2 Diabetes Screening | 49 | 30 | 309 | - | 5,138 | | (94)% | 5,658 | 12,043 | 309 | - | - |
| Type 2 Diabetes Screening | 49 | 30 | 309 | - | 5,138 | | (94)% | 5,658 | 12,043 | 309 | - | - |
| Type 2 Diabetes_Controlled Condition | - | - | - | - | 6 | | (100)% | 6 | 12 | - | - | - |
| Type 2 Diabetes_Controlled Condition | - | - | - | - | 6 | | (100)% | 6 | 12 | - | - | - |
| Voluntary Medical Male Circumcision | - | 21,472 | 176,149 | 200,000 | 235,097 | | (25)% | 243,971 | 638,814 | 176,149 | - | 1,193,566 |
| Voluntary Medical Male Circumcision | - | 21,472 | 176,149 | 200,000 | 235,097 | | (25)% | 243,971 | 638,814 | 176,149 | - | 1,193,566 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Franco/Lusophone Africa Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 11/2019

| | New HIV Infections | STI Deaths | PWID Deaths | TB Deaths | CYP* | Maternal Deaths | Unintended Pregnancies | Malaria Deaths | Diarrhea Deaths | Pneumonia Deaths | Cervical Cancer Death | Sum of All Deaths |
|------------------------------------|--------------------|------------|-------------|-----------|-----------|-----------------|------------------------|----------------|-----------------|------------------|-----------------------|-------------------|
| Franco/Lusophone Africa Market Gro | 8,740 | 4 | - | - | 1,620,269 | 2,334 | 651,295 | 2,852 | 433 | - | - | 19,350 |
| Angola | 278 | - | - | - | 132,337 | 312 | 52,681 | 1,788 | 19 | - | - | 3,464 |
| Benin | 969 | - | - | - | 322,135 | 326 | 125,153 | - | 225 | - | - | 2,612 |
| Burundi | 919 | 4 | - | - | 48,025 | 72 | 15,438 | 997 | - | - | - | 1,456 |
| Cameroon | 2,760 | - | - | - | 434,521 | 650 | 169,989 | 25 | 58 | - | - | 4,253 |
| Cote d'Ivoire | 59 | - | - | - | 169,012 | 301 | 78,331 | - | 26 | - | - | 1,630 |
| Mozambique | 3,388 | - | - | - | 308,529 | 306 | 124,504 | - | 98 | - | - | 3,698 |
| Niger | 129 | - | - | - | 115,743 | 181 | 49,118 | - | - | - | - | 1,451 |
| PSI Benin | - | - | - | - | 44,746 | 158 | 20,312 | - | - | - | - | 489 |
| Senegal | 236 | - | - | - | 45,222 | 29 | 15,768 | 42 | 8 | - | - | 296 |

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 11
 Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|------------------|------------------|
| Franco/Lusophone Africa Market Group | | | | | | | | | | 1,620,269 | 1,902,820 |
| Acute Malnutrition Screening_CU5 | - | - | - | 312 | 518 | (100)% | 518 | 1,895 | - | - | - |
| Antiretroviral Treatment (Currently Enrolled) | 6,040 | 6,411 | 55,966 | 7,723 | 16,071 | 248% | 19,016 | 81,612 | 4,664 | - | 9,368 |
| Antiretroviral Treatment (Newly Enrolled) | 156 | 149 | 1,265 | 1,396 | 1,752 | (28)% | 1,807 | 3,486 | 1,265 | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 122 | (100)% | 122 | 1,327 | - | - | - |
| Cervical Cancer-VIA and Cryotherapy | 3 | 1 | 13 | - | 46 | (72)% | 48 | 387 | 13 | - | 2 |
| Cervical Cancer-VIA/VILI Screening | 4,314 | 2,680 | 25,347 | - | 45,503 | (44)% | 50,592 | 176,822 | 25,347 | - | - |
| Condom | 3,930,749 | 3,103,577 | 35,274,796 | 59,938,298 | 45,226,474 | (22)% | 51,015,576 | 362,150,927 | 264,561 | 264,561 | 445,821 |
| Counseling & Tx for Moderate Acute Malnutrition | - | - | - | 4 | - | -% | - | - | - | - | - |
| Diarrhea Treatment Kit | 11,988 | 28,814 | 299,408 | 424,000 | 404,486 | (26)% | 431,332 | 4,434,937 | 269,467 | - | 17,537 |
| Emergency Contraception | 3,173 | 1,724 | 38,848 | 255,200 | 132,415 | (71)% | 135,874 | 209,791 | 1,748 | 1,748 | 1,062 |
| Emergency Contraception Provided | 284 | 306 | 3,714 | 3,000 | 2,514 | 48% | 2,877 | 7,117 | 186 | 186 | 116 |
| Fecal Sludge Management (Households) | - | 53 | 3,311 | 350 | 1,116 | 197% | 1,374 | 4,685 | 16,595 | - | - |
| Fecal Sludge Management (Liters) | - | 772,667 | 11,141,000 | 13,559,190 | 4,479,000 | 149% | 5,110,000 | 16,251,000 | - | - | 1,325 |
| Female Condom | 309,030 | 106,319 | 1,437,980 | 1,160,132 | 975,137 | 47% | 1,160,677 | 11,035,472 | 10,785 | 10,785 | 15,321 |
| Fever Cases Attended | - | - | - | 8,385 | 14,143 | (100)% | 14,143 | 26,907 | - | - | - |
| Fever Cases Tested with RDTs | - | - | - | 8,385 | 14,143 | (100)% | 14,143 | 42,041 | - | - | - |
| Free Condom | 29,020 | 378,487 | 14,031,761 | 5,193,631 | 3,162,015 | 344% | 3,201,731 | 36,357,642 | 105,238 | 105,238 | 89,391 |
| Free Female Condom | 6,000 | 1,700 | 97,100 | 52,000 | 33,536 | 190% | 49,536 | 357,429 | 728 | 728 | 1,010 |
| HIV Self-Testing Kit | - | - | - | 1,388 | - | -% | - | - | - | - | - |
| HIV Testing Services | 6,083 | 6,841 | 81,420 | 93,415 | 99,814 | (18)% | 106,415 | 1,062,549 | 81,420 | - | 623 |
| Implant 3 | 3,094 | 2,241 | 11,670 | (4,896) | 4,572 | 155% | 7,414 | 38,114 | 10,503 | 26,258 | 22,006 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Implant 3 Insertion | 4,981 | 6,256 | 60,458 | 27,532 | 21,376 | 183% | 24,546 | 104,332 | 60,458 | 151,145 | 143,203 |
| Implant 4 Insertion | - | - | 21 | - | 2 | 950% | 2 | 41 | 21 | 67 | 40 |
| Implant 5 | 4,190 | 3,942 | 25,481 | 29,052 | 25,332 | 1% | 27,721 | 19,784 | 22,933 | 87,145 | 75,199 |
| Implant 5 Insertion | 10,759 | 7,386 | 79,984 | 71,842 | 70,806 | 13% | 76,301 | 382,201 | 79,984 | 303,939 | 272,611 |
| Injectable 2 | (480) | 3,670 | 21,594 | 20,016 | 45,522 | (53)% | 54,602 | 315,938 | 3,239 | 3,239 | 1,728 |
| Injectable 2 Provided | 974 | 904 | 10,810 | 50,000 | 14,833 | (27)% | 15,848 | 49,560 | 1,802 | 1,802 | 968 |
| Injectable 3-IM | 17,207 | 22,873 | 182,512 | 105,000 | 107,929 | 69% | 272,940 | 461,809 | 41,065 | 41,065 | 27,893 |
| Injectable 3-IM Provided | 31,487 | 21,915 | 275,274 | 255,395 | 255,976 | 8% | 272,082 | 894,244 | 68,819 | 68,819 | 53,670 |
| Injectable 3-SC | 5,933 | 7,038 | 185,505 | 151,480 | 22,079 | 740% | 26,328 | 214,448 | 41,739 | 41,739 | 31,609 |
| Injectable 3-SC Provided | 4,658 | 8,706 | 69,366 | 39,163 | - | -% | 5,729 | 75,095 | 17,342 | 17,342 | 13,459 |
| IUD 10 | 919 | 1,356 | 10,895 | 28,463 | 27,714 | (61)% | 29,864 | 223,302 | 9,806 | 45,105 | 34,187 |
| IUD 10 Insertion | 5,226 | 6,803 | 72,696 | 76,812 | 69,321 | 5% | 73,738 | 327,338 | 72,696 | 334,402 | 303,866 |
| LLIN | 62,866 | 69,984 | 1,071,361 | 3,964,115 | 4,308,977 | (75)% | 4,602,963 | 31,931,481 | 1,735,605 | - | 108,740 |
| Lubricant | - | 2,667 | 8,855 | - | 35,046 | (75)% | 45,024 | 622,212 | - | - | - |
| Malaria PPT (ACT) | 333 | 49,582 | 408,482 | 326,390 | 289,081 | 41% | 297,174 | 893,423 | 367,634 | - | 113,465 |
| Malaria RDK | 105,275 | - | 147,125 | 250,000 | 138,510 | 6% | 177,919 | 1,239,746 | 132,413 | - | - |
| Manual Vacuum Aspiration for PAC | 1,135 | 1,361 | 12,007 | 1,918 | 1,997 | 501% | 2,579 | 16,390 | 12,007 | - | 5,497 |
| Manual Vacuum Aspiration for SA | 141 | 135 | 1,096 | 507 | 424 | 158% | 562 | 2,279 | 1,096 | - | 437 |
| Medical Abortion | 420 | 97 | 2,227 | 19,550 | 65 | 3,326% | 215 | 2,337 | 2,004 | - | 779 |
| Medical Abortion (Misoprostol) Provided | 18 | 16 | 583 | 1,051 | 239 | 144% | 309 | 892 | 583 | - | 210 |
| Medical Abortion Provided | 25 | 17 | 133 | - | 51 | 161% | 51 | 374 | 133 | - | 50 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Micronutrient Powder | 90,290 | 3,330 | 315,411 | 35,000 | 946,742 | (67)% | 948,572 | 2,652,003 | 778 | - | - |
| Misoprostol for PAC Provided | 856 | 1,500 | 9,591 | 2,222 | 1,780 | 439% | 2,304 | 12,969 | 9,591 | - | 5,321 |
| Misoprostol for Safe Abortion | 150,530 | 41,973 | 535,403 | 424,360 | 669,359 | (20)% | 745,045 | 2,079,697 | 28,109 | - | 10,398 |
| OCs | (10,780) | 206,192 | 1,345,956 | 851,499 | 1,233,260 | 9% | 1,347,096 | 7,016,665 | 80,757 | 80,757 | 53,007 |
| OCs Provided | 41,213 | 61,437 | 481,204 | 683,520 | 339,725 | 42% | 367,827 | 1,428,225 | 32,080 | 32,080 | 27,463 |
| Pneumonia PPT | - | - | - | - | 30,399 | (100)% | 30,316 | 477,424 | - | - | - |
| Positive RDTs | - | - | - | - | 13,716 | (100)% | 13,716 | 40,358 | - | - | - |
| Positive RDTs Given First Line Treatment | - | - | - | - | 13,647 | (100)% | 13,647 | 39,926 | - | - | - |
| QAACs Provided after Confirmatory Diagnosis | - | - | - | - | 13,647 | (100)% | 13,647 | 13,647 | - | - | - |
| Referral to HIV Testing Services | - | - | - | 9,600 | - | -% | - | - | - | - | - |
| Referral to Linkage to HIV Care | - | - | - | 1,279 | - | -% | - | - | - | - | - |
| Safe Water Solution | 101,172 | 70,976 | 1,475,634 | 1,400,000 | 720,831 | 105% | 870,831 | 7,581,364 | 1,212,850 | - | 6,331 |
| SDM (Cycle Beads) | (2) | 446 | 1,459 | 306 | 1,454 | -% | 1,533 | 49,488 | 1,313 | 1,970 | 1,510 |
| SDM (Cycle Beads) Provided | 2 | 7 | 100 | 2,550 | 83 | 20% | 96 | 363 | 100 | 150 | 115 |
| Seasonal Malaria Chemoprevention | - | - | - | 990,000 | 344,748 | (100)% | 344,748 | 344,748 | - | - | - |
| Skilled Birth Attendance | 95 | 97 | 1,469 | 9,000 | 9,095 | (84)% | 9,160 | 27,804 | 1,469 | - | 1,861 |
| STI Screening | 616 | 640 | 8,831 | - | 8,194 | 8% | 8,747 | 39,817 | 8,831 | - | - |
| Toilets Sold | 2,805 | 1,365 | 13,408 | 8,107 | 3,283 | 308% | 4,017 | 17,424 | 75,268 | - | 2,851 |
| Toilets Sold - All | 3,288 | 2,137 | 19,747 | - | 4,023 | 391% | 5,726 | 25,473 | 107,666 | - | - |
| Treatment for Cervicitis | 1 | 2 | 24 | - | - | -% | - | 24 | 24 | - | - |
| Treatment for Genital Herpes | 29 | 28 | 453 | - | 26 | 1,642% | 42 | 517 | 453 | - | 7 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Treatment for Inguinal Bubo | 5 | 3 | 51 | - | 28 | 82% | 33 | 118 | 51 | - | - |
| Treatment for Lower Abdominal Pain | 62 | 96 | 943 | - | 626 | 51% | 693 | 2,010 | 943 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 98 | 98 | 998 | - | 933 | 7% | 1,027 | 2,787 | 998 | - | 128 |
| Treatment for Severe Acute Malnutrition | - | - | - | 8 | - | -% | - | - | - | - | - |
| Treatment for Urethral Discharge (Men) | 164 | 149 | 1,854 | - | 1,517 | 22% | 1,631 | 4,810 | 3,708 | - | 22 |
| Treatment for Urethral Discharge (Women) | 245 | 249 | 3,076 | - | 1,886 | 63% | 2,054 | 6,601 | 3,076 | - | 77 |
| Treatment for Vaginitis | 1 | - | 150 | - | 2 | 7,400% | 2 | 157 | 150 | - | - |
| Tubal Ligation | - | - | - | - | 102 | (100)% | 204 | 204 | - | - | - |
| Vasectomy | - | - | - | - | 53 | (100)% | 104 | 104 | - | - | - |
| Water Treatment Tablets | (99,820) | 1,239,040 | 18,155,420 | 20,485,262 | 18,869,870 | (4)% | 20,217,570 | 172,012,500 | 298,445 | - | 2,536 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|------------------|------------------|
| Franco/Lusophone Africa Market Group | | | | | | | | | | | 1,620,269 | 1,902,820 |
| Angola | | | | | | | | | | | 132,337 | 289,956 |
| Condom | 57,816 | 319,656 | 2,426,832 | 5,700,000 | 3,515,552 | | (31)% | 3,793,904 | 21,040,986 | 18,201 | 18,201 | 21,955 |
| Sensual Champagne | 684 | 504 | 29,556 | 700,000 | 306,000 | | (90)% | 314,100 | 714,276 | 222 | 222 | 267 |
| Sensual Chocolate | 252 | 432 | 420,516 | 1,250,000 | 708,408 | 12/12 | (41)% | 804,168 | 4,095,600 | 3,154 | 3,154 | 3,804 |
| Sensual Maracuja | 5,940 | 74,436 | 467,748 | 1,250,000 | 551,772 | | (15)% | 631,476 | 1,737,468 | 3,508 | 3,508 | 4,232 |
| Sensual Menta | 28,368 | 99,924 | 429,120 | 1,250,000 | 1,138,688 | 12/12 | (62)% | 1,138,688 | 5,248,188 | 3,218 | 3,218 | 3,882 |
| Sensual Morango | 17,100 | 80,124 | 802,908 | 1,250,000 | 810,684 | 12/12 | (1)% | 905,472 | 5,374,827 | 6,022 | 6,022 | 7,264 |
| Sensual Saliências | 5,472 | 64,236 | 276,984 | - | - | 11/13 | -% | - | 3,870,627 | 2,077 | 2,077 | 2,506 |
| Emergency Contraception | 3,367 | 1,600 | 32,636 | 250,000 | 44,762 | | (27)% | 45,514 | 78,150 | 1,469 | 1,469 | 909 |
| Pronta | 3,367 | 1,600 | 32,636 | 250,000 | 44,762 | | (27)% | 45,514 | 78,150 | 1,469 | 1,469 | 909 |
| Implant 5 | 4 | 8 | 77 | 1,000 | 1,331 | | (94)% | 1,334 | 1,911 | 69 | 263 | 286 |
| Jadelle | 4 | 8 | 77 | 1,000 | 1,331 | 12/17 | (94)% | 1,334 | 1,911 | 69 | 263 | 286 |
| Injectable 3-SC | - | - | 123,600 | 120,000 | - | | 0% | - | 123,600 | 27,810 | 27,810 | 22,604 |
| Sayana Press | - | - | 123,600 | 120,000 | - | | -% | - | 123,600 | 27,810 | 27,810 | 22,604 |
| IUD 10 | (1,252) | (485) | (8,046) | - | (58) | | 0% | 981 | 224 | (7,241) | (33,310) | (34,649) |
| Copper T 380 A – ENOVA | - | 1,963 | 15,223 | 15,000 | 18,133 | | (16)% | 20,092 | 45,000 | 13,701 | 63,023 | 65,556 |
| (b)PSI IUD 10 Distributed Inserted | (1,252) | (2,448) | (23,269) | (15,000) | (18,191) | | -% | (19,111) | (44,776) | (20,942) | (96,334) | (100,205) |
| IUD 10 Insertion | 1,252 | 2,448 | 23,269 | 15,000 | 18,191 | | 28% | 19,111 | 44,776 | 23,269 | 107,037 | 111,339 |
| PSI IUD 10 Inserted | 1,252 | 2,448 | 23,269 | 15,000 | 18,191 | | 28% | 19,111 | 44,776 | 23,269 | 107,037 | 111,339 |
| LLIN | 94 | 713 | 250,913 | 120,000 | 3,289,444 | | (92)% | 3,520,905 | 13,278,507 | 406,479 | - | 33,580 |
| Generic LLINs | - | - | 143,875 | - | 3,178,567 | 4/11 | (95)% | 3,409,889 | 12,303,308 | 233,078 | - | 19,255 |
| Joia | 94 | 713 | 107,038 | 20,000 | 10,877 | 11/04 | 884% | 11,016 | 452,997 | 173,402 | - | 14,325 |
| PermaNet | - | - | - | 100,000 | 100,000 | 10/12 | (100)% | 100,000 | 522,202 | - | - | - |
| Malaria PPT (ACT) | 333 | 49,582 | 408,482 | 326,390 | 273,163 | | 50% | 281,787 | 790,415 | 367,634 | - | 113,465 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| ALU 20mg/120mg, 12's, 3-8Yrs (15-24Kg) | 95 | 12,631 | 98,944 | 96,000 | 57,452 | 6/17 | 72% | 59,156 | 187,527 | 89,050 | - | 27,484 |
| ALU 20mg/120mg, 18's, 9-14Yrs (25-34Kg) | 30 | 12,085 | 85,055 | 64,000 | 87,705 | 6/17 | (3)% | 89,660 | 189,560 | 76,550 | - | 23,626 |
| ALU 20mg/120mg, 24's, >14Yrs (>34Kg) | 146 | 11,895 | 87,621 | 64,000 | 83,236 | 6/17 | 5% | 85,439 | 200,306 | 78,859 | - | 24,339 |
| ALU 20mg/120mg, 6's, >3Yrs (5-14Kg) | 62 | 12,972 | 136,862 | 96,000 | 44,770 | 6/17 | 206% | 47,532 | 213,022 | 123,176 | - | 38,017 |
| AZAQ 100 mg AS/270 mg AQ, 3 tablets | - | - | - | 639 | - | | -% | - | - | - | - | - |
| AZAQ 100 mg AS/270 mg AQ, 6 tablets | - | - | - | 639 | - | | -% | - | - | - | - | - |
| AZAQ 25 mg AS/67.5 mg AQ, 3 tablets | - | - | - | 2,556 | - | | -% | - | - | - | - | - |
| AZAQ 50 mg AS/135 mg AQ, 3 tablets | - | - | - | 2,556 | - | | -% | - | - | - | - | - |
| Malaria RDK | 105,275 | - | 147,125 | 250,000 | 121,925 | | 21% | 161,350 | 1,022,900 | 132,413 | - | - |
| Bioline (RDT) | - | - | 41,825 | 250,000 | 121,925 | 2/14 | (66)% | 161,350 | 917,600 | 37,643 | - | - |
| mRDT Allere | 105,275 | - | 105,300 | - | - | | -% | - | 105,300 | 94,770 | - | - |
| Manual Vacuum Aspiration for PAC | 945 | 1,122 | 9,607 | - | - | | 0% | - | 9,830 | 9,607 | - | 4,509 |
| MVA for PAC | 945 | 1,122 | 9,607 | - | - | 11/16 | -% | - | 9,830 | 9,607 | - | 4,509 |
| Misoprostol for PAC Provided | 715 | 1,279 | 7,489 | - | - | | 0% | - | 7,489 | 7,489 | - | 4,126 |
| PSI Misoprostol for PAC Provided | 715 | 1,279 | 7,489 | - | - | | -% | - | 7,489 | 7,489 | - | 4,126 |
| Misoprostol for Safe Abortion | 52,924 | 245 | 47,776 | 100,000 | 152,464 | | (69)% | 195,208 | 489,912 | 2,508 | - | 1,222 |
| ACE Miso (Misoprostol 200mcg tablet) | 55,784 | 5,361 | 77,732 | 100,000 | 152,464 | 3/18 | (49)% | 195,208 | 519,868 | 4,081 | - | 1,988 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (2,860) | (5,116) | (29,956) | - | - | | -% | - | (29,956) | (1,573) | - | (766) |
| OCs | 1,823 | 1,327 | 181,108 | 190,000 | 121,311 | | 49% | 123,041 | 325,800 | 10,866 | 10,866 | 9,318 |
| MEURI | 1,823 | 1,327 | 181,108 | 190,000 | 121,311 | | 49% | 123,041 | 325,800 | 10,866 | 10,866 | 9,318 |
| Water Treatment Tablets | 131,500 | 692,400 | 7,874,600 | 10,000,000 | 7,767,400 | | 1% | 7,883,400 | 75,989,062 | 129,445 | - | 1,292 |
| Certeza Water Tabs | 131,500 | 692,400 | 7,874,600 | 10,000,000 | 7,767,400 | 4/11 | 1% | 7,883,400 | 75,989,062 | 129,445 | - | 1,292 |
| Benin | | | | | | | | | | | 322,135 | 248,885 |
| Cervical Cancer-VIA and Cryotherapy | 3 | 1 | 13 | - | 46 | | (72)% | 48 | 387 | 13 | - | 2 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Cervical Cancer-VIA and Cryotherapy | 3 | 1 | 13 | - | 46 | 2/13 | (72)% | 48 | 387 | 13 | - | 2 |
| Cervical Cancer-VIA/VILI Screening | 4,314 | 2,680 | 25,347 | - | 45,503 | | (44)% | 50,592 | 176,822 | 25,347 | - | - |
| Cervical Cancer-VIA/VILI Screening | 4,314 | 2,680 | 25,347 | - | 45,503 | | (44)% | 50,592 | 176,822 | 25,347 | - | - |
| Condom | 362,496 | 362,108 | 4,456,570 | 7,300,000 | 4,383,390 | | 2% | 4,658,955 | 81,180,507 | 33,424 | 33,424 | 25,045 |
| Kool | 39,360 | 22,279 | 106,196 | - | 176,099 | 2/10 | (40)% | 176,099 | 16,909,498 | 796 | 796 | 597 |
| Kool Banane | - | 47,617 | 437,154 | 600,000 | 325,935 | 4/18 | 34% | 360,744 | 797,898 | 3,279 | 3,279 | 2,457 |
| Kool Fraise | - | 47,896 | 436,341 | 750,000 | 317,313 | 4/18 | 38% | 352,122 | 788,463 | 3,273 | 3,273 | 2,452 |
| Kool Menthe | - | 31,140 | 424,113 | 950,000 | 372,495 | 4/18 | 14% | 407,334 | 831,447 | 3,181 | 3,181 | 2,383 |
| Prudence Plus | 323,136 | 213,177 | 3,052,766 | 5,000,000 | 3,191,548 | 1/08 | (4)% | 3,362,656 | 61,853,201 | 22,896 | 22,896 | 17,156 |
| Diarrhea Treatment Kit | 38 | 19,658 | 201,370 | 350,000 | 380,145 | | (47)% | 399,297 | 3,556,845 | 181,233 | - | 12,616 |
| Orasel Zinc DTK | 38 | 19,658 | 201,370 | 350,000 | 380,145 | 4/08 | (47)% | 399,297 | 3,556,845 | 181,233 | - | 12,616 |
| Fecal Sludge Management (Households) | - | - | 2,909 | - | 820 | | 255% | 1,059 | 3,968 | 14,545 | - | - |
| Fecal Sludge Management (Households) | - | - | 2,909 | - | 820 | | 255% | 1,059 | 3,968 | 14,545 | - | - |
| Fecal Sludge Management (Liters) | - | - | 5,212,000 | 7,868,190 | 1,371,000 | | 280% | 1,743,000 | 6,955,000 | - | - | 747 |
| Fecal Sludge Management (Liters) | - | - | 5,212,000 | 7,868,190 | 1,371,000 | | 280% | 1,743,000 | 6,955,000 | - | - | 747 |
| Female Condom | 3,550 | 202 | 4,974 | 5,202 | 9,985 | | (50)% | 9,985 | 38,620 | 37 | 37 | 26 |
| Cupid | 3,550 | 202 | 4,974 | 5,202 | 9,985 | 3/14 | (50)% | 9,985 | 38,620 | 37 | 37 | 26 |
| Free Condom | 28,400 | 4,620 | 11,846,061 | 3,000,000 | 645,000 | | 1737% | 683,616 | 14,783,156 | 88,845 | 88,845 | 66,573 |
| No Logo | 28,400 | 4,620 | 11,846,061 | 3,000,000 | 645,000 | 1/12 | 1,737% | 683,616 | 14,783,156 | 88,845 | 88,845 | 66,573 |
| HIV Testing Services | 3,633 | 3,111 | 40,545 | 40,171 | 47,190 | | (14)% | 47,885 | 665,296 | 40,545 | - | 214 |
| VCT Individual (HIV-Negative) | 3,629 | 3,102 | 40,426 | 40,171 | 46,630 | 1/10 | (13)% | 47,316 | 658,065 | 40,426 | - | 214 |
| VCT Individual (HIV-Positive) | 4 | 9 | 119 | - | 560 | 1/10 | (79)% | 569 | 7,231 | 119 | - | 1 |
| Implant 3 | 504 | 600 | 3,306 | - | - | | 0% | - | 3,306 | 2,975 | 7,439 | 5,403 |
| Implanon | 504 | 600 | 3,306 | - | - | 4/17 | -% | - | 3,306 | 2,975 | 7,439 | 5,403 |
| Implant 5 | 814 | 496 | 10,601 | 27,440 | 25,829 | | (59)% | 28,303 | 7,391 | 9,541 | 36,255 | 25,911 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Implant 5 (insertion) | 1,510 | 1,207 | 17,900 | 35,000 | 34,286 | 12/09 | (48)% | 37,266 | 147,537 | 16,110 | 61,218 | 43,751 |
| (b)PSI Implant 5 Distributed Inserted | (696) | (711) | (7,299) | (7,560) | (8,457) | | -% | (8,963) | (140,146) | (6,569) | (24,963) | (17,840) |
| Implant 5 Insertion | 4,601 | 1,765 | 22,591 | 22,060 | 35,953 | | (37)% | 38,442 | 215,211 | 22,591 | 85,846 | 61,352 |
| Non-PSI Implant 5 Inserted | 3,905 | 1,054 | 15,292 | 14,410 | 27,496 | | (44)% | 29,479 | 75,065 | 15,292 | 58,110 | 41,529 |
| PSI Implant 5 Inserted | 696 | 711 | 7,299 | 7,650 | 8,457 | | (14)% | 8,963 | 140,146 | 7,299 | 27,736 | 19,822 |
| Injectable 2 | (480) | 3,670 | 21,594 | 20,016 | 45,522 | | (53)% | 54,602 | 315,938 | 3,239 | 3,239 | 1,728 |
| Noristerat | - | 4,161 | 27,958 | 65,016 | 53,232 | 1/12 | (47)% | 62,728 | 346,739 | 4,194 | 4,194 | 2,237 |
| (b)PSI Injectable 2 Distributed Provided | (480) | (491) | (6,364) | (45,000) | (7,710) | | -% | (8,126) | (30,801) | (955) | (955) | (509) |
| Injectable 2 Provided | 892 | 777 | 9,736 | 50,000 | 13,828 | | (30)% | 14,475 | 47,113 | 1,623 | 1,623 | 866 |
| Non-PSI Injectable 2 Provided | 412 | 286 | 3,372 | 5,000 | 6,118 | | (45)% | 6,349 | 16,312 | 562 | 562 | 300 |
| PSI Injectable 2 Provided | 480 | 491 | 6,364 | 45,000 | 7,710 | | (17)% | 8,126 | 30,801 | 1,061 | 1,061 | 566 |
| Injectable 3-IM | - | (87) | (261) | - | - | | 0% | - | (7,229) | (59) | (59) | (31) |
| (b)PSI Injectable 3 IM Distributed Provided | - | (87) | (261) | - | - | | -% | - | (7,229) | (59) | (59) | (31) |
| Injectable 3-IM Provided | - | 96 | 289 | - | - | | 0% | - | 7,257 | 72 | 72 | 39 |
| Non-PSI Injectable 3 IM Provided | - | 9 | 28 | - | - | | -% | - | 28 | 7 | 7 | 4 |
| PSI Injectable 3 IM Provided | - | 87 | 261 | - | - | | -% | - | 7,229 | 65 | 65 | 35 |
| Injectable 3-SC | (80) | 37 | 9,714 | 10,000 | - | | 0% | - | 9,714 | 2,186 | 2,186 | 1,166 |
| (b)PSI Injectable 3 SC Distributed Provided | (105) | (236) | (2,286) | - | - | | -% | - | (2,286) | (514) | (514) | (274) |
| Sayana Press | 25 | 273 | 12,000 | 10,000 | - | | -% | - | 12,000 | 2,700 | 2,700 | 1,440 |
| Injectable 3-SC Provided | 127 | 275 | 2,579 | - | - | | 0% | - | 2,579 | 645 | 645 | 344 |
| Non-PSI Injectable 3 SC Provided | 22 | 39 | 293 | - | - | | -% | - | 293 | 73 | 73 | 39 |
| PSI Injectable 3 SC Provided | 105 | 236 | 2,286 | - | - | | -% | - | 2,286 | 572 | 572 | 305 |
| IUD 10 | (972) | (870) | (6,826) | 10,487 | (6,269) | | 0% | (6,402) | 38,500 | (6,143) | (28,260) | (19,336) |
| IUD (insertion) | - | - | - | - | 1,109 | 12/09 | (100)% | 1,109 | 13,420 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| IUD Copper-T TCU 380A | 100 | 182 | 4,485 | 14,000 | 6,603 | 9/09 | (32)% | 7,435 | 143,493 | 4,037 | 18,568 | 12,704 |
| (b)PSI IUD 10 Distributed Inserted | (1,072) | (1,052) | (11,311) | (3,513) | (13,981) | | -% | (14,946) | (118,413) | (10,180) | (46,828) | (32,040) |
| IUD 10 Insertion | 1,632 | 1,317 | 15,652 | 10,513 | 18,853 | | (17)% | 20,070 | 133,987 | 15,652 | 71,999 | 49,263 |
| Non-PSI IUD 10 Inserted | 560 | 265 | 4,341 | 7,000 | 4,872 | | (11)% | 5,124 | 15,574 | 4,341 | 19,969 | 13,663 |
| PSI IUD 10 Inserted | 1,072 | 1,052 | 11,311 | 3,513 | 13,981 | | (19)% | 14,946 | 118,413 | 11,311 | 52,031 | 35,600 |
| LLIN | 10 | - | 35 | - | 5,018 | | (99)% | 5,018 | 734,486 | 57 | - | 5 |
| Super Moustiquaire Longue Durée | - | - | - | - | 4,808 | 5/06 | (100)% | 4,808 | 730,601 | - | - | - |
| SuperMoustiquaire (blanche 1 place) | 10 | - | 35 | - | 210 | 9/15 | (83)% | 210 | 3,885 | 57 | - | 5 |
| Lubricant | - | - | - | - | - | | 0% | 9,920 | 485,348 | - | - | - |
| Gel Lubricant 5 mL | - | - | - | - | - | 12/16 | -% | 9,920 | 485,348 | - | - | - |
| Manual Vacuum Aspiration for PAC | 97 | 109 | 1,138 | - | 718 | | 58% | 803 | 3,108 | 1,138 | - | 364 |
| MVA for PAC | 97 | 109 | 1,138 | - | 718 | 10/16 | 58% | 803 | 3,108 | 1,138 | - | 364 |
| Manual Vacuum Aspiration for SA | 141 | 135 | 898 | - | 196 | | 358% | 211 | 1,730 | 898 | - | 352 |
| Manual Vacuum Aspiration for SA | 141 | 135 | 898 | - | 196 | | 358% | 211 | 1,730 | 898 | - | 352 |
| Medical Abortion | (25) | (17) | (133) | - | - | | 0% | - | (238) | (120) | - | (45) |
| (b)PSI Medical Abortion Distributed Provided | (25) | (17) | (133) | - | - | | -% | - | (238) | (120) | - | (45) |
| Medical Abortion (Misoprostol) Provided | 18 | 16 | 176 | - | 87 | | 102% | 93 | 269 | 176 | - | 59 |
| PSI Medical Abortion (Misoprostol) Provided | 18 | 16 | 176 | - | 87 | | 102% | 93 | 269 | 176 | - | 59 |
| Medical Abortion Provided | 25 | 17 | 133 | - | - | | 0% | - | 238 | 133 | - | 50 |
| PSI Medical Abortion Provided | 25 | 17 | 133 | - | - | | -% | - | 238 | 133 | - | 50 |
| Misoprostol for PAC Provided | 39 | 44 | 543 | - | 424 | | 28% | 459 | 1,279 | 543 | - | 206 |
| PSI Misoprostol for PAC Provided | 39 | 44 | 543 | - | 424 | | 28% | 459 | 1,279 | 543 | - | 206 |
| Misoprostol for Safe Abortion | (372) | (364) | (4,284) | - | (2,740) | | 0% | (2,952) | (8,344) | (225) | - | (76) |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (372) | (364) | (4,284) | - | (2,740) | | -% | (2,952) | (8,344) | (225) | - | (76) |
| OCs | 40,159 | 37,433 | 272,684 | 70,934 | 215,313 | | 27% | 215,192 | 1,569,809 | 16,361 | 16,361 | 9,208 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Laafia Pilule | 40,813 | 37,955 | 276,669 | 300,434 | 218,481 | 6/12 | 27% | 218,541 | 1,602,263 | 16,600 | 16,600 | 9,342 |
| (b)PSI OCs Distributed Provided | (654) | (523) | (3,985) | (229,500) | (3,168) | | -% | (3,349) | (32,454) | (239) | (239) | (135) |
| OCs Provided | 953 | 682 | 5,431 | 255,000 | 4,828 | | 12% | 5,041 | 37,007 | 362 | 362 | 204 |
| Non-PSI OCs Provided | 299 | 160 | 1,446 | 25,500 | 1,660 | | (13)% | 1,692 | 4,553 | 96 | 96 | 54 |
| PSI OCs Provided | 654 | 523 | 3,985 | 229,500 | 3,168 | | 26% | 3,349 | 32,454 | 266 | 266 | 150 |
| SDM (Cycle Beads) | (2) | 446 | 1,459 | 306 | 1,441 | | 1% | 1,520 | 38,781 | 1,313 | 1,970 | 1,510 |
| CycleBeads | - | 451 | 1,550 | 2,601 | 1,521 | 12/04 | 2% | 1,612 | 39,120 | 1,395 | 2,093 | 1,604 |
| (b)PSI SDM (Cycle Beads) Distributed Provided | (2) | (5) | (91) | (2,295) | (80) | | -% | (92) | (339) | (82) | (123) | (94) |
| SDM (Cycle Beads) Provided | 2 | 7 | 100 | 2,550 | 83 | | 20% | 96 | 363 | 100 | 150 | 115 |
| Non-PSI SDM (Cycle Beads) Provided | - | 1 | 9 | 255 | 3 | | 200% | 4 | 24 | 9 | 14 | 10 |
| PSI SDM (Cycle Beads) Provided | 2 | 5 | 91 | 2,295 | 80 | | 14% | 92 | 339 | 91 | 137 | 105 |
| Skilled Birth Attendance | 95 | 97 | 1,469 | 9,000 | 9,095 | | (84)% | 9,160 | 27,804 | 1,469 | - | 1,861 |
| Skilled Birth Attendance | 95 | 97 | 1,469 | 9,000 | 9,095 | | (84)% | 9,160 | 27,804 | 1,469 | - | 1,861 |
| STI Screening | 153 | 169 | 2,268 | - | 3,176 | | (29)% | 3,265 | 21,050 | 2,268 | - | - |
| STI Screening | 153 | 169 | 2,268 | - | 3,176 | | (29)% | 3,265 | 21,050 | 2,268 | - | - |
| Toilets Sold | 2,331 | 852 | 7,888 | 3,428 | 2,584 | | 205% | 2,776 | 10,665 | 39,442 | - | 1,973 |
| Toilets Sold | 2,331 | 852 | 7,888 | 3,428 | 2,584 | | 205% | 2,776 | 10,665 | 39,442 | - | 1,973 |
| Toilets Sold - All | 2,679 | 1,436 | 11,521 | - | 3,096 | | 272% | 3,296 | 14,817 | 57,605 | - | - |
| Toilets Sold - All | 2,679 | 1,436 | 11,521 | - | 3,096 | | 272% | 3,296 | 14,817 | 57,605 | - | - |
| Treatment for Cervicitis | 1 | 2 | 24 | - | - | | 0% | - | 24 | 24 | - | - |
| Treatment for Cervicitis | 1 | 2 | 24 | - | - | | -% | - | 24 | 24 | - | - |
| Treatment for Genital Herpes | 23 | 14 | 171 | - | - | | 0% | - | 171 | 171 | - | - |
| Treatment for Genital Herpes | 23 | 14 | 171 | - | - | | -% | - | 171 | 171 | - | - |
| Treatment for Inguinal Bubo | - | 1 | 14 | - | - | | 0% | - | 14 | 14 | - | - |
| Treatment for Inguinal Bubo | - | 1 | 14 | - | - | | -% | - | 14 | 14 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Treatment for Lower Abdominal Pain | 9 | 15 | 164 | - | - | | 0% | - | 164 | 164 | - | - |
| Treatment for Lower Abdominal Pain | 9 | 15 | 164 | - | - | | -% | - | 164 | 164 | - | - |
| Treatment for Nonherpetic Genital Ulcer | - | 8 | 136 | - | - | | 0% | - | 136 | 136 | - | - |
| Treatment for Nonherpetic Genital Ulcer | - | 8 | 136 | - | - | | -% | - | 136 | 136 | - | - |
| Treatment for Urethral Discharge (Men) | 28 | 24 | 338 | - | - | | 0% | - | 454 | 676 | - | 3 |
| Treatment for Urethral Discharge (Men) | 28 | 24 | 338 | - | - | | -% | - | 454 | 676 | - | 3 |
| Treatment for Urethral Discharge (Women) | 81 | 89 | 1,062 | - | - | | 0% | - | 1,200 | 1,062 | - | 12 |
| Treatment for Urethral Discharge (Women) | 81 | 89 | 1,062 | - | - | | -% | - | 1,200 | 1,062 | - | 12 |
| Treatment for Vaginitis | - | - | 148 | - | - | | 0% | - | 148 | 148 | - | - |
| Treatment for Vaginitis | - | - | 148 | - | - | | -% | - | 148 | 148 | - | - |
| Water Treatment Tablets | - | 436,000 | 8,878,000 | 8,605,083 | 7,578,760 | | 17% | 8,283,060 | 82,929,530 | 145,940 | - | 1,157 |
| Aquatab | - | 436,000 | 8,878,000 | 8,605,083 | 7,578,760 | 1/08 | 17% | 8,283,060 | 82,929,530 | 145,940 | - | 1,157 |
| Burundi | | | | | | | | | | | 48,025 | 144,317 |
| Antiretroviral Treatment (Currently Enrolled) | 2,648 | 2,571 | 26,927 | 2,500 | 8,482 | | 217% | 10,802 | 44,359 | 2,244 | - | 5,058 |
| Antiretroviral Treatment (Currently Enrolled) | 2,648 | 2,571 | 26,927 | 2,500 | 8,482 | | 217% | 10,802 | 44,359 | 2,244 | - | 5,058 |
| Antiretroviral Treatment (Newly Enrolled) | 61 | 52 | 575 | 443 | 1,292 | | (55)% | 1,346 | 2,335 | 575 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 61 | 52 | 575 | 443 | 1,292 | | (55)% | 1,346 | 2,335 | 575 | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 56 | | (100)% | 56 | 539 | - | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 56 | | (100)% | 56 | 539 | - | - | - |
| Condom | 90 | 672,000 | 3,382,740 | 3,500,000 | 4,440,790 | | (24)% | 5,134,060 | 32,545,453 | 25,371 | 25,371 | 41,574 |
| Prudence Class | 90 | 672,000 | 3,382,740 | 3,500,000 | 4,440,790 | 12/09 | (24)% | 5,134,060 | 32,545,453 | 25,371 | 25,371 | 41,574 |
| Emergency Contraception | (172) | 136 | 1,419 | 1,000 | 3,764 | | (62)% | 3,720 | 5,439 | 64 | 64 | 40 |
| Nowill | 90 | 428 | 4,600 | 4,000 | 5,449 | 9/17 | (16)% | 5,699 | 10,758 | 207 | 207 | 130 |
| (b)PSI Emergency Contraception Distributed Provided | (262) | (292) | (3,181) | (3,000) | (1,685) | | -% | (1,979) | (5,319) | (143) | (143) | (90) |
| Emergency Contraception Provided | 262 | 292 | 3,181 | 3,000 | 1,685 | | 89% | 1,979 | 5,319 | 159 | 159 | 100 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| PSI Emergency Contraception Provided | 262 | 292 | 3,181 | 3,000 | 1,685 | | 89% | 1,979 | 5,319 | 159 | 159 | 100 |
| Free Condom | - | - | 1,000,800 | 1,500,000 | 1,000,800 | | 0% | 1,000,800 | 11,272,016 | 7,506 | 7,506 | 12,300 |
| Free Male Condoms | - | - | 1,000,800 | 1,500,000 | 1,000,800 | 5/11 | -% | 1,000,800 | 11,272,016 | 7,506 | 7,506 | 12,300 |
| Free Female Condom | - | - | - | 40,000 | 16,000 | | (100)% | 16,000 | 160,930 | - | - | - |
| Free Female Condoms | - | - | - | 40,000 | 16,000 | 5/11 | (100)% | 16,000 | 160,930 | - | - | - |
| HIV Testing Services | 1,418 | 1,519 | 18,237 | 22,923 | 22,255 | | (18)% | 24,249 | 149,270 | 18,237 | - | 120 |
| VCT Individual (HIV-Negative) | 1,354 | 1,463 | 17,584 | 22,449 | 21,684 | 12/09 | (19)% | 23,617 | 146,632 | 17,584 | - | 116 |
| VCT Individual (HIV-Positive) | 64 | 56 | 653 | 474 | 571 | 12/09 | 14% | 632 | 2,638 | 653 | - | 4 |
| Implant 5 | (96) | 47 | (40) | 500 | 105 | | (138)% | 88 | 1,043 | (36) | (137) | (151) |
| Jadelle | - | 157 | 1,197 | 2,000 | 1,343 | 2/14 | (11)% | 1,413 | 6,955 | 1,077 | 4,094 | 4,512 |
| (b)PSI Implant 5 Distributed Inserted | (96) | (110) | (1,237) | (1,500) | (1,238) | | -% | (1,325) | (5,912) | (1,113) | (4,231) | (4,662) |
| Implant 5 Insertion | 96 | 110 | 1,237 | 1,500 | 1,238 | | 0% | 1,325 | 5,912 | 1,237 | 4,701 | 5,180 |
| PSI Implant 5 Inserted | 96 | 110 | 1,237 | 1,500 | 1,238 | | -% | 1,325 | 5,912 | 1,237 | 4,701 | 5,180 |
| Injectable 3-IM | (1,155) | 132 | 67 | 3,000 | 1,643 | | (96)% | 2,296 | 11,733 | 15 | 15 | 12 |
| DMPA 3-month Injectable | 1,160 | 2,470 | 24,088 | 20,000 | 20,627 | 2/14 | 17% | 23,387 | 89,977 | 5,420 | 5,420 | 4,468 |
| (b)PSI Injectable 3 IM Distributed Provided | (2,315) | (2,338) | (24,021) | (17,000) | (18,984) | | -% | (21,091) | (78,244) | (5,405) | (5,405) | (4,456) |
| Injectable 3-IM Provided | 2,315 | 2,338 | 24,021 | 17,000 | 18,984 | | 27% | 21,091 | 78,244 | 6,005 | 6,005 | 4,951 |
| PSI Injectable 3 IM Provided | 2,315 | 2,338 | 24,021 | 17,000 | 18,984 | | 27% | 21,091 | 78,244 | 6,005 | 6,005 | 4,951 |
| IUD 10 | (34) | 1 | 302 | 400 | 92 | | 228% | 126 | 1,582 | 272 | 1,250 | 1,318 |
| Copper-T 380-A IUD | - | 34 | 721 | 1,000 | 613 | 2/14 | 18% | 670 | 3,675 | 649 | 2,985 | 3,145 |
| (b)PSI IUD 10 Distributed Inserted | (34) | (33) | (419) | (600) | (521) | | -% | (544) | (2,093) | (377) | (1,735) | (1,828) |
| IUD 10 Insertion | 34 | 33 | 419 | 600 | 521 | | (20)% | 544 | 2,093 | 419 | 1,927 | 2,031 |
| PSI IUD 10 Inserted | 34 | 33 | 419 | 600 | 521 | | (20)% | 544 | 2,093 | 419 | 1,927 | 2,031 |
| LLIN | 68,200 | 57,133 | 698,977 | 704,115 | 731,161 | | (4)% | 790,442 | 8,596,164 | 1,132,343 | - | 70,274 |
| MII Permant Free | - | - | - | 704,115 | - | 4/10 | -% | - | 6,624,958 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| MILDA - DAWA PLUS 2.0 | 68,200 | 57,133 | 698,977 | - | 731,161 | 5/17 | (4)% | 790,442 | 1,971,206 | 1,132,343 | - | 70,274 |
| Manual Vacuum Aspiration for PAC | 15 | 11 | 118 | 80 | 48 | | 146% | 66 | 271 | 118 | - | 73 |
| MVA for PAC | 15 | 11 | 118 | 80 | 48 | 6/16 | 146% | 66 | 271 | 118 | - | 73 |
| Misoprostol for PAC Provided | 20 | 26 | 308 | 500 | 133 | | 132% | 179 | 650 | 308 | - | 227 |
| PSI Misoprostol for PAC Provided | 20 | 26 | 308 | 500 | 133 | | 132% | 179 | 650 | 308 | - | 227 |
| Misoprostol for Safe Abortion | (80) | (93) | (583) | - | 933 | | (162)% | 779 | 1,284 | (31) | - | (20) |
| Misoprostol for Safe Abortion | - | 11 | 649 | 2,000 | 1,465 | 3/18 | (56)% | 1,495 | 3,884 | 34 | - | 23 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (80) | (104) | (1,232) | (2,000) | (532) | | -% | (716) | (2,600) | (65) | - | (43) |
| OCs | (642) | 457 | 6,666 | 5,000 | 3,759 | | 77% | 4,428 | 25,657 | 400 | 400 | 348 |
| Confiance OC | 630 | 1,637 | 18,120 | 15,000 | 14,703 | 2/14 | 23% | 16,422 | 69,705 | 1,087 | 1,087 | 946 |
| (b)PSI OCs Distributed Provided | (1,272) | (1,180) | (11,454) | (10,000) | (10,944) | | -% | (11,994) | (44,048) | (687) | (687) | (598) |
| OCs Provided | 1,272 | 1,180 | 11,454 | 10,000 | 10,944 | | 5% | 11,994 | 44,048 | 764 | 764 | 664 |
| PSI OCs Provided | 1,272 | 1,180 | 11,454 | 10,000 | 10,944 | | 5% | 11,994 | 44,048 | 764 | 764 | 664 |
| STI Screening | 463 | 471 | 6,563 | - | 5,018 | | 31% | 5,482 | 18,767 | 6,563 | - | - |
| STI Screening | 463 | 471 | 6,563 | - | 5,018 | | 31% | 5,482 | 18,767 | 6,563 | - | - |
| Treatment for Genital Herpes | 6 | 14 | 282 | - | 26 | | 985% | 42 | 346 | 282 | - | 7 |
| Treatment for Genital Herpes | 6 | 14 | 282 | - | 26 | | 985% | 42 | 346 | 282 | - | 7 |
| Treatment for Inguinal Bubo | 5 | 2 | 37 | - | 28 | | 32% | 33 | 104 | 37 | - | - |
| Treatment for Inguinal Bubo | 5 | 2 | 37 | - | 28 | | 32% | 33 | 104 | 37 | - | - |
| Treatment for Lower Abdominal Pain | 53 | 81 | 779 | - | 626 | | 24% | 693 | 1,846 | 779 | - | - |
| Treatment for Lower Abdominal Pain | 53 | 81 | 779 | - | 626 | | 24% | 693 | 1,846 | 779 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 98 | 90 | 862 | - | 933 | | (8)% | 1,027 | 2,651 | 862 | - | 128 |
| Treatment for Nonherpetic Genital Ulcer | 98 | 90 | 862 | - | 933 | | (8)% | 1,027 | 2,651 | 862 | - | 128 |
| Treatment for Urethral Discharge (Men) | 136 | 124 | 1,516 | - | 1,517 | | 0% | 1,631 | 4,356 | 3,032 | - | 18 |
| Treatment for Urethral Discharge (Men) | 136 | 124 | 1,516 | - | 1,517 | | -% | 1,631 | 4,356 | 3,032 | - | 18 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Treatment for Urethral Discharge (Women) | 164 | 160 | 2,014 | - | 1,886 | | 7% | 2,054 | 5,401 | 2,014 | - | 65 |
| Treatment for Urethral Discharge (Women) | 164 | 160 | 2,014 | - | 1,886 | | 7% | 2,054 | 5,401 | 2,014 | - | 65 |
| Treatment for Vaginitis | 1 | - | 2 | - | 2 | | 0% | 2 | 9 | 2 | - | - |
| Treatment for Vaginitis | 1 | - | 2 | - | 2 | | -% | 2 | 9 | 2 | - | - |
| Cameroon | | | | | | | | | | | 434,521 | 458,703 |
| Condom | 2,835,771 | 955,370 | 14,956,814 | 20,364,000 | 16,076,912 | | (7)% | 18,305,203 | 86,389,521 | 112,176 | 112,176 | 167,711 |
| Lovers Plus | - | - | (2,010) | - | (10,681) | 1/15 | -% | (15,109) | 3,213,161 | (15) | (15) | (23) |
| Préservatif Masculin Aromatisé UNFPA | 16,272 | - | 16,272 | 41,000 | 7,200 | 12/15 | 126% | 7,200 | 25,546 | 122 | 122 | 182 |
| Préservatif Masculin UNFPA | 110,218 | 101,300 | 1,594,330 | 323,000 | 213,090 | 12/15 | 648% | 932,290 | 2,647,460 | 11,957 | 11,957 | 17,877 |
| Prudence Plus Nouveau | 2,709,281 | 854,070 | 13,348,222 | 20,000,000 | 15,867,303 | 1/15 | (16)% | 17,380,822 | 80,503,354 | 100,112 | 100,112 | 149,673 |
| Diarrhea Treatment Kit | 11,950 | 9,156 | 98,038 | 74,000 | 24,341 | | 303% | 32,035 | 878,092 | 88,234 | - | 4,921 |
| Orasel Zinc | 11,950 | 9,156 | 98,038 | 74,000 | 24,341 | 10/09 | 303% | 32,035 | 878,092 | 88,234 | - | 4,921 |
| Emergency Contraception | (22) | (12) | 4,793 | 4,200 | 83,889 | | (94)% | 86,640 | 126,202 | 216 | 216 | 113 |
| Norlevo | - | - | 4,945 | 4,200 | 84,179 | 11/15 | (94)% | 86,934 | 126,858 | 223 | 223 | 116 |
| (b)PSI Emergency Contraception Distributed Provided | (22) | (12) | (152) | - | (290) | | -% | (294) | (656) | (7) | (7) | (4) |
| Emergency Contraception Provided | 22 | 12 | 153 | - | 303 | | (50)% | 307 | 675 | 8 | 8 | 4 |
| Non-PSI Emergency Contraception Provided | - | - | 1 | - | 13 | | (92)% | 13 | 19 | - | - | - |
| PSI Emergency Contraception Provided | 22 | 12 | 152 | - | 290 | | (48)% | 294 | 656 | 8 | 8 | 4 |
| Female Condom | 305,480 | 106,117 | 1,433,006 | 1,154,930 | 965,152 | | 48% | 1,150,692 | 10,996,852 | 10,748 | 10,748 | 15,295 |
| Préservatif Féminin CUPID | - | - | - | - | 160,327 | 7/14 | (100)% | 160,327 | 1,125,022 | - | - | - |
| Préservatif Féminins UNFPA | 212,880 | 13,784 | 294,722 | 608,930 | 24,160 | 3/15 | 1,120% | 26,300 | 1,125,141 | 2,210 | 2,210 | 3,146 |
| Protectiv | - | - | - | 546,000 | - | 11/02 | -% | - | 4,184,561 | - | - | - |
| Protectiv Plus | 92,600 | 92,333 | 675,800 | - | - | 4/14 | -% | - | 1,633,957 | 5,068 | 5,068 | 7,213 |
| Securite Plus Female Condom | - | - | 462,484 | - | 780,665 | 11/13 | (41)% | 964,065 | 2,928,171 | 3,469 | 3,469 | 4,936 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Fever Cases Attended | - | - | - | 8,385 | 14,143 | | (100)% | 14,143 | 26,907 | - | - | - |
| Fever Cases Attended | - | - | - | 8,385 | 14,143 | | (100)% | 14,143 | 26,907 | - | - | - |
| Fever Cases Tested with RDTs | - | - | - | 8,385 | 14,143 | | (100)% | 14,143 | 42,041 | - | - | - |
| Fever Cases Tested with RDTs | - | - | - | 8,385 | 14,143 | | (100)% | 14,143 | 42,041 | - | - | - |
| Free Condom | - | - | 3,300 | - | 418,055 | | (99)% | 419,155 | 1,350,160 | 25 | 25 | 37 |
| Generic MC | - | - | 3,300 | - | 418,055 | 11/16 | (99)% | 419,155 | 1,350,160 | 25 | 25 | 37 |
| Free Female Condom | 6,000 | - | 92,000 | - | 7,300 | | 1160% | 23,300 | 118,400 | 690 | 690 | 982 |
| Generic FC | 6,000 | - | 92,000 | - | 7,300 | 1/08 | 1,160% | 23,300 | 118,400 | 690 | 690 | 982 |
| HIV Testing Services | - | - | 7,402 | 9,600 | 2,274 | | 226% | 5,827 | 74,445 | 7,402 | - | 173 |
| VCT Individual (HIV-Negative) | - | - | 7,247 | 9,380 | 2,204 | 1/10 | 229% | 5,742 | 70,507 | 7,247 | - | 169 |
| VCT Individual (HIV-Positive) | - | - | 155 | 220 | 70 | 1/10 | 121% | 85 | 3,938 | 155 | - | 4 |
| Implant 3 | 2,086 | 914 | 5,680 | (4,896) | 4,572 | | 24% | 7,414 | 32,124 | 5,112 | 12,780 | 11,915 |
| Implanon NXT | 3,715 | 3,277 | 29,405 | 11,000 | 17,410 | 12/15 | 69% | 22,089 | 83,681 | 26,465 | 66,161 | 61,681 |
| (b)PSI Implant 3 Distributed Inserted | (1,629) | (2,363) | (23,725) | (15,896) | (12,838) | 3/16 | -% | (14,675) | (51,557) | (21,353) | (53,381) | (49,767) |
| Implant 3 Insertion | 1,631 | 2,371 | 23,805 | 15,896 | 12,842 | | 85% | 14,684 | 51,649 | 23,805 | 59,513 | 55,483 |
| Non-PSI Implant 3 Inserted | 2 | 8 | 80 | - | 4 | | 1,900% | 9 | 92 | 80 | 200 | 186 |
| PSI Implant 3 Inserted | 1,629 | 2,363 | 23,725 | 15,896 | 12,838 | 3/16 | 85% | 14,675 | 51,557 | 23,725 | 59,313 | 55,296 |
| Implant 5 | 668 | 972 | 3,574 | - | (1,302) | | 0% | (1,373) | 6,559 | 3,217 | 12,223 | 11,201 |
| Jadelle UNFPA | 780 | 1,100 | 4,850 | - | 550 | 3/15 | 782% | 550 | 39,266 | 4,365 | 16,587 | 15,200 |
| (b)PSI Implant 5 Distributed Inserted | (112) | (128) | (1,276) | - | (1,852) | | -% | (1,923) | (32,707) | (1,148) | (4,364) | (3,999) |
| Implant 5 Insertion | 120 | 151 | 1,614 | - | 3,094 | | (48)% | 3,201 | 35,484 | 1,614 | 6,133 | 5,620 |
| Non-PSI Implant 5 Inserted | 8 | 23 | 338 | - | 1,242 | | (73)% | 1,278 | 2,777 | 338 | 1,284 | 1,177 |
| PSI Implant 5 Inserted | 112 | 128 | 1,276 | - | 1,852 | | (31)% | 1,923 | 32,707 | 1,276 | 4,849 | 4,443 |
| Injectable 3-IM | 16,962 | 20,528 | 186,115 | 102,000 | 122,660 | | 52% | 130,960 | 343,326 | 41,876 | 41,876 | 28,699 |
| Equilibre | 23,600 | 22,383 | 246,341 | 132,000 | 157,947 | 5/16 | 56% | 170,812 | 470,755 | 55,427 | 55,427 | 37,986 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| (b)PSI Injectable 3 IM Distributed Provided | (6,638) | (1,855) | (60,226) | (30,000) | (35,287) | | -% | (39,852) | (127,429) | (13,551) | (13,551) | (9,287) |
| Injectable 3-IM Provided | 6,671 | 1,866 | 60,532 | 30,000 | 36,194 | | 67% | 40,845 | 129,203 | 15,133 | 15,133 | 10,371 |
| Non-PSI Injectable 3 IM Provided | 33 | 11 | 306 | - | 907 | | (66)% | 993 | 1,774 | 77 | 77 | 52 |
| PSI Injectable 3 IM Provided | 6,638 | 1,855 | 60,226 | 30,000 | 35,287 | | 71% | 39,852 | 127,429 | 15,057 | 15,057 | 10,319 |
| Injectable 3-SC | - | (3,090) | (5,786) | 2,400 | 3,276 | | (277)% | 3,476 | (2,310) | (1,302) | (1,302) | (892) |
| (b)PSI Injectable 3 SC Distributed Provided | - | (3,770) | (11,310) | - | - | | -% | - | (11,310) | (2,545) | (2,545) | (1,744) |
| Sayana Press | - | 680 | 5,524 | 2,400 | 3,276 | 3/18 | 69% | 3,476 | 9,000 | 1,243 | 1,243 | 852 |
| Injectable 3-SC Provided | - | 3,775 | 11,326 | - | - | | 0% | - | 11,326 | 2,832 | 2,832 | 1,941 |
| Non-PSI Injectable 3 SC Provided | - | 5 | 16 | - | - | | -% | - | 16 | 4 | 4 | 3 |
| PSI Injectable 3 SC Provided | - | 3,770 | 11,310 | - | - | | -% | - | 11,310 | 2,828 | 2,828 | 1,938 |
| IUD 10 | 1,727 | 1,075 | 12,188 | 16,220 | 19,921 | | (39)% | 20,481 | 133,303 | 10,969 | 50,458 | 44,217 |
| DIU UNFPA | - | - | - | 11,000 | 2,077 | 3/15 | (100)% | 2,077 | 24,810 | - | - | - |
| IUD | 1,500 | 2,233 | 22,751 | - | 23,500 | 9/09 | (3)% | 25,200 | 175,973 | 20,476 | 94,189 | 82,539 |
| IUD Copper T 380A | 1,096 | 642 | 10,085 | 23,220 | 11,916 | 2/16 | (15)% | 12,066 | 40,061 | 9,077 | 41,752 | 36,588 |
| (b)PSI IUD 10 Distributed Inserted | (869) | (1,800) | (20,648) | (18,000) | (17,572) | | -% | (18,862) | (107,541) | (18,583) | (85,483) | (74,910) |
| IUD 10 Insertion | 923 | 1,861 | 21,396 | 18,000 | 20,373 | | 5% | 21,794 | 112,450 | 21,396 | 98,422 | 86,248 |
| Non-PSI IUD 10 Inserted | 54 | 61 | 748 | - | 2,801 | | (73)% | 2,932 | 4,909 | 748 | 3,441 | 3,015 |
| PSI IUD 10 Inserted | 869 | 1,800 | 20,648 | 18,000 | 17,572 | | 18% | 18,862 | 107,541 | 20,648 | 94,981 | 83,233 |
| LLIN | 418 | 659 | 11,719 | 2,975,000 | 14,737 | | (20)% | 15,521 | 8,027,646 | 18,985 | - | 1,817 |
| Super Moustiquaire | 367 | 593 | 11,468 | 2,975,000 | 9,021 | 1/09 | 27% | 9,665 | 8,021,495 | 18,578 | - | 1,778 |
| Super Moustiquaire Interceptor | 51 | 67 | 251 | - | 5,716 | 10/15 | (96)% | 5,856 | 6,151 | 407 | - | 39 |
| Lubricant | - | - | 855 | - | 16,128 | | (95)% | 16,186 | 37,415 | - | - | - |
| Lubricant 60 mL bottle | - | - | 855 | - | 6,028 | 12/15 | (86)% | 6,061 | 16,415 | - | - | - |
| Water-based Lubricant, 4 mL sachet | - | - | - | - | 10,100 | 12/16 | (100)% | 10,125 | 21,000 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Malaria PPT (ACT) | - | - | - | - | 15,835 | | (100)% | 15,227 | 109,448 | - | - | - |
| ACT 1 (ASAQ 25 / 67.5 mg, 3 tablets)_2 -11 months | - | - | - | - | (83) | 2/15 | -% | (160) | 6,440 | - | - | - |
| ACT 2 (ASAQ 50 / 135.5 mg, 3 tablets)_1 - 5 years | - | - | - | - | 11,632 | 2/15 | (100)% | 11,449 | 67,905 | - | - | - |
| ACT 3 (ASAQ 100 / 270 mg, 3 tablets)_6 - 13 years | - | - | - | - | 1,861 | 2/15 | (100)% | 1,685 | 17,250 | - | - | - |
| ACT 4 (ASAQ 100 / 270 mg, 6 tablets)_14 years & up | - | - | - | - | 2,425 | 2/15 | (100)% | 2,253 | 17,853 | - | - | - |
| Malaria RDK | - | - | - | - | 16,585 | | (100)% | 16,569 | 216,846 | - | - | - |
| Malaria Ag Pf/Pan_PA | - | - | - | - | 16,585 | 12/12 | (100)% | 16,569 | 216,846 | - | - | - |
| Manual Vacuum Aspiration for PAC | - | - | 451 | 578 | 854 | | (47)% | 1,309 | 2,087 | 451 | - | 159 |
| MVA for PAC | - | - | 451 | 578 | 854 | | (47)% | 1,309 | 2,087 | 451 | - | 159 |
| Manual Vacuum Aspiration for SA | - | - | 198 | 426 | 228 | | (13)% | 351 | 549 | 198 | - | 85 |
| Manual Vacuum Aspiration for SA | - | - | 198 | 426 | 228 | | (13)% | 351 | 549 | 198 | - | 85 |
| Medical Abortion | - | - | 785 | 19,550 | 22 | | 3468% | 172 | 897 | 707 | - | 292 |
| Mifepack | - | - | 785 | 19,550 | 65 | | 1,108% | 215 | 1,000 | 707 | - | 292 |
| (b)PSI Medical Abortion Distributed Provided | - | - | - | - | (43) | | -% | (43) | (103) | - | - | - |
| Medical Abortion (Misoprostol) Provided | - | - | 407 | 868 | 152 | | 168% | 216 | 623 | 407 | - | 151 |
| Non-PSI Medical Abortion (Misoprostol) Provided | - | - | 36 | - | 24 | | 50% | 24 | 60 | 36 | - | 13 |
| PSI Medical Abortion (Misoprostol) Provided | - | - | 371 | 868 | 128 | | 190% | 192 | 563 | 371 | - | 137 |
| Medical Abortion Provided | - | - | - | - | 51 | | (100)% | 51 | 136 | - | - | - |
| Non-PSI Medical Abortion Provided | - | - | - | - | 8 | | (100)% | 8 | 33 | - | - | - |
| PSI Medical Abortion Provided | - | - | - | - | 43 | | (100)% | 43 | 103 | - | - | - |
| Micronutrient Powder | 90,290 | 3,330 | 315,411 | 35,000 | 946,742 | | (67)% | 948,572 | 2,652,003 | 778 | - | - |
| Super Bebe | 90,290 | 3,330 | 315,411 | 35,000 | 946,742 | 9/16 | (67)% | 948,572 | 2,652,003 | 778 | - | - |
| Misoprostol for PAC Provided | - | - | 248 | 594 | 684 | | (64)% | 1,105 | 1,987 | 248 | - | 104 |
| Non-PSI Misoprostol for PAC Provided | - | - | 12 | - | 183 | | (93)% | 183 | 195 | 12 | - | 5 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| PSI Misoprostol for PAC Provided | - | - | 236 | 594 | 501 | | (53)% | 922 | 1,792 | 236 | - | 99 |
| Misoprostol for Safe Abortion | 40 | 16,543 | 149,712 | 117,208 | 226,226 | | (34)% | 243,174 | 892,247 | 7,860 | - | 2,910 |
| Misoprostol for Safe Abortion | 40 | 16,543 | 155,108 | 130,000 | 229,766 | 3/18 | (32)% | 249,166 | 906,171 | 8,143 | - | 3,015 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | - | - | (5,396) | (12,792) | (3,540) | | -% | (5,992) | (13,924) | (283) | - | (105) |
| OCs | (3,984) | 21,258 | 167,032 | 85,000 | 344,775 | | (52)% | 341,853 | 1,176,952 | 10,022 | 10,022 | 7,246 |
| Microgynon Ed Fe | - | 24,478 | 105,435 | - | 19,981 | 7/14 | 428% | 19,981 | 583,608 | 6,326 | 6,326 | 4,574 |
| Microlut | - | - | - | - | 5,001 | 12/17 | (100)% | 5,001 | 5,001 | - | - | - |
| Novelle Duo | 70 | 296 | 100,000 | 100,000 | 340,259 | 1/08 | (71)% | 340,259 | 670,368 | 6,000 | 6,000 | 4,338 |
| (b)PSI OCs Distributed Provided | (4,054) | (3,516) | (38,403) | (15,000) | (20,466) | | -% | (23,388) | (82,025) | (2,304) | (2,304) | (1,666) |
| OCs Provided | 4,058 | 3,516 | 38,547 | 15,000 | 20,787 | | 85% | 23,718 | 82,694 | 2,570 | 2,570 | 1,858 |
| Non-PSI OCs Provided | 4 | 1 | 144 | - | 321 | | (55)% | 330 | 669 | 10 | 10 | 7 |
| PSI OCs Provided | 4,054 | 3,516 | 38,403 | 15,000 | 20,466 | | 88% | 23,388 | 82,025 | 2,560 | 2,560 | 1,851 |
| Pneumonia PPT | - | - | - | - | 30,399 | | (100)% | 30,316 | 477,424 | - | - | - |
| Amoxicillin 500mg x 15's -- Children 1-5 years | - | - | - | - | 28,750 | 1/13 | (100)% | 28,750 | 326,142 | - | - | - |
| Amoxicillin 500mg x 7's - Children 2-11 months | - | - | - | - | 1,649 | 1/13 | (100)% | 1,566 | 151,282 | - | - | - |
| Positive RDTs | - | - | - | - | 13,716 | | (100)% | 13,716 | 40,358 | - | - | - |
| Positive RDTs | - | - | - | - | 13,716 | | (100)% | 13,716 | 40,358 | - | - | - |
| Positive RDTs Given First Line Treatment | - | - | - | - | 13,647 | | (100)% | 13,647 | 39,926 | - | - | - |
| Positive RDTs Given First Line Treatment | - | - | - | - | 13,647 | | (100)% | 13,647 | 39,926 | - | - | - |
| QAACTs Provided after Confirmatory Diagnosis | - | - | - | - | 13,647 | | (100)% | 13,647 | 13,647 | - | - | - |
| Non-PSI QAACTs Provided after Confirmed Diagnosis | - | - | - | - | 13,647 | | (100)% | 13,647 | 13,647 | - | - | - |
| Referral to HIV Testing Services | - | - | - | 9,600 | - | | 0% | - | - | - | - | - |
| Referral to HIV Testing Services | - | - | - | 9,600 | - | 12/13 | -% | - | - | - | - | - |
| Tubal Ligation | - | - | - | - | 102 | | (100)% | 204 | 204 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Tubal Ligation | - | - | - | - | 102 | | (100)% | 204 | 204 | - | - | - |
| Vasectomy | - | - | - | - | 53 | | (100)% | 104 | 104 | - | - | - |
| Vasectomy | - | - | - | - | 53 | | (100)% | 104 | 104 | - | - | - |
| Water Treatment Tablets | 5,780 | 15,567 | 417,200 | 20,000 | 1,725,610 | | (76)% | 2,071,710 | 2,642,622 | 6,858 | - | 43 |
| Aquatabs 67 mg (20 L) | 5,780 | 15,567 | 417,200 | 20,000 | 1,725,610 | 12/15 | (76)% | 2,071,710 | 2,642,622 | 6,858 | - | 43 |
| Cote d'Ivoire | | | | | | | | | | | 169,012 | 131,909 |
| Antiretroviral Treatment (Currently Enrolled) | 3,392 | 3,187 | 23,293 | 5,223 | 7,589 | | 207% | 7,589 | 30,882 | 1,941 | - | 3,213 |
| Antiretroviral Treatment (Currently Enrolled) | 3,392 | 3,187 | 23,293 | 5,223 | 7,589 | | 207% | 7,589 | 30,882 | 1,941 | - | 3,213 |
| Antiretroviral Treatment (Newly Enrolled) | 95 | 91 | 659 | 953 | 460 | | 43% | 460 | 1,119 | 659 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 95 | 91 | 659 | 953 | 460 | | 43% | 460 | 1,119 | 659 | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 66 | | (100)% | 66 | 788 | - | - | - |
| CD4 Tests Provided to HIV+ Clients | - | - | - | - | 66 | | (100)% | 66 | 788 | - | - | - |
| Emergency Contraception Provided | - | - | - | - | 14 | | (100)% | 16 | 16 | - | - | - |
| Non-PSI Emergency Contraception Provided | - | - | - | - | 14 | | (100)% | 16 | 16 | - | - | - |
| Fecal Sludge Management (Households) | - | 53 | 402 | 350 | 296 | | 36% | 315 | 717 | 2,050 | - | - |
| Fecal Sludge Management (Households) | - | 53 | 402 | 350 | 296 | | 36% | 315 | 717 | 2,050 | - | - |
| Fecal Sludge Management (Liters) | - | 772,667 | 5,929,000 | 5,691,000 | 3,108,000 | | 91% | 3,367,000 | 9,296,000 | - | - | 578 |
| Fecal Sludge Management (Liters) | - | 772,667 | 5,929,000 | 5,691,000 | 3,108,000 | | 91% | 3,367,000 | 9,296,000 | - | - | 578 |
| Free Condom | 620 | 33,547 | 160,640 | 393,631 | 1,091,536 | | (85)% | 1,091,536 | 6,479,453 | 1,205 | 1,205 | 942 |
| Free Distribution | 620 | 33,547 | 160,640 | 393,631 | 1,091,536 | 1/08 | (85)% | 1,091,536 | 6,479,453 | 1,205 | 1,205 | 942 |
| Free Female Condom | - | 1,700 | 5,100 | 12,000 | 10,236 | | (50)% | 10,236 | 78,099 | 38 | 38 | 28 |
| Female Condom Free | - | 1,700 | 5,100 | 12,000 | 10,236 | 8/12 | (50)% | 10,236 | 78,099 | 38 | 38 | 28 |
| HIV Self-Testing Kit | - | - | - | 1,388 | - | | 0% | - | - | - | - | - |
| HIV Self-Testing Kit (Oral Fluid) | - | - | - | 1,388 | - | | -% | - | - | - | - | - |
| HIV Testing Services | 1,032 | 1,010 | 7,618 | 17,622 | 13,282 | | (43)% | 13,282 | 134,103 | 7,618 | - | 55 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|----------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| VCT Individual (HIV-Negative) | 894 | 914 | 6,928 | 16,343 | 12,419 | 1/10 | (44)% | 12,419 | 127,141 | 6,928 | - | 50 |
| VCT Individual (HIV-Positive) | 138 | 96 | 690 | 1,279 | 863 | 1/10 | (20)% | 863 | 6,962 | 690 | - | 5 |
| Implant 3 | 504 | 727 | 2,684 | - | - | | 0% | - | 2,684 | 2,416 | 6,039 | 4,688 |
| Implanon NXT | 504 | 727 | 2,684 | - | - | | -% | - | 2,684 | 2,416 | 6,039 | 4,688 |
| Implant 3 Insertion | 1,650 | 2,055 | 17,474 | 3,308 | 1,221 | | 1331% | 2,070 | 19,544 | 17,474 | 43,685 | 33,914 |
| Non-PSI Implant 3 Inserted | 1,650 | 2,055 | 17,474 | 3,308 | 1,221 | | 1,331% | 2,070 | 19,544 | 17,474 | 43,685 | 33,914 |
| Implant 5 | 500 | 646 | 2,439 | - | - | | 0% | - | 2,439 | 2,195 | 8,341 | 6,364 |
| Jadelle | 500 | 646 | 2,439 | - | - | | -% | - | 2,439 | 2,195 | 8,341 | 6,364 |
| Implant 5 Insertion | 1,680 | 2,554 | 22,883 | 17,956 | 2,271 | | 908% | 2,823 | 25,706 | 22,883 | 86,955 | 66,342 |
| Non-PSI Implant 5 Inserted | 1,680 | 2,554 | 22,883 | 17,956 | 2,271 | | 908% | 2,823 | 25,706 | 22,883 | 86,955 | 66,342 |
| Injectable 2 Provided | 82 | 127 | 1,074 | - | 1,005 | | 7% | 1,373 | 2,447 | 179 | 179 | 102 |
| Non-PSI Injectable 2 Provided | 82 | 127 | 1,074 | - | 1,005 | | 7% | 1,373 | 2,447 | 179 | 179 | 102 |
| Injectable 3-IM | 1,000 | 650 | 2,950 | - | - | | 0% | - | 2,950 | 664 | 664 | 379 |
| Depo-Provera | 1,000 | 650 | 2,950 | - | - | 5/10 | -% | - | 2,950 | 664 | 664 | 379 |
| Injectable 3-IM Provided | 1,778 | 2,230 | 20,721 | 7,144 | 8,007 | | 159% | 7,836 | 28,557 | 5,180 | 5,180 | 2,957 |
| Non-PSI Injectable 3 IM Provided | 1,778 | 2,230 | 20,721 | 7,144 | 8,007 | | 159% | 7,836 | 28,557 | 5,180 | 5,180 | 2,957 |
| Injectable 3-SC | 10 | 436 | 1,318 | - | - | | 0% | - | 1,318 | 297 | 297 | 169 |
| Sayana Press | 10 | 436 | 1,318 | - | - | | -% | - | 1,318 | 297 | 297 | 169 |
| Injectable 3-SC Provided | 652 | 909 | 6,724 | 9,808 | - | | 0% | 1,258 | 7,982 | 1,681 | 1,681 | 960 |
| Non-PSI Injectable 3 SC Provided | 652 | 909 | 6,724 | 9,808 | - | | -% | 1,258 | 7,982 | 1,681 | 1,681 | 960 |
| IUD 10 | - | 248 | 745 | - | - | | 0% | - | 745 | 671 | 3,084 | 2,250 |
| Eve's TCu380A | - | 248 | 745 | - | - | | -% | - | 745 | 671 | 3,084 | 2,250 |
| IUD 10 Insertion | 183 | 298 | 2,348 | 4,576 | 256 | | 817% | 390 | 2,738 | 2,348 | 10,801 | 7,879 |
| Non-PSI IUD 10 Inserted | 183 | 298 | 2,348 | 4,576 | 256 | | 817% | 390 | 2,738 | 2,348 | 10,801 | 7,879 |
| Lubricant | - | 2,667 | 8,000 | - | 18,918 | | (58)% | 18,918 | 99,449 | - | - | - |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Gel Lubricant 4.5 g | - | 2,667 | 8,000 | - | 18,918 | 9/12 | (58)% | 18,918 | 99,449 | - | - | - |
| OCs | 240 | 430 | 1,530 | - | - | | 0% | - | 1,530 | 92 | 92 | 55 |
| Microgynon | 120 | 123 | 490 | - | - | | -% | - | 490 | 29 | 29 | 18 |
| Microlut | 120 | 307 | 1,040 | - | - | | -% | - | 1,040 | 62 | 62 | 38 |
| OCs Provided | 534 | 1,187 | 11,561 | 9,584 | 3,991 | | 190% | 4,743 | 16,304 | 771 | 771 | 464 |
| Non-PSI OCs Provided | 534 | 1,187 | 11,561 | 9,584 | 3,991 | | 190% | 4,743 | 16,304 | 771 | 771 | 464 |
| Referral to Linkage to HIV Care | - | - | - | 1,279 | - | | 0% | - | - | - | - | - |
| Referral to Linkage to HIV Care | - | - | - | 1,279 | - | | -% | - | - | - | - | - |
| Toilets Sold | 273 | 403 | 3,120 | 679 | 42 | | 7315% | 282 | 3,403 | 15,914 | - | 571 |
| Toilets Sold | 273 | 403 | 3,120 | 679 | 42 | | 7,315% | 282 | 3,403 | 15,914 | - | 571 |
| Toilets Sold - All | 407 | 545 | 5,692 | - | 270 | | 2008% | 1,472 | 7,164 | 29,029 | - | - |
| Toilets Sold - All | 407 | 545 | 5,692 | - | 270 | | 2,008% | 1,472 | 7,164 | 29,029 | - | - |
| Mozambique | | | | | | | | | | | 308,529 | 436,620 |
| Condom | 848,376 | 599,808 | 8,565,192 | 17,000,000 | 11,455,824 | | (25)% | 13,175,544 | 108,563,652 | 64,239 | 64,239 | 176,708 |
| J0.1 | - | - | 853,920 | 1,700,000 | 144 | 10/17 | 592,900% | 144 | 2,582,064 | 6,404 | 6,404 | 17,617 |
| J1 | 427,896 | 23,784 | 3,345,120 | 5,100,000 | 3,888,480 | 10/12 | (14)% | 4,752,480 | 51,102,432 | 25,088 | 25,088 | 69,013 |
| J14 | - | - | - | 1,700,000 | - | 4/14 | -% | - | 141,840 | - | - | - |
| J18 | - | - | - | 1,700,000 | 1,728,000 | 4/18 | (100)% | 1,728,000 | 1,728,000 | - | - | - |
| J2 | - | 24 | 1,353,672 | 1,700,000 | 1,469,880 | 10/12 | (8)% | 1,469,880 | 18,753,192 | 10,153 | 10,153 | 27,928 |
| J24 | - | - | - | - | 1,728,000 | 10/17 | (100)% | 1,728,000 | 3,456,000 | - | - | - |
| J3 | 420,480 | 576,000 | 3,012,480 | 5,100,000 | 2,593,368 | 10/12 | 16% | 3,449,088 | 25,961,040 | 22,594 | 22,594 | 62,150 |
| Jeito 4 | - | - | - | - | 44,568 | 11/13 | (100)% | 44,568 | 3,487,464 | - | - | - |
| Jeito 5 | - | - | - | - | 3,384 | 1/14 | (100)% | 3,384 | 1,351,620 | - | - | - |
| Emergency Contraception Provided | - | 2 | 380 | - | 512 | | (26)% | 575 | 1,107 | 19 | 19 | 12 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Non-PSI Emergency Contraception Provided | - | 2 | 380 | - | 512 | | (26)% | 575 | 1,107 | 19 | 19 | 12 |
| Free Condom | - | - | - | - | 6,624 | | (100)% | 6,624 | 697,377 | - | - | - |
| No Logo Condom Lubricant Combo | - | - | - | - | 6,624 | 5/15 | (100)% | 6,624 | 697,377 | - | - | - |
| Implant 3 Insertion | 114 | 131 | 750 | - | 40 | | 1775% | 40 | 790 | 750 | 1,875 | 2,140 |
| Non-PSI Implant 3 Inserted | 114 | 131 | 750 | - | 40 | | 1,775% | 40 | 790 | 750 | 1,875 | 2,140 |
| Implant 5 | 2,000 | 1,431 | 7,210 | - | (631) | | 0% | (631) | (1,179) | 6,489 | 24,658 | 27,628 |
| Jadelle | 2,000 | 1,431 | 7,961 | - | 3,135 | 12/15 | 154% | 3,427 | 19,095 | 7,165 | 27,227 | 30,506 |
| (b)PSI Implant 5 Distributed Inserted | - | - | (751) | - | (3,766) | | -% | (4,058) | (20,274) | (676) | (2,568) | (2,878) |
| Implant 5 Insertion | 3,841 | 2,320 | 27,051 | 24,990 | 26,702 | | 1% | 28,867 | 91,921 | 27,051 | 102,794 | 115,175 |
| Non-PSI Implant 5 Inserted | 3,841 | 2,320 | 26,300 | 24,990 | 22,936 | | 15% | 24,809 | 71,647 | 26,300 | 99,940 | 111,978 |
| PSI Implant 5 Inserted | - | - | 751 | - | 3,766 | | (80)% | 4,058 | 20,274 | 751 | 2,854 | 3,198 |
| Injectable 3-IM | 400 | 1,650 | 6,687 | - | (16,374) | | 0% | 139,684 | 124,075 | 1,505 | 1,505 | 1,264 |
| Enaf Injectable | 400 | 1,650 | 8,139 | - | 5,858 | 6/13 | 39% | 162,512 | 246,332 | 1,831 | 1,831 | 1,538 |
| (b)PSI Injectable 3 IM Distributed Provided | - | - | (1,452) | - | (22,232) | | -% | (22,828) | (122,257) | (327) | (327) | (274) |
| Injectable 3-IM Provided | 12,163 | 6,323 | 78,092 | 156,870 | 154,351 | | (49)% | 161,823 | 498,002 | 19,523 | 19,523 | 16,401 |
| Non-PSI Injectable 3 IM Provided | 12,163 | 6,323 | 76,640 | 156,870 | 132,119 | | (42)% | 138,995 | 375,745 | 19,160 | 19,160 | 16,096 |
| PSI Injectable 3 IM Provided | - | - | 1,452 | - | 22,232 | | (93)% | 22,828 | 122,257 | 363 | 363 | 305 |
| Injectable 3-SC | 6,003 | 3,615 | 33,949 | - | 8,203 | | 314% | 8,364 | 42,313 | 7,639 | 7,639 | 6,417 |
| (b)PSI Injectable 3 SC Distributed Provided | - | - | (3,829) | - | - | | -% | (1,038) | (4,867) | (862) | (862) | (724) |
| Sayana Press | 6,003 | 3,615 | 37,778 | - | 8,203 | | 361% | 9,402 | 47,180 | 8,500 | 8,500 | 7,141 |
| Injectable 3-SC Provided | 3,615 | 3,241 | 41,753 | 29,355 | - | | 0% | 4,471 | 46,224 | 10,438 | 10,438 | 8,769 |
| Non-PSI Injectable 3 SC Provided | 3,615 | 3,241 | 37,924 | 29,355 | - | | -% | 3,433 | 41,357 | 9,481 | 9,481 | 7,965 |
| PSI Injectable 3 SC Provided | - | - | 3,829 | - | - | | -% | 1,038 | 4,867 | 957 | 957 | 804 |
| IUD 10 | 800 | 547 | 3,062 | - | - | | 0% | - | 24,800 | 2,756 | 12,677 | 13,562 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| DIU Copper T 380A | 800 | 547 | 3,062 | - | - | 1/15 | -% | - | 24,800 | 2,756 | 12,677 | 13,562 |
| IUD 10 Insertion | 1,048 | 647 | 7,382 | 14,055 | 7,731 | | (5)% | 8,354 | 23,976 | 7,382 | 33,957 | 36,330 |
| Non-PSI IUD 10 Inserted | 1,048 | 647 | 7,382 | 14,055 | 7,731 | 3/16 | (5)% | 8,354 | 23,976 | 7,382 | 33,957 | 36,330 |
| LLIN | - | - | - | - | 695 | | (100)% | 695 | 199,832 | - | - | - |
| Serena | - | - | - | - | 695 | 4/14 | (100)% | 695 | 199,832 | - | - | - |
| OCs | 6,056 | 76,741 | 288,241 | - | (1,935) | | 0% | (1,935) | 285,954 | 17,294 | 17,294 | 15,327 |
| Microginon Mobiz | - | - | - | - | 1,682 | 5/15 | (100)% | 1,682 | 7,430 | - | - | - |
| Microlenyn 30 Combined OC | 5,856 | 74,935 | 244,125 | - | 35,167 | 6/13 | 594% | 38,163 | 446,391 | 14,648 | 14,648 | 12,981 |
| Progestyn OC | 200 | 1,807 | 55,652 | - | 9,385 | 6/13 | 493% | 10,218 | 145,358 | 3,339 | 3,339 | 2,959 |
| (b)PSI OCs Distributed Provided | - | - | (11,536) | - | (48,169) | | -% | (51,998) | (313,225) | (692) | (692) | (613) |
| OCs Provided | 20,371 | 16,627 | 178,664 | 285,460 | 209,969 | | (15)% | 223,704 | 842,364 | 11,911 | 11,911 | 10,556 |
| Non-PSI OCs Provided | 20,371 | 16,627 | 167,128 | 285,460 | 161,800 | | 3% | 171,706 | 529,139 | 11,142 | 11,142 | 9,874 |
| PSI OCs Provided | - | - | 11,536 | - | 48,169 | | (76)% | 51,998 | 313,225 | 769 | 769 | 682 |
| Safe Water Solution | 101,172 | 70,976 | 1,475,634 | 1,400,000 | 720,831 | | 105% | 870,831 | 7,581,364 | 1,212,850 | - | 6,331 |
| Certeza Commercial ISM | 66,528 | 28,043 | 401,451 | 700,000 | 323,748 | 9/12 | 24% | 323,748 | 3,389,466 | 329,960 | - | 1,722 |
| Certeza Free ISM | 34,644 | 42,933 | 1,074,183 | 700,000 | 397,083 | 9/12 | 171% | 547,083 | 4,191,898 | 882,890 | - | 4,608 |
| SDM (Cycle Beads) | - | - | - | - | 13 | | (100)% | 13 | 10,707 | - | - | - |
| Missangas Ciclo | - | - | - | - | 13 | 2/11 | (100)% | 13 | 10,707 | - | - | - |
| Niger | | | | | | | | | | | 115,743 | 123,205 |
| Antiretroviral Treatment (Currently Enrolled) | - | 653 | 5,746 | - | - | | 0% | 625 | 6,371 | 479 | - | 1,097 |
| Antiretroviral Treatment (Currently Enrolled) | - | 653 | 5,746 | - | - | | -% | 625 | 6,371 | 479 | - | 1,097 |
| Antiretroviral Treatment (Newly Enrolled) | - | 6 | 31 | - | - | | 0% | 1 | 32 | 31 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | - | 6 | 31 | - | - | | -% | 1 | 32 | 31 | - | - |
| Free Condom | - | 340,320 | 1,020,960 | 300,000 | - | | 0% | - | 1,775,480 | 7,657 | 7,657 | 9,540 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Generic Condom | - | 340,320 | 1,020,960 | 300,000 | - | 6/16 | -% | - | 1,775,480 | 7,657 | 7,657 | 9,540 |
| HIV Testing Services | - | 1,200 | 7,618 | 3,008 | 14,499 | | (47)% | 14,858 | 38,532 | 7,618 | - | 61 |
| VCT Individual (HIV-Negative) | - | 1,194 | 7,567 | 3,000 | 14,466 | | (48)% | 14,820 | 37,833 | 7,567 | - | 61 |
| VCT Individual (HIV-Positive) | - | 6 | 51 | 8 | 33 | | 55% | 38 | 699 | 51 | - | - |
| Implant 3 | - | - | - | - | (91) | | 0% | (91) | (91) | - | - | - |
| (b)PSI Implant 3 Distributed Inserted | - | - | - | - | (91) | | -% | (91) | (91) | - | - | - |
| Implant 3 Insertion | 1,586 | 1,685 | 18,260 | 8,287 | 7,157 | | 155% | 7,625 | 31,986 | 18,260 | 45,650 | 51,411 |
| Non-PSI Implant 3 Inserted | 1,586 | 1,685 | 18,260 | 8,287 | 7,066 | | 158% | 7,534 | 31,895 | 18,260 | 45,650 | 51,411 |
| PSI Implant 3 Inserted | - | - | - | - | 91 | | (100)% | 91 | 91 | - | - | - |
| Implant 5 | - | - | - | - | (1) | | 0% | (1) | (1) | - | - | - |
| (b)PSI Implant 5 Distributed Inserted | - | - | - | - | (1) | | -% | (1) | (1) | - | - | - |
| Implant 5 Insertion | 421 | 476 | 4,382 | 1,634 | 1,414 | | 210% | 1,486 | 7,505 | 4,382 | 16,652 | 18,430 |
| Non-PSI Implant 5 Inserted | 421 | 476 | 4,382 | 1,634 | 1,413 | | 210% | 1,485 | 7,504 | 4,382 | 16,652 | 18,430 |
| PSI Implant 5 Inserted | - | - | - | - | 1 | | (100)% | 1 | 1 | - | - | - |
| Injectable 3-IM | - | - | (13,046) | - | - | | 0% | - | (13,046) | (2,935) | (2,935) | (2,431) |
| (b)PSI Injectable 3 IM Distributed Provided | - | - | (13,046) | - | - | | -% | - | (13,046) | (2,935) | (2,935) | (2,431) |
| Injectable 3-IM Provided | 8,560 | 9,051 | 91,472 | 44,336 | 38,272 | | 139% | 40,305 | 152,551 | 22,868 | 22,868 | 18,935 |
| Non-PSI Injectable 3 IM Provided | 8,560 | 9,051 | 78,426 | 44,336 | 38,272 | | 105% | 40,305 | 139,505 | 19,607 | 19,607 | 16,235 |
| PSI Injectable 3 IM Provided | - | - | 13,046 | - | - | | -% | - | 13,046 | 3,262 | 3,262 | 2,701 |
| Injectable 3-SC | - | - | (1,463) | - | - | | 0% | - | (1,463) | (329) | (329) | (273) |
| (b)PSI Injectable 3 SC Distributed Provided | - | - | (1,463) | - | - | | -% | - | (1,463) | (329) | (329) | (273) |
| Injectable 3-SC Provided | 264 | 505 | 6,984 | - | - | | 0% | - | 6,984 | 1,746 | 1,746 | 1,446 |
| Non-PSI Injectable 3 SC Provided | 264 | 505 | 5,521 | - | - | | -% | - | 5,521 | 1,380 | 1,380 | 1,143 |
| PSI Injectable 3 SC Provided | - | - | 1,463 | - | - | | -% | - | 1,463 | 366 | 366 | 303 |
| IUD 10 | - | - | - | - | (60) | | 0% | (60) | (60) | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| (b)PSI IUD 10 Distributed Inserted | - | - | - | - | (60) | | -% | (60) | (60) | - | - | - |
| IUD 10 Insertion | 154 | 196 | 2,195 | 3,727 | 3,371 | | (35)% | 3,448 | 7,237 | 2,195 | 10,097 | 10,685 |
| Non-PSI IUD 10 Inserted | 154 | 196 | 2,195 | 3,727 | 3,311 | | (34)% | 3,388 | 7,177 | 2,195 | 10,097 | 10,685 |
| PSI IUD 10 Inserted | - | - | - | - | 60 | | (100)% | 60 | 60 | - | - | - |
| Manual Vacuum Aspiration for PAC | 78 | 119 | 693 | 450 | 377 | | 84% | 401 | 1,094 | 693 | - | 392 |
| MVA for PAC | 78 | 119 | 693 | 450 | 377 | 1/16 | 84% | 401 | 1,094 | 693 | - | 392 |
| Misoprostol for PAC Provided | 82 | 151 | 1,003 | 600 | 539 | | 86% | 561 | 1,564 | 1,003 | - | 658 |
| Non-PSI Misoprostol for PAC Provided | 82 | 151 | 1,003 | 600 | 539 | | 86% | 561 | 1,564 | 1,003 | - | 658 |
| Misoprostol for Safe Abortion | 818 | 4,707 | 23,818 | 8,000 | 99,276 | | (76)% | 99,856 | 176,654 | 1,250 | - | 727 |
| Misoprostol for Safe Abortion | 818 | 4,707 | 23,818 | 8,000 | 99,276 | 3/18 | (76)% | 99,856 | 176,654 | 1,250 | - | 727 |
| OCs | - | - | (22,753) | - | - | | 0% | - | (22,753) | (1,365) | (1,365) | (1,193) |
| (b)PSI OCs Distributed Provided | - | - | (22,753) | - | - | | -% | - | (22,753) | (1,365) | (1,365) | (1,193) |
| OCs Provided | 14,025 | 38,245 | 235,543 | 108,471 | 89,191 | | 164% | 98,610 | 405,781 | 15,703 | 15,703 | 13,717 |
| Non-PSI OCs Provided | 14,025 | 38,245 | 212,790 | 108,471 | 89,191 | | 139% | 98,610 | 383,028 | 14,186 | 14,186 | 12,392 |
| PSI OCs Provided | - | - | 22,753 | - | - | | -% | - | 22,753 | 1,517 | 1,517 | 1,325 |
| Seasonal Malaria Chemoprevention | - | - | - | 990,000 | 344,748 | | (100)% | 344,748 | 344,748 | - | - | - |
| SMC for Children ages 12-59 months | - | - | - | 825,000 | 291,064 | | (100)% | 291,064 | 291,064 | - | - | - |
| SMC for Infants ages 3-11 months | - | - | - | 165,000 | 53,684 | | (100)% | 53,684 | 53,684 | - | - | - |
| PSI Benin | | | | | | | | | | | 44,746 | 36,952 |
| Implant 5 | 300 | 343 | 1,620 | 112 | - | | 0% | - | 1,620 | 1,458 | 5,540 | 3,960 |
| Jadelle | 300 | 343 | 1,620 | 3,766 | - | 1/18 | -% | - | 1,620 | 1,458 | 5,540 | 3,960 |
| (b)PSI Implant 5 Distributed Inserted | - | - | - | (3,654) | - | | -% | - | - | - | - | - |
| Implant 5 Insertion | - | - | - | 3,654 | - | | 0% | - | - | - | - | - |
| PSI Implant 5 Inserted | - | - | - | 3,654 | - | | -% | - | - | - | - | - |
| IUD 10 | 650 | 840 | 9,470 | 1,356 | 14,028 | | (32)% | 14,678 | 24,148 | 8,523 | 39,206 | 26,825 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| IUD Copper T 380A | 650 | 840 | 9,470 | 11,690 | 14,028 | 1/18 | (32)% | 14,678 | 24,148 | 8,523 | 39,206 | 26,825 |
| (b)PSI IUD 10 Distributed Inserted | - | - | - | (10,334) | - | | -% | - | - | - | - | - |
| IUD 10 Insertion | - | - | - | 10,334 | - | | 0% | - | - | - | - | - |
| PSI IUD 10 Inserted | - | - | - | 10,334 | - | | -% | - | - | - | - | - |
| Manual Vacuum Aspiration for PAC | - | - | - | 810 | - | | 0% | - | - | - | - | - |
| MVA for PAC | - | - | - | 810 | - | | -% | - | - | - | - | - |
| Manual Vacuum Aspiration for SA | - | - | - | 81 | - | | 0% | - | - | - | - | - |
| Manual Vacuum Aspiration for SA | - | - | - | 81 | - | | -% | - | - | - | - | - |
| Medical Abortion | 445 | 113 | 1,575 | - | - | | 0% | - | 1,575 | 1,418 | - | 531 |
| Mifeso | 445 | 113 | 1,575 | - | - | | -% | - | 1,575 | 1,418 | - | 531 |
| Medical Abortion (Misoprostol) Provided | - | - | - | 183 | - | | 0% | - | - | - | - | - |
| PSI Medical Abortion (Misoprostol) Provided | - | - | - | 183 | - | | -% | - | - | - | - | - |
| Misoprostol for PAC Provided | - | - | - | 528 | - | | 0% | - | - | - | - | - |
| PSI Misoprostol for PAC Provided | - | - | - | 528 | - | | -% | - | - | - | - | - |
| Misoprostol for Safe Abortion | 97,200 | 20,935 | 318,964 | 199,152 | 193,200 | | 65% | 208,980 | 527,944 | 16,746 | - | 5,636 |
| Misoprostol for Safe Abortion | 97,200 | 20,935 | 318,964 | 203,460 | 193,200 | 3/18 | 65% | 208,980 | 527,944 | 16,746 | - | 5,636 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | - | - | - | (4,308) | - | | -% | - | - | - | - | - |
| Senegal | | | | | | | | | | | 45,222 | 32,272 |
| Acute Malnutrition Screening_CU5 | - | - | - | 312 | 518 | | (100)% | 518 | 1,895 | - | - | - |
| Acute Malnutrition Screening_CU5 | - | - | - | 312 | 518 | | (100)% | 518 | 1,895 | - | - | - |
| Condom | (173,800) | 194,635 | 1,486,648 | 6,074,298 | 5,354,006 | | (72)% | 5,947,910 | 32,430,808 | 11,150 | 11,150 | 12,829 |
| Fagaru | (60,488) | 43,227 | 345,192 | 2,100,223 | 2,639,035 | 11/12 | (87)% | 2,751,835 | 12,164,377 | 2,589 | 2,589 | 2,979 |
| Protec Fraise | (26,656) | 29,280 | 243,008 | 710,207 | 715,344 | 1/13 | (66)% | 822,288 | 4,398,612 | 1,823 | 1,823 | 2,097 |
| Protec Naturel | (86,656) | 122,128 | 898,448 | 3,263,868 | 1,999,627 | 1/13 | (55)% | 2,373,787 | 15,867,819 | 6,738 | 6,738 | 7,753 |
| Counseling & Tx for Moderate Acute MalnutritionCU! | - | - | - | 4 | - | | 0% | - | - | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Counseling & Tx for Moderate Acute MalnutritionCU5 | - | - | - | 4 | - | | -% | - | - | - | - | - |
| HIV Testing Services | - | - | - | 91 | 314 | | (100)% | 314 | 903 | - | - | - |
| VCT Individual (HIV-Negative) | - | - | - | 90 | 313 | | (100)% | 313 | 888 | - | - | - |
| VCT Individual (HIV-Positive) | - | - | - | 1 | 1 | | (100)% | 1 | 15 | - | - | - |
| Implant 3 Insertion | - | 14 | 169 | 41 | 116 | | 46% | 127 | 363 | 169 | 423 | 255 |
| Non-PSI Implant 3 Inserted | - | 14 | 169 | 41 | 116 | | 46% | 127 | 363 | 169 | 423 | 255 |
| Implant 4 Insertion | - | - | 21 | - | 2 | | 950% | 2 | 41 | 21 | 67 | 40 |
| Non-PSI Implant 4 Inserted | - | - | 21 | - | 2 | | 950% | 2 | 41 | 21 | 67 | 40 |
| Implant 5 Insertion | - | 10 | 226 | 48 | 134 | | 69% | 157 | 462 | 226 | 859 | 510 |
| Non-PSI Implant 5 Inserted | - | 10 | 226 | 48 | 134 | | 69% | 157 | 462 | 226 | 859 | 510 |
| Injectable 3-IM Provided | - | 10 | 147 | 45 | 168 | | (13)% | 182 | 430 | 37 | 37 | 16 |
| Non-PSI Injectable 3 IM Provided | - | 10 | 147 | 45 | 168 | | (13)% | 182 | 430 | 37 | 37 | 16 |
| Injectable 3-SC | - | 6,040 | 24,173 | 19,080 | 10,600 | | 128% | 14,488 | 41,276 | 5,439 | 5,439 | 2,417 |
| Securil Press | - | 6,040 | 24,173 | 19,080 | 10,600 | | 128% | 14,488 | 41,276 | 5,439 | 5,439 | 2,417 |
| IUD 10 Insertion | - | 2 | 35 | 7 | 25 | | 40% | 27 | 81 | 35 | 161 | 91 |
| Non-PSI IUD 10 Inserted | - | 2 | 35 | 7 | 25 | | 40% | 27 | 81 | 35 | 161 | 91 |
| LLIN | (5,856) | 11,478 | 109,717 | 165,000 | 267,922 | | (59)% | 270,382 | 1,094,846 | 177,742 | - | 3,064 |
| MILDA | (5,856) | 11,478 | 109,717 | 165,000 | 267,922 | 8/13 | (59)% | 270,382 | 1,094,846 | 177,742 | - | 3,064 |
| OCs | (54,432) | 68,545 | 451,448 | 500,565 | 550,037 | | (18)% | 664,517 | 3,653,716 | 27,087 | 27,087 | 12,699 |
| Securil | (54,432) | 68,545 | 451,448 | 500,565 | 550,037 | 11/12 | (18)% | 664,517 | 3,653,716 | 27,087 | 27,087 | 12,699 |
| OCs Provided | - | - | 4 | 5 | 15 | | (73)% | 17 | 27 | - | - | - |
| Non-PSI OCs Provided | - | - | 4 | 5 | 15 | | (73)% | 17 | 27 | - | - | - |
| Toilets Sold | 202 | 110 | 2,399 | 4,000 | 657 | | 265% | 958 | 3,357 | 19,912 | - | 306 |
| Toilets Sold | 202 | 110 | 2,399 | 4,000 | 657 | | 265% | 958 | 3,357 | 19,912 | - | 306 |
| Toilets Sold - All | 202 | 155 | 2,534 | - | 657 | | 286% | 958 | 3,492 | 21,032 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Toilets Sold - All | 202 | 155 | 2,534 | - | 657 | | 286% | 958 | 3,492 | 21,032 | - | - |
| Treatment for Severe Acute Malnutrition | - | - | - | 8 | - | | 0% | - | - | - | - | - |
| Treatment for Severe Acute Malnutrition | - | - | - | 8 | - | | -% | - | - | - | - | - |
| Water Treatment Tablets | (237,100) | 95,073 | 985,620 | 1,860,179 | 1,798,100 | | (45)% | 1,979,400 | 10,451,286 | 16,202 | - | 43 |
| Aquatabs 67 mg (20 L) | (237,100) | 95,073 | 985,620 | 1,860,179 | 1,798,100 | 11/12 | (45)% | 1,979,400 | 10,451,286 | 16,202 | - | 43 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Latin America & Asia Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 11/2019

| | New HIV Infections | STI Deaths | PWID Deaths | TB Deaths | CYP* | Maternal Deaths | Unintended Pregnancies | Malaria Deaths | Diarrhea Deaths | Pneumonia Deaths | Cervical Cancer Death | Sum of All Deaths |
|-----------------------------------|--------------------|------------|-------------|-----------|-----------|-----------------|------------------------|----------------|-----------------|------------------|-----------------------|-------------------|
| Latin America & Asia Market Group | 3,995 | - | 48 | 2,001 | 3,879,647 | 1,785 | 1,481,935 | 2 | 76 | - | - | 13,158 |
| Cambodia | 1,517 | - | - | - | 620,631 | 478 | 234,774 | - | 75 | - | - | 1,845 |
| Caribbean | - | - | - | - | - | - | - | - | - | - | - | - |
| Costa Rica | 47 | - | - | - | 11,797 | - | 3,322 | - | - | - | - | 3 |
| Dominican Republic | 475 | - | - | - | 100,231 | 12 | 28,239 | - | - | - | - | 92 |
| El Salvador | 179 | - | - | - | 38,096 | 3 | 11,267 | - | - | - | - | 27 |
| El Salvador SA | 47 | - | - | - | 45,510 | 6 | 19,318 | - | - | - | - | 47 |
| Guatemala | 190 | - | - | - | 49,707 | 5 | 14,416 | - | - | - | - | 77 |
| Guatemala SA | 114 | - | - | - | 310,311 | 50 | 137,967 | - | - | - | - | 731 |
| Honduras | 175 | - | - | - | 19,848 | 4 | 6,613 | - | - | - | - | 23 |
| Honduras SA | 161 | - | - | - | 13,203 | 2 | 3,718 | - | - | - | - | 13 |
| Kazakhstan | 18 | - | - | - | 656 | - | 185 | - | - | - | - | - |
| Kyrgyzstan | 13 | - | - | - | 273 | - | 77 | - | - | - | - | - |
| Laos | 93 | - | - | 14 | 81,365 | 34 | 32,362 | 2 | - | - | - | 241 |
| Nepal | - | - | - | - | 70,756 | 226 | 32,018 | - | - | - | - | 358 |
| Nicaragua | 135 | - | - | - | 77,573 | 23 | 30,468 | - | - | - | - | 133 |
| Pakistan | 517 | - | - | 1,987 | 1,552,614 | 683 | 589,440 | - | - | - | - | 6,884 |
| Panama | 80 | - | - | - | 15,672 | 2 | 4,414 | - | - | - | - | 12 |
| Papua New Guinea | 11 | - | - | - | 1,351 | 1 | 376 | - | - | - | - | 6 |
| PSI Pakistan | 199 | - | - | - | 862,254 | 256 | 329,708 | - | - | - | - | 2,613 |
| Tajikistan | 25 | - | 48 | - | 1,229 | - | 346 | - | - | - | - | 49 |
| Viet Nam | - | - | - | - | 6,570 | 1 | 2,907 | - | 1 | - | - | 4 |

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|------------------|------------------|
| Latin America & Asia Market Group | | | | | | | | | | 3,879,647 | 1,186,530 |
| Antiretroviral Treatment (Currently Enrolled) | 767 | 925 | 7,541 | - | 233 | 3,136% | 233 | 7,774 | 628 | - | 1,049 |
| Antiretroviral Treatment (Newly Enrolled) | 88 | 40 | 449 | - | 92 | 388% | 92 | 541 | 449 | - | - |
| Cervical Cancer-HPV DNA Screening | - | 146 | 777 | - | - | -% | - | 777 | 777 | - | - |
| Cervical Cancer-Pap Smear Screening | 31 | 47 | 408 | - | 92 | 343% | 92 | 736 | 408 | - | - |
| Condom | 11,658,825 | 20,653,880 | 166,126,123 | 196,479,173 | 162,707,899 | 2% | 187,077,716 | 3,650,069,099 | 1,245,946 | 1,245,946 | 358,910 |
| Diarrhea Treatment Kit | 1,630 | 1,100 | 37,750 | 91,951 | 57,190 | (34)% | 57,190 | 986,426 | 33,975 | - | 743 |
| Emergency Contraception | 146,757 | 294,593 | 2,291,194 | 981,837 | 1,833,444 | 25% | 2,139,292 | 11,499,213 | 103,104 | 103,104 | 17,917 |
| Emergency Contraception Provided | 4,405 | 1,978 | 26,558 | 1,146,567 | 12,851 | 107% | 15,372 | 70,408 | 1,328 | 1,328 | 231 |
| Female Condom | - | - | - | - | 100 | (100)% | 100 | 338,539 | - | - | - |
| Fever Cases Attended | 8,768 | 8,700 | 79,879 | 75,685 | 112,593 | (29)% | 118,263 | 359,804 | 79,879 | - | - |
| Fever Cases Tested with Microscopy | - | 2,246 | 6,737 | - | - | -% | - | 6,737 | 6,737 | - | - |
| Fever Cases Tested with RDTs | 11,898 | 11,860 | 105,090 | 95,551 | 126,427 | (17)% | 134,061 | 400,777 | 105,090 | - | - |
| Free Condom | 124,572 | 540,270 | 3,685,316 | 3,124,160 | 2,698,447 | 37% | 3,430,359 | 14,280,049 | 27,640 | 27,640 | 7,779 |
| Free Female Condom | 5,310 | 3,398 | 15,504 | 30,000 | 21,200 | (27)% | 21,200 | 61,274 | 116 | 116 | 75 |
| HIV Self-Testing Kit | - | 323 | 968 | 7,200 | - | -% | - | 968 | 871 | - | - |
| HIV Testing Services | 6,316 | 4,225 | 67,431 | 78,439 | 93,829 | (28)% | 98,169 | 421,231 | 67,431 | - | 150 |
| Hypertension Diagnosis | - | - | 7,961 | 14,572 | 26,102 | (70)% | 26,102 | 60,396 | 7,961 | - | - |
| Hypertension Screening | 1 | - | 191,920 | 150,000 | 383,656 | (50)% | 413,477 | 807,614 | 191,920 | - | - |
| Hypertension_Controlled Condition | - | - | 12,035 | 13,009 | 28,481 | (58)% | 30,443 | 62,586 | 4,814 | - | - |
| Implant 3 | 292 | 465 | 2,703 | 4,920 | 1,683 | 61% | 1,681 | 5,246 | 2,433 | 6,082 | 838 |
| Implant 3 Insertion | 894 | 979 | 11,265 | 12,195 | 12,945 | (13)% | 12,809 | 38,025 | 11,265 | 28,163 | 6,452 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|----------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Implant 5 | 261 | 2,089 | 12,034 | 3,342 | 21,587 | (44)% | 21,705 | 87,627 | 10,831 | 41,156 | 9,307 |
| Implant 5 Insertion | 1,306 | 1,731 | 19,864 | 12,712 | 21,314 | (7)% | 21,679 | 107,596 | 19,864 | 75,483 | 15,615 |
| Injectable 1 | 22,900 | 24,148 | 188,584 | 150,016 | 120,778 | 56% | 131,181 | 2,157,098 | 13,056 | 13,056 | 3,015 |
| Injectable 1 Provided | 12,772 | 8,889 | 98,075 | 44,525 | 84,860 | 16% | 88,483 | 323,031 | 7,544 | 7,544 | 1,506 |
| Injectable 2 | (105) | 13,087 | 124,894 | 19,731 | 117,769 | 6% | 134,028 | 7,208,977 | 18,734 | 18,734 | 4,300 |
| Injectable 2 Provided | 4,860 | 2,932 | 39,039 | 132,422 | 57,553 | (32)% | 58,184 | 185,615 | 6,507 | 6,507 | 1,056 |
| Injectable 3-IM | 9,945 | 23,738 | 310,645 | 560,836 | 638,067 | (51)% | 688,678 | 8,747,868 | 69,895 | 69,895 | 12,903 |
| Injectable 3-IM Provided | 103,314 | 28,553 | 485,581 | 761,629 | 663,160 | (27)% | 705,711 | 1,641,131 | 121,395 | 121,395 | 23,671 |
| Injectable 3-SC | (102) | - | (102) | 1,400 | - | -% | - | (102) | (23) | (23) | (1) |
| Injectable 3-SC Provided | 749 | 7 | 769 | 5,600 | - | -% | - | 769 | 192 | 192 | 5 |
| IUD 10 | (2,303) | 1,920 | 74,176 | 102,474 | 88,958 | (17)% | 67,041 | 203,093 | 66,758 | 307,089 | 84,776 |
| IUD 10 Insertion | 36,288 | 5,977 | 126,627 | 123,733 | 139,477 | (9)% | 148,352 | 885,095 | 126,627 | 582,484 | 142,762 |
| IUD 5 | 9,220 | 11,111 | 46,225 | 94,294 | 21,894 | 111% | 22,736 | 3,065,398 | 41,602 | 137,288 | 41,423 |
| IUD 5 Insertion | 12,535 | 13,995 | 151,253 | 65,998 | 63,573 | 138% | 63,576 | 1,090,538 | 151,253 | 499,135 | 155,800 |
| IUS 5 Insertion | - | 1 | 7 | - | 2 | 250% | 2 | 10 | 7 | 23 | 4 |
| LLIN (Hammock net) | - | - | 781 | 1,350 | 1,259 | (38)% | 1,259 | 2,085 | 703 | - | - |
| Lubricant | 120,195 | 487,924 | 2,767,315 | 731,208 | 1,347,018 | 105% | 1,423,274 | 19,299,115 | - | - | - |
| Malaria PPT (ACT) | (72) | (35) | (398) | - | 287 | (239)% | 147 | 860,087 | (358) | - | (50) |
| Malaria PPT (Non-ACT) | (1) | (12) | (67) | - | (98) | -% | (141) | (208) | (60) | - | (10) |
| Malaria RDK | 3,810 | 3,183 | 28,380 | 25,000 | 305,159 | (91)% | 305,189 | 3,310,856 | 25,542 | - | - |
| Manual Vacuum Aspiration for PAC | 3,635 | 8,536 | 81,042 | 7,295 | 29,956 | 171% | 34,966 | 187,006 | 81,042 | - | 3,935 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Manual Vacuum Aspiration for SA | 61 | 59 | 675 | 236 | 251 | 169% | 251 | 926 | 675 | - | 100 |
| Medical Abortion | 30,298 | 20,612 | 334,629 | 459,996 | 418,883 | (20)% | 457,337 | 2,445,789 | 301,166 | - | 30,527 |
| Medical Abortion Provided | 1,931 | 957 | 11,672 | 4,788 | 11,357 | 3% | 12,104 | 31,746 | 11,672 | - | 1,134 |
| Misoprostol for PAC Provided | 7,919 | 8,731 | 77,803 | 3,935 | 49,293 | 58% | 53,383 | 134,836 | 77,803 | - | 4,610 |
| Misoprostol for Safe Abortion | 106,450 | 78,547 | 1,514,126 | 320,448 | 1,242,127 | 22% | 1,285,943 | 3,500,263 | 79,492 | - | 6,050 |
| Multivitamin | 1,400 | 6,340 | 20,420 | - | - | -% | - | 20,420 | 102 | - | 19 |
| Naloxone | - | 167 | 1,995 | 3,089 | 2,500 | (20)% | 2,570 | 18,708 | 1,796 | - | 2,722 |
| Needle & Syringe | 43,200 | 78,533 | 1,066,900 | 1,355,860 | 5,062,315 | (79)% | 5,815,215 | 26,575,968 | 3,722 | - | 11,901 |
| OCs | 678,156 | 565,810 | 6,830,029 | 6,917,751 | 5,924,910 | 15% | 6,487,754 | 71,384,165 | 409,802 | 409,802 | 77,236 |
| OCs Provided | 352,689 | 42,758 | 1,207,443 | 1,601,361 | 790,594 | 53% | 921,067 | 2,830,797 | 80,496 | 80,496 | 19,240 |
| ORS | 22,800 | 39,442 | 635,337 | - | - | -% | 500,000 | 1,164,571 | 285,902 | - | 6,009 |
| Positive RDTs | 144 | 125 | 1,844 | 3,333 | 11,486 | (84)% | 11,799 | 40,417 | 1,844 | - | - |
| Positive RDTs Given First Line Treatment | 101 | 92 | 1,451 | 2,474 | 9,825 | (85)% | 10,103 | 36,999 | 1,451 | - | - |
| QAACTs Provided after Confirmatory Diagnosis | 104 | 80 | 1,122 | 2,254 | 9,743 | (88)% | 9,977 | 36,572 | 1,122 | - | 201 |
| Referral to Emergency Contraception | - | 1 | 2 | - | 31 | (94)% | 31 | 109 | 2 | - | - |
| Referral to HIV Testing Services | - | 1 | 17 | 6 | 10 | 70% | 10 | 20,745 | 17 | - | - |
| Referral to Implant 3 Insertion | 203 | 176 | 1,945 | - | - | -% | 1,455 | 3,400 | 1,945 | 2,431 | 329 |
| Referral to Implant 5 Insertion | 2 | 59 | 495 | - | 197 | 151% | 221 | 1,522 | 495 | 940 | 210 |
| Referral to Implant Insertion (duration unknown) | 7 | 2 | 20 | - | - | -% | - | 20 | 20 | 25 | 3 |
| Referral to Injectable 1 | 13 | 1 | 25 | - | 9 | 178% | 11 | 36 | 25 | 1 | - |
| Referral to Injectable 3 | - | 91 | 890 | - | 359 | 148% | 396 | 2,525 | 890 | 111 | 19 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Referral to IUD 10 Insertion | 209 | 223 | 2,096 | - | 660 | 218% | 729 | 60,340 | 2,096 | 4,821 | 844 |
| Referral to IUD Insertion (duration unknown) | 4 | 2 | 19 | - | - | -% | - | 19 | 19 | 31 | 4 |
| Referral to Linkage to HIV Care | 291 | 303 | 3,048 | 1,627 | 2,562 | 19% | 2,800 | 9,180 | 3,048 | - | 2,541 |
| Referral to OCs | 1 | 78 | 903 | - | 326 | 177% | 391 | 1,845 | 903 | 30 | 6 |
| Referral to Opioid Treatment | 3 | 5 | 76 | 37 | 124 | (39)% | 135 | 548 | 76 | - | - |
| Referral to TB DOTS (completion confirmed) | 27 | 6 | 81 | 110 | 148 | (45)% | 148 | 472 | 81 | - | 28 |
| Referral to TB DOTS (completion unknown) | - | - | 4 | - | 43 | (91)% | 43 | 248 | 4 | - | 1 |
| Referral to TB Screening | - | - | - | - | 21 | (100)% | 21 | 50 | - | - | - |
| Referral to Vasectomy | - | - | 1 | - | - | -% | - | 1 | 1 | 5 | 1 |
| SDM (Cycle Beads) Provided | - | - | 4 | - | 7 | (43)% | 7 | 126 | 4 | 6 | 1 |
| STI Screening | 17 | 42 | 242 | - | 99 | 144% | 99 | 4,135 | 242 | - | - |
| TB Diagnosis | 2,553 | 2,505 | 26,341 | 385 | 27,573 | (4)% | 29,853 | 111,977 | 26,341 | - | - |
| TB DOTS | 1,970 | 2,170 | 23,475 | - | 23,920 | (2)% | 26,012 | 136,950 | 23,475 | - | 107,432 |
| TB Screening | 6,417 | 5,114 | 56,228 | 4,086 | 67,874 | (17)% | 72,433 | 197,744 | 56,228 | - | - |
| Toilets Sold | - | 175 | 1,113 | 750 | 3,573 | (69)% | 4,405 | 7,416 | 4,675 | - | 39 |
| Toilets Sold - All | - | 175 | 1,113 | - | 3,327 | (67)% | 4,159 | 5,272 | 4,675 | - | - |
| Treatment for Cervicitis | 3 | 13 | 89 | - | 28 | 218% | 28 | 132 | 89 | - | - |
| Treatment for Genital Herpes | - | - | 1 | - | - | -% | - | 9 | 1 | - | - |
| Treatment for Lower Abdominal Pain | - | 2 | 7 | - | - | -% | - | 7 | 7 | - | - |
| Treatment for Nonherpetic Genital Ulcer | - | 1 | 2 | - | - | -% | - | 4 | 2 | - | - |
| Treatment for Urethral Discharge (Women) | - | - | 1 | - | 1 | -% | 1 | 9 | 1 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Treatment for Vaginitis | 14 | 27 | 199 | - | 25 | 696% | 25 | 227 | 199 | - | - |
| Tubal Ligation | 683 | 1,097 | 8,571 | - | 11,899 | (28)% | 11,913 | 35,992 | 8,571 | 85,710 | 20,405 |
| Type 2 Diabetes Diagnosis | - | - | 1 | - | 1 | -% | 1 | 2 | 1 | - | - |
| Type 2 Diabetes Screening | - | - | 3 | - | 1 | 200% | 1 | 6 | 3 | - | - |
| Type 2 Diabetes_Controlled Condition | - | - | 2 | - | - | -% | - | 2 | - | - | - |
| Vasectomy | 1 | 33 | 290 | - | 318 | (9)% | 318 | 1,191 | 290 | 2,900 | 704 |
| Vivax Treatment after Confirmatory Diagnosis | 29 | 57 | 246 | 248 | 112 | 120% | 156 | 411 | 246 | - | 46 |
| Water Treatment Tablets | 2,750 | 500 | 70,110 | 80,000 | 91,160 | (23)% | 91,160 | 1,048,893 | 1,152 | - | 3 |
| Zika Prevention Kit | - | - | - | - | 714 | (100)% | 725 | 2,621 | - | - | - |
| Zinc | 70 | - | 132 | - | - | -% | - | 32,976 | 119 | - | 1 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|------------------|------------------|
| Latin America & Asia Market Group | | | | | | | | | | | 3,879,647 | 1,186,530 |
| Cambodia | | | | | | | | | | | 620,631 | 203,369 |
| Condom | 363,690 | 626,254 | 9,499,326 | 12,214,854 | 9,769,344 | | (3)% | 10,667,766 | 395,563,877 | 71,245 | 71,245 | 70,395 |
| Number One | (59,688) | 231,576 | 2,627,496 | 4,448,814 | 4,101,984 | 12/94 | (36)% | 4,440,816 | 271,899,565 | 19,706 | 19,706 | 19,471 |
| OK Condom | 423,378 | 394,678 | 6,871,830 | 7,766,040 | 5,667,360 | 2/04 | 21% | 6,226,950 | 123,664,312 | 51,539 | 51,539 | 50,924 |
| Diarrhea Treatment Kit | 1,630 | 1,100 | 37,750 | 89,037 | 57,190 | | (34)% | 57,190 | 968,190 | 33,975 | - | 743 |
| Orasel Kit | 1,630 | 1,100 | 37,750 | 89,037 | 57,190 | 3/09 | (34)% | 57,190 | 968,190 | 33,975 | - | 743 |
| Emergency Contraception | 3,587 | 3,834 | 59,917 | 94,412 | 67,180 | | (11)% | 73,948 | 362,452 | 2,696 | 2,696 | 357 |
| NEXT 72 EC | 3,590 | 3,837 | 59,960 | 90,602 | 67,210 | 8/13 | (11)% | 73,979 | 362,559 | 2,698 | 2,698 | 357 |
| Pronta1 | - | - | - | 3,810 | - | | -% | - | - | - | - | - |
| (b)PSI Emergency Contraception Distributed Provided | (3) | (2) | (43) | - | (30) | | -% | (31) | (107) | (2) | (2) | - |
| Emergency Contraception Provided | 3 | 2 | 43 | - | 30 | | 43% | 31 | 107 | 2 | 2 | - |
| PSI Emergency Contraception Provided | 3 | 2 | 43 | - | 30 | | 43% | 31 | 107 | 2 | 2 | - |
| Fever Cases Attended | 1,997 | 1,029 | 13,201 | 15,685 | 73,320 | | (82)% | 75,172 | 238,974 | 13,201 | - | - |
| Fever Cases Attended | 1,997 | 1,029 | 13,201 | 15,685 | 73,320 | | (82)% | 75,172 | 238,974 | 13,201 | - | - |
| Fever Cases Tested with RDTs | 1,997 | 1,029 | 12,836 | 15,551 | 73,236 | | (82)% | 75,088 | 238,503 | 12,836 | - | - |
| Fever Cases Tested with RDTs | 1,997 | 1,029 | 12,836 | 15,551 | 73,236 | | (82)% | 75,088 | 238,503 | 12,836 | - | - |
| Implant 3 Insertion | 32 | 21 | 267 | - | 98 | | 172% | 112 | 379 | 267 | 668 | 158 |
| Non-PSI Implant 3 Inserted | 32 | 21 | 267 | - | 98 | | 172% | 112 | 379 | 267 | 668 | 158 |
| Implant 5 | (18) | 369 | 6,099 | 8,643 | 8,095 | | (25)% | 8,131 | 28,127 | 5,489 | 20,859 | 4,839 |
| Implant 5 | 234 | 529 | 8,074 | 11,184 | 10,328 | 5/09 | (22)% | 10,570 | 61,400 | 7,267 | 27,613 | 6,405 |
| (b)PSI Implant 5 Distributed Inserted | (252) | (160) | (1,975) | (2,541) | (2,233) | | -% | (2,439) | (33,273) | (1,778) | (6,754) | (1,567) |
| Implant 5 Insertion | 252 | 160 | 1,975 | 2,541 | 2,233 | | (12)% | 2,439 | 33,273 | 1,975 | 7,505 | 1,741 |
| PSI Implant 5 Inserted | 252 | 160 | 1,975 | 2,541 | 2,233 | | (12)% | 2,439 | 33,273 | 1,975 | 7,505 | 1,741 |
| Injectable 3-IM | 10,924 | 23,673 | 241,400 | 334,044 | 268,008 | | (10)% | 290,704 | 5,795,629 | 54,315 | 54,315 | 9,435 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| OK Injection-3 | 11,500 | 23,950 | 245,425 | 334,044 | 271,200 | 2/02 | (10)% | 294,200 | 5,813,984 | 55,221 | 55,221 | 9,593 |
| (b)PSI Injectable 3 IM Distributed Provided | (576) | (277) | (4,025) | - | (3,192) | | -% | (3,496) | (18,355) | (906) | (906) | (157) |
| Injectable 3-IM Provided | 576 | 277 | 4,025 | - | 3,192 | | 26% | 3,496 | 18,355 | 1,006 | 1,006 | 175 |
| PSI Injectable 3 IM Provided | 576 | 277 | 4,025 | - | 3,192 | | 26% | 3,496 | 18,355 | 1,006 | 1,006 | 175 |
| IUD 10 | (306) | 956 | 12,144 | 25,008 | 19,647 | | (38)% | 20,787 | 104,678 | 10,930 | 50,276 | 11,144 |
| IUD Copper T | 1,190 | 2,163 | 27,550 | 40,488 | 37,800 | 1/10 | (27)% | 40,515 | 263,875 | 24,795 | 114,057 | 25,281 |
| (b)PSI IUD 10 Distributed Inserted | (1,496) | (1,207) | (15,406) | (15,480) | (18,153) | | -% | (19,728) | (159,197) | (13,865) | (63,781) | (14,137) |
| IUD 10 Insertion | 1,496 | 1,207 | 15,406 | 15,480 | 18,153 | | (15)% | 19,728 | 159,197 | 15,406 | 70,868 | 15,708 |
| PSI IUD 10 Inserted | 1,496 | 1,207 | 15,406 | 15,480 | 18,153 | | (15)% | 19,728 | 159,197 | 15,406 | 70,868 | 15,708 |
| Lubricant | 51,120 | 32,740 | 596,040 | - | 496,260 | | 20% | 521,340 | 9,774,140 | - | - | - |
| OK Plus Lubricant | 51,120 | 32,740 | 596,040 | - | 496,260 | 6/09 | 20% | 521,340 | 9,774,140 | - | - | - |
| Malaria PPT (ACT) | (31) | (14) | (227) | - | (7,339) | | 0% | (7,425) | 14,991 | (204) | - | (25) |
| ASMQ for Adult | - | - | - | - | 776 | 5/16 | (100)% | 776 | 46,378 | - | - | - |
| ASMQ for Children | - | - | - | - | 175 | 10/16 | (100)% | 175 | 2,033 | - | - | - |
| (b)PSI QAACTs Distributed Provided after Diagnosis | (31) | (14) | (227) | - | (8,290) | | -% | (8,376) | (33,420) | (204) | - | (25) |
| Malaria RDK | - | - | - | - | 276,500 | | (100)% | 276,500 | 1,896,300 | - | - | - |
| Malaria RDT (Diagnosis) | - | - | - | - | 276,500 | 6/15 | (100)% | 276,500 | 1,896,300 | - | - | - |
| Medical Abortion | 15,669 | 10,912 | 243,659 | 360,280 | 307,095 | | (21)% | 334,762 | 1,989,776 | 219,293 | - | 19,200 |
| Medabon | 9,743 | 11,738 | 170,680 | 185,650 | 235,374 | 11/09 | (27)% | 240,656 | 1,830,661 | 153,612 | - | 13,449 |
| Mifeso | 7,550 | (145) | 82,438 | 174,630 | 81,815 | | 1% | 104,939 | 187,377 | 74,194 | - | 6,496 |
| (b)PSI Medical Abortion Distributed Provided | (1,624) | (682) | (9,459) | - | (10,094) | | -% | (10,833) | (28,262) | (8,513) | - | (745) |
| Medical Abortion Provided | 1,624 | 682 | 9,459 | - | 10,094 | | (6)% | 10,833 | 28,262 | 9,459 | - | 828 |
| PSI Medical Abortion Provided | 1,624 | 682 | 9,459 | - | 10,094 | | (6)% | 10,833 | 28,262 | 9,459 | - | 828 |
| OCs | 393,653 | 502,655 | 5,626,634 | 6,233,333 | 4,903,492 | | 15% | 5,456,565 | 65,817,467 | 337,598 | 337,598 | 61,868 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Marvelon | 69,653 | 101,461 | 1,085,135 | 1,006,355 | 831,300 | 12/12 | 31% | 908,657 | 3,449,347 | 65,108 | 65,108 | 11,932 |
| OK Pills | 324,900 | 401,568 | 4,545,612 | 5,226,978 | 4,075,860 | 9/97 | 12% | 4,551,732 | 62,384,792 | 272,737 | 272,737 | 49,982 |
| (b)PSI OCs Distributed Provided | (900) | (374) | (4,113) | - | (3,668) | | -% | (3,824) | (16,672) | (247) | (247) | (45) |
| OCs Provided | 900 | 374 | 4,113 | - | 3,669 | | 12% | 3,825 | 16,674 | 274 | 274 | 50 |
| Non-PSI OCs Provided | - | - | - | - | 1 | | (100)% | 1 | 2 | - | - | - |
| PSI OCs Provided | 900 | 374 | 4,113 | - | 3,668 | | 12% | 3,824 | 16,672 | 274 | 274 | 50 |
| ORS | 22,800 | 39,442 | 633,225 | - | - | | 0% | 500,000 | 1,133,225 | 284,951 | - | 5,983 |
| Orasel ORS Sachet | 22,800 | 39,442 | 633,225 | - | - | | -% | 500,000 | 1,133,225 | 284,951 | - | 5,983 |
| Positive RDTs | 31 | 17 | 355 | 1,143 | 9,752 | | (96)% | 9,841 | 36,229 | 355 | - | - |
| Positive RDTs | 31 | 17 | 355 | 1,143 | 9,752 | | (96)% | 9,841 | 36,229 | 355 | - | - |
| Positive RDTs Given First Line Treatment | 31 | 14 | 227 | 1,099 | 8,290 | | (97)% | 8,376 | 33,420 | 227 | - | - |
| Positive RDTs Given First Line Treatment | 31 | 14 | 227 | 1,099 | 8,290 | | (97)% | 8,376 | 33,420 | 227 | - | - |
| QAACTs Provided after Confirmatory Diagnosis | 31 | 14 | 228 | 1,099 | 8,314 | | (97)% | 8,400 | 33,476 | 228 | - | 33 |
| Non-PSI QAACTs Provided after Confirmed Diagnosis | - | - | 1 | 1,099 | 24 | | (96)% | 24 | 56 | 1 | - | - |
| PSI QAACTs Provided after Confirmed Diagnosis | 31 | 14 | 227 | - | 8,290 | | (97)% | 8,376 | 33,420 | 227 | - | 33 |
| Referral to Emergency Contraception | - | 1 | 2 | - | 31 | | (94)% | 31 | 109 | 2 | - | - |
| Referral to Emergency Contraception | - | 1 | 2 | - | 31 | | (94)% | 31 | 109 | 2 | - | - |
| Referral to Implant 5 Insertion | - | 52 | 426 | - | 173 | | 146% | 190 | 1,397 | 426 | 809 | 188 |
| Referral to Implant 5 Insertion | - | 52 | 426 | - | 173 | | 146% | 190 | 1,397 | 426 | 809 | 188 |
| Referral to Injectable 3 | - | 88 | 872 | - | 359 | | 143% | 396 | 2,507 | 872 | 109 | 19 |
| Referral to Injectable 3 | - | 88 | 872 | - | 359 | | 143% | 396 | 2,507 | 872 | 109 | 19 |
| Referral to IUD 10 Insertion | - | 142 | 1,031 | - | 620 | | 66% | 677 | 10,510 | 1,031 | 2,371 | 526 |
| Referral to IUD 10 Insertion | - | 142 | 1,031 | - | 620 | 12/11 | 66% | 677 | 10,510 | 1,031 | 2,371 | 526 |
| Referral to OCs | - | 78 | 898 | - | 325 | | 176% | 389 | 1,838 | 898 | 30 | 5 |
| Referral to OCs | - | 78 | 898 | - | 325 | | 176% | 389 | 1,838 | 898 | 30 | 5 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Caribbean | | | | | | | | | | | - | - |
| Cervical Cancer-HPV DNA Screening | - | 146 | 777 | - | - | | 0% | - | 777 | 777 | - | - |
| Cervical Cancer-HPV DNA Screening | - | 146 | 777 | - | - | | -% | - | 777 | 777 | - | - |
| Costa Rica | | | | | | | | | | | 11,797 | 1,924 |
| Condom | 115,160 | 137,131 | 1,572,918 | 2,062,125 | 1,798,868 | | (13)% | 1,937,134 | 20,318,981 | 11,797 | 11,797 | 1,924 |
| Combo-Pack Lub Fresa | 20 | 503 | 16,308 | 27,338 | 28,076 | 10/10 | (42)% | 29,308 | 102,139 | 122 | 122 | 20 |
| Vive | 91,002 | 76,651 | 930,498 | 243,763 | 425,931 | 12/97 | 118% | 504,093 | 6,094,006 | 6,979 | 6,979 | 1,138 |
| Vive Amor | - | 208 | 624 | 999,666 | 602,928 | 6/04 | (100)% | 602,928 | 8,043,545 | 5 | 5 | 1 |
| Vive Colors/Mas Colors | 10,167 | 27,047 | 334,170 | 487,706 | 451,635 | 5/03 | (26)% | 489,846 | 4,009,887 | 2,506 | 2,506 | 409 |
| Vive Mas Fuerte /Retardante | 5,310 | 16,098 | 140,982 | 127,286 | 125,601 | 6/04 | 12% | 133,953 | 918,570 | 1,057 | 1,057 | 172 |
| Vive Mas Natural /Sensitivo | 8,661 | 16,624 | 150,336 | 176,366 | 164,697 | 6/04 | (9)% | 177,006 | 1,150,834 | 1,128 | 1,128 | 184 |
| Lubricant | 3,673 | 2,444 | 29,903 | - | 20,331 | | 47% | 22,294 | 191,704 | - | - | - |
| Vive Lub Natural (sachet) | 400 | 483 | 7,150 | - | 5,184 | 5/11 | 38% | 5,532 | 61,664 | - | - | - |
| Vive Lub Natural (tube) | 512 | 481 | 6,511 | - | 4,758 | 5/11 | 37% | 5,433 | 29,866 | - | - | - |
| Vive Lub Sachet Fresa 5 mL | 1,700 | 767 | 7,700 | - | 3,309 | 5/12 | 133% | 3,809 | 65,888 | - | - | - |
| Vive Lub Tubo Fresa 120 mL | 1,061 | 712 | 8,542 | - | 7,080 | 1/12 | 21% | 7,520 | 34,286 | - | - | - |
| Dominican Republic | | | | | | | | | | | 100,231 | 26,220 |
| Antiretroviral Treatment (Currently Enrolled) | 767 | 925 | 7,541 | - | 233 | | 3136% | 233 | 7,774 | 628 | - | 1,049 |
| Antiretroviral Treatment (Currently Enrolled) | 767 | 925 | 7,541 | - | 233 | | 3,136% | 233 | 7,774 | 628 | - | 1,049 |
| Antiretroviral Treatment (Newly Enrolled) | 88 | 40 | 449 | - | 92 | | 388% | 92 | 541 | 449 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 88 | 40 | 449 | - | 92 | | 388% | 92 | 541 | 449 | - | - |
| Condom | 469,876 | 1,794,354 | 10,123,235 | 5,720,648 | 6,090,826 | | 66% | 7,560,134 | 52,689,813 | 75,924 | 75,924 | 19,036 |
| Pante | 448,540 | 1,791,090 | 10,031,099 | 5,433,008 | 6,085,258 | 6/14 | 65% | 7,554,566 | 52,592,109 | 75,233 | 75,233 | 18,863 |
| Vive Colors/Mas Colors | 10,032 | 1,568 | 44,688 | 244,800 | 2,784 | | 1,505% | 2,784 | 47,472 | 335 | 335 | 84 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| VIVE Mas/Sensitivo | 3,600 | 664 | 21,720 | 24,480 | 1,392 | | 1,460% | 1,392 | 23,112 | 163 | 163 | 41 |
| Vive Mas/Texturizado | 7,704 | 1,032 | 25,728 | 18,360 | 1,392 | | 1,748% | 1,392 | 27,120 | 193 | 193 | 48 |
| Free Condom | 2,000 | 476,000 | 3,233,000 | 2,511,000 | 2,130,000 | | 52% | 2,214,000 | 11,090,423 | 24,247 | 24,247 | 6,080 |
| No Logo | 2,000 | 476,000 | 3,233,000 | 2,511,000 | 2,130,000 | 6/14 | 52% | 2,214,000 | 11,090,423 | 24,247 | 24,247 | 6,080 |
| HIV Testing Services | 3,589 | 1,041 | 19,440 | 25,152 | 31,033 | | (37)% | 31,033 | 127,305 | 19,440 | - | 47 |
| VCT Individual (HIV-Negative) | 3,469 | 985 | 18,725 | 24,237 | 30,230 | 9/13 | (38)% | 30,230 | 123,939 | 18,725 | - | 45 |
| VCT Individual (HIV-Positive) | 120 | 57 | 715 | 915 | 803 | 9/13 | (11)% | 803 | 3,366 | 715 | - | 2 |
| Lubricant | - | 262,667 | 1,037,000 | 236,000 | 262,000 | | 296% | 278,000 | 2,825,992 | - | - | - |
| No Logo Lubricant (4.5 gram sachet) | - | 262,667 | 1,037,000 | 236,000 | 262,000 | 6/14 | 296% | 278,000 | 2,825,992 | - | - | - |
| Referral to Implant Insertion (duration unknown) | 7 | 2 | 20 | - | - | | 0% | - | 20 | 20 | 25 | 3 |
| Referral to Implant Insertion (duration unknown) | 7 | 2 | 20 | - | - | | -% | - | 20 | 20 | 25 | 3 |
| Referral to Injectable 1 | 12 | - | 12 | - | - | | 0% | - | 12 | 12 | - | - |
| Referral to Injectable 1 | 12 | - | 12 | - | - | | -% | - | 12 | 12 | - | - |
| Referral to Injectable 3 | - | 3 | 16 | - | - | | 0% | - | 16 | 16 | 2 | - |
| Referral to Injectable 3 | - | 3 | 16 | - | - | | -% | - | 16 | 16 | 2 | - |
| Referral to IUD Insertion (duration unknown) | 4 | 2 | 19 | - | - | | 0% | - | 19 | 19 | 31 | 4 |
| Referral to IUD Insertion (duration unknown) | 4 | 2 | 19 | - | - | | -% | - | 19 | 19 | 31 | 4 |
| Referral to Linkage to HIV Care | - | - | - | - | 371 | | (100)% | 371 | 412 | - | - | - |
| Referral to Linkage to HIV Care | - | - | - | - | 371 | | (100)% | 371 | 412 | - | - | - |
| Referral to OCs | 1 | - | 3 | - | - | | 0% | - | 3 | 3 | - | - |
| Referral to OCs | 1 | - | 3 | - | - | | -% | - | 3 | 3 | - | - |
| EI Salvador | | | | | | | | | | | 38,096 | 8,710 |
| Cervical Cancer-Pap Smear Screening | 31 | 47 | 408 | - | 92 | | 343% | 92 | 736 | 408 | - | - |
| Cervical Cancer-Pap Smear Screening | 31 | 47 | 408 | - | 92 | | 343% | 92 | 736 | 408 | - | - |
| Condom | 5 | 828,727 | 4,346,854 | 3,630,855 | 2,781,618 | | 56% | 3,210,525 | 44,548,590 | 32,601 | 32,601 | 8,223 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Combo-Mix Lub Natural | - | - | - | - | 48 | 10/10 | (100)% | 48 | 19,432 | - | - | - |
| Combo-Pack Lub Fresa | 2 | 9,403 | 28,514 | 4,682 | 4,896 | 5/12 | 482% | 4,896 | 38,738 | 214 | 214 | 54 |
| Vive | - | 209,936 | 1,110,432 | 960,267 | 661,728 | 4/98 | 68% | 739,008 | 16,315,276 | 8,328 | 8,328 | 2,101 |
| Vive Amor | - | 296,400 | 1,631,520 | 1,617,436 | 1,279,920 | 7/04 | 27% | 1,534,176 | 16,089,937 | 12,236 | 12,236 | 3,086 |
| Vive Colors/Mas Colors | - | 238,562 | 1,163,046 | 695,657 | 540,297 | 10/03 | 115% | 597,348 | 8,466,660 | 8,723 | 8,723 | 2,200 |
| Vive Mas Fuerte /Retardante | 3 | 52,880 | 280,422 | 263,210 | 175,680 | 7/04 | 60% | 206,016 | 1,834,850 | 2,103 | 2,103 | 530 |
| Vive Mas Natural /Sensitivo | - | 21,547 | 132,920 | 89,603 | 77,865 | 7/04 | 71% | 87,849 | 933,625 | 997 | 997 | 251 |
| Vive Mas/Texturizado | - | - | - | - | 41,184 | 7/04 | (100)% | 41,184 | 850,072 | - | - | - |
| HIV Testing Services | 463 | 392 | 4,378 | 2,340 | 2,723 | | 61% | 2,945 | 49,182 | 4,378 | - | 6 |
| VCT Individual (HIV-Negative) | 440 | 377 | 4,198 | 2,206 | 2,609 | 12/09 | 61% | 2,823 | 48,350 | 4,198 | - | 6 |
| VCT Individual (HIV-Positive) | 23 | 15 | 180 | 134 | 114 | 12/09 | 58% | 122 | 832 | 180 | - | - |
| Hypertension Screening | 1 | - | 4 | - | 2 | | 100% | 2 | 9 | 4 | - | - |
| Hypertension Screening | 1 | - | 4 | - | 2 | | 100% | 2 | 9 | 4 | - | - |
| Implant 5 | - | (1) | (12) | (7,072) | 28 | | (143)% | (25) | 4,351 | (11) | (41) | (4) |
| Jadelle | 20 | 16 | 110 | - | 325 | 12/08 | (66)% | 336 | 5,726 | 99 | 376 | 35 |
| (b)PSI Implant 5 Distributed Inserted | (20) | (17) | (122) | (7,072) | (297) | | -% | (361) | (1,375) | (110) | (417) | (39) |
| Implant 5 Insertion | 20 | 17 | 122 | 7,072 | 297 | | (59)% | 361 | 1,375 | 122 | 464 | 43 |
| PSI Implant 5 Inserted | 20 | 17 | 122 | 7,072 | 297 | | (59)% | 361 | 1,375 | 122 | 464 | 43 |
| Injectable 1 | - | - | (6) | - | - | | 0% | (2) | (18) | - | - | - |
| (b)PSI Injectable 1 Distributed Provided | - | - | (6) | - | - | | -% | (2) | (18) | - | - | - |
| Injectable 1 Provided | - | - | 9 | - | 17 | | (47)% | 19 | 89 | 1 | 1 | - |
| Non-PSI Injectable 1 Provided | - | - | 3 | - | 17 | | (82)% | 17 | 71 | - | - | - |
| PSI Injectable 1 Provided | - | - | 6 | - | - | | -% | 2 | 18 | - | - | - |
| IUD 10 | (12) | (22) | (140) | (255) | (688) | | 0% | (761) | (25,321) | (126) | (580) | (52) |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| (b)PSI IUD 10 Distributed Inserted | (12) | (22) | (140) | (255) | (688) | | -% | (761) | (25,321) | (126) | (580) | (52) |
| IUD 10 Insertion | 12 | 22 | 140 | 255 | 1,045 | | (87)% | 1,118 | 36,556 | 140 | 644 | 58 |
| Non-PSI IUD 10 Inserted | - | - | - | - | 357 | 11/13 | (100)% | 357 | 11,235 | - | - | - |
| PSI IUD 10 Inserted | 12 | 22 | 140 | 255 | 688 | | (80)% | 761 | 25,321 | 140 | 644 | 58 |
| Lubricant | 3 | 138,423 | 524,122 | 236,034 | 157,013 | | 234% | 175,111 | 1,951,701 | - | - | - |
| Vive Lub (sachet) | - | 61,567 | 236,000 | 116,513 | 86,650 | 12/06 | 172% | 94,900 | 1,038,390 | - | - | - |
| Vive Lub (tube) | 1 | 7,557 | 36,789 | - | 7,093 | 12/06 | 419% | 8,084 | 99,848 | - | - | - |
| Vive Lub (tube) 5ml | - | - | - | 2,464 | - | | -% | - | - | - | - | - |
| Vive Lub Natural (sachet) | - | 67,283 | 240,550 | 117,057 | 57,400 | 1/10 | 319% | 65,700 | 773,402 | - | - | - |
| Vive Lub Natural (tube) | 2 | 2,016 | 10,783 | - | 5,870 | 1/10 | 84% | 6,427 | 40,061 | - | - | - |
| Manual Vacuum Aspiration for PAC | - | - | - | - | 109 | | (100)% | 109 | 2,666 | - | - | - |
| MVA for PAC | - | - | - | - | 109 | 8/16 | (100)% | 109 | 2,666 | - | - | - |
| OCs | 10 | 19,972 | 81,995 | - | 20,461 | | 301% | 22,861 | 253,936 | 4,920 | 4,920 | 363 |
| (b)PSI OCs Distributed Provided | - | (1) | (11) | - | (8) | | -% | (17) | (37) | (1) | (1) | - |
| Segura Plus | 10 | 19,973 | 82,006 | - | 20,469 | 2/12 | 301% | 22,878 | 253,973 | 4,920 | 4,920 | 363 |
| OCs Provided | - | 1 | 11 | - | 42 | | (74)% | 51 | 77 | 1 | 1 | - |
| Non-PSI OCs Provided | - | - | - | - | 34 | | (100)% | 34 | 40 | - | - | - |
| PSI OCs Provided | - | 1 | 11 | - | 8 | | 38% | 17 | 37 | 1 | 1 | - |
| Referral to HIV Testing Services | - | 1 | 3 | - | 2 | | 50% | 2 | 472 | 3 | - | - |
| Referral to HIV Testing Services | - | 1 | 3 | - | 2 | 12/13 | 50% | 2 | 472 | 3 | - | - |
| Referral to Implant 5 Insertion | - | 4 | 24 | - | 4 | | 500% | 4 | 30 | 24 | 46 | 4 |
| Referral to Implant 5 Insertion | - | 4 | 24 | - | 4 | 12/11 | 500% | 4 | 30 | 24 | 46 | 4 |
| Referral to Injectable 1 | - | 1 | 7 | - | 5 | | 40% | 6 | 13 | 7 | - | - |
| Referral to Injectable 1 | - | 1 | 7 | - | 5 | | 40% | 6 | 13 | 7 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Referral to IUD 10 Insertion | - | 2 | 18 | - | 3 | | 500% | 4 | 18,956 | 18 | 41 | 4 |
| Referral to IUD 10 Insertion | - | 2 | 18 | - | 3 | 12/11 | 500% | 4 | 18,956 | 18 | 41 | 4 |
| Referral to Linkage to HIV Care | 12 | 12 | 131 | - | 36 | | 264% | 41 | 321 | 131 | - | 65 |
| Referral to Linkage to HIV Care | 12 | 12 | 131 | - | 36 | | 264% | 41 | 321 | 131 | - | 65 |
| Referral to OCs | - | - | 2 | - | - | | 0% | - | 2 | 2 | - | - |
| Referral to OCs | - | - | 2 | - | - | | -% | - | 2 | 2 | - | - |
| STI Screening | 17 | 42 | 242 | - | 60 | | 303% | 60 | 2,937 | 242 | - | - |
| STI Screening | 17 | 42 | 242 | - | 60 | | 303% | 60 | 2,937 | 242 | - | - |
| Treatment for Cervicitis | 3 | 13 | 89 | - | 28 | | 218% | 28 | 132 | 89 | - | - |
| Treatment for Cervicitis | 3 | 13 | 89 | - | 28 | | 218% | 28 | 132 | 89 | - | - |
| Treatment for Genital Herpes | - | - | 1 | - | - | | 0% | - | 9 | 1 | - | - |
| Treatment for Genital Herpes | - | - | 1 | - | - | | -% | - | 9 | 1 | - | - |
| Treatment for Lower Abdominal Pain | - | 2 | 7 | - | - | | 0% | - | 7 | 7 | - | - |
| Treatment for Lower Abdominal Pain | - | 2 | 7 | - | - | | -% | - | 7 | 7 | - | - |
| Treatment for Nonherpetic Genital Ulcer | - | 1 | 2 | - | - | | 0% | - | 4 | 2 | - | - |
| Treatment for Nonherpetic Genital Ulcer | - | 1 | 2 | - | - | | -% | - | 4 | 2 | - | - |
| Treatment for Urethral Discharge (Women) | - | - | 1 | - | 1 | | 0% | 1 | 9 | 1 | - | - |
| Treatment for Urethral Discharge (Women) | - | - | 1 | - | 1 | | -% | 1 | 9 | 1 | - | - |
| Treatment for Vaginitis | 14 | 27 | 199 | - | 25 | | 696% | 25 | 227 | 199 | - | - |
| Treatment for Vaginitis | 14 | 27 | 199 | - | 25 | | 696% | 25 | 227 | 199 | - | - |
| Type 2 Diabetes Diagnosis | - | - | 1 | - | 1 | | 0% | 1 | 2 | 1 | - | - |
| Type 2 Diabetes Diagnosis | - | - | 1 | - | 1 | | -% | 1 | 2 | 1 | - | - |
| Type 2 Diabetes Screening | - | - | 3 | - | 1 | | 200% | 1 | 6 | 3 | - | - |
| Type 2 Diabetes Screening | - | - | 3 | - | 1 | | 200% | 1 | 6 | 3 | - | - |
| Type 2 Diabetes_Controlled Condition | - | - | 2 | - | - | | 0% | - | 2 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Type 2 Diabetes_Controlled Condition | - | - | 2 | - | - | | -% | - | 2 | - | - | - |
| Zika Prevention Kit | - | - | - | - | 714 | | (100)% | 725 | 2,621 | - | - | - |
| Zika Prevention Kit | - | - | - | - | 714 | 7/16 | (100)% | 725 | 2,621 | - | - | - |
| EI Salvador SA | | | | | | | | | | | 45,510 | 5,560 |
| Condom | 441,712 | 230,712 | 1,141,480 | - | 27,600 | | 4036% | 30,048 | 1,171,528 | 8,561 | 8,561 | 2,159 |
| Combo-Pack Lub Fresa | 16 | - | 16 | - | - | | -% | - | 16 | - | - | - |
| Vive | 123,792 | 60,384 | 304,944 | - | - | | -% | - | 304,944 | 2,287 | 2,287 | 577 |
| Vive Amor | 229,056 | 102,432 | 543,984 | - | 27,600 | 10/17 | 1,871% | 30,048 | 574,032 | 4,080 | 4,080 | 1,029 |
| Vive Colors/Mas Colors | 65,592 | 43,224 | 195,264 | - | - | | -% | - | 195,264 | 1,464 | 1,464 | 369 |
| Vive Mas Fuerte /Retardante | 15,648 | 16,464 | 65,040 | - | - | | -% | - | 65,040 | 488 | 488 | 123 |
| Vive Mas Natural /Sensitivo | 7,608 | 8,208 | 32,232 | - | - | | -% | - | 32,232 | 242 | 242 | 61 |
| Implant 3 Insertion | 61 | 52 | 487 | - | - | | 0% | - | 487 | 487 | 1,218 | 116 |
| Non-PSI Implant 3 Inserted | 61 | 52 | 487 | - | - | | -% | - | 487 | 487 | 1,218 | 116 |
| Implant 5 | 413 | 184 | 3,526 | 574 | 790 | | 346% | 911 | 4,437 | 3,173 | 12,059 | 1,130 |
| Jadelle | 420 | 193 | 3,609 | 1,032 | 845 | 10/17 | 327% | 976 | 4,585 | 3,248 | 12,343 | 1,156 |
| (b)PSI Implant 5 Distributed Inserted | (7) | (9) | (83) | (458) | (55) | | -% | (65) | (148) | (75) | (284) | (27) |
| Implant 5 Insertion | 7 | 9 | 83 | 458 | 59 | | 41% | 69 | 152 | 83 | 315 | 30 |
| Non-PSI Implant 5 Inserted | - | - | - | - | 4 | | (100)% | 4 | 4 | - | - | - |
| PSI Implant 5 Inserted | 7 | 9 | 83 | 458 | 55 | | 51% | 65 | 148 | 83 | 315 | 30 |
| Injectable 1 Provided | 1 | 4 | 48 | - | 3 | | 1500% | 4 | 52 | 4 | 4 | - |
| Non-PSI Injectable 1 Provided | 1 | 4 | 48 | - | 3 | | 1,500% | 4 | 52 | 4 | 4 | - |
| IUD 10 | 125 | 204 | 2,008 | 150 | 2,325 | | (14)% | 2,576 | 4,584 | 1,807 | 8,313 | 746 |
| Copper T 380 | 242 | 347 | 3,606 | 3,660 | 3,671 | 10/17 | (2)% | 4,021 | 7,627 | 3,245 | 14,929 | 1,339 |
| (b)PSI IUD 10 Distributed Inserted | (117) | (143) | (1,598) | (3,510) | (1,346) | | -% | (1,445) | (3,043) | (1,438) | (6,616) | (593) |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| IUD 10 Insertion | 234 | 312 | 3,143 | 3,510 | 2,730 | | 15% | 2,956 | 6,099 | 3,143 | 14,458 | 1,297 |
| Non-PSI IUD 10 Inserted | 117 | 169 | 1,545 | - | 1,384 | | 12% | 1,511 | 3,056 | 1,545 | 7,107 | 638 |
| PSI IUD 10 Inserted | 117 | 143 | 1,598 | 3,510 | 1,346 | | 19% | 1,445 | 3,043 | 1,598 | 7,351 | 659 |
| Lubricant | 14,438 | 8,119 | 38,796 | - | 12 | | 323200% | 12 | 38,808 | - | - | - |
| Vive Lub (sachet) | 10,750 | 4,967 | 25,650 | - | - | | -% | - | 25,650 | - | - | - |
| Vive Lub (tube) | 3,163 | 2,615 | 11,007 | - | - | | -% | - | 11,007 | - | - | - |
| Vive Lub Natural (tube) | 525 | 538 | 2,139 | - | 12 | 10/17 | 17,725% | 12 | 2,151 | - | - | - |
| Manual Vacuum Aspiration for PAC | 40 | 29 | 472 | 1,800 | 873 | | (46)% | 965 | 1,437 | 472 | - | 8 |
| MVA for PAC | 40 | 29 | 472 | 1,800 | 873 | | (46)% | 965 | 1,437 | 472 | - | 8 |
| Medical Abortion | - | - | - | - | - | | 0% | (3) | (3) | - | - | - |
| (b)PSI Medical Abortion Distributed Provided | - | - | - | - | - | | -% | (3) | (3) | - | - | - |
| Medical Abortion Provided | - | - | - | - | - | | 0% | 8 | 8 | - | - | - |
| Non-PSI Medical Abortion Provided | - | - | - | - | - | | -% | 5 | 5 | - | - | - |
| PSI Medical Abortion Provided | - | - | - | - | - | | -% | 3 | 3 | - | - | - |
| Misoprostol for PAC Provided | 3 | 11 | 271 | 360 | 291 | | (7)% | 291 | 562 | 271 | - | 5 |
| Non-PSI Misoprostol for PAC Provided | - | 9 | 235 | - | 250 | | (6)% | 250 | 485 | 235 | - | 4 |
| PSI Misoprostol for PAC Provided | 3 | 2 | 36 | 360 | 41 | | (12)% | 41 | 77 | 36 | - | 1 |
| Misoprostol for Safe Abortion | 504 | 4,375 | 28,656 | 23,552 | 5,288 | | 442% | 5,928 | 34,584 | 1,504 | - | 26 |
| Misoprostol for Safe Abortion | 516 | 4,384 | 28,800 | 24,992 | 5,452 | 3/18 | 428% | 6,092 | 34,892 | 1,512 | - | 26 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (12) | (9) | (144) | (1,440) | (164) | | -% | (164) | (308) | (8) | - | - |
| OCs | 60 | 3,149 | 9,506 | - | 100 | | 9406% | 100 | 9,606 | 570 | 570 | 42 |
| Segura Plus | 60 | 3,149 | 9,506 | - | 100 | 10/17 | 9,406% | 100 | 9,606 | 570 | 570 | 42 |
| OCs Provided | 1 | 3 | 29 | - | - | | 0% | - | 29 | 2 | 2 | - |
| Non-PSI OCs Provided | 1 | 3 | 29 | - | - | | -% | - | 29 | 2 | 2 | - |
| Tubal Ligation | - | - | 1 | - | 1 | | 0% | 1 | 2 | 1 | 10 | 1 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Tubal Ligation | - | - | 1 | - | 1 | | -% | 1 | 2 | 1 | 10 | 1 |
| Guatemala | | | | | | | | | | | 49,707 | 14,264 |
| Condom | - | 496 | 6,050,778 | 12,678,434 | 9,981,072 | | (39)% | 11,280,624 | 150,841,319 | 45,381 | 45,381 | 13,488 |
| Combo Pack | - | 496 | 15,024 | 33,486 | 26,112 | 4/05 | (42)% | 28,752 | 462,280 | 113 | 113 | 33 |
| Vive | - | - | 2,082,912 | 4,031,144 | 3,403,680 | 4/98 | (39)% | 3,743,136 | 59,787,789 | 15,622 | 15,622 | 4,643 |
| Vive Amor | - | - | 3,237,840 | 7,075,590 | 5,487,648 | 7/04 | (41)% | 6,293,856 | 70,365,759 | 24,284 | 24,284 | 7,218 |
| Vive Colors/Mas Colors | - | - | 409,146 | 938,160 | 645,864 | 4/02 | (37)% | 725,880 | 14,714,920 | 3,069 | 3,069 | 912 |
| Vive Mas Fuerte /Retardante | - | - | 226,608 | 495,025 | 333,744 | 7/04 | (32)% | 393,648 | 3,388,784 | 1,700 | 1,700 | 505 |
| Vive Mas Natural /Sensitivo | - | - | 67,224 | 105,029 | 78,264 | 7/04 | (14)% | 86,712 | 1,150,093 | 504 | 504 | 150 |
| Vive Mas/Texturizado | - | - | 12,024 | - | 5,760 | 7/04 | 109% | 8,640 | 971,694 | 90 | 90 | 27 |
| Emergency Contraception | - | - | - | - | (1) | | 0% | (1) | (1) | - | - | - |
| (b)PSI Emergency Contraception Distributed Provided | - | - | - | - | (1) | | -% | (1) | (1) | - | - | - |
| Emergency Contraception Provided | - | - | - | - | 1 | | (100)% | 1 | 1 | - | - | - |
| PSI Emergency Contraception Provided | - | - | - | - | 1 | | (100)% | 1 | 1 | - | - | - |
| HIV Testing Services | 165 | 204 | 2,622 | 2,912 | 2,513 | | 4% | 2,755 | 54,520 | 2,622 | - | 7 |
| VCT Individual (HIV-Negative) | 162 | 194 | 2,534 | 2,749 | 2,411 | 12/09 | 5% | 2,647 | 53,645 | 2,534 | - | 6 |
| VCT Individual (HIV-Positive) | 3 | 10 | 88 | 163 | 102 | 12/09 | (14)% | 108 | 875 | 88 | - | - |
| Implant 5 | - | - | - | - | (867) | | 0% | (867) | (14,210) | - | - | - |
| (b)PSI Implant 5 Distributed Inserted | - | - | - | - | (867) | | -% | (867) | (14,210) | - | - | - |
| Implant 5 Insertion | - | - | - | - | 2,308 | | (100)% | 2,308 | 34,014 | - | - | - |
| Non-PSI Implant 5 Inserted | - | - | - | - | 1,441 | | (100)% | 1,441 | 19,804 | - | - | - |
| PSI Implant 5 Inserted | - | - | - | - | 867 | | (100)% | 867 | 14,210 | - | - | - |
| Injectable 1 | - | - | 23,566 | 40,420 | 26,100 | | (10)% | 29,950 | 281,246 | 1,631 | 1,631 | 273 |
| Cyclofem | - | - | 23,566 | 40,420 | 27,111 | 5/11 | (13)% | 30,961 | 288,460 | 1,631 | 1,631 | 273 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| (b)PSI Injectable 1 Distributed Provided | - | - | - | - | (1,011) | | -% | (1,011) | (7,214) | - | - | - |
| Injectable 1 Provided | - | - | - | - | 14,790 | | (100)% | 14,790 | 62,320 | - | - | - |
| Non-PSI Injectable 1 Provided | - | - | - | - | 13,779 | | (100)% | 13,779 | 55,106 | - | - | - |
| PSI Injectable 1 Provided | - | - | - | - | 1,011 | | (100)% | 1,011 | 7,214 | - | - | - |
| Injectable 2 Provided | - | - | - | - | 13,271 | | (100)% | 13,271 | 34,974 | - | - | - |
| Non-PSI Injectable 2 Provided | - | - | - | - | 13,271 | | (100)% | 13,271 | 34,974 | - | - | - |
| Injectable 3-IM Provided | - | - | - | - | 130,743 | | (100)% | 130,743 | 266,096 | - | - | - |
| Non-PSI Injectable 3 IM Provided | - | - | - | - | 130,743 | | (100)% | 130,743 | 266,096 | - | - | - |
| IUD 10 | - | - | - | - | (2,251) | | 0% | (2,251) | (88,649) | - | - | - |
| (b)PSI IUD 10 Distributed Inserted | - | - | - | - | (2,251) | | -% | (2,251) | (88,649) | - | - | - |
| IUD 10 Insertion | - | - | - | - | 2,939 | | (100)% | 2,939 | 111,458 | - | - | - |
| Non-PSI IUD 10 Inserted | - | - | - | - | 688 | | (100)% | 688 | 22,809 | - | - | - |
| PSI IUD 10 Inserted | - | - | - | - | 2,251 | | (100)% | 2,251 | 88,649 | - | - | - |
| Lubricant | - | - | 107,862 | - | 108,808 | | (1)% | 115,766 | 1,658,856 | - | - | - |
| Vive Lub (sachet) | - | - | 52,210 | - | 52,853 | 4/05 | (1)% | 54,903 | 1,051,851 | - | - | - |
| Vive Lub (tube) | - | - | 15,309 | - | 13,489 | 4/05 | 13% | 14,996 | 163,075 | - | - | - |
| Vive Lub Natural (sachet) | - | - | 23,900 | - | 27,400 | 1/10 | (13)% | 29,200 | 325,677 | - | - | - |
| Vive Lub Natural (tube) | - | - | 16,443 | - | 15,066 | 1/10 | 9% | 16,667 | 118,253 | - | - | - |
| Manual Vacuum Aspiration for PAC | - | - | - | - | 1,431 | | (100)% | 1,431 | 9,176 | - | - | - |
| MVA for PAC | - | - | - | - | 1,431 | 5/16 | (100)% | 1,431 | 9,176 | - | - | - |
| Misoprostol for PAC Provided | - | - | - | - | 2,281 | | (100)% | 2,281 | 5,883 | - | - | - |
| Non-PSI Misoprostol for PAC Provided | - | - | - | - | 1,452 | | (100)% | 1,452 | 3,049 | - | - | - |
| PSI Misoprostol for PAC Provided | - | - | - | - | 829 | | (100)% | 829 | 2,834 | - | - | - |
| Misoprostol for Safe Abortion | - | - | - | - | (3,316) | | 0% | (3,316) | (11,336) | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| (b)PSI Misoprostol for Safe Abortion Dist Provided | - | - | - | - | (3,316) | | -% | (3,316) | (11,336) | - | - | - |
| OCs | - | - | 40,983 | 89,184 | 54,647 | | (25)% | 63,764 | 230,644 | 2,459 | 2,459 | 400 |
| (b)PSI OCs Distributed Provided | - | - | - | - | (699) | | -% | (699) | (4,667) | - | - | - |
| Segura Plus | - | - | 40,983 | 89,184 | 55,346 | 5/14 | (26)% | 64,463 | 235,311 | 2,459 | 2,459 | 400 |
| OCs Provided | - | - | - | - | 31,295 | | (100)% | 31,295 | 85,031 | - | - | - |
| Non-PSI OCs Provided | - | - | - | - | 30,596 | | (100)% | 30,596 | 80,364 | - | - | - |
| PSI OCs Provided | - | - | - | - | 699 | | (100)% | 699 | 4,667 | - | - | - |
| Referral to Implant 5 Insertion | 2 | 3 | 45 | - | 20 | | 125% | 27 | 95 | 45 | 85 | 18 |
| Referral to Implant 5 Insertion | 2 | 3 | 45 | - | 20 | 12/11 | 125% | 27 | 95 | 45 | 85 | 18 |
| Referral to Injectable 1 | 1 | - | 6 | - | 4 | | 50% | 5 | 11 | 6 | - | - |
| Referral to Injectable 1 | 1 | - | 6 | - | 4 | | 50% | 5 | 11 | 6 | - | - |
| Referral to IUD 10 Insertion | 3 | 8 | 63 | - | 37 | | 70% | 48 | 29,890 | 63 | 145 | 29 |
| Referral to IUD 10 Insertion | 3 | 8 | 63 | - | 37 | 12/11 | 70% | 48 | 29,890 | 63 | 145 | 29 |
| Referral to Linkage to HIV Care | 6 | 7 | 69 | - | 52 | | 33% | 55 | 290 | 69 | - | 48 |
| Referral to Linkage to HIV Care | 6 | 7 | 69 | - | 52 | | 33% | 55 | 290 | 69 | - | 48 |
| Referral to OCs | - | - | - | - | 1 | | (100)% | 2 | 2 | - | - | - |
| Referral to OCs | - | - | - | - | 1 | | (100)% | 2 | 2 | - | - | - |
| Referral to Vasectomy | - | - | 1 | - | - | | 0% | - | 1 | 1 | 5 | 1 |
| Referral to Vasectomy | - | - | 1 | - | - | | -% | - | 1 | 1 | 5 | 1 |
| SDM (Cycle Beads) Provided | - | - | - | - | 1 | | (100)% | 1 | 116 | - | - | - |
| Non-PSI SDM (Cycle Beads) Provided | - | - | - | - | 1 | | (100)% | 1 | 116 | - | - | - |
| Tubal Ligation | - | - | - | - | 1,807 | | (100)% | 1,807 | 17,292 | - | - | - |
| Tubal Ligation | - | - | - | - | 1,807 | 7/12 | (100)% | 1,807 | 17,292 | - | - | - |
| Vasectomy | - | - | - | - | 77 | | (100)% | 77 | 660 | - | - | - |
| Vasectomy | - | - | - | - | 77 | 7/12 | (100)% | 77 | 660 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Guatemala SA | | | | | | | | | | | 310,311 | 65,431 |
| Condom | 1,535,632 | 683,067 | 3,635,952 | - | 93,312 | | 3797% | 95,328 | 3,731,280 | 27,270 | 27,270 | 8,105 |
| Combo Pack | 2,560 | 2,827 | 11,040 | - | - | | -% | - | 11,040 | 83 | 83 | 25 |
| Vive | 536,256 | 245,440 | 1,272,576 | - | 50,832 | 7/17 | 2,403% | 50,832 | 1,323,408 | 9,544 | 9,544 | 2,837 |
| Vive Amor | 829,392 | 320,672 | 1,842,528 | - | 42,480 | 7/17 | 4,237% | 44,496 | 1,887,024 | 13,819 | 13,819 | 4,107 |
| Vive Colors/Mas Colors | 103,584 | 69,384 | 311,736 | - | - | | -% | - | 311,736 | 2,338 | 2,338 | 695 |
| Vive Mas Fuerte /Retardante | 58,800 | 25,120 | 134,160 | - | - | | -% | - | 134,160 | 1,006 | 1,006 | 299 |
| Vive Mas Natural /Sensitivo | 5,040 | 19,624 | 63,912 | - | - | | -% | - | 63,912 | 479 | 479 | 142 |
| Emergency Contraception | - | - | - | - | (4) | | 0% | (4) | (4) | - | - | - |
| (b)PSI Emergency Contraception Distributed Provided | - | - | - | - | (4) | | -% | (4) | (4) | - | - | - |
| Emergency Contraception Provided | 2 | 1 | 22 | - | 6 | | 267% | 6 | 28 | 1 | 1 | - |
| Non-PSI Emergency Contraception Provided | 2 | 1 | 22 | - | 2 | | 1,000% | 2 | 24 | 1 | 1 | - |
| PSI Emergency Contraception Provided | - | - | - | - | 4 | | (100)% | 4 | 4 | - | - | - |
| Implant 5 | (46) | 40 | (2,579) | 1,152 | 1,586 | | (263)% | 1,602 | (977) | (2,321) | (8,820) | (1,820) |
| Jadelle | 55 | 170 | 576 | 3,365 | 3,634 | 7/17 | (84)% | 3,672 | 4,248 | 518 | 1,970 | 406 |
| (b)PSI Implant 5 Distributed Inserted | (101) | (130) | (3,155) | (2,213) | (2,048) | | -% | (2,070) | (5,225) | (2,840) | (10,790) | (2,227) |
| Implant 5 Insertion | 939 | 1,465 | 16,944 | 2,213 | 15,625 | | 8% | 15,706 | 32,650 | 16,944 | 64,387 | 13,286 |
| Non-PSI Implant 5 Inserted | 838 | 1,335 | 13,789 | - | 13,577 | | 2% | 13,636 | 27,425 | 13,789 | 52,398 | 10,812 |
| PSI Implant 5 Inserted | 101 | 130 | 3,155 | 2,213 | 2,048 | | 54% | 2,070 | 5,225 | 3,155 | 11,989 | 2,474 |
| Injectable 1 | 5,356 | 4,568 | 17,420 | - | 563 | | 2994% | 417 | 17,837 | 1,206 | 1,206 | 202 |
| Cyclofem | 5,414 | 4,652 | 19,883 | - | 2,072 | 7/17 | 860% | 2,127 | 22,010 | 1,377 | 1,377 | 230 |
| (b)PSI Injectable 1 Distributed Provided | (58) | (84) | (2,463) | - | (1,509) | | -% | (1,710) | (4,173) | (171) | (171) | (29) |
| Injectable 1 Provided | 8,439 | 5,321 | 58,109 | - | 50,443 | | 15% | 50,852 | 108,961 | 4,470 | 4,470 | 747 |
| Non-PSI Injectable 1 Provided | 8,381 | 5,236 | 55,646 | - | 48,934 | | 14% | 49,142 | 104,788 | 4,280 | 4,280 | 716 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| PSI Injectable 1 Provided | 58 | 84 | 2,463 | - | 1,509 | | 63% | 1,710 | 4,173 | 189 | 189 | 32 |
| Injectable 2 Provided | 4,755 | 2,196 | 34,871 | - | 34,337 | | 2% | 34,427 | 69,298 | 5,812 | 5,812 | 897 |
| Non-PSI Injectable 2 Provided | 4,755 | 2,196 | 34,871 | - | 34,337 | | 2% | 34,427 | 69,298 | 5,812 | 5,812 | 897 |
| Injectable 3-IM | - | (14) | (41) | - | - | | 0% | - | (41) | (9) | (9) | (1) |
| (b)PSI Injectable 3 IM Distributed Provided | - | (14) | (41) | - | - | | -% | - | (41) | (9) | (9) | (1) |
| Injectable 3-IM Provided | 24,520 | 18,631 | 206,487 | - | 224,154 | | (8)% | 224,719 | 431,206 | 51,622 | 51,622 | 7,966 |
| Non-PSI Injectable 3 IM Provided | 24,520 | 18,617 | 206,446 | - | 224,154 | | (8)% | 224,719 | 431,165 | 51,612 | 51,612 | 7,965 |
| PSI Injectable 3 IM Provided | - | 14 | 41 | - | - | | -% | - | 41 | 10 | 10 | 2 |
| IUD 10 | (219) | (470) | (2,409) | (778) | 4,129 | | (158)% | 4,388 | 1,979 | (2,168) | (9,973) | (1,968) |
| Copper T 380 | 131 | 248 | 3,948 | 7,000 | 10,822 | 7/17 | (64)% | 11,187 | 15,135 | 3,553 | 16,345 | 3,225 |
| Copper T 380 Postpartum | - | 7 | 2,066 | - | 1,064 | 7/17 | 94% | 1,084 | 3,150 | 1,859 | 8,553 | 1,688 |
| (b)PSI IUD 10 Distributed Inserted | (350) | (725) | (8,423) | (7,778) | (7,757) | | -% | (7,883) | (16,306) | (7,581) | (34,871) | (6,881) |
| IUD 10 Insertion | 3,505 | 1,126 | 16,125 | 9,133 | 11,665 | | 38% | 11,810 | 27,935 | 16,125 | 74,175 | 14,638 |
| Non-PSI IUD 10 Inserted | 3,155 | 400 | 7,702 | 1,355 | 3,908 | | 97% | 3,927 | 11,629 | 7,702 | 35,429 | 6,992 |
| PSI IUD 10 Inserted | 350 | 725 | 8,423 | 7,778 | 7,757 | | 9% | 7,883 | 16,306 | 8,423 | 38,746 | 7,646 |
| IUD 5 | 5 | - | 6 | - | 1,002 | | (99)% | 1,002 | 1,008 | 5 | 18 | 4 |
| IUD Sleek | 5 | - | 6 | - | 1,002 | 7/17 | (99)% | 1,002 | 1,008 | 5 | 18 | 4 |
| Lubricant | 20,306 | 18,526 | 76,124 | - | 115 | | 66095% | 136 | 76,260 | - | - | - |
| Vive Lub (sachet) | 9,900 | 13,583 | 50,650 | - | - | | -% | - | 50,650 | - | - | - |
| Vive Lub (tube) | 4,894 | 3,070 | 14,205 | - | 63 | 7/17 | 22,448% | 74 | 14,279 | - | - | - |
| Vive Lub Natural (tube) | 5,512 | 1,873 | 11,269 | - | 52 | 7/17 | 21,571% | 62 | 11,331 | - | - | - |
| Manual Vacuum Aspiration for PAC | 92 | 1,064 | 7,878 | 4,675 | - | | 0% | 4,901 | 12,779 | 7,878 | - | 212 |
| MVA for PAC | 92 | 1,064 | 7,878 | 4,675 | - | | -% | 4,901 | 12,779 | 7,878 | - | 212 |
| Misoprostol for PAC Provided | 9 | 554 | 5,536 | 3,275 | - | | 0% | 4,088 | 9,624 | 5,536 | - | 183 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Non-PSI Misoprostol for PAC Provided | - | 125 | 1,061 | - | - | | -% | 2,240 | 3,301 | 1,061 | - | 35 |
| PSI Misoprostol for PAC Provided | 9 | 429 | 4,475 | 3,275 | - | | -% | 1,848 | 6,323 | 4,475 | - | 148 |
| Misoprostol for Safe Abortion | (36) | (153) | 48,678 | 59,100 | 63,760 | | (24)% | 56,728 | 105,406 | 2,556 | - | 74 |
| Misoprostol for Safe Abortion | - | 1,563 | 66,578 | 72,200 | 63,760 | 3/18 | 4% | 64,120 | 130,698 | 3,495 | - | 102 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (36) | (1,716) | (17,900) | (13,100) | - | | -% | (7,392) | (25,292) | (940) | - | (27) |
| OCs | 186,771 | 7,539 | 209,234 | - | (981) | | 0% | (1,020) | 208,214 | 12,554 | 12,554 | 2,044 |
| (b)PSI OCs Distributed Provided | (69) | (67) | (1,378) | - | (2,276) | | -% | (2,320) | (3,698) | (83) | (83) | (13) |
| Segura Plus | 186,840 | 7,607 | 210,612 | - | 1,295 | 7/17 | 16,163% | 1,300 | 211,912 | 12,637 | 12,637 | 2,057 |
| OCs Provided | 3,680 | 1,770 | 27,197 | - | 40,771 | | (33)% | 40,905 | 68,102 | 1,813 | 1,813 | 295 |
| Non-PSI OCs Provided | 3,611 | 1,703 | 25,819 | - | 38,495 | | (33)% | 38,585 | 64,404 | 1,721 | 1,721 | 280 |
| PSI OCs Provided | 69 | 67 | 1,378 | - | 2,276 | | (39)% | 2,320 | 3,698 | 92 | 92 | 15 |
| SDM (Cycle Beads) Provided | - | - | 4 | - | 6 | | (33)% | 6 | 10 | 4 | 6 | 1 |
| Non-PSI SDM (Cycle Beads) Provided | - | - | 4 | - | 6 | | (33)% | 6 | 10 | 4 | 6 | 1 |
| Tubal Ligation | 667 | 1,067 | 8,288 | - | 9,981 | | (17)% | 9,992 | 18,280 | 8,288 | 82,880 | 19,863 |
| Tubal Ligation | 667 | 1,067 | 8,288 | - | 9,981 | | (17)% | 9,992 | 18,280 | 8,288 | 82,880 | 19,863 |
| Vasectomy | 1 | 33 | 290 | - | 241 | | 20% | 241 | 531 | 290 | 2,900 | 704 |
| Vasectomy | 1 | 33 | 290 | - | 241 | | 20% | 241 | 531 | 290 | 2,900 | 704 |
| Honduras | | | | | | | | | | | 19,848 | 9,260 |
| Condom | - | 240 | 1,895,352 | 4,436,599 | 4,085,968 | | (54)% | 4,116,704 | 52,240,120 | 14,215 | 14,215 | 8,450 |
| Combo-Pack Lub Fresa | - | - | 4,096 | 5,355 | 6,672 | 2/16 | (39)% | 6,880 | 20,144 | 31 | 31 | 18 |
| Combo-Pack Lub Natural | - | - | (736) | - | 688 | 10/10 | (207)% | 688 | 26,912 | (6) | (6) | (3) |
| Vive | - | 240 | 394,464 | 1,082,225 | 1,086,432 | 9/00 | (64)% | 1,088,832 | 15,815,395 | 2,958 | 2,958 | 1,759 |
| Vive Amor | - | - | 1,075,104 | 2,593,241 | 2,337,072 | 8/04 | (54)% | 2,348,928 | 25,213,976 | 8,063 | 8,063 | 4,793 |
| Vive Colors/Mas Colors | - | - | 308,880 | 560,470 | 441,408 | 4/02 | (30)% | 455,400 | 8,922,718 | 2,317 | 2,317 | 1,377 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Vive Mas Fuerte /Retardante | - | - | 89,136 | 154,949 | 144,528 | 8/04 | (38)% | 145,680 | 1,210,392 | 669 | 669 | 397 |
| Vive Mas Natural /Sensitivo | - | - | 23,688 | 40,359 | 44,040 | 8/04 | (46)% | 45,096 | 513,506 | 178 | 178 | 106 |
| Vive Mas/Texturizado | - | - | 720 | - | 25,128 | 8/04 | (97)% | 25,200 | 517,077 | 5 | 5 | 3 |
| HIV Testing Services | 368 | 319 | 3,326 | 2,407 | 3,092 | | 8% | 3,254 | 18,443 | 3,326 | - | 8 |
| VCT Individual (HIV-Negative) | 349 | 304 | 3,141 | 2,271 | 3,000 | 4/12 | 5% | 3,156 | 17,984 | 3,141 | - | 7 |
| VCT Individual (HIV-Positive) | 19 | 15 | 185 | 136 | 92 | 4/14 | 101% | 98 | 459 | 185 | - | - |
| Implant 3 Insertion | 4 | 6 | 52 | - | 1,432 | | (96)% | 22 | 113 | 52 | 130 | 18 |
| Non-PSI Implant 3 Inserted | 4 | 6 | 52 | - | 1,432 | | (96)% | 22 | 113 | 52 | 130 | 18 |
| Injectable 1 | - | - | - | 3,268 | - | | 0% | - | - | - | - | - |
| Cyclofem | - | - | - | 3,268 | - | | -% | - | - | - | - | - |
| Injectable 1 Provided | - | 2 | 12 | - | 7 | | 71% | 9 | 70 | 1 | 1 | - |
| Non-PSI Injectable 1 Provided | - | 2 | 12 | - | 7 | | 71% | 9 | 70 | 1 | 1 | - |
| Injectable 3-IM Provided | 1 | 3 | 25 | - | 19 | | 32% | 21 | 103 | 6 | 6 | 1 |
| Non-PSI Injectable 3 IM Provided | 1 | 3 | 25 | - | 19 | | 32% | 21 | 103 | 6 | 6 | 1 |
| IUD 10 | - | - | (91) | - | (544) | | 0% | (570) | (664) | (82) | (377) | (48) |
| (b)PSI IUD 10 Distributed Inserted | - | - | (91) | - | (544) | | -% | (570) | (664) | (82) | (377) | (48) |
| IUD 10 Insertion | 19 | 10 | 256 | - | 949 | | (73)% | 977 | 1,264 | 256 | 1,178 | 149 |
| Non-PSI IUD 10 Inserted | 19 | 10 | 165 | - | 405 | | (59)% | 407 | 600 | 165 | 759 | 96 |
| PSI IUD 10 Inserted | - | - | 91 | - | 544 | | (83)% | 570 | 664 | 91 | 419 | 53 |
| Lubricant | - | - | 53,401 | 111,654 | 108,198 | | (51)% | 113,476 | 960,148 | - | - | - |
| Vive Lub (sachet) | - | - | 22,600 | 64,092 | 49,652 | 3/05 | (54)% | 49,802 | 602,279 | - | - | - |
| Vive Lub (tube) | - | - | 11,675 | - | 13,992 | 3/05 | (17)% | 14,051 | 106,475 | - | - | - |
| Vive Lub (tube) 5ml | - | - | - | 2,777 | - | | -% | - | - | - | - | - |
| Vive Lub Natural (sachet) | - | - | 12,676 | 44,785 | 32,782 | 1/10 | (61)% | 37,832 | 187,224 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Vive Lub Natural (tube) | - | - | 6,450 | - | 11,772 | 1/10 | (45)% | 11,791 | 64,170 | - | - | - |
| OCs Provided | - | - | - | - | 2 | | (100)% | 2 | 15 | - | - | - |
| Non-PSI OCs Provided | - | - | - | - | 2 | | (100)% | 2 | 15 | - | - | - |
| Referral to Implant 3 Insertion | 203 | 176 | 1,945 | - | - | | 0% | 1,455 | 3,400 | 1,945 | 2,431 | 329 |
| Referral to Implant 3 Insertion | 203 | 176 | 1,945 | - | - | | -% | 1,455 | 3,400 | 1,945 | 2,431 | 329 |
| Referral to Injectable 3 | - | - | 2 | - | - | | 0% | - | 2 | 2 | - | - |
| Referral to Injectable 3 | - | - | 2 | - | - | | -% | - | 2 | 2 | - | - |
| Referral to IUD 10 Insertion | 206 | 70 | 984 | - | - | | 0% | - | 984 | 984 | 2,263 | 286 |
| Referral to IUD 10 Insertion | 206 | 70 | 984 | - | - | | -% | - | 984 | 984 | 2,263 | 286 |
| Referral to Linkage to HIV Care | 12 | 12 | 108 | - | 70 | | 54% | 75 | 279 | 108 | - | 68 |
| Referral to Linkage to HIV Care | 12 | 12 | 108 | - | 70 | | 54% | 75 | 279 | 108 | - | 68 |
| Honduras SA | | | | | | | | | | | 13,203 | 7,848 |
| Condom | 618,080 | 380,768 | 1,760,384 | - | - | | 0% | - | 1,760,384 | 13,203 | 13,203 | 7,848 |
| Combo-Pack Lub Fresa | 1,760 | 448 | 3,104 | - | - | | -% | - | 3,104 | 23 | 23 | 14 |
| Vive | 158,928 | 99,024 | 456,000 | - | - | | -% | - | 456,000 | 3,420 | 3,420 | 2,033 |
| Vive Amor | 346,320 | 212,448 | 983,664 | - | - | | -% | - | 983,664 | 7,377 | 7,377 | 4,385 |
| Vive Colors/Mas Colors | 79,920 | 49,024 | 226,992 | - | - | | -% | - | 226,992 | 1,702 | 1,702 | 1,012 |
| Vive Mas Fuerte /Retardante | 29,616 | 15,992 | 77,592 | - | - | | -% | - | 77,592 | 582 | 582 | 346 |
| Vive Mas Natural /Sensitivo | 1,440 | 3,864 | 13,032 | - | - | | -% | - | 13,032 | 98 | 98 | 58 |
| Vive Mas/Texturizado | 96 | (32) | - | - | - | | -% | - | - | - | - | - |
| Lubricant | 17,064 | 8,870 | 43,675 | - | - | | 0% | - | 43,675 | - | - | - |
| Vive Lub (sachet) | 8,050 | 4,983 | 23,000 | - | - | | -% | - | 23,000 | - | - | - |
| Vive Lub (tube) | 4,622 | 2,835 | 13,127 | - | - | | -% | - | 13,127 | - | - | - |
| Vive Lub Natural (sachet) | 2,600 | 17 | 2,650 | - | - | | -% | - | 2,650 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|-----------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Vive Lub Natural (tube) | 1,792 | 1,035 | 4,898 | - | - | | -% | - | 4,898 | - | - | - |
| Kazakhstan | | | | | | | | | | | 656 | 977 |
| Free Condom | - | 29,171 | 87,514 | 23,000 | 46,385 | | 89% | 46,385 | 761,064 | 656 | 656 | 95 |
| Generic Male Condom | - | 29,171 | 87,514 | 23,000 | 46,385 | 8/16 | 89% | 46,385 | 761,064 | 656 | 656 | 95 |
| Free Female Condom | - | - | - | - | 8,200 | | (100)% | 8,200 | 32,770 | - | - | - |
| Generic Female Condom | - | - | - | - | 8,200 | 8/16 | (100)% | 8,200 | 32,770 | - | - | - |
| HIV Self-Testing Kit | - | 38 | 113 | 200 | - | | 0% | - | 113 | 102 | - | - |
| HIV Self-Testing Kit (Oral Fluid) | - | - | - | 200 | - | | -% | - | - | - | - | - |
| INSTI HIVST (Blood based) | - | 38 | 113 | - | - | | -% | - | 113 | 102 | - | - |
| HIV Testing Services | 100 | 162 | 1,672 | 2,298 | 2,190 | | (24)% | 2,373 | 7,575 | 1,672 | - | 3 |
| VCT Individual (HIV-Negative) | 72 | 143 | 1,474 | 2,210 | 2,052 | | (28)% | 2,219 | 7,166 | 1,474 | - | 2 |
| VCT Individual (HIV-Positive) | 28 | 19 | 198 | 88 | 138 | | 43% | 154 | 409 | 198 | - | - |
| Referral to HIV Testing Services | - | - | 11 | - | 4 | | 175% | 4 | 5,163 | 11 | - | - |
| Referral to HIV Testing Services | - | - | 11 | - | 4 | 12/13 | 175% | 4 | 5,163 | 11 | - | - |
| Referral to Linkage to HIV Care | 87 | 104 | 972 | 590 | 884 | | 10% | 997 | 2,688 | 972 | - | 879 |
| Referral to Linkage to HIV Care | 87 | 104 | 972 | 590 | 884 | | 10% | 997 | 2,688 | 972 | - | 879 |
| Referral to Opioid Treatment | 3 | 2 | 27 | - | 24 | | 13% | 26 | 120 | 27 | - | - |
| Referral to Opioid Treatment | 3 | 2 | 27 | - | 24 | | 13% | 26 | 120 | 27 | - | - |
| Referral to TB Screening | - | - | - | - | 7 | | (100)% | 7 | 17 | - | - | - |
| Referrals to TB Screening | - | - | - | - | 7 | | (100)% | 7 | 17 | - | - | - |
| TB Diagnosis | 4 | 3 | 25 | 5 | 11 | | 127% | 11 | 69 | 25 | - | - |
| TB Diagnosis | 4 | 3 | 25 | 5 | 11 | | 127% | 11 | 69 | 25 | - | - |
| TB Screening | 445 | 102 | 1,875 | 1,086 | 2,292 | | (18)% | 2,591 | 7,504 | 1,875 | - | - |
| TB Screening | 445 | 102 | 1,875 | 1,086 | 2,292 | | (18)% | 2,591 | 7,504 | 1,875 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Kyrgyzstan | | | | | | | | | | | 273 | 670 |
| Free Condom | 4,000 | 3,336 | 36,408 | 70,000 | 30,144 | | 21% | 30,144 | 66,552 | 273 | 273 | 65 |
| Generic Male Condom | 4,000 | 3,336 | 36,408 | 70,000 | 30,144 | 11/17 | 21% | 30,144 | 66,552 | 273 | 273 | 65 |
| Free Female Condom | - | - | - | - | 13,000 | | (100)% | 13,000 | 13,000 | - | - | - |
| Generic Female Condom | - | - | - | - | 13,000 | 11/17 | (100)% | 13,000 | 13,000 | - | - | - |
| HIV Self-Testing Kit | - | 268 | 803 | 5,000 | - | | 0% | - | 803 | 723 | - | - |
| HIV Self-Testing Kit (Oral Fluid) | - | - | - | 5,000 | - | | -% | - | - | - | - | - |
| ORAQUICK HIV Self-Testing Kit (Saliva based) | - | 268 | 803 | - | - | | -% | - | 803 | 723 | - | - |
| HIV Testing Services | 307 | 684 | 12,264 | 16,165 | 23,209 | | (47)% | 25,008 | 50,740 | 12,264 | - | 23 |
| VCT Individual (HIV-Negative) | 273 | 646 | 11,876 | 15,831 | 22,835 | | (48)% | 24,608 | 49,716 | 11,876 | - | 22 |
| VCT Individual (HIV-Positive) | 34 | 38 | 388 | 334 | 374 | | 4% | 400 | 1,024 | 388 | - | 1 |
| Lubricant | 4,000 | 669 | 6,008 | - | - | | 0% | - | 7,008 | - | - | - |
| Personal lubricants water based 4.5 g | 4,000 | 669 | 6,008 | - | - | 7/13 | -% | - | 7,008 | - | - | - |
| Referral to Linkage to HIV Care | 71 | 63 | 554 | 287 | 422 | | 31% | 456 | 2,072 | 554 | - | 581 |
| Referral to Linkage to HIV Care | 71 | 63 | 554 | 287 | 422 | | 31% | 456 | 2,072 | 554 | - | 581 |
| Referral to Opioid Treatment | - | - | 3 | - | 39 | | (92)% | 44 | 193 | 3 | - | - |
| Referral to Opioid Treatment | - | - | 3 | - | 39 | | (92)% | 44 | 193 | 3 | - | - |
| Referral to TB Screening | - | - | - | - | 13 | | (100)% | 13 | 25 | - | - | - |
| Referrals to TB Screening | - | - | - | - | 13 | | (100)% | 13 | 25 | - | - | - |
| TB Diagnosis | - | 1 | 8 | 10 | 6 | | 33% | 8 | 46 | 8 | - | - |
| TB Diagnosis | - | 1 | 8 | 10 | 6 | | 33% | 8 | 46 | 8 | - | - |
| TB Screening | 265 | 232 | 1,619 | 1,000 | 1,287 | | 26% | 1,418 | 8,210 | 1,619 | - | - |
| TB Screening | 265 | 232 | 1,619 | 1,000 | 1,287 | | 26% | 1,418 | 8,210 | 1,619 | - | - |
| Laos | | | | | | | | | | | 81,365 | 21,827 |
| Condom | 343,836 | 446,196 | 3,458,376 | 3,500,000 | 3,327,477 | | 4% | 3,760,689 | 34,679,847 | 25,938 | 25,938 | 7,391 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| No 1 Condom Grp | - | - | 330,624 | 328,032 | 541,029 | 11/10 | (39)% | 628,416 | 5,239,492 | 2,480 | 2,480 | 707 |
| No 1 Condom Orange | - | - | - | 372,032 | - | | -% | - | - | - | - | - |
| No 1 Condom Strw | 161,568 | 191,088 | 1,341,792 | 1,277,856 | 1,728,351 | 8/08 | (22)% | 1,901,232 | 17,408,904 | 10,063 | 10,063 | 2,867 |
| No 1 Condom Super Thin | - | - | - | 148,608 | - | | -% | - | - | - | - | - |
| No.1 Orange | 11,232 | 81,648 | 256,176 | - | - | | -% | - | 256,176 | 1,921 | 1,921 | 547 |
| No.1 Super Thin | 28,476 | 39,396 | 146,664 | - | - | | -% | - | 146,664 | 1,100 | 1,100 | 313 |
| Number One Rose | 142,560 | 134,064 | 1,383,120 | 1,373,472 | 1,058,097 | 4/08 | 31% | 1,231,041 | 11,628,611 | 10,373 | 10,373 | 2,956 |
| Fever Cases Attended | 6,771 | 7,671 | 66,678 | 60,000 | 39,273 | | 70% | 43,091 | 120,830 | 66,678 | - | - |
| Fever Cases Attended | 6,771 | 7,671 | 66,678 | 60,000 | 39,273 | | 70% | 43,091 | 120,830 | 66,678 | - | - |
| Fever Cases Tested with Microscopy | - | 2,246 | 6,737 | - | - | | 0% | - | 6,737 | 6,737 | - | - |
| Fever Cases Tested with Microscopy | - | 2,246 | 6,737 | - | - | | -% | - | 6,737 | 6,737 | - | - |
| Fever Cases Tested with RDTs | 6,771 | 7,671 | 66,678 | 60,000 | 39,257 | | 70% | 43,075 | 120,800 | 66,678 | - | - |
| Fever Cases Tested with RDTs | 6,771 | 7,671 | 66,678 | 60,000 | 39,257 | | 70% | 43,075 | 120,800 | 66,678 | - | - |
| HIV Testing Services | 589 | 526 | 5,492 | 5,641 | 4,917 | | 12% | 5,345 | 24,889 | 5,492 | - | 4 |
| VCT Individual (HIV-Negative) | 589 | 524 | 5,464 | 5,621 | 4,882 | 2/10 | 12% | 5,309 | 24,688 | 5,464 | - | 4 |
| VCT Individual (HIV-Positive) | - | 2 | 28 | 20 | 35 | 4/10 | (20)% | 36 | 201 | 28 | - | - |
| Implant 3 Insertion | 558 | 727 | 8,821 | 11,031 | 10,266 | | (14)% | 11,434 | 33,118 | 8,821 | 22,053 | 5,537 |
| Non-PSI Implant 3 Inserted | 558 | 727 | 8,821 | 11,031 | 10,266 | 3/16 | (14)% | 11,434 | 33,118 | 8,821 | 22,053 | 5,537 |
| Injectable 3-IM | - | - | - | - | (1,586) | | 0% | (1,586) | (1,586) | - | - | - |
| (b)PSI Injectable 3 IM Distributed Provided | - | - | - | - | (1,586) | | -% | (1,586) | (1,586) | - | - | - |
| Injectable 3-IM Provided | 1,186 | 1,636 | 16,361 | 17,304 | 17,898 | | (9)% | 19,748 | 53,818 | 4,090 | 4,090 | 759 |
| Non-PSI Injectable 3 IM Provided | 1,186 | 1,636 | 16,361 | 17,304 | 16,312 | 3/16 | -% | 18,162 | 52,232 | 4,090 | 4,090 | 759 |
| PSI Injectable 3 IM Provided | - | - | - | - | 1,586 | | (100)% | 1,586 | 1,586 | - | - | - |
| IUD 10 | (30) | (48) | (586) | - | (206) | | 0% | (260) | (846) | (527) | (2,426) | (567) |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| (b)PSI IUD 10 Distributed Inserted | (30) | (48) | (586) | - | (206) | | -% | (260) | (846) | (527) | (2,426) | (567) |
| IUD 10 Insertion | 337 | 391 | 6,337 | 10,176 | 9,993 | | (37)% | 11,005 | 52,026 | 6,337 | 29,150 | 6,815 |
| Non-PSI IUD 10 Inserted | 307 | 344 | 5,751 | 10,176 | 9,787 | | (41)% | 10,745 | 51,180 | 5,751 | 26,455 | 6,185 |
| PSI IUD 10 Inserted | 30 | 48 | 586 | - | 206 | | 184% | 260 | 846 | 586 | 2,696 | 630 |
| IUD 5 | - | 83 | 250 | - | 800 | | (69)% | 800 | 2,860 | 225 | 742 | 186 |
| IUD Cu375 | - | 83 | 250 | - | 800 | 7/12 | (69)% | 800 | 2,860 | 225 | 742 | 186 |
| Manual Vacuum Aspiration for PAC | - | - | - | 220 | - | | 0% | - | - | - | - | - |
| Manual Vacuum Aspiration for PAC | - | - | - | 220 | - | | -% | - | - | - | - | - |
| Manual Vacuum Aspiration for SA | - | - | - | - | 81 | | (100)% | 81 | 81 | - | - | - |
| Manual Vacuum Aspiration for SA | - | - | - | - | 81 | | (100)% | 81 | 81 | - | - | - |
| Misoprostol for PAC Provided | - | - | - | - | 70 | | (100)% | 70 | 70 | - | - | - |
| Non-PSI Misoprostol for PAC Provided | - | - | - | - | 52 | | (100)% | 52 | 52 | - | - | - |
| PSI Misoprostol for PAC Provided | - | - | - | - | 18 | | (100)% | 18 | 18 | - | - | - |
| Misoprostol for Safe Abortion | - | 34,033 | 243,100 | 172,876 | 173,928 | | 40% | 202,928 | 839,498 | 12,763 | - | 1,159 |
| Misoprostol for Safe Abortion | - | 34,033 | 243,100 | 172,876 | 174,000 | 3/18 | 40% | 203,000 | 839,570 | 12,763 | - | 1,159 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | - | - | - | - | (72) | | -% | (72) | (72) | - | - | - |
| OCs | - | - | - | - | (2,241) | | 0% | (2,241) | (2,241) | - | - | - |
| (b)PSI OCs Distributed Provided | - | - | - | - | (2,241) | | -% | (2,241) | (2,241) | - | - | - |
| OCs Provided | 1,815 | 3,183 | 27,268 | 24,784 | 26,905 | | 1% | 29,665 | 80,980 | 1,818 | 1,818 | 356 |
| Non-PSI OCs Provided | 1,815 | 3,183 | 27,268 | 24,784 | 24,664 | 3/16 | 11% | 27,424 | 78,739 | 1,818 | 1,818 | 356 |
| PSI OCs Provided | - | - | - | - | 2,241 | | (100)% | 2,241 | 2,241 | - | - | - |
| Positive RDTs | 28 | 45 | 685 | 1,500 | 1,230 | | (44)% | 1,324 | 2,572 | 685 | - | - |
| Positive RDTs | 28 | 45 | 685 | 1,500 | 1,230 | | (44)% | 1,324 | 2,572 | 685 | - | - |
| Positive RDTs Given First Line Treatment | 28 | 45 | 685 | 825 | 1,230 | | (44)% | 1,324 | 2,572 | 685 | - | - |
| Positive RDTs Given First Line Treatment | 28 | 45 | 685 | 825 | 1,230 | | (44)% | 1,324 | 2,572 | 685 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| QAACTs Provided after Confirmatory Diagnosis | 28 | 45 | 685 | 825 | 1,230 | | (44)% | 1,324 | 2,572 | 685 | - | 129 |
| Non-PSI QAACTs Provided after Confirmed Diagnosis | 28 | 45 | 685 | 825 | 1,230 | | (44)% | 1,324 | 2,572 | 685 | - | 129 |
| Referral to TB DOTS (completion confirmed) | 27 | 6 | 81 | 110 | 148 | | (45)% | 148 | 472 | 81 | - | 28 |
| Referral to TB DOTS (completion confirmed) | 27 | 6 | 81 | 110 | 148 | 3/16 | (45)% | 148 | 472 | 81 | - | 28 |
| Referral to TB DOTS (completion unknown) | - | - | 4 | - | 43 | | (91)% | 43 | 248 | 4 | - | 1 |
| Referral to TB DOTS (completion unknown) | - | - | 4 | - | 43 | 12/13 | (91)% | 43 | 248 | 4 | - | 1 |
| TB Diagnosis | 65 | 20 | 228 | 370 | 185 | | 23% | 185 | 1,017 | 228 | - | - |
| TB Diagnosis | 65 | 20 | 228 | 370 | 185 | | 23% | 185 | 1,017 | 228 | - | - |
| TB Screening | 204 | 88 | 918 | - | 755 | | 22% | 755 | 3,935 | 918 | - | - |
| TB Screening | 204 | 88 | 918 | - | 755 | | 22% | 755 | 3,935 | 918 | - | - |
| Vivax Treatment after Confirmatory Diagnosis | 28 | 45 | 163 | - | - | | 0% | - | 163 | 163 | - | 31 |
| Non-PSI Vivax Treatment after Confirmed Diagnosis | 28 | 45 | 163 | - | - | | -% | - | 163 | 163 | - | 31 |
| Nepal | | | | | | | | | | | 70,756 | 24,235 |
| Emergency Contraception | - | - | - | - | 221 | | (100)% | 221 | 221 | - | - | - |
| i-pill | - | - | - | - | 221 | 7/17 | (100)% | 221 | 221 | - | - | - |
| Free Condom | - | - | - | - | 2,148 | | (100)% | 2,148 | 574,282 | - | - | - |
| Generic Condom | - | - | - | - | 2,148 | 1/16 | (100)% | 2,148 | 574,282 | - | - | - |
| Implant 5 | (88) | - | 212 | - | (34) | | 0% | (34) | 19,549 | 191 | 725 | 135 |
| Jadelle | - | - | 300 | - | - | 8/09 | -% | - | 21,014 | 270 | 1,026 | 191 |
| (b)PSI Implant 5 Distributed Inserted | (88) | - | (88) | - | (34) | | -% | (34) | (1,465) | (79) | (301) | (56) |
| Implant 5 Insertion | 88 | 79 | 717 | 428 | 73 | | 882% | 75 | 2,402 | 717 | 2,725 | 508 |
| Non-PSI Implant 5 Inserted | - | 79 | 629 | 428 | 39 | | 1,513% | 41 | 937 | 629 | 2,390 | 445 |
| PSI Implant 5 Inserted | 88 | - | 88 | - | 34 | | 159% | 34 | 1,465 | 88 | 334 | 62 |
| IUD 10 | (1,960) | 434 | (2,839) | 3,959 | 14,263 | | (120)% | (9,464) | (182,994) | (2,555) | (11,753) | (2,070) |
| OK IUD | - | 2,341 | 13,700 | 21,141 | 45,560 | 5/04 | (70)% | 23,060 | 55,010 | 12,330 | 56,718 | 9,990 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Pregna T Cu 380A | - | 50 | 555 | - | 20 | 7/17 | 2,675% | 20 | 595 | 500 | 2,298 | 405 |
| (b)PSI IUD 10 Distributed Inserted | (1,960) | (1,957) | (17,094) | (17,182) | (31,317) | | -% | (32,544) | (238,599) | (15,385) | (70,769) | (12,464) |
| IUD 10 Insertion | 1,964 | 1,960 | 17,187 | 17,182 | 32,224 | | (47)% | 33,521 | 250,112 | 17,187 | 79,060 | 13,925 |
| Non-PSI IUD 10 Inserted | 4 | 2 | 93 | - | 907 | | (90)% | 977 | 11,512 | 93 | 428 | 75 |
| PSI IUD 10 Inserted | 1,960 | 1,957 | 17,094 | 17,182 | 31,317 | | (45)% | 32,544 | 238,599 | 17,094 | 78,632 | 13,849 |
| Manual Vacuum Aspiration for PAC | 3 | 5 | 51 | - | 12 | | 325% | 12 | 63 | 51 | - | 4 |
| Manual Vacuum Aspiration for PAC | 3 | 5 | 51 | - | 12 | | 325% | 12 | 63 | 51 | - | 4 |
| Manual Vacuum Aspiration for SA | 61 | 59 | 675 | 236 | 170 | | 297% | 170 | 845 | 675 | - | 100 |
| Manual Vacuum Aspiration for SA | 61 | 59 | 675 | 236 | 170 | | 297% | 170 | 845 | 675 | - | 100 |
| Medical Abortion | 14,629 | 9,701 | 90,970 | 99,716 | 111,788 | | (19)% | 122,575 | 456,013 | 81,873 | - | 11,327 |
| Medabon | 14,918 | 9,965 | 93,055 | 104,504 | 113,011 | 12/08 | (18)% | 123,798 | 459,321 | 83,750 | - | 11,587 |
| (b)PSI Medical Abortion Distributed Provided | (289) | (264) | (2,085) | (4,788) | (1,223) | | -% | (1,223) | (3,308) | (1,877) | - | (260) |
| Medical Abortion Provided | 307 | 275 | 2,213 | 4,788 | 1,263 | | 75% | 1,263 | 3,476 | 2,213 | - | 306 |
| Non-PSI Medical Abortion Provided | 18 | 11 | 128 | - | 40 | | 220% | 40 | 168 | 128 | - | 18 |
| PSI Medical Abortion Provided | 289 | 264 | 2,085 | 4,788 | 1,223 | | 70% | 1,223 | 3,308 | 2,085 | - | 288 |
| Misoprostol for PAC Provided | - | - | 8 | - | - | | 0% | - | 8 | 8 | - | 1 |
| Non-PSI Misoprostol for PAC Provided | - | - | 8 | - | - | | -% | - | 8 | 8 | - | 1 |
| OCs | - | - | - | - | 15,134 | | (100)% | 15,134 | 158,306 | - | - | - |
| Zinnia | - | - | - | - | 554 | 8/15 | (100)% | 554 | 143,726 | - | - | - |
| Zinnia - F | - | - | - | - | 14,580 | 7/17 | (100)% | 14,580 | 14,580 | - | - | - |
| STI Screening | - | - | - | - | 39 | | (100)% | 39 | 1,198 | - | - | - |
| STI Screening | - | - | - | - | 39 | | (100)% | 39 | 1,198 | - | - | - |
| Nicaragua | | | | | | | | | | | 77,573 | 16,797 |
| Condom | 530,448 | 331,681 | 4,186,227 | - | 3,697,821 | | 13% | 3,880,941 | 78,983,456 | 31,397 | 31,397 | 9,089 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Bodyguard | - | - | - | - | (1,613) | 2/04 | -% | (1,613) | 11,095,477 | - | - | - |
| Combo-Pack Lub Fresa | - | 432 | 3,024 | - | 14,866 | 5/11 | (80)% | 14,866 | 72,442 | 23 | 23 | 7 |
| Combo-Pack Lub Natural | - | - | - | - | (3,374) | 10/10 | -% | (3,374) | 23,618 | - | - | - |
| Vive | 406,272 | 243,984 | 2,973,504 | - | 2,487,963 | 4/98 | 20% | 2,580,363 | 51,084,347 | 22,301 | 22,301 | 6,456 |
| Vive Colors/Mas Colors | 59,304 | 48,353 | 763,059 | - | 807,078 | 4/02 | (5)% | 864,750 | 12,367,565 | 5,723 | 5,723 | 1,657 |
| Vive Mas Fuerte /Retardante | 50,616 | 29,376 | 352,677 | - | 304,176 | 6/04 | 16% | 325,560 | 2,507,291 | 2,645 | 2,645 | 766 |
| Vive Mas Natural /Sensitivo | 14,256 | 9,536 | 94,059 | - | 77,325 | 6/04 | 22% | 88,989 | 1,082,819 | 705 | 705 | 204 |
| Vive Mas/Texturizado | - | - | (96) | - | 11,400 | 6/04 | (101)% | 11,400 | 749,897 | (1) | (1) | - |
| HIV Testing Services | 72 | 63 | 834 | 614 | 643 | | 30% | 687 | 8,552 | 834 | - | 1 |
| VCT Individual (HIV-Negative) | 68 | 58 | 775 | 578 | 607 | 12/09 | 28% | 648 | 8,362 | 775 | - | 1 |
| VCT Individual (HIV-Positive) | 4 | 5 | 59 | 36 | 36 | 12/09 | 64% | 39 | 190 | 59 | - | - |
| Implant 3 | 199 | 381 | 2,079 | - | 838 | | 148% | 789 | 3,429 | 1,871 | 4,678 | 784 |
| Implanon | 307 | 503 | 3,161 | - | 1,505 | 7/15 | 110% | 1,506 | 6,176 | 2,845 | 7,112 | 1,192 |
| (b)PSI Implant 3 Distributed Inserted | (108) | (121) | (1,082) | - | (667) | 3/16 | -% | (717) | (2,747) | (974) | (2,435) | (408) |
| Implant 3 Insertion | 124 | 163 | 1,446 | - | 891 | | 62% | 974 | 3,389 | 1,446 | 3,615 | 606 |
| Non-PSI Implant 3 Inserted | 16 | 42 | 364 | - | 224 | | 63% | 257 | 642 | 364 | 910 | 153 |
| PSI Implant 3 Inserted | 108 | 121 | 1,082 | - | 667 | 3/16 | 62% | 717 | 2,747 | 1,082 | 2,705 | 453 |
| Implant 5 | - | (1) | (8) | - | 476 | | (102)% | 474 | 2,365 | (7) | (27) | (5) |
| Jadelle | - | - | - | - | 1,195 | 12/08 | (100)% | 1,195 | 6,080 | - | - | - |
| (b)PSI Implant 5 Distributed Inserted | - | (1) | (8) | - | (719) | | -% | (721) | (3,715) | (7) | (27) | (5) |
| Implant 5 Insertion | - | 1 | 8 | - | 719 | | (99)% | 721 | 3,715 | 8 | 30 | 5 |
| PSI Implant 5 Inserted | - | 1 | 8 | - | 719 | | (99)% | 721 | 3,715 | 8 | 30 | 5 |
| Injectable 1 Provided | 76 | 74 | 594 | - | 302 | | 97% | 312 | 1,194 | 46 | 46 | 6 |
| Non-PSI Injectable 1 Provided | 76 | 74 | 594 | - | 302 | | 97% | 312 | 1,194 | 46 | 46 | 6 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Injectable 3-IM Provided | 45 | 26 | 200 | - | 58 | | 245% | 62 | 311 | 50 | 50 | 6 |
| Non-PSI Injectable 3 IM Provided | 45 | 26 | 200 | - | 58 | | 245% | 62 | 311 | 50 | 50 | 6 |
| IUD 10 | 99 | 701 | 3,806 | - | 2,881 | | 32% | 2,979 | 44,016 | 3,425 | 15,757 | 2,483 |
| Copper T 380 | 284 | 835 | 5,528 | - | 5,108 | 12/08 | 8% | 5,325 | 90,403 | 4,975 | 22,886 | 3,606 |
| Copper-T 380-A IUD | - | 53 | 251 | - | 65 | 3/16 | 286% | 84 | 397 | 226 | 1,039 | 164 |
| (b)PSI IUD 10 Distributed Inserted | (185) | (187) | (1,973) | - | (2,292) | | -% | (2,430) | (46,784) | (1,776) | (8,168) | (1,287) |
| IUD 10 Insertion | 185 | 187 | 1,973 | - | 2,292 | | (14)% | 2,430 | 46,784 | 1,973 | 9,076 | 1,430 |
| PSI IUD 10 Inserted | 185 | 187 | 1,973 | - | 2,292 | | (14)% | 2,430 | 46,784 | 1,973 | 9,076 | 1,430 |
| IUD 5 | 2,903 | 37 | 3,257 | - | 659 | | 394% | 659 | 4,244 | 2,931 | 9,673 | 1,622 |
| Copper T375 Sleek | 2,926 | 49 | 3,379 | - | 729 | 3/16 | 364% | 732 | 4,451 | 3,041 | 10,036 | 1,683 |
| (b)PSI IUD 5 Distributed Inserted | (23) | (11) | (122) | - | (70) | | -% | (73) | (207) | (110) | (362) | (61) |
| IUD 5 Insertion | 23 | 11 | 122 | - | 70 | | 74% | 73 | 207 | 122 | 403 | 68 |
| PSI IUD 5 Inserted | 23 | 11 | 122 | - | 70 | | 74% | 73 | 207 | 122 | 403 | 68 |
| IUS 5 Insertion | - | 1 | 7 | - | 2 | | 250% | 2 | 10 | 7 | 23 | 4 |
| Non-PSI IUS 5 Inserted | - | 1 | 7 | - | 2 | | 250% | 2 | 10 | 7 | 23 | 4 |
| Lubricant | 6,785 | 18,479 | 163,962 | - | 166,126 | | (1)% | 175,397 | 1,195,230 | - | - | - |
| Vive Lub (sachet) | 2,700 | 7,400 | 66,862 | - | 69,950 | 3/05 | (4)% | 74,450 | 533,255 | - | - | - |
| Vive Lub (tube) | 2,108 | 2,088 | 21,795 | - | 17,714 | 3/05 | 23% | 18,659 | 148,779 | - | - | - |
| Vive Lub Natural (sachet) | - | 7,200 | 55,855 | - | 60,738 | 1/10 | (8)% | 63,538 | 408,038 | - | - | - |
| Vive Lub Natural (tube) | 1,977 | 1,791 | 19,450 | - | 17,724 | 1/10 | 10% | 18,750 | 105,158 | - | - | - |
| Manual Vacuum Aspiration for PAC | 36 | 54 | 648 | - | 479 | | 35% | 496 | 2,056 | 648 | - | 25 |
| MVA for PAC | 36 | 54 | 648 | - | 479 | 5/16 | 35% | 496 | 2,056 | 648 | - | 25 |
| Misoprostol for PAC Provided | 22 | 30 | 243 | - | 80 | | 204% | 82 | 373 | 243 | - | 12 |
| PSI Misoprostol for PAC Provided | 22 | 30 | 243 | - | 80 | | 204% | 82 | 373 | 243 | - | 12 |
| Misoprostol for Safe Abortion | 722 | 3,499 | 37,172 | - | 38,433 | | (3)% | 37,641 | 82,737 | 1,952 | - | 78 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Misoprostol for Safe Abortion | 810 | 3,620 | 38,144 | - | 38,753 | 3/18 | (2)% | 37,969 | 84,229 | 2,003 | - | 80 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (88) | (121) | (972) | - | (320) | | -% | (328) | (1,492) | (51) | - | (2) |
| OCs Provided | 51 | 56 | 499 | - | 274 | | 82% | 300 | 971 | 33 | 33 | 4 |
| Non-PSI OCs Provided | 51 | 56 | 499 | - | 274 | | 82% | 300 | 971 | 33 | 33 | 4 |
| Referral to Linkage to HIV Care | 6 | 4 | 54 | - | 1 | | 5300% | 2 | 93 | 54 | - | 37 |
| Referral to Linkage to HIV Care | 6 | 4 | 54 | - | 1 | | 5,300% | 2 | 93 | 54 | - | 37 |
| Tubal Ligation | 16 | 30 | 282 | - | 110 | | 156% | 113 | 418 | 282 | 2,820 | 541 |
| Tubal Ligation | 16 | 30 | 282 | - | 110 | | 156% | 113 | 418 | 282 | 2,820 | 541 |
| Nicaragua SA | | | | | | | | | | | | |
| Condom | - | - | - | 4,306,525 | - | | 0% | - | - | - | - | - |
| Combo-Pack Lub Fresa | - | - | - | 15,530 | - | | -% | - | - | - | - | - |
| Vive | - | - | - | 2,948,290 | - | | -% | - | - | - | - | - |
| Vive Colors/Mas Colors | - | - | - | 872,758 | - | | -% | - | - | - | - | - |
| Vive Mas Fuerte /Retardante | - | - | - | 378,032 | - | | -% | - | - | - | - | - |
| Vive Mas Natural /Sensitivo | - | - | - | 91,915 | - | | -% | - | - | - | - | - |
| Implant 3 | - | - | - | 4,860 | - | | 0% | - | - | - | - | - |
| Implanon | - | - | - | 5,784 | - | | -% | - | - | - | - | - |
| (b)PSI Implant 3 Distributed Inserted | - | - | - | (924) | - | | -% | - | - | - | - | - |
| Implant 3 Insertion | - | - | - | 924 | - | | 0% | - | - | - | - | - |
| PSI Implant 3 Inserted | - | - | - | 924 | - | | -% | - | - | - | - | - |
| Injectable 1 | - | - | - | 13,832 | - | | 0% | - | - | - | - | - |
| Cyclofem | - | - | - | 13,832 | - | | -% | - | - | - | - | - |
| IUD 10 | - | - | - | 3,612 | - | | 0% | - | - | - | - | - |
| Copper T 380 | - | - | - | 6,000 | - | | -% | - | - | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|------------------|------------------|
| (b)PSI IUD 10 Distributed Inserted | - | - | - | (2,388) | - | | -% | - | - | - | - | - |
| IUD 10 Insertion | - | - | - | 2,388 | - | | 0% | - | - | - | - | - |
| PSI IUD 10 Inserted | - | - | - | 2,388 | - | | -% | - | - | - | - | - |
| Lubricant | - | - | - | 121,046 | - | | 0% | - | - | - | - | - |
| Vive Lub (sachet) | - | - | - | 64,210 | - | | -% | - | - | - | - | - |
| Vive Lub Natural (sachet) | - | - | - | 56,836 | - | | -% | - | - | - | - | - |
| Manual Vacuum Aspiration for PAC | - | - | - | 600 | - | | 0% | - | - | - | - | - |
| MVA for PAC | - | - | - | 600 | - | | -% | - | - | - | - | - |
| Misoprostol for PAC Provided | - | - | - | 300 | - | | 0% | - | - | - | - | - |
| PSI Misoprostol for PAC Provided | - | - | - | 300 | - | | -% | - | - | - | - | - |
| Misoprostol for Safe Abortion | - | - | - | 64,920 | - | | 0% | - | - | - | - | - |
| Misoprostol for Safe Abortion | - | - | - | 66,120 | - | | -% | - | - | - | - | - |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | - | - | - | (1,200) | - | | -% | - | - | - | - | - |
| OCs | - | - | - | 120,000 | - | | 0% | - | - | - | - | - |
| Segura Plus | - | - | - | 120,000 | - | | -% | - | - | - | - | - |
| Pakistan | | | | | | | | | | | 1,552,614 | 532,279 |
| Condom | 6,584,526 | 14,515,619 | 84,021,920 | 106,540,076 | 114,789,940 | | (27)% | 133,792,588 | 2,732,129,699 | 630,164 | 630,164 | 143,471 |
| Do | 347,040 | 181,416 | 1,515,867 | 2,002,578 | 1,448,244 | 8/17 | 5% | 1,581,084 | 4,265,871 | 11,369 | 11,369 | 2,588 |
| Sathi | 3,848,832 | 11,167,412 | 62,325,451 | 89,986,310 | 98,629,110 | 1/87 | (37)% | 116,349,078 | 2,451,052,964 | 467,441 | 467,441 | 106,423 |
| Sathi Plus | 560,160 | 397,280 | 3,024,981 | 2,550,929 | 1,930,080 | 8/17 | 57% | 2,133,120 | 6,274,101 | 22,687 | 22,687 | 5,165 |
| Touch | 1,483,380 | 2,183,590 | 13,765,220 | 11,226,177 | 12,124,066 | 4/96 | 14% | 13,002,106 | 265,544,722 | 103,239 | 103,239 | 23,505 |
| Touch Delay | 312,714 | 128,106 | 1,984,557 | 774,082 | 658,440 | 8/17 | 201% | 727,200 | 3,586,197 | 14,884 | 14,884 | 3,389 |
| Touch Strawberry | 32,400 | 457,815 | 1,405,844 | - | - | | -% | - | 1,405,844 | 10,544 | 10,544 | 2,401 |
| Emergency Contraception | 143,170 | 290,758 | 1,589,502 | 857,425 | 1,766,043 | | (10)% | 2,065,123 | 10,494,765 | 71,528 | 71,528 | 12,509 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| ECP | 130,260 | 222,908 | 1,389,210 | 857,425 | 1,778,632 | 9/14 | (22)% | 2,080,232 | 10,337,366 | 62,514 | 62,514 | 10,933 |
| Levonorgestrel Tablet 0.75 mg x 2's | 17,160 | 69,825 | 226,635 | - | - | | -% | - | 226,635 | 10,199 | 10,199 | 1,784 |
| (b)PSI Emergency Contraception Distributed Provided | (4,250) | (1,975) | (26,343) | - | (12,589) | | -% | (15,109) | (69,236) | (1,185) | (1,185) | (207) |
| Emergency Contraception Provided | 4,250 | 1,975 | 26,343 | - | 12,589 | | 109% | 15,109 | 69,236 | 1,317 | 1,317 | 230 |
| PSI Emergency Contraception Provided | 4,250 | 1,975 | 26,343 | - | 12,589 | | 109% | 15,109 | 69,236 | 1,317 | 1,317 | 230 |
| Implant 5 | - | 1,498 | 4,796 | 45 | 10,646 | | (55)% | 10,646 | 29,775 | 4,316 | 16,402 | 5,032 |
| Jadelle | - | 1,498 | 4,796 | 45 | 10,646 | 12/11 | (55)% | 10,646 | 29,775 | 4,316 | 16,402 | 5,032 |
| Injectable 1 | 17,544 | 19,581 | 116,350 | 92,496 | 93,104 | | 25% | 99,805 | 1,819,565 | 8,055 | 8,055 | 2,003 |
| Femi-ject | 21,800 | 23,068 | 155,651 | 92,496 | 112,400 | 6/03 | 38% | 122,300 | 1,969,864 | 10,776 | 10,776 | 2,680 |
| (b)PSI Injectable 1 Distributed Provided | (4,256) | (3,488) | (39,301) | - | (19,296) | | -% | (22,495) | (150,299) | (2,721) | (2,721) | (677) |
| Injectable 1 Provided | 4,256 | 3,488 | 39,301 | - | 19,296 | | 104% | 22,495 | 150,299 | 3,023 | 3,023 | 752 |
| PSI Injectable 1 Provided | 4,256 | 3,488 | 39,301 | - | 19,296 | | 104% | 22,495 | 150,299 | 3,023 | 3,023 | 752 |
| Injectable 2 | (105) | 13,087 | 45,946 | 19,731 | 117,769 | | (61)% | 134,028 | 7,130,029 | 6,892 | 6,892 | 1,582 |
| Novaject | - | 13,822 | 50,114 | 19,731 | 127,714 | 12/96 | (61)% | 144,514 | 7,211,372 | 7,517 | 7,517 | 1,725 |
| (b)PSI Injectable 2 Distributed Provided | (105) | (735) | (4,168) | - | (9,945) | | -% | (10,486) | (81,343) | (625) | (625) | (144) |
| Injectable 2 Provided | 105 | 735 | 4,168 | - | 9,945 | | (58)% | 10,486 | 81,343 | 695 | 695 | 159 |
| PSI Injectable 2 Provided | 105 | 735 | 4,168 | - | 9,945 | | (58)% | 10,486 | 81,343 | 695 | 695 | 159 |
| Injectable 3-IM | (900) | - | (11,132) | 226,792 | 378,184 | | (103)% | 406,105 | 2,879,760 | (2,505) | (2,505) | (575) |
| Depo-Provera | - | - | 4,271 | 226,792 | 417,316 | 7/11 | (99)% | 451,716 | 3,000,454 | 961 | 961 | 221 |
| (b)PSI Injectable 3 IM Distributed Provided | (900) | - | (15,403) | - | (39,132) | | -% | (45,611) | (120,694) | (3,466) | (3,466) | (796) |
| Injectable 3-IM Provided | 900 | - | 15,403 | - | 39,132 | | (61)% | 45,611 | 120,694 | 3,851 | 3,851 | 884 |
| PSI Injectable 3 IM Provided | 900 | - | 15,403 | - | 39,132 | | (61)% | 45,611 | 120,694 | 3,851 | 3,851 | 884 |
| IUD 10 | - | 1 | 59,094 | 70,778 | 47,101 | | 25% | 47,316 | 254,353 | 53,185 | 244,649 | 71,761 |
| Safeload | - | 1 | 59,094 | 70,778 | 47,101 | 8/14 | 25% | 47,316 | 254,353 | 53,185 | 244,649 | 71,761 |
| IUD 5 | 6,312 | 10,990 | 12,359 | 94,294 | 19,433 | | (36)% | 20,275 | 3,026,933 | 11,123 | 36,706 | 11,462 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Multiload | 18,824 | 23,533 | 159,171 | - | 81,008 | 12/95 | 96% | 81,850 | 4,105,697 | 143,254 | 472,738 | 147,615 |
| Protect 5 | - | - | - | 94,294 | - | | -% | - | - | - | - | - |
| (b)PSI IUD 5 Distributed Inserted | (12,512) | (12,544) | (146,812) | - | (61,575) | | -% | (61,575) | (1,078,764) | (132,131) | (436,032) | (136,154) |
| IUD 5 Insertion | 12,512 | 12,544 | 146,812 | - | 61,575 | | 138% | 61,575 | 1,078,764 | 146,812 | 484,480 | 151,282 |
| PSI IUD 5 Inserted | 12,512 | 12,544 | 146,812 | - | 61,575 | | 138% | 61,575 | 1,078,764 | 146,812 | 484,480 | 151,282 |
| Manual Vacuum Aspiration for PAC | 3,464 | 7,384 | 71,993 | - | 27,052 | | 166% | 27,052 | 158,829 | 71,993 | - | 3,685 |
| Manual Vacuum Aspiration for PAC | 3,464 | 7,384 | 71,993 | - | 27,052 | | 166% | 27,052 | 158,829 | 71,993 | - | 3,685 |
| Misoprostol for PAC Provided | 7,885 | 8,135 | 71,745 | - | 46,571 | | 54% | 46,571 | 118,316 | 71,745 | - | 4,410 |
| PSI Misoprostol for PAC Provided | 7,885 | 8,135 | 71,745 | - | 46,571 | | 54% | 46,571 | 118,316 | 71,745 | - | 4,410 |
| Misoprostol for Safe Abortion | 105,260 | 36,793 | 1,156,520 | - | 960,646 | | 20% | 982,646 | 2,437,966 | 60,717 | - | 4,713 |
| Misoprostol for Safe Abortion | 136,800 | 69,333 | 1,443,500 | - | 1,146,930 | 3/18 | 26% | 1,168,930 | 2,911,230 | 75,784 | - | 5,883 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (31,540) | (32,540) | (286,980) | - | (186,284) | | -% | (186,284) | (473,264) | (15,066) | - | (1,170) |
| Multivitamin | 1,400 | 6,340 | 20,420 | - | - | | 0% | - | 20,420 | 102 | - | 19 |
| Mi-Care | 1,400 | 6,340 | 20,420 | - | - | | -% | - | 20,420 | 102 | - | 19 |
| OCs | 97,662 | 32,495 | 777,738 | 475,234 | 964,983 | | (19)% | 963,276 | 4,651,011 | 46,664 | 46,664 | 11,300 |
| Novadol | 98,640 | 33,990 | 788,121 | 475,234 | 1,004,418 | 1/08 | (22)% | 1,004,634 | 4,869,501 | 47,287 | 47,287 | 11,451 |
| (b)PSI OCs Distributed Provided | (978) | (1,495) | (10,383) | - | (39,435) | | -% | (41,358) | (218,490) | (623) | (623) | (151) |
| OCs Provided | 978 | 1,495 | 10,383 | - | 39,435 | | (74)% | 41,358 | 218,490 | 692 | 692 | 168 |
| PSI OCs Provided | 978 | 1,495 | 10,383 | - | 39,435 | | (74)% | 41,358 | 218,490 | 692 | 692 | 168 |
| TB Diagnosis | 2,483 | 2,481 | 26,077 | - | 26,937 | | (3)% | 29,215 | 105,453 | 26,077 | - | - |
| TB Diagnosis | 2,483 | 2,481 | 26,077 | - | 26,937 | | (3)% | 29,215 | 105,453 | 26,077 | - | - |
| TB DOTS | 1,970 | 2,170 | 23,475 | - | 23,920 | | (2)% | 26,012 | 136,950 | 23,475 | - | 107,432 |
| TB DOTS | 1,970 | 2,170 | 23,475 | - | 23,920 | 4/05 | (2)% | 26,012 | 136,950 | 23,475 | - | 107,432 |
| TB Screening | 5,057 | 4,608 | 50,381 | - | 61,777 | | (18)% | 65,777 | 169,679 | 50,381 | - | - |
| TB Screening | 5,057 | 4,608 | 50,381 | - | 61,777 | | (18)% | 65,777 | 169,679 | 50,381 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Panama | | | | | | | | | | | 15,672 | 4,189 |
| Condom | 147,792 | 121,992 | 2,089,632 | 3,696,114 | 3,205,824 | | (35)% | 3,308,400 | 45,276,990 | 15,672 | 15,672 | 4,103 |
| Vive | 106,848 | 90,256 | 1,644,720 | 2,951,521 | 2,620,272 | 7/00 | (37)% | 2,656,128 | 37,474,049 | 12,335 | 12,335 | 3,229 |
| Vive Colors/Mas Colors | 18,096 | 16,536 | 212,064 | 376,881 | 220,392 | 3/05 | (4)% | 263,112 | 4,248,996 | 1,590 | 1,590 | 416 |
| Vive Mas Fuerte /Retardante | 22,824 | 13,752 | 165,672 | 259,851 | 223,488 | 3/05 | (26)% | 240,288 | 1,928,959 | 1,243 | 1,243 | 325 |
| Vive Mas Natural /Sensitivo | 24 | 1,528 | 55,800 | 107,861 | 92,832 | 3/05 | (40)% | 92,832 | 915,593 | 418 | 418 | 110 |
| Vive Mas/Texturizado | - | (80) | 11,376 | - | 48,840 | 3/05 | (77)% | 56,040 | 709,393 | 85 | 85 | 22 |
| HIV Testing Services | 143 | 165 | 1,986 | 1,731 | 1,311 | | 51% | 1,395 | 20,763 | 1,986 | - | 4 |
| VCT Individual (HIV-Negative) | 129 | 147 | 1,775 | 1,564 | 1,181 | 12/11 | 50% | 1,259 | 19,875 | 1,775 | - | 3 |
| VCT Individual (HIV-Positive) | 14 | 18 | 211 | 167 | 130 | 12/11 | 62% | 136 | 888 | 211 | - | - |
| Lubricant | 2,550 | (3,014) | 90,166 | 26,474 | 28,155 | | 220% | 21,742 | 557,352 | - | - | - |
| Vive Lub (sachet) | - | (3,667) | 45,550 | 20,215 | 9,200 | 2/09 | 395% | 9,200 | 313,776 | - | - | - |
| Vive Lub (tube) | 825 | 580 | 13,321 | - | 10,856 | 2/09 | 23% | 10,843 | 89,604 | - | - | - |
| Vive Lub Natural (sachet) | - | (1,300) | 16,350 | 6,259 | 5,550 | 5/11 | 195% | (850) | 75,755 | - | - | - |
| Vive Lub Natural (tube) | 1,725 | 1,372 | 14,945 | - | 2,549 | 5/11 | 486% | 2,549 | 78,217 | - | - | - |
| Referral to Linkage to HIV Care | 13 | 15 | 174 | - | 103 | | 69% | 112 | 436 | 174 | - | 82 |
| Referral to Linkage to HIV Care | 13 | 15 | 174 | - | 103 | | 69% | 112 | 436 | 174 | - | 82 |
| Papua New Guinea | | | | | | | | | | | 1,351 | 957 |
| Condom | - | - | - | 200,000 | 62,259 | | (100)% | 62,259 | 8,050,159 | - | - | - |
| Seif Raida | - | - | - | 120,000 | 59,552 | 1/08 | (100)% | 59,552 | 6,969,005 | - | - | - |
| Seif Raida Orange Plus | - | - | - | 80,000 | 2,707 | 8/13 | (100)% | 2,707 | 1,081,154 | - | - | - |
| Diarrhea Treatment Kit | - | - | - | 2,914 | - | | 0% | - | 18,236 | - | - | - |
| DTK | - | - | - | 2,914 | - | 2/15 | -% | - | 18,236 | - | - | - |
| Emergency Contraception | - | - | - | 30,000 | - | | 0% | - | - | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Emergency Contraception | - | - | - | 30,000 | - | | -% | - | - | - | - | - |
| Female Condom | - | - | - | - | 100 | | (100)% | 100 | 338,539 | - | - | - |
| Stap Seif | - | - | - | - | 100 | 2/09 | (100)% | 100 | 338,539 | - | - | - |
| Free Condom | 104,544 | 20,016 | 164,592 | 300,800 | - | | 0% | - | 164,592 | 1,234 | 1,234 | 852 |
| Generic Male Condom | 104,544 | 20,016 | 164,592 | 300,800 | - | | -% | - | 164,592 | 1,234 | 1,234 | 852 |
| Free Female Condom | 5,310 | 3,398 | 15,504 | 30,000 | - | | 0% | - | 15,504 | 116 | 116 | 75 |
| Generic Female Condom | 5,310 | 3,398 | 15,504 | 30,000 | - | | -% | - | 15,504 | 116 | 116 | 75 |
| Lubricant | 256 | - | 256 | - | - | | 0% | - | 18,241 | - | - | - |
| Glide Lubricant | 256 | - | 256 | - | - | 2/10 | -% | - | 18,241 | - | - | - |
| Malaria PPT (ACT) | - | - | - | - | 7,782 | | (100)% | 7,782 | 845,477 | - | - | - |
| Coartem 1x12's for 1-5 years old | - | - | - | - | 95 | 8/15 | (100)% | 95 | 125,793 | - | - | - |
| Coartem 1x18's for 6-13 years old | - | - | - | - | 4,535 | 8/15 | (100)% | 4,535 | 275,970 | - | - | - |
| Coartem 1x24's for 14+ years old | - | - | - | - | 1,490 | 8/15 | (100)% | 1,490 | 259,952 | - | - | - |
| Coartem 1x6's for 2-11 months | - | - | - | - | 1,662 | 8/15 | (100)% | 1,662 | 183,762 | - | - | - |
| Malaria RDK | - | - | - | - | 4,469 | | (100)% | 4,469 | 1,361,956 | - | - | - |
| Carestart Malaria HRP2/pLDH (pf/PAN) | - | - | - | - | 4,469 | 10/13 | (100)% | 4,469 | 1,361,956 | - | - | - |
| ORS | - | - | 2,112 | - | - | | 0% | - | 31,346 | 950 | - | 26 |
| ORS | - | - | 2,112 | - | - | 12/11 | -% | - | 31,346 | 950 | - | 26 |
| Water Treatment Tablets | 2,750 | 500 | 70,110 | 80,000 | 91,160 | | (23)% | 91,160 | 1,048,893 | 1,152 | - | 3 |
| Aquatab | 2,750 | 500 | 70,110 | 80,000 | 91,160 | 12/11 | (23)% | 91,160 | 1,048,893 | 1,152 | - | 3 |
| Zinc | 70 | - | 132 | - | - | | 0% | - | 32,976 | 119 | - | 1 |
| Zinc 20 mg | 70 | - | 132 | - | - | 12/11 | -% | - | 32,976 | 119 | - | 1 |
| PSI Pakistan | | | | | | | | | | | 862,254 | 225,584 |
| Condom | 508,068 | 556,642 | 32,343,689 | 37,492,943 | 2,990,983 | | 981% | 3,369,589 | 39,202,151 | 242,578 | 242,578 | 55,228 |
| Do | - | - | 519,141 | - | - | | -% | - | 519,141 | 3,894 | 3,894 | 886 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Generic Male Condom | 508,068 | 556,642 | 5,314,639 | 37,492,943 | 2,990,983 | 4/16 | 78% | 3,369,589 | 12,173,101 | 39,860 | 39,860 | 9,075 |
| Sathi | - | - | 22,835,062 | - | - | | -% | - | 22,835,062 | 171,263 | 171,263 | 38,992 |
| Sathi Plus | - | - | 1,135,731 | - | - | | -% | - | 1,135,731 | 8,518 | 8,518 | 1,939 |
| Touch | - | - | 1,943,841 | - | - | | -% | - | 1,943,841 | 14,579 | 14,579 | 3,319 |
| Touch Delay | - | - | 595,275 | - | - | | -% | - | 595,275 | 4,465 | 4,465 | 1,016 |
| Emergency Contraception | - | - | 641,775 | - | - | | 0% | - | 641,775 | 28,880 | 28,880 | 5,051 |
| ECP | - | - | 641,775 | - | - | | -% | - | 641,775 | 28,880 | 28,880 | 5,051 |
| Emergency Contraception Provided | - | - | - | 1,146,567 | - | | 0% | - | - | - | - | - |
| Non-PSI Emergency Contraception Provided | - | - | - | 1,146,567 | - | | -% | - | - | - | - | - |
| Injectable 1 | - | - | 31,254 | - | - | | 0% | - | 31,254 | 2,164 | 2,164 | 538 |
| Femi-ject | - | - | 31,254 | - | - | | -% | - | 31,254 | 2,164 | 2,164 | 538 |
| Injectable 1 Provided | - | - | - | 44,525 | - | | 0% | - | - | - | - | - |
| Non-PSI Injectable 1 Provided | - | - | - | 44,525 | - | | -% | - | - | - | - | - |
| Injectable 2 | - | - | 78,948 | - | - | | 0% | - | 78,948 | 11,842 | 11,842 | 2,718 |
| Novaject | - | - | 78,948 | - | - | | -% | - | 78,948 | 11,842 | 11,842 | 2,718 |
| Injectable 2 Provided | - | - | - | 132,422 | - | | 0% | - | - | - | - | - |
| Non-PSI Injectable 2 Provided | - | - | - | 132,422 | - | | -% | - | - | - | - | - |
| Injectable 3-IM | - | - | 78,008 | - | (8,571) | | 0% | (8,571) | 69,437 | 17,552 | 17,552 | 4,029 |
| Depo-Provera | - | - | 88,445 | - | - | | -% | - | 88,445 | 19,900 | 19,900 | 4,568 |
| (b)PSI Injectable 3 IM Distributed Provided | - | - | (10,437) | - | (8,571) | | -% | (8,571) | (19,008) | (2,348) | (2,348) | (539) |
| Injectable 3-IM Provided | 75,614 | 7,723 | 241,712 | 744,325 | 247,253 | | (2)% | 280,576 | 747,623 | 60,428 | 60,428 | 13,871 |
| Non-PSI Injectable 3 IM Provided | 75,614 | 7,723 | 231,275 | 744,325 | 238,682 | | (3)% | 272,005 | 728,615 | 57,819 | 57,819 | 13,272 |
| PSI Injectable 3 IM Provided | - | - | 10,437 | - | 8,571 | | 22% | 8,571 | 19,008 | 2,609 | 2,609 | 599 |
| IUD 10 | - | - | 2,697 | - | - | | 0% | - | 2,697 | 2,427 | 11,166 | 3,275 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Safeload | - | - | 2,697 | - | - | | -% | - | 2,697 | 2,427 | 11,166 | 3,275 |
| IUD 10 Insertion | 28,317 | 749 | 65,731 | 65,609 | 57,136 | | 15% | 61,472 | 192,713 | 65,731 | 302,363 | 88,689 |
| Non-PSI IUD 10 Inserted | 28,317 | 749 | 65,731 | 65,609 | 57,136 | | 15% | 61,472 | 192,713 | 65,731 | 302,363 | 88,689 |
| IUD 5 | - | - | 30,353 | - | - | | 0% | - | 30,353 | 27,318 | 90,148 | 28,149 |
| Multiload | - | - | 30,353 | - | - | | -% | - | 30,353 | 27,318 | 90,148 | 28,149 |
| IUD 5 Insertion | - | 1,440 | 4,319 | 65,998 | 1,928 | | 124% | 1,928 | 11,567 | 4,319 | 14,253 | 4,450 |
| Non-PSI IUD 5 Inserted | - | 1,440 | 4,319 | 65,998 | 1,928 | | 124% | 1,928 | 11,567 | 4,319 | 14,253 | 4,450 |
| OCs | - | - | 83,939 | - | (33,625) | | 0% | (33,625) | 50,314 | 5,036 | 5,036 | 1,220 |
| Novadol | - | - | 144,168 | - | - | | -% | - | 144,168 | 8,650 | 8,650 | 2,095 |
| (b)PSI OCs Distributed Provided | - | - | (60,229) | - | (33,625) | | -% | (33,625) | (93,854) | (3,614) | (3,614) | (875) |
| OCs Provided | 344,996 | 35,877 | 1,137,675 | 1,576,577 | 647,634 | | 76% | 773,098 | 2,358,642 | 75,845 | 75,845 | 18,366 |
| Non-PSI OCs Provided | 344,996 | 35,877 | 1,077,446 | 1,576,577 | 614,009 | | 75% | 739,473 | 2,264,788 | 71,830 | 71,830 | 17,394 |
| PSI OCs Provided | - | - | 60,229 | - | 33,625 | | 79% | 33,625 | 93,854 | 4,015 | 4,015 | 972 |
| Tajikistan | | | | | | | | | | | 1,229 | 14,227 |
| Free Condom | 14,028 | 11,747 | 163,802 | 219,360 | 489,770 | | (67)% | 1,137,682 | 1,623,136 | 1,229 | 1,229 | 687 |
| Generic Male Condom | 14,028 | 11,747 | 163,802 | 219,360 | 489,770 | 8/16 | (67)% | 1,137,682 | 1,623,136 | 1,229 | 1,229 | 687 |
| HIV Self-Testing Kit | - | 17 | 52 | 2,000 | - | | 0% | - | 52 | 47 | - | - |
| HIV Self-Testing Kit (Oral Fluid) | - | - | - | 2,000 | - | | -% | - | - | - | - | - |
| ORAQUICK HIV Self-Testing Kit (Saliva based) | - | 17 | 52 | - | - | | -% | - | 52 | 47 | - | - |
| HIV Testing Services | 520 | 669 | 14,865 | 18,627 | 15,510 | | (4)% | 16,547 | 46,659 | 14,865 | - | 48 |
| VCT Individual (HIV-Negative) | 453 | 605 | 14,275 | 18,094 | 15,070 | | (5)% | 16,076 | 45,219 | 14,275 | - | 46 |
| VCT Individual (HIV-Positive) | 67 | 65 | 590 | 533 | 440 | | 34% | 471 | 1,440 | 590 | - | 2 |
| Naloxone | - | 167 | 1,995 | 3,089 | 2,500 | | (20)% | 2,570 | 18,708 | 1,796 | - | 2,722 |
| Naloxone | - | 167 | 1,995 | 3,089 | 2,500 | 1/11 | (20)% | 2,570 | 18,708 | 1,796 | - | 2,722 |
| Needle & Syringe | 43,200 | 78,533 | 796,800 | 1,085,760 | 669,365 | | 19% | 689,065 | 3,654,818 | 2,780 | - | 10,001 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Needle/Syringe | 43,200 | 78,533 | 796,800 | 1,085,760 | 669,365 | 1/11 | 19% | 689,065 | 3,654,818 | 2,780 | - | 10,001 |
| Referral to HIV Testing Services | - | - | 3 | 6 | 4 | | (25)% | 4 | 15,110 | 3 | - | - |
| Referral to HIV Testing Services | - | - | 3 | 6 | 4 | 12/13 | (25)% | 4 | 15,110 | 3 | - | - |
| Referral to Linkage to HIV Care | 84 | 87 | 967 | 731 | 623 | | 55% | 691 | 2,570 | 967 | - | 769 |
| Referral to Linkage to HIV Care | 84 | 87 | 967 | 731 | 623 | | 55% | 691 | 2,570 | 967 | - | 769 |
| Referral to Opioid Treatment | - | 3 | 46 | 37 | 61 | | (25)% | 65 | 235 | 46 | - | - |
| Referral to Opioid Treatment | - | 3 | 46 | 37 | 61 | | (25)% | 65 | 235 | 46 | - | - |
| Referral to TB Screening | - | - | - | - | 1 | | (100)% | 1 | 8 | - | - | - |
| Referrals to TB Screening | - | - | - | - | 1 | | (100)% | 1 | 8 | - | - | - |
| TB Diagnosis | 1 | - | 3 | - | - | | 0% | - | 21 | 3 | - | - |
| TB Diagnosis | 1 | - | 3 | - | - | | -% | - | 21 | 3 | - | - |
| TB Screening | 446 | 85 | 1,435 | 2,000 | 1,763 | | (19)% | 1,892 | 8,416 | 1,435 | - | - |
| TB Screening | 446 | 85 | 1,435 | 2,000 | 1,763 | | (19)% | 1,892 | 8,416 | 1,435 | - | - |
| Viet Nam | | | | | | | | | | | 6,570 | 2,205 |
| Emergency Contraception | - | - | - | - | (52) | | 0% | (52) | (104) | - | - | - |
| (b)PSI Emergency Contraception Distributed Provided | - | - | - | - | (52) | | -% | (52) | (104) | - | - | - |
| Emergency Contraception Provided | 150 | - | 150 | - | 225 | | (33)% | 225 | 1,036 | 8 | 8 | - |
| Non-PSI Emergency Contraception Provided | 150 | - | 150 | - | 173 | | (13)% | 173 | 932 | 8 | 8 | - |
| PSI Emergency Contraception Provided | - | - | - | - | 52 | | (100)% | 52 | 104 | - | - | - |
| Fever Cases Tested with RDTs | 3,130 | 3,161 | 25,576 | 20,000 | 13,934 | | 84% | 15,898 | 41,474 | 25,576 | - | - |
| Fever Cases Tested with RDTs | 3,130 | 3,161 | 25,576 | 20,000 | 13,934 | | 84% | 15,898 | 41,474 | 25,576 | - | - |
| HIV Testing Services | - | - | 552 | 552 | 6,688 | | (92)% | 6,827 | 12,603 | 552 | - | 1 |
| VCT Individual (HIV-Negative) | - | - | 527 | 527 | 6,267 | | (92)% | 6,402 | 11,753 | 527 | - | 1 |
| VCT Individual (HIV-Positive) | - | - | 25 | 25 | 421 | | (94)% | 425 | 850 | 25 | - | - |
| Hypertension Diagnosis | - | - | 7,961 | 14,572 | 26,102 | | (70)% | 26,102 | 60,396 | 7,961 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Hypertension Diagnosis | - | - | 7,961 | 14,572 | 26,102 | | (70)% | 26,102 | 60,396 | 7,961 | - | - |
| Hypertension Screening | - | - | 191,916 | 150,000 | 383,654 | | (50)% | 413,475 | 807,605 | 191,916 | - | - |
| Hypertension Screening | - | - | 191,916 | 150,000 | 383,654 | | (50)% | 413,475 | 807,605 | 191,916 | - | - |
| Hypertension_Controlled Condition | - | - | 12,035 | 13,009 | 28,481 | | (58)% | 30,443 | 62,586 | 4,814 | - | - |
| Hypertension_Controlled Condition | - | - | 12,035 | 13,009 | 28,481 | | (58)% | 30,443 | 62,586 | 4,814 | - | - |
| Implant 3 | 93 | 84 | 624 | 60 | 845 | | (26)% | 892 | 1,817 | 562 | 1,404 | 54 |
| Implanon NXT | 93 | 84 | 670 | 300 | 1,091 | 2/17 | (39)% | 1,147 | 2,153 | 603 | 1,508 | 58 |
| (b)PSI Implant 3 Distributed Inserted | - | - | (46) | (240) | (246) | | -% | (255) | (336) | (41) | (104) | (4) |
| Implant 3 Insertion | 115 | 10 | 192 | 240 | 258 | | (26)% | 267 | 539 | 192 | 480 | 18 |
| Non-PSI Implant 3 Inserted | 115 | 10 | 146 | - | 12 | | 1,117% | 12 | 203 | 146 | 365 | 14 |
| PSI Implant 3 Inserted | - | - | 46 | 240 | 246 | | (81)% | 255 | 336 | 46 | 115 | 4 |
| Implant 5 Insertion | - | - | 15 | - | - | | 0% | - | 15 | 15 | 57 | 2 |
| Non-PSI Implant 5 Inserted | - | - | 15 | - | - | | -% | - | 15 | 15 | 57 | 2 |
| Injectable 1 | - | - | - | - | (2) | | 0% | (2) | (4) | - | - | - |
| (b)PSI Injectable 1 Distributed Provided | - | - | - | - | (2) | | -% | (2) | (4) | - | - | - |
| Injectable 1 Provided | - | - | 2 | - | 2 | | 0% | 2 | 46 | - | - | - |
| Non-PSI Injectable 1 Provided | - | - | 2 | - | - | | -% | - | 42 | - | - | - |
| PSI Injectable 1 Provided | - | - | - | - | 2 | | (100)% | 2 | 4 | - | - | - |
| Injectable 3-IM | (79) | 78 | 2,410 | - | 446 | | 440% | 440 | 3,083 | 542 | 542 | 15 |
| Depoteron | 393 | 336 | 3,724 | - | 712 | 2/17 | 423% | 712 | 4,907 | 838 | 838 | 24 |
| (b)PSI Injectable 3 IM Distributed Provided | (472) | (257) | (1,314) | - | (266) | | -% | (272) | (1,824) | (296) | (296) | (8) |
| Injectable 3-IM Provided | 472 | 257 | 1,368 | - | 711 | | 92% | 735 | 2,925 | 342 | 342 | 10 |
| Non-PSI Injectable 3 IM Provided | - | - | 54 | - | 445 | | (88)% | 463 | 1,101 | 14 | 14 | - |
| PSI Injectable 3 IM Provided | 472 | 257 | 1,314 | - | 266 | | 394% | 272 | 1,824 | 329 | 329 | 9 |
| Injectable 3-SC | (102) | - | (102) | 1,400 | - | | 0% | - | (102) | (23) | (23) | (1) |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| (b)PSI Injectable 3 SC Distributed Provided | (102) | - | (102) | (5,600) | - | | -% | - | (102) | (23) | (23) | (1) |
| Sayana Press | - | - | - | 7,000 | - | | -% | - | - | - | - | - |
| Injectable 3-SC Provided | 749 | 7 | 769 | 5,600 | - | | 0% | - | 769 | 192 | 192 | 5 |
| Non-PSI Injectable 3 SC Provided | 647 | 7 | 667 | - | - | | -% | - | 667 | 167 | 167 | 5 |
| PSI Injectable 3 SC Provided | 102 | - | 102 | 5,600 | - | | -% | - | 102 | 26 | 26 | 1 |
| IUD 10 | - | 164 | 492 | - | 50 | | 884% | 50 | 611 | 443 | 2,037 | 73 |
| Copper-T 380-A IUD | - | 165 | 494 | - | 50 | 9/16 | 888% | 50 | 644 | 445 | 2,045 | 74 |
| (b)PSI IUD 10 Distributed Inserted | - | (1) | (2) | - | - | | -% | - | (33) | (2) | (8) | - |
| IUD 10 Insertion | 219 | 12 | 329 | - | 351 | | (6)% | 396 | 951 | 329 | 1,513 | 54 |
| Non-PSI IUD 10 Inserted | 219 | 11 | 327 | - | 351 | | (7)% | 396 | 918 | 327 | 1,504 | 54 |
| PSI IUD 10 Inserted | - | 1 | 2 | - | - | | -% | - | 33 | 2 | 9 | - |
| LLIN (Hammock net) | - | - | 781 | 1,350 | 1,259 | | (38)% | 1,259 | 2,085 | 703 | - | - |
| Tana Nets | - | - | 781 | 1,350 | 1,259 | | (38)% | 1,259 | 2,085 | 703 | - | - |
| Malaria PPT (ACT) | (41) | (21) | (171) | - | (156) | | 0% | (210) | (381) | (154) | - | (24) |
| (b)PSI QAACts Distributed Provided after Diagnosis | (41) | (21) | (171) | - | (156) | | -% | (210) | (381) | (154) | - | (24) |
| Malaria PPT (Non-ACT) | (1) | (12) | (67) | - | (98) | | 0% | (141) | (208) | (60) | - | (10) |
| (b)PSI Vivax Tx Distributed Provided after Diagnosis | (1) | (12) | (67) | - | (98) | | -% | (141) | (208) | (60) | - | (10) |
| Malaria RDK | 3,810 | 3,183 | 28,380 | 25,000 | 24,190 | | 17% | 24,220 | 52,600 | 25,542 | - | - |
| On-site Malaria Pf/Pv Ag Rapid Test | 1,650 | 1,180 | 5,440 | - | 24,190 | 10/17 | (78)% | 24,220 | 29,660 | 4,896 | - | - |
| SD Bioline Malaria Ag Pf/Pv Rapid Test | 2,160 | 2,003 | 22,940 | 25,000 | - | | -% | - | 22,940 | 20,646 | - | - |
| Needle & Syringe | - | - | 270,100 | 270,100 | 4,392,950 | | (94)% | 5,126,150 | 22,921,150 | 942 | - | 1,900 |
| B-braun Omnican 40 (U-40 Insulin/40I.U.) | - | - | 270,100 | 270,100 | 4,353,050 | 9/13 | (94)% | 4,610,150 | 22,405,150 | 942 | - | 1,900 |
| Co-pack LDS | - | - | - | - | 39,900 | | (100)% | 516,000 | 516,000 | - | - | - |
| OCs | - | - | - | - | (70) | | 0% | (70) | (187) | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| (b)PSI OCs Distributed Provided | - | - | - | - | (70) | | -% | (70) | (187) | - | - | - |
| OCs Provided | 268 | - | 268 | - | 567 | | (53)% | 568 | 1,786 | 18 | 18 | 1 |
| Non-PSI OCs Provided | 268 | - | 268 | - | 497 | | (46)% | 498 | 1,599 | 18 | 18 | 1 |
| PSI OCs Provided | - | - | - | - | 70 | | (100)% | 70 | 187 | - | - | - |
| Positive RDTs | 85 | 63 | 804 | 690 | 504 | | 60% | 634 | 1,616 | 804 | - | - |
| Positive RDTs | 85 | 63 | 804 | 690 | 504 | | 60% | 634 | 1,616 | 804 | - | - |
| Positive RDTs Given First Line Treatment | 42 | 33 | 539 | 550 | 305 | | 77% | 403 | 1,007 | 539 | - | - |
| Positive RDTs Given First Line Treatment | 42 | 33 | 539 | 550 | 305 | | 77% | 403 | 1,007 | 539 | - | - |
| QAACTs Provided after Confirmatory Diagnosis | 45 | 21 | 209 | 330 | 199 | | 5% | 253 | 524 | 209 | - | 39 |
| Non-PSI QAACTs Provided after Confirmed Diagnosis | 4 | - | 38 | 330 | 43 | | (12)% | 43 | 143 | 38 | - | 7 |
| PSI QAACTs Provided after Confirmed Diagnosis | 41 | 21 | 171 | - | 156 | | 10% | 210 | 381 | 171 | - | 32 |
| Referral to Linkage to HIV Care | - | - | 19 | 19 | - | | 0% | - | 19 | 19 | - | 11 |
| Referral to Linkage to HIV Care | - | - | 19 | 19 | - | | -% | - | 19 | 19 | - | 11 |
| TB Diagnosis | - | - | - | - | 434 | | (100)% | 434 | 5,371 | - | - | - |
| TB Diagnosis | - | - | - | - | 434 | | (100)% | 434 | 5,371 | - | - | - |
| Toilets Sold | - | 175 | 1,113 | 750 | 3,573 | | (69)% | 4,405 | 7,416 | 4,675 | - | 39 |
| Toilet Type 1, Direct Sales | - | 175 | 1,113 | - | 3,573 | | (69)% | 4,405 | 7,416 | 4,675 | - | 39 |
| Toilets Sold | - | - | - | 750 | - | | -% | - | - | - | - | - |
| Toilets Sold - All | - | 175 | 1,113 | - | 3,327 | | (67)% | 4,159 | 5,272 | 4,675 | - | - |
| Toilets Sold - All | - | 175 | 1,113 | - | 3,327 | | (67)% | 4,159 | 5,272 | 4,675 | - | - |
| Vivax Treatment after Confirmatory Diagnosis | 1 | 12 | 83 | 248 | 112 | | (26)% | 156 | 248 | 83 | - | 15 |
| Non-PSI Vivax Treatment after Confirmed Diagnosis | - | - | 16 | 248 | 14 | | 14% | 15 | 40 | 16 | - | 3 |
| PSI Vivax Treatment after Confirmed Diagnosis | 1 | 12 | 67 | - | 98 | | (32)% | 141 | 208 | 67 | - | 13 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Foundation Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 11/2019

| | New HIV Infections | STI Deaths | PWID Deaths | TB Deaths | CYP* | Maternal Deaths | Unintended Pregnancies | Malaria Deaths | Diarrhea Deaths | Pneumonia Deaths | Cervical Cancer Death | Sum of All Deaths |
|-------------------------|--------------------|------------|-------------|-----------|-----------|-----------------|------------------------|----------------|-----------------|------------------|-----------------------|-------------------|
| Foundation Market Group | 2,696 | 2 | - | 677 | 1,432,630 | 1,692 | 561,291 | 34,511 | 211 | 786 | 2 | 49,177 |
| Haiti | 591 | - | - | 677 | 27,921 | 13 | 8,432 | 365 | 62 | - | - | 1,210 |
| Liberia | 89 | - | - | - | 7,934 | 10 | 2,234 | - | 1 | - | - | 47 |
| Madagascar | 1,999 | 2 | - | - | 980,385 | 800 | 358,437 | 4,337 | 24 | 601 | - | 10,691 |
| Mali | 15 | - | - | - | 411,496 | 810 | 189,895 | 20,227 | 2 | - | 1 | 25,983 |
| Somaliland | 4 | - | - | - | 4,894 | 58 | 2,292 | 12 | 121 | 185 | - | 1,677 |
| South Sudan | - | - | - | - | - | - | - | 9,570 | - | - | - | 9,570 |

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 11
 Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|------------------|------------------|
| Foundation Market Group | | | | | | | | | | 1,432,630 | 3,952,020 |
| Acute Malnutrition Screening_CU5 | - | - | 389 | - | 619,055 | (100)% | 619,055 | 619,444 | 389 | - | - |
| Antiretroviral Treatment (Currently Enrolled) | 34,836 | 23,212 | 104,473 | 29,957 | 216,577 | (52)% | 216,577 | 591,048 | 8,706 | - | 17,752 |
| Antiretroviral Treatment (Newly Enrolled) | 888 | 1,818 | 6,436 | 3,317 | 3,637 | 77% | 3,898 | 14,635 | 6,436 | - | - |
| Cervical Cancer-Pap and Cryotherapy | - | - | - | - | 4 | (100)% | 4 | 4 | - | - | - |
| Cervical Cancer-VIA and Cryotherapy | 13 | 20 | 143 | 700 | 171 | (16)% | 189 | 1,485 | 143 | - | 44 |
| Cervical Cancer-VIA/VILI Screening | 5,059 | 4,002 | 22,407 | 35,000 | 12,002 | 87% | 13,295 | 96,107 | 22,407 | - | - |
| Chlorhexidine | 2,036 | 7,763 | 31,431 | 9,000 | 107,120 | (71)% | 107,120 | 464,275 | 28,288 | - | 1,839 |
| Condom | 154,896 | 327,972 | 1,749,228 | 2,920,716 | 2,987,434 | (41)% | 3,347,338 | 71,047,240 | 13,119 | 13,119 | 15,642 |
| Counseling & Tx for Moderate Acute Malnutrition | 3,347 | 1,406 | 18,707 | 20,942 | 9,126 | 105% | 20,332 | 39,039 | 18,707 | - | 58,514 |
| Diarrhea Treatment Kit | - | 1 | 82,653 | 264,416 | 156,128 | (47)% | 179,738 | 2,346,077 | 74,388 | - | 7,913 |
| Diarrhea Treatment Kit Provided | - | - | - | - | 1,812 | (100)% | 1,812 | 12,274 | - | - | - |
| Emergency Contraception | (6) | (5) | 44,764 | 15,700 | 40,026 | 12% | 40,018 | 83,725 | 2,014 | 2,014 | 548 |
| Emergency Contraception Provided | 6 | 5 | 119 | - | 274 | (57)% | 282 | 1,458 | 6 | 6 | 2 |
| Fever Cases Attended | 19,835 | 18,382 | 176,480 | 202,868 | 77,339 | 128% | 86,150 | 642,639 | 176,480 | - | - |
| Fever Cases Tested with Microscopy | 3,275 | 2,953 | 33,389 | 30,340 | 50,817 | (34)% | 56,797 | 217,631 | 33,389 | - | - |
| Fever Cases Tested with RDTs | 26,755 | 25,617 | 264,494 | 172,438 | 235,613 | 12% | 274,829 | 1,401,333 | 264,494 | - | - |
| Free Condom | 95,304 | 4,655,281 | 18,515,156 | 21,468,907 | 25,979,571 | (29)% | 28,342,179 | 54,226,284 | 138,864 | 138,864 | 156,300 |
| Free Female Condom | - | - | - | - | 253 | (100)% | 253 | 21,253 | - | - | - |
| HIV Testing Services | 46,844 | 95,636 | 502,545 | 191,074 | 365,364 | 38% | 395,037 | 1,918,231 | 502,545 | - | 3,018 |
| Implant 3 | 1,821 | 1,520 | 11,592 | 1,560 | 10,247 | 13% | 8,075 | 22,073 | 10,433 | 26,082 | 24,105 |
| Implant 3 Insertion | 5,481 | 5,256 | 53,159 | 62,393 | 42,204 | 26% | 48,078 | 152,497 | 53,159 | 132,898 | 98,379 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Implant 4 | (1) | - | (96) | - | (11) | -% | (14) | (2,624) | (86) | (276) | (265) |
| Implant 4 Insertion | 1 | - | 181 | - | 11 | 1,545% | 14 | 2,709 | 181 | 579 | 567 |
| Implant 5 | (5) | 2,393 | 20,435 | - | 5,134 | 298% | 5,334 | 134,694 | 18,392 | 69,888 | 79,435 |
| Implant 5 Insertion | 6,787 | 3,631 | 39,433 | 50,000 | 34,246 | 15% | 38,472 | 146,119 | 39,433 | 149,845 | 169,919 |
| Injectable 1 Provided | - | - | 270 | - | - | -% | - | 270 | 21 | 21 | 17 |
| Injectable 3-IM | 130,078 | 270,028 | 1,908,814 | 1,988,500 | 1,553,071 | 23% | 1,669,487 | 21,785,070 | 429,483 | 429,483 | 192,158 |
| Injectable 3-IM Provided | 8,820 | 6,520 | 69,747 | 35,040 | 69,658 | -% | 77,146 | 315,029 | 17,437 | 17,437 | 11,977 |
| Injectable 3-SC | 1,000 | 15,143 | 509,564 | 618,160 | 509,672 | -% | 535,592 | 1,926,358 | 114,652 | 114,652 | 51,237 |
| Injectable 3-SC Provided | 165 | 190 | 1,445 | - | - | -% | 175 | 1,620 | 361 | 361 | 216 |
| IPTp2 | 941 | 439 | 5,713 | 291,388 | 81,352 | (93)% | 81,911 | 291,065 | 5,713 | - | 639 |
| Iron Folic Acid Tablet | - | - | - | 19,843 | - | -% | - | - | - | - | - |
| IUD 10 | 3,884 | 722 | 11,257 | 7,000 | 7,406 | 52% | 7,568 | 56,470 | 10,131 | 46,604 | 56,136 |
| IUD 10 Insertion | 4,005 | 3,009 | 34,207 | 46,654 | 36,834 | (7)% | 40,411 | 302,251 | 34,207 | 157,352 | 129,201 |
| IUD 5 Insertion | 34 | 23 | 238 | 311 | 250 | (5)% | 299 | 537 | 238 | 785 | 785 |
| IUS 3 | 4 | (23) | (36) | 2,500 | 99 | (136)% | 98 | 62 | (32) | (81) | (46) |
| IUS 3 Insertion | 125 | 130 | 1,043 | - | 116 | 799% | 135 | 1,178 | 1,043 | 2,608 | 1,486 |
| IUS 5 | 10 | 7 | (11) | - | - | -% | - | (11) | (10) | (33) | (81) |
| IUS 5 Insertion | - | - | 82 | - | - | -% | - | 82 | 82 | 271 | 276 |
| LLIN | 2,370,787 | 379,048 | 5,338,473 | 11,942,257 | 15,027,926 | (64)% | 19,624,561 | 76,311,073 | 8,648,326 | - | 1,797,224 |
| Lubricant | 23,710 | 368,197 | 3,479,494 | 2,500,000 | 1,008,813 | 245% | 1,223,813 | 5,422,148 | - | - | - |
| Malaria PPT (ACT) | 668,764 | 315,294 | 2,840,584 | 6,053,942 | 6,708,494 | (58)% | 6,990,357 | 28,233,513 | 2,556,526 | - | 814,104 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Malaria PPT (Non-ACT) | 20,000 | 34,133 | 213,800 | 80,000 | - | -% | - | 530,040 | 192,420 | - | 23,177 |
| Malaria RDK | 1,433,175 | 191,925 | 2,689,800 | 3,650,121 | 10,860,342 | (75)% | 10,954,467 | 28,281,558 | 2,420,820 | - | - |
| Manual Vacuum Aspiration for PAC | 753 | 589 | 6,633 | 5,784 | 5,579 | 19% | 6,247 | 20,519 | 6,633 | - | 3,201 |
| Micronutrient Powder | - | - | - | - | 5,797,980 | (100)% | 5,797,980 | 16,505,640 | - | - | - |
| Misoprostol for PAC Provided | 1,611 | 1,454 | 14,908 | 15,430 | 11,622 | 28% | 12,741 | 40,468 | 14,908 | - | 7,592 |
| Misoprostol for PPH | 500 | 2,667 | 15,500 | 4,500 | 27,300 | (43)% | 30,800 | 210,208 | 4,650 | - | 101 |
| Misoprostol for Safe Abortion | 1,992 | 15,321 | 91,596 | 119,780 | 35,183 | 160% | 81,047 | 155,403 | 4,809 | - | 1,627 |
| Multivitamin | - | - | - | 24,202 | - | -% | - | - | - | - | - |
| OCs | 229,763 | 137,458 | 2,150,244 | 1,777,420 | 1,992,855 | 8% | 2,094,239 | 43,141,227 | 129,015 | 129,015 | 60,678 |
| OCs Provided | 1,553 | 996 | 11,253 | 7,495 | 15,237 | (26)% | 16,628 | 109,832 | 750 | 750 | 517 |
| ORS | 3,240 | 33,944 | 220,122 | 300,000 | 1,249,743 | (82)% | 1,249,743 | 15,827,464 | 99,055 | - | 5,540 |
| ORS Provided | 3,568 | 1,264 | 25,557 | 13,914 | 10,942 | 134% | 13,509 | 39,066 | 25,557 | - | 1,332 |
| Pneumonia PPT | 8,550 | 31,432 | 139,915 | 96,000 | 738,319 | (81)% | 738,319 | 2,979,027 | 125,924 | - | 51,346 |
| Pneumonia PPT Provided | 2,520 | 664 | 13,706 | - | 9,945 | 38% | 11,575 | 25,281 | 13,706 | - | 15,836 |
| Positive RDTs | 3,788 | 2,764 | 23,553 | 8,000 | 15,206 | 55% | 17,054 | 176,746 | 23,553 | - | - |
| QAACTs Provided after Confirmatory Diagnosis | 300 | 113 | 1,661 | 1,928 | 1,371 | 21% | 1,872 | 3,533 | 1,661 | - | 373 |
| Referral to HIV Testing Services | - | - | - | - | 5 | (100)% | 5 | 607 | - | - | - |
| Referral to Linkage to HIV Care | - | - | - | 300 | - | -% | - | - | - | - | - |
| Safe Water Solution | - | 9,618 | 370,369 | 31,680 | 1,297,351 | (71)% | 1,345,883 | 23,928,544 | 429,034 | - | 1,452 |
| SDM (Cycle Beads) | (14) | (14) | (181) | - | 5,144 | (104)% | 5,121 | 143,336 | (163) | (244) | (156) |
| SDM (Cycle Beads) Provided | 17 | 21 | 221 | - | 469 | (53)% | 503 | 5,378 | 221 | 332 | 245 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|-----------------|------------------|
| Seasonal Malaria Chemoprevention | - | - | - | 5,385,721 | 1,665,225 | (100)% | 1,665,225 | 4,076,234 | - | - | - |
| Skilled Birth Attendance | 3,111 | 1,108 | 16,909 | 17,196 | 13,771 | 23% | 16,695 | 33,604 | 16,909 | - | 24,092 |
| STI Screening | 951 | 656 | 8,459 | 83,325 | 140,029 | (94)% | 142,852 | 622,541 | 8,459 | - | - |
| TB Diagnosis | - | - | 10,115 | 12,000 | 18,240 | (45)% | 18,240 | 49,245 | 10,115 | - | - |
| TB DOTS | - | - | 11,108 | 9,960 | 22,400 | (50)% | 22,400 | 54,142 | 11,108 | - | 38,021 |
| TB Screening | - | - | 38,860 | 14,000 | 76,668 | (49)% | 76,668 | 139,061 | 38,860 | - | - |
| Toilets Sold | 5 | 2 | 86 | 4,000 | 27 | 216% | 27 | 6,384 | 493 | - | 19 |
| Toilets Sold - All | 103 | 59 | 1,781 | - | 1,515 | 18% | 1,515 | 3,296 | 10,152 | - | - |
| Treatment for Inguinal Bubo | 2 | 1 | 25 | - | 42 | (40)% | 53 | 161 | 25 | - | - |
| Treatment for Lower Abdominal Pain | 39 | 38 | 459 | - | 697 | (34)% | 800 | 2,556 | 459 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 54 | 53 | 639 | - | 5,097 | (87)% | 5,172 | 14,229 | 639 | - | 72 |
| Treatment for Pre-Eclampsia (with MgSO4) | 63 | 21 | 323 | 353 | 287 | 13% | 343 | 666 | 323 | - | 1,121 |
| Treatment for Severe Acute Malnutrition | 1,282 | 464 | 6,637 | 9,888 | 12,024 | (45)% | 12,893 | 61,176 | 6,637 | - | 25,299 |
| Treatment for Urethral Discharge (Men) | 290 | 270 | 3,304 | - | 5,216 | (37)% | 5,596 | 16,521 | 6,608 | - | 19 |
| Treatment for Urethral Discharge (Women) | - | - | - | - | - | -% | 15 | 15 | - | - | - |
| Treatment for Vaginitis | 276 | 281 | 3,001 | - | 4,658 | (36)% | 4,978 | 15,034 | 3,001 | - | 26 |
| Tubal Ligation | 3 | 5 | 30 | - | 40 | (25)% | 42 | 146 | 30 | 300 | 137 |
| Water Treatment Tablets | 572,600 | 347,047 | 4,810,742 | 6,710,250 | 10,062,080 | (52)% | 10,958,880 | 151,335,784 | 79,081 | - | 598 |
| Zinc | 2,550 | - | 2,690 | - | 512,836 | (99)% | 512,836 | 1,908,926 | 2,421 | - | 61 |
| Zinc Provided | 3,573 | 1,260 | 25,038 | 12,189 | 9,296 | 169% | 11,834 | 36,872 | 25,038 | - | 656 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|------------------|------------------|
| Foundation Market Group | | | | | | | | | | | 1,432,630 | 3,952,020 |
| Haiti | | | | | | | | | | | 27,921 | 116,908 |
| Antiretroviral Treatment (Currently Enrolled) | 34,642 | 23,212 | 104,279 | 29,957 | 216,577 | | (52)% | 216,577 | 590,854 | 8,690 | - | 17,700 |
| Antiretroviral Treatment (Currently Enrolled) | 34,642 | 23,212 | 104,279 | 29,957 | 216,577 | | (52)% | 216,577 | 590,854 | 8,690 | - | 17,700 |
| Antiretroviral Treatment (Newly Enrolled) | 334 | 1,818 | 5,788 | 3,317 | 3,561 | | 63% | 3,561 | 13,650 | 5,788 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 334 | 1,818 | 5,788 | 3,317 | 3,561 | | 63% | 3,561 | 13,650 | 5,788 | - | - |
| Cervical Cancer-VIA and Cryotherapy | - | - | 1 | - | 5 | | (80)% | 5 | 124 | 1 | - | - |
| Cervical Cancer-VIA and Cryotherapy | - | - | 1 | - | 5 | | (80)% | 5 | 124 | 1 | - | - |
| Cervical Cancer-VIA/VILI Screening | - | - | 7 | - | 28 | | (75)% | 31 | 820 | 7 | - | - |
| Cervical Cancer-VIA/VILI Screening | - | - | 7 | - | 28 | | (75)% | 31 | 820 | 7 | - | - |
| Emergency Contraception | - | - | 44,880 | 15,700 | 40,300 | | 11% | 40,300 | 85,180 | 2,020 | 2,020 | 549 |
| Levonorgestrel 1.5 mg Tablet | - | - | 44,880 | - | 40,300 | 9/17 | 11% | 40,300 | 85,180 | 2,020 | 2,020 | 549 |
| Pronta1 | - | - | - | 15,700 | - | 3/17 | -% | - | - | - | - | - |
| Emergency Contraception Provided | - | - | 3 | - | - | | 0% | - | 3 | - | - | - |
| Non-PSI Emergency Contraception Provided | - | - | 3 | - | - | | -% | - | 3 | - | - | - |
| Fever Cases Attended | 647 | 438 | 4,077 | 202,868 | 7,778 | | (48)% | 9,014 | 50,646 | 4,077 | - | - |
| Fever Cases Attended | 647 | 438 | 4,077 | 202,868 | 7,778 | | (48)% | 9,014 | 50,646 | 4,077 | - | - |
| Fever Cases Tested with Microscopy | 2,351 | 1,939 | 27,184 | 30,340 | 48,857 | | (44)% | 54,725 | 202,419 | 27,184 | - | - |
| Fever Cases Tested with Microscopy | 2,351 | 1,939 | 27,184 | 30,340 | 48,857 | | (44)% | 54,725 | 202,419 | 27,184 | - | - |
| Fever Cases Tested with RDTs | 11,967 | 11,717 | 134,142 | 172,438 | 187,811 | | (29)% | 221,408 | 901,982 | 134,142 | - | - |
| Fever Cases Tested with RDTs | 11,967 | 11,717 | 134,142 | 172,438 | 187,811 | | (29)% | 221,408 | 901,982 | 134,142 | - | - |
| Free Condom | - | 204,144 | 2,874,510 | 2,000,000 | 6,427,738 | | (55)% | 8,256,538 | 11,131,048 | 21,559 | 21,559 | 15,806 |
| Generic Condom | - | 204,144 | 2,874,510 | 2,000,000 | 6,427,738 | 3/17 | (55)% | 8,256,538 | 11,131,048 | 21,559 | 21,559 | 15,806 |
| HIV Testing Services | 14,175 | 79,204 | 251,788 | 136,153 | 127,117 | | 98% | 127,117 | 918,746 | 251,788 | - | 2,030 |
| VCT Individual (HIV-Negative) | 13,865 | 77,426 | 246,143 | 133,702 | 122,702 | 4/10 | 101% | 122,702 | 879,784 | 246,143 | - | 1,985 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|----------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| VCT Individual (HIV-Positive) | 310 | 1,778 | 5,645 | 2,451 | 4,415 | 4/10 | 28% | 4,415 | 38,962 | 5,645 | - | 46 |
| Implant 3 | - | - | - | 1,200 | 2,016 | | (100)% | 2,016 | 4,032 | - | - | - |
| Implanon NXT | - | - | - | 1,200 | 2,016 | 7/17 | (100)% | 2,016 | 4,032 | - | - | - |
| Implant 3 Insertion | 14 | 8 | 115 | 120 | 447 | | (74)% | 465 | 802 | 115 | 288 | 140 |
| Non-PSI Implant 3 Inserted | 14 | 8 | 115 | 120 | 447 | | (74)% | 465 | 802 | 115 | 288 | 140 |
| Injectable 3-IM Provided | - | - | - | - | 949 | | (100)% | 949 | 1,137 | - | - | - |
| Non-PSI Injectable 3 IM Provided | - | - | - | - | 949 | | (100)% | 949 | 1,137 | - | - | - |
| Injectable 3-SC | - | - | - | 10,560 | 12,500 | | (100)% | 12,500 | 12,500 | - | - | - |
| Sayana Press | - | - | - | 10,560 | 12,500 | 3/17 | (100)% | 12,500 | 12,500 | - | - | - |
| Injectable 3-SC Provided | 82 | 55 | 734 | - | - | | 0% | 175 | 909 | 184 | 184 | 66 |
| Non-PSI Injectable 3 SC Provided | 82 | 55 | 734 | - | - | | -% | 175 | 909 | 184 | 184 | 66 |
| IUD 10 | - | - | 450 | - | 50 | | 800% | 50 | 2,747 | 405 | 1,863 | 854 |
| Confiance Plus IUD | - | - | 450 | - | 50 | 12/13 | 800% | 50 | 2,747 | 405 | 1,863 | 854 |
| IUD 10 Insertion | 3 | 7 | 65 | 900 | 116 | | (44)% | 125 | 389 | 65 | 299 | 137 |
| Non-PSI IUD 10 Inserted | 3 | 7 | 65 | 900 | 116 | | (44)% | 125 | 389 | 65 | 299 | 137 |
| IUD 5 Insertion | 8 | - | 9 | - | - | | 0% | - | 9 | 9 | 30 | 14 |
| Non-PSI IUD 5 Inserted | 8 | - | 9 | - | - | | -% | - | 9 | 9 | 30 | 14 |
| IUS 5 | 10 | 7 | 30 | - | - | | 0% | - | 30 | 27 | 89 | 43 |
| LNG IUS - Bayer | 10 | 7 | 30 | - | - | | -% | - | 30 | 27 | 89 | 43 |
| LLIN | - | 61,119 | 226,310 | 272,770 | 33,536 | | 575% | 36,486 | 3,931,636 | 366,622 | - | 12,373 |
| LLIN Free | - | 61,119 | 226,310 | 272,770 | 33,536 | 1/08 | 575% | 36,486 | 3,931,636 | 366,622 | - | 12,373 |
| Lubricant | - | 173,333 | 2,170,072 | 500,000 | 8,000 | | 27026% | 223,000 | 2,393,072 | - | - | - |
| Lube Sachet Free | - | 173,333 | 2,170,072 | 500,000 | 8,000 | 3/17 | 27,026% | 223,000 | 2,393,072 | - | - | - |
| Malaria PPT (Non-ACT) | 20,000 | 34,133 | 213,800 | 80,000 | - | | 0% | - | 530,040 | 192,420 | - | 23,177 |
| Chloroquine | 20,000 | 34,133 | 213,800 | 80,000 | - | 3/12 | -% | - | 530,040 | 192,420 | - | 23,177 |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| OCs | - | - | 25,532 | 21,120 | 76,322 | | (67)% | 76,322 | 101,854 | 1,532 | 1,532 | 577 |
| MEURI | - | - | 25,532 | 21,120 | 76,322 | 3/17 | (67)% | 76,322 | 101,854 | 1,532 | 1,532 | 577 |
| OCs Provided | 150 | 114 | 888 | - | 1,146 | | (23)% | 1,413 | 2,643 | 59 | 59 | 22 |
| Non-PSI OCs Provided | 150 | 114 | 888 | - | 1,146 | | (23)% | 1,413 | 2,643 | 59 | 59 | 22 |
| ORS | 240 | 33,944 | 217,042 | 300,000 | - | | 0% | - | 10,264,380 | 97,669 | - | 5,398 |
| Sel Lavi | 240 | 33,944 | 217,042 | 300,000 | - | 10/99 | -% | - | 10,264,380 | 97,669 | - | 5,398 |
| Positive RDTs | 686 | 495 | 4,568 | 8,000 | 7,201 | | (37)% | 8,354 | 44,252 | 4,568 | - | - |
| Positive RDTs | 686 | 495 | 4,568 | 8,000 | 7,201 | | (37)% | 8,354 | 44,252 | 4,568 | - | - |
| STI Screening | - | - | - | 80,737 | 127,773 | | (100)% | 127,773 | 535,770 | - | - | - |
| STI Screening | - | - | - | 80,737 | 127,773 | | (100)% | 127,773 | 535,770 | - | - | - |
| TB Diagnosis | - | - | 10,115 | 12,000 | 18,240 | | (45)% | 18,240 | 49,245 | 10,115 | - | - |
| TB Diagnosis | - | - | 10,115 | 12,000 | 18,240 | | (45)% | 18,240 | 49,245 | 10,115 | - | - |
| TB DOTS | - | - | 11,108 | 9,960 | 22,400 | | (50)% | 22,400 | 54,142 | 11,108 | - | 38,021 |
| TB DOTS | - | - | 11,108 | 9,960 | 22,400 | | (50)% | 22,400 | 54,142 | 11,108 | - | 38,021 |
| TB Screening | - | - | 38,860 | 14,000 | 76,668 | | (49)% | 76,668 | 139,061 | 38,860 | - | - |
| TB Screening | - | - | 38,860 | 14,000 | 76,668 | | (49)% | 76,668 | 139,061 | 38,860 | - | - |
| Treatment for Nonherpetic Genital Ulcer | - | - | - | - | 4,007 | | (100)% | 4,007 | 10,724 | - | - | - |
| Treatment for Nonherpetic Genital Ulcer | - | - | - | - | 4,007 | | (100)% | 4,007 | 10,724 | - | - | - |
| Liberia | | | | | | | | | | | 7,934 | 7,826 |
| Antiretroviral Treatment (Currently Enrolled) | 194 | - | 194 | - | - | | 0% | - | 194 | 16 | - | 52 |
| Antiretroviral Treatment (Currently Enrolled) | 194 | - | 194 | - | - | | -% | - | 194 | 16 | - | 52 |
| Antiretroviral Treatment (Newly Enrolled) | 554 | - | 648 | - | 76 | | 753% | 337 | 985 | 648 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 554 | - | 648 | - | 76 | | 753% | 337 | 985 | 648 | - | - |
| Condom | - | - | 132,672 | - | 986,692 | | (87)% | 1,042,072 | 6,628,730 | 995 | 995 | 952 |
| STAR | - | - | 132,672 | - | 986,692 | 7/09 | (87)% | 1,042,072 | 6,628,730 | 995 | 995 | 952 |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Free Condom | 28,800 | 165,600 | 925,200 | 3,758,480 | 390,240 | | 137% | 606,240 | 1,680,581 | 6,939 | 6,939 | 6,640 |
| Generic Condom | 28,800 | 165,600 | 925,200 | 3,758,480 | 390,240 | 5/17 | 137% | 606,240 | 1,680,581 | 6,939 | 6,939 | 6,640 |
| Free Female Condom | - | - | - | - | 253 | | (100)% | 253 | 21,253 | - | - | - |
| Generic Female Condom | - | - | - | - | 253 | 5/17 | (100)% | 253 | 21,253 | - | - | - |
| HIV Testing Services | 2,826 | 2,106 | 14,855 | 17,084 | 10,998 | | 35% | 12,049 | 29,160 | 14,855 | - | 90 |
| VCT Individual (HIV-Negative) | 2,750 | 1,985 | 14,203 | 17,084 | 10,483 | 5/14 | 35% | 11,479 | 27,861 | 14,203 | - | 86 |
| VCT Individual (HIV-Positive) | 76 | 121 | 652 | - | 515 | 5/14 | 27% | 570 | 1,299 | 652 | - | 4 |
| Lubricant | 8,000 | 188,000 | 1,259,000 | 2,000,000 | 431,750 | | 192% | 431,750 | 1,860,891 | - | - | - |
| Lube Sachet Free | 8,000 | 188,000 | 1,259,000 | 2,000,000 | 431,750 | 5/17 | 192% | 431,750 | 1,860,891 | - | - | - |
| Referral to HIV Testing Services | - | - | - | - | 5 | | (100)% | 5 | 607 | - | - | - |
| Referral to HIV Testing Services | - | - | - | - | 5 | 12/13 | (100)% | 5 | 607 | - | - | - |
| Referral to Linkage to HIV Care | - | - | - | 300 | - | | 0% | - | - | - | - | - |
| Referral to Linkage to HIV Care | - | - | - | 300 | - | | -% | - | - | - | - | - |
| Safe Water Solution | - | 1,328 | 25,774 | 31,680 | 33,480 | | (23)% | 37,800 | 798,463 | 21,184 | - | 91 |
| WaterGuard | - | 1,328 | 25,774 | 31,680 | 33,480 | 7/09 | (23)% | 37,800 | 798,463 | 21,184 | - | 91 |
| STI Screening | - | - | - | - | - | | 0% | 63 | 64 | - | - | - |
| STI Screening | - | - | - | - | - | | -% | 63 | 64 | - | - | - |
| Treatment for Lower Abdominal Pain | - | - | - | - | - | | 0% | 48 | 48 | - | - | - |
| Treatment for Lower Abdominal Pain | - | - | - | - | - | | -% | 48 | 48 | - | - | - |
| Treatment for Urethral Discharge (Women) | - | - | - | - | - | | 0% | 15 | 15 | - | - | - |
| Treatment for Urethral Discharge (Women) | - | - | - | - | - | | -% | 15 | 15 | - | - | - |
| Madagascar | | | | | | | | | | | 980,385 | 987,612 |
| Cervical Cancer-Pap and Cryotherapy | - | - | - | - | 4 | | (100)% | 4 | 4 | - | - | - |
| Cervical Cancer-PAP and Cryotherapy | - | - | - | - | 4 | | (100)% | 4 | 4 | - | - | - |
| Cervical Cancer-VIA and Cryotherapy | 2 | 2 | 24 | - | 57 | | (58)% | 63 | 204 | 24 | - | 8 |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Cervical Cancer-VIA and Cryotherapy | 2 | 2 | 24 | - | 57 | | (58)% | 63 | 204 | 24 | - | 8 |
| Cervical Cancer-VIA/VILI Screening | 58 | 53 | 592 | - | 833 | | (29)% | 899 | 3,024 | 592 | - | - |
| Cervical Cancer-VIA/VILI Screening | 58 | 53 | 592 | - | 833 | | (29)% | 899 | 3,024 | 592 | - | - |
| Chlorhexidine | 2,036 | 7,763 | 31,431 | 9,000 | 107,120 | | (71)% | 107,120 | 464,275 | 28,288 | - | 1,839 |
| Arofoitra | 2,036 | 7,763 | 31,431 | 9,000 | 107,120 | 9/15 | (71)% | 107,120 | 464,275 | 28,288 | - | 1,839 |
| Condom | 154,896 | 327,972 | 1,616,556 | 2,920,716 | 2,000,742 | | (19)% | 2,305,266 | 64,418,510 | 12,124 | 12,124 | 14,690 |
| Protector Plus | 154,896 | 324,672 | 1,347,456 | 2,680,416 | 516,432 | 1/08 | 161% | 573,456 | 59,714,690 | 10,106 | 10,106 | 12,244 |
| YES | - | 3,300 | 269,100 | 240,300 | 1,484,310 | 9/14 | (82)% | 1,731,810 | 4,703,820 | 2,018 | 2,018 | 2,445 |
| Diarrhea Treatment Kit | - | 1 | 2,653 | 44,000 | 45,958 | | (94)% | 49,568 | 1,157,847 | 2,388 | - | 56 |
| Hydrazinc | - | - | - | - | 13,754 | 1/10 | (100)% | 13,754 | 701,539 | - | - | - |
| ORS-Zinc | - | 1 | 2,653 | 44,000 | 34,016 | 8/14 | (92)% | 37,626 | 468,582 | 2,388 | - | 56 |
| (b)PSI Diarrhea Treatment Kit Distributed Provided | - | - | - | - | (1,812) | | -% | (1,812) | (12,274) | - | - | - |
| Diarrhea Treatment Kit Provided | - | - | - | - | 1,812 | | (100)% | 1,812 | 12,274 | - | - | - |
| PSI Diarrhea Treatment Kit Provided | - | - | - | - | 1,812 | | (100)% | 1,812 | 12,274 | - | - | - |
| Emergency Contraception | (6) | (5) | (116) | - | (274) | | 0% | (282) | (1,455) | (5) | (5) | (2) |
| (b)PSI Emergency Contraception Distributed Provided | (6) | (5) | (116) | - | (274) | | -% | (282) | (1,455) | (5) | (5) | (2) |
| Emergency Contraception Provided | 6 | 5 | 116 | - | 274 | | (58)% | 282 | 1,455 | 6 | 6 | 2 |
| PSI Emergency Contraception Provided | 6 | 5 | 116 | - | 274 | | (58)% | 282 | 1,455 | 6 | 6 | 2 |
| Fever Cases Attended | 19,188 | 17,945 | 172,403 | - | 69,561 | | 148% | 77,136 | 591,993 | 172,403 | - | - |
| Fever Cases Attended | 19,188 | 17,945 | 172,403 | - | 69,561 | | 148% | 77,136 | 591,993 | 172,403 | - | - |
| Fever Cases Tested with Microscopy | 924 | 1,014 | 6,205 | - | 1,960 | | 217% | 2,072 | 15,212 | 6,205 | - | - |
| Fever Cases Tested with Microscopy | 924 | 1,014 | 6,205 | - | 1,960 | | 217% | 2,072 | 15,212 | 6,205 | - | - |
| Fever Cases Tested with RDTs | 14,788 | 13,901 | 130,352 | - | 47,802 | | 173% | 53,421 | 499,351 | 130,352 | - | - |
| Fever Cases Tested with RDTs | 14,788 | 13,901 | 130,352 | - | 47,802 | | 173% | 53,421 | 499,351 | 130,352 | - | - |
| Free Condom | 66,504 | 4,267,337 | 14,603,846 | 15,510,427 | 19,161,393 | | (24)% | 19,479,201 | 41,302,855 | 109,529 | 109,529 | 132,707 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Generic Condom | - | - | - | - | 15,700 | 10/16 | (100)% | 15,700 | 7,235,508 | - | - | - |
| KPOTY | 66,504 | 4,267,337 | 14,603,846 | 15,510,427 | 19,145,693 | 1/18 | (24)% | 19,463,501 | 34,067,347 | 109,529 | 109,529 | 132,707 |
| HIV Testing Services | 27,587 | 13,313 | 219,329 | 24,117 | 218,819 | | 0% | 243,365 | 941,246 | 219,329 | - | 739 |
| VCT Individual (HIV-Negative) | 27,558 | 13,256 | 218,708 | 23,065 | 218,262 | 12/09 | -% | 242,688 | 938,921 | 218,708 | - | 737 |
| VCT Individual (HIV-Positive) | 29 | 57 | 621 | 1,052 | 557 | 12/09 | 11% | 677 | 2,325 | 621 | - | 2 |
| Implant 3 | 1,022 | 1,452 | 4,591 | - | 6,935 | | (34)% | 4,681 | 9,195 | 4,132 | 10,330 | 6,266 |
| Implanon | - | - | - | - | 2,007 | 7/06 | (100)% | 2,007 | 35,127 | - | - | - |
| Implanon NXT | 4,998 | 5,720 | 44,514 | 44,320 | 34,212 | 5/17 | 30% | 36,178 | 84,219 | 40,063 | 100,157 | 60,760 |
| (b)PSI Implant 3 Distributed Inserted | (3,976) | (4,268) | (39,923) | (44,320) | (29,284) | | -% | (33,504) | (110,151) | (35,931) | (89,827) | (54,493) |
| Implant 3 Insertion | 3,976 | 4,268 | 39,923 | 44,320 | 29,284 | | 36% | 33,504 | 110,151 | 39,923 | 99,808 | 60,548 |
| PSI Implant 3 Inserted | 3,976 | 4,268 | 39,923 | 44,320 | 29,284 | | 36% | 33,504 | 110,151 | 39,923 | 99,808 | 60,548 |
| Implant 4 | (1) | - | (11) | - | (11) | | 0% | (14) | (2,539) | (10) | (32) | (19) |
| (b)PSI Implant 4 Distributed Inserted | (1) | - | (11) | - | (11) | | -% | (14) | (2,539) | (10) | (32) | (19) |
| Implant 4 Insertion | 1 | - | 11 | - | 11 | | 0% | 14 | 2,539 | 11 | 35 | 21 |
| PSI Implant 4 Inserted | 1 | - | 11 | - | 11 | | -% | 14 | 2,539 | 11 | 35 | 21 |
| Implant 5 | (5) | (7) | (66) | - | (265) | | 0% | (265) | 1,440 | (59) | (226) | (134) |
| Jadelle | - | - | - | - | 20 | 7/14 | (100)% | 20 | 3,703 | - | - | - |
| (b)PSI Implant 5 Distributed Inserted | (5) | (7) | (66) | - | (285) | | -% | (285) | (2,263) | (59) | (226) | (134) |
| Implant 5 Insertion | 5 | 7 | 66 | - | 285 | | (77)% | 285 | 2,263 | 66 | 251 | 149 |
| PSI Implant 5 Inserted | 5 | 7 | 66 | - | 285 | | (77)% | 285 | 2,263 | 66 | 251 | 149 |
| Injectable 3-IM | 129,578 | 269,861 | 1,906,219 | 1,985,000 | 1,548,127 | | 23% | 1,664,193 | 21,754,222 | 428,899 | 428,899 | 191,671 |
| Confiance Injectable | - | 6,771 | 384,066 | 1,985,000 | 1,583,535 | 10/98 | (76)% | 1,702,545 | 20,435,562 | 86,415 | 86,415 | 38,618 |
| (b)PSI Injectable 3 IM Distributed Provided | (2,269) | (2,483) | (27,657) | - | (35,408) | | -% | (38,352) | (231,150) | (6,223) | (6,223) | (2,781) |
| Triclofem Injection 150 mg/mL | 131,847 | 265,573 | 1,549,810 | - | - | | -% | - | 1,549,810 | 348,707 | 348,707 | 155,834 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Injectable 3-IM Provided | 2,269 | 2,483 | 27,657 | - | 35,408 | | (22)% | 38,352 | 231,150 | 6,914 | 6,914 | 3,090 |
| PSI Injectable 3 IM Provided | 2,269 | 2,483 | 27,657 | - | 35,408 | | (22)% | 38,352 | 231,150 | 6,914 | 6,914 | 3,090 |
| Injectable 3-SC | 1,000 | 15,143 | 509,564 | 607,600 | 497,172 | | 2% | 523,092 | 1,913,858 | 114,652 | 114,652 | 51,237 |
| Sayana Press | 1,000 | 15,143 | 509,564 | 607,600 | 497,172 | 9/15 | 2% | 523,092 | 1,913,858 | 114,652 | 114,652 | 51,237 |
| IPTp2 | - | - | - | 287,518 | 78,153 | | (100)% | 78,153 | 281,594 | - | - | - |
| IPTp2 | - | - | - | 287,518 | 78,153 | | (100)% | 78,153 | 281,594 | - | - | - |
| IUD 10 | 1,510 | (395) | (3,084) | - | 1,867 | | (265)% | 1,979 | 15,259 | (2,776) | (12,768) | (7,249) |
| Copper T | 56 | 335 | 2,168 | 17,754 | 4,295 | 5/06 | (50)% | 4,320 | 199,920 | 1,951 | 8,976 | 5,096 |
| IUD 1 x 5 | - | - | - | - | 25 | 8/11 | (100)% | 25 | 5,285 | - | - | - |
| Pregna T Cu 380A | 3,135 | 992 | 12,197 | - | 13,483 | 7/17 | (10)% | 15,143 | 32,497 | 10,977 | 50,496 | 28,669 |
| (b)PSI IUD 10 Distributed Inserted | (1,681) | (1,722) | (17,449) | (17,754) | (15,936) | | -% | (17,509) | (222,443) | (15,704) | (72,239) | (41,014) |
| IUD 10 Insertion | 1,681 | 1,722 | 17,449 | 17,754 | 15,936 | | 9% | 17,509 | 222,443 | 17,449 | 80,265 | 45,571 |
| PSI IUD 10 Inserted | 1,681 | 1,722 | 17,449 | 17,754 | 15,936 | | 9% | 17,509 | 222,443 | 17,449 | 80,265 | 45,571 |
| IUS 3 | 4 | (23) | (36) | 2,500 | 99 | | (136)% | 98 | 62 | (32) | (81) | (46) |
| Avibela (52 mg levonorgestrel) | 129 | 106 | 1,007 | 2,500 | 215 | 2/18 | 368% | 233 | 1,240 | 906 | 2,266 | 1,291 |
| (b)PSI IUS 3 Distributed Inserted | (125) | (130) | (1,043) | - | (116) | | -% | (135) | (1,178) | (939) | (2,347) | (1,337) |
| IUS 3 Insertion | 125 | 130 | 1,043 | - | 116 | | 799% | 135 | 1,178 | 1,043 | 2,608 | 1,486 |
| PSI IUS 3 Inserted | 125 | 130 | 1,043 | - | 116 | | 799% | 135 | 1,178 | 1,043 | 2,608 | 1,486 |
| LLIN | 156,320 | 333 | 747,976 | 2,377,984 | 9,910,832 | | (92)% | 13,921,182 | 34,021,579 | 1,211,721 | - | 29,584 |
| Dawa Plus Blue | - | - | - | - | 1,111,214 | | (100)% | 1,161,814 | 1,161,814 | - | - | - |
| Dawa Plus White | - | - | 131,050 | - | 4,575,896 | 4/18 | (97)% | 6,891,750 | 7,022,800 | 212,301 | - | 5,183 |
| Generic net "PERMANET WHITE" | - | - | 130 | - | 1,760 | 5/15 | (93)% | 1,760 | 9,216,166 | 211 | - | 5 |
| Interceptor White | - | - | - | 1,000,000 | - | 5/09 | -% | - | 1,099,951 | - | - | - |
| PermaNet | 100 | - | 39,150 | - | 1,261,812 | 3/07 | (97)% | 2,216,858 | 4,705,781 | 63,423 | - | 1,548 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Safe Net Blue | - | - | 8,650 | - | 1,293,650 | | (99)% | 1,732,600 | 1,741,250 | 14,013 | - | 342 |
| Safe Net White | - | - | 363,400 | - | 442,800 | | (18)% | 495,650 | 859,050 | 588,708 | - | 14,373 |
| Super Moustiquaire | 156,220 | 333 | 173,946 | 450,000 | 455,722 | 9/01 | (62)% | 482,572 | 3,834,550 | 281,793 | - | 6,880 |
| Yorkool Blue (Generic Net) | - | - | - | 927,984 | 218,400 | 7/15 | (100)% | 313,000 | 1,378,824 | - | - | - |
| Yorkool White (Generic Net) | - | - | 31,650 | - | 549,578 | 9/13 | (94)% | 625,178 | 3,001,393 | 51,273 | - | 1,252 |
| Lubricant | 15,710 | 6,863 | 50,422 | - | 569,063 | | (91)% | 569,063 | 1,168,185 | - | - | - |
| Gel Lubricant 5 mL | 15,710 | 6,863 | 50,422 | - | 569,063 | 12/16 | (91)% | 569,063 | 1,168,185 | - | - | - |
| Malaria PPT (ACT) | 447,005 | 23,644 | 1,325,195 | 1,403,822 | 3,507,514 | | (62)% | 3,507,514 | 8,003,914 | 1,192,676 | - | 336,444 |
| ACT 100 mg (1x3's) | - | - | - | - | 331,575 | 7/15 | (100)% | 331,575 | 574,532 | - | - | - |
| ACT 100 mg (1x6's) | - | - | - | - | 318,325 | 7/15 | (100)% | 318,325 | 560,050 | - | - | - |
| ACT 25 mg (1x3's) | - | - | - | - | 280,575 | 7/15 | (100)% | 280,575 | 520,199 | - | - | - |
| ACT 50 mg (1x3's) | - | - | - | - | 773,650 | 7/15 | (100)% | 773,650 | 1,454,575 | - | - | - |
| AL for Adolescent, 20/120mg, 18's | - | - | - | - | 20,581 | 7/16 | (100)% | 20,581 | 67,103 | - | - | - |
| AL for Adult, 20/120mg, 24's | - | - | - | - | 28,330 | 7/16 | (100)% | 28,330 | 98,705 | - | - | - |
| AL for Infant, 20/120mg, 6's | - | - | - | - | 11,097 | 7/16 | (100)% | 11,097 | 43,625 | - | - | - |
| AL for Toddler, 20/120mg, 12's | - | - | - | - | 37,176 | 7/16 | (100)% | 37,176 | 100,505 | - | - | - |
| ASAQ for Adolescent, 100/270mg, 3's | - | - | 146,247 | - | 503,415 | 7/16 | (71)% | 503,415 | 1,034,823 | 131,622 | - | 37,130 |
| ASAQ for Adult, 100/270mg, 6's | - | - | 196,332 | - | 542,613 | 7/16 | (64)% | 542,613 | 1,196,686 | 176,699 | - | 49,845 |
| ASAQ for Infant, 25/67.5mg, 3's | 25 | 23,629 | 125,758 | - | 69,596 | 7/16 | 81% | 69,596 | 371,787 | 113,182 | - | 31,928 |
| ASAQ for Toddler, 50/135mg, 3's | - | 14 | 263,628 | - | 590,581 | 7/16 | (55)% | 590,581 | 1,388,094 | 237,265 | - | 66,931 |
| PRIVATE - AS/AQ 100mg+270mg (base) - 3 - Blister-3 | - | - | - | 46,149 | - | | -% | - | - | - | - | - |
| PRIVATE - AS/AQ 100mg+270mg (base) - 3 - Blister-6 | - | - | - | 127,100 | - | | -% | - | - | - | - | - |
| PRIVATE - AS/AQ 25mg+67.5mg (base) - 3 - Blister-3 | - | - | - | 35,331 | - | | -% | - | - | - | - | - |
| PRIVATE - AS/AQ 50mg+135mg (base) - 3 - Blister-3 | - | - | - | 145,989 | - | | -% | - | - | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| PRIVATE A/L(20/120mg,FDC,24's,Indiv) | - | - | - | 30,501 | - | | -% | - | - | - | - | - |
| PRIVATE A/L(20/120mg,FDC,6x1,Indiv) | - | - | - | 11,602 | - | | -% | - | - | - | - | - |
| PRIVATE A/L(20/120mg,FDC,6x2,Indiv) | - | - | - | 21,214 | - | | -% | - | - | - | - | - |
| PRIVATE A/L(20/120mg,FDC,6x3,Indiv) | - | - | - | 15,839 | - | | -% | - | - | - | - | - |
| PUBLIC - AS/AQ 100mg+270mg (base) - 3 - Blister-3 | 28,335 | - | 28,335 | 144,112 | - | | -% | - | 28,335 | 25,502 | - | 7,194 |
| PUBLIC - AS/AQ 100mg+270mg (base) - 3 - Blister-6 | - | - | - | 138,865 | - | | -% | - | - | - | - | - |
| PUBLIC - AS/AQ 25mg+67.5mg (base) - 3 - Blister-3 | 137,675 | - | 157,925 | 157,923 | - | | -% | - | 157,925 | 142,133 | - | 40,094 |
| PUBLIC - AS/AQ 50mg+135mg (base) - 3 - Blister-3 | 280,970 | - | 406,970 | 407,046 | - | | -% | - | 406,970 | 366,273 | - | 103,323 |
| PUBLIC A/L(20/120mg,FDC,6x1,Indiv) | - | - | - | 12,217 | - | | -% | - | - | - | - | - |
| PUBLIC A/L(20/120mg,FDC,6x2,Indiv) | - | - | - | 31,424 | - | | -% | - | - | - | - | - |
| PUBLIC A/L(20/120mg,FDC,6x3,Indiv) | - | - | - | 19,574 | - | | -% | - | - | - | - | - |
| PUBLIC A/L(20/120mg,FDC,6x4,Indiv) | - | - | - | 58,936 | - | | -% | - | - | - | - | - |
| Malaria RDK | 1,394,175 | 68,200 | 2,111,975 | 2,374,725 | 7,698,425 | | (73)% | 7,698,425 | 19,211,838 | 1,900,778 | - | - |
| RDT Malaria | 1,394,175 | 68,200 | 2,111,975 | 2,374,725 | 7,698,425 | 8/11 | (73)% | 7,698,425 | 19,211,838 | 1,900,778 | - | - |
| Manual Vacuum Aspiration for PAC | 399 | 272 | 2,737 | 2,334 | 2,458 | | 11% | 2,719 | 8,913 | 2,737 | - | 864 |
| MVA for PAC | 399 | 272 | 2,737 | 2,334 | 2,458 | 12/16 | 11% | 2,719 | 8,913 | 2,737 | - | 864 |
| Micronutrient Powder | - | - | - | - | 5,797,980 | | (100)% | 5,797,980 | 16,505,640 | - | - | - |
| ZAZATOMADY (ZZT) | - | - | - | - | 5,797,980 | 2/13 | (100)% | 5,797,980 | 16,505,640 | - | - | - |
| Misoprostol for PAC Provided | 1,002 | 884 | 8,346 | 4,430 | 5,779 | | 44% | 6,438 | 19,694 | 8,346 | - | 3,093 |
| PSI Misoprostol for PAC Provided | 1,002 | 884 | 8,346 | 4,430 | 5,779 | | 44% | 6,438 | 19,694 | 8,346 | - | 3,093 |
| Misoprostol for Safe Abortion | 1,992 | 15,321 | 91,596 | 69,780 | 35,183 | | 160% | 81,047 | 153,003 | 4,809 | - | 1,627 |
| Misoprostol 200 mcg Tablet | 6,000 | 18,857 | 124,980 | 87,500 | 58,299 | 3/18 | 114% | 106,799 | 231,779 | 6,561 | - | 2,220 |
| (b)PSI Misoprostol for Safe Abortion Dist Provided | (4,008) | (3,536) | (33,384) | (17,720) | (23,116) | | -% | (25,752) | (78,776) | (1,753) | - | (593) |
| OCs | 229,763 | 137,458 | 2,124,712 | 1,730,300 | 1,893,444 | | 12% | 1,994,828 | 42,889,333 | 127,483 | 127,483 | 60,101 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Combination 3 | 1,000 | 9,656 | 742,440 | - | - | | -% | - | 742,440 | 44,546 | 44,546 | 21,001 |
| Microgynon | 229,118 | 98,692 | 1,176,481 | - | 1,446,825 | 2/18 | (19)% | 1,471,355 | 2,647,836 | 70,589 | 70,589 | 33,279 |
| Pilplan | - | 29,470 | 209,745 | 1,730,300 | 453,813 | 10/98 | (54)% | 531,113 | 39,591,072 | 12,585 | 12,585 | 5,933 |
| (b)PSI OCs Distributed Provided | (355) | (359) | (3,954) | - | (7,194) | | -% | (7,640) | (92,015) | (237) | (237) | (112) |
| OCs Provided | 355 | 359 | 3,954 | - | 7,194 | | (45)% | 7,640 | 92,015 | 264 | 264 | 124 |
| PSI OCs Provided | 355 | 359 | 3,954 | - | 7,194 | | (45)% | 7,640 | 92,015 | 264 | 264 | 124 |
| ORS | - | - | 80 | - | 39,368 | | (100)% | 39,368 | 39,448 | 36 | - | 1 |
| SRO Generique | - | - | 80 | - | 39,368 | 4/18 | (100)% | 39,368 | 39,448 | 36 | - | 1 |
| Pneumonia PPT | 8,550 | 31,432 | 139,915 | 96,000 | 157,872 | | (11)% | 157,872 | 931,329 | 125,924 | - | 51,346 |
| Pneumox 250 (10's) | 8,550 | 31,432 | 139,915 | - | - | | -% | - | 139,915 | 125,924 | - | 51,346 |
| Pneumox 250 (10's) for Children under 12 months | - | - | - | 96,000 | 157,872 | 7/16 | (100)% | 157,872 | 791,414 | - | - | - |
| Positive RDTs | 3,102 | 2,269 | 18,985 | - | 8,005 | | 137% | 8,700 | 132,494 | 18,985 | - | - |
| Positive RDTs | 3,102 | 2,269 | 18,985 | - | 8,005 | | 137% | 8,700 | 132,494 | 18,985 | - | - |
| Safe Water Solution | - | 8,290 | 344,595 | - | 1,263,871 | | (73)% | 1,308,083 | 23,130,081 | 407,849 | - | 1,361 |
| Sur Eau Vaovao | - | 8,290 | 344,595 | - | 1,263,871 | 9/04 | (73)% | 1,308,083 | 23,130,081 | 407,849 | - | 1,361 |
| SDM (Cycle Beads) | (14) | (14) | (181) | - | 5,144 | | (104)% | 5,121 | 143,336 | (163) | (244) | (156) |
| (b)PSI SDM (Cycle Beads) Distributed Provided | (14) | (14) | (183) | - | (444) | | -% | (467) | (5,294) | (165) | (247) | (158) |
| Rojo | - | - | 2 | - | 5,588 | 3/12 | (100)% | 5,588 | 148,630 | 2 | 3 | 2 |
| SDM (Cycle Beads) Provided | 14 | 14 | 183 | - | 444 | | (59)% | 467 | 5,294 | 183 | 275 | 176 |
| PSI SDM (Cycle Beads) Provided | 14 | 14 | 183 | - | 444 | | (59)% | 467 | 5,294 | 183 | 275 | 176 |
| STI Screening | 669 | 651 | 7,519 | - | 11,863 | | (37)% | 12,714 | 83,465 | 7,519 | - | - |
| STI Screening | 669 | 651 | 7,519 | - | 11,863 | | (37)% | 12,714 | 83,465 | 7,519 | - | - |
| Treatment for Inguinal Bubo | 2 | 1 | 25 | - | 42 | | (40)% | 53 | 161 | 25 | - | - |
| Treatment for Inguinal Bubo | 2 | 1 | 25 | - | 42 | | (40)% | 53 | 161 | 25 | - | - |
| Treatment for Lower Abdominal Pain | 39 | 38 | 459 | - | 697 | | (34)% | 752 | 2,508 | 459 | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Treatment for Lower Abdominal Pain | 39 | 38 | 459 | - | 697 | | (34)% | 752 | 2,508 | 459 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 54 | 53 | 639 | - | 1,090 | | (41)% | 1,165 | 3,505 | 639 | - | 72 |
| Treatment for Nonherpetic Genital Ulcer | 54 | 53 | 639 | - | 1,090 | | (41)% | 1,165 | 3,505 | 639 | - | 72 |
| Treatment for Severe Acute Malnutrition | - | - | - | - | 187 | | (100)% | 187 | 187 | - | - | - |
| Treatment for Severe Acute Malnutrition | - | - | - | - | 187 | | (100)% | 187 | 187 | - | - | - |
| Treatment for Urethral Discharge (Men) | 290 | 270 | 3,304 | - | 5,216 | | (37)% | 5,596 | 16,521 | 6,608 | - | 19 |
| Treatment for Urethral Discharge (Men) | 290 | 270 | 3,304 | - | 5,216 | | (37)% | 5,596 | 16,521 | 6,608 | - | 19 |
| Treatment for Vaginitis | 276 | 281 | 3,001 | - | 4,658 | | (36)% | 4,978 | 15,034 | 3,001 | - | 26 |
| Treatment for Vaginitis | 276 | 281 | 3,001 | - | 4,658 | | (36)% | 4,978 | 15,034 | 3,001 | - | 26 |
| Tubal Ligation | 3 | 5 | 30 | - | 40 | | (25)% | 42 | 146 | 30 | 300 | 137 |
| Tubal Ligation | 3 | 5 | 30 | - | 40 | | (25)% | 42 | 146 | 30 | 300 | 137 |
| Water Treatment Tablets | 82,400 | 317,180 | 2,958,780 | 3,600,000 | 5,646,200 | | (48)% | 6,183,000 | 31,248,410 | 48,637 | - | 162 |
| SUR'EAU PILINA (67mg tablet) | 82,400 | 317,180 | 2,958,780 | 3,600,000 | 5,646,200 | 10/14 | (48)% | 6,183,000 | 31,248,410 | 48,637 | - | 162 |
| Zinc | - | - | 140 | - | 13,132 | | (99)% | 13,132 | 13,272 | 126 | - | 1 |
| Zinc | - | - | 140 | - | 13,132 | 1/08 | (99)% | 13,132 | 13,272 | 126 | - | 1 |
| Mali | | | | | | | | | | | 411,496 | 1,946,057 |
| Cervical Cancer-VIA and Cryotherapy | 11 | 18 | 118 | 700 | 109 | | 8% | 121 | 1,157 | 118 | - | 35 |
| Cervical Cancer-VIA and Cryotherapy | 11 | 18 | 118 | 700 | 109 | 12/13 | 8% | 121 | 1,157 | 118 | - | 35 |
| Cervical Cancer-VIA/VILI Screening | 5,001 | 3,949 | 21,808 | 35,000 | 11,141 | | 96% | 12,365 | 92,263 | 21,808 | - | - |
| Cervical Cancer-VIA/VILI Screening | 5,001 | 3,949 | 21,808 | 35,000 | 11,141 | | 96% | 12,365 | 92,263 | 21,808 | - | - |
| Free Condom | - | 18,200 | 111,600 | 200,000 | 200 | | 55700% | 200 | 111,800 | 837 | 837 | 1,148 |
| Generic Condom | - | 18,200 | 111,600 | 200,000 | 200 | | 55,700% | 200 | 111,800 | 837 | 837 | 1,148 |
| Implant 3 | - | - | 5,936 | - | 1,336 | | 344% | 1,336 | 7,472 | 5,342 | 13,356 | 15,397 |
| Implanon NXT | - | - | 5,936 | - | 1,336 | 2/16 | 344% | 1,336 | 7,472 | 5,342 | 13,356 | 15,397 |
| Implant 3 Insertion | 1,448 | 947 | 12,750 | 17,600 | 12,019 | | 6% | 13,564 | 40,277 | 12,750 | 31,875 | 36,746 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|----------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Non-PSI Implant 3 Inserted | 1,448 | 947 | 12,750 | 17,600 | 12,019 | | 6% | 13,564 | 40,277 | 12,750 | 31,875 | 36,746 |
| Implant 5 | - | 2,400 | 20,501 | - | 5,399 | | 280% | 5,599 | 133,254 | 18,451 | 70,113 | 79,569 |
| Jadelle | - | 2,400 | 20,501 | - | 5,399 | 7/09 | 280% | 5,599 | 133,254 | 18,451 | 70,113 | 79,569 |
| Implant 5 Insertion | 6,782 | 3,624 | 39,367 | 50,000 | 33,961 | | 16% | 38,187 | 143,856 | 39,367 | 149,595 | 169,769 |
| Non-PSI Implant 5 Inserted | 6,782 | 3,624 | 39,367 | 50,000 | 33,961 | | 16% | 38,187 | 143,856 | 39,367 | 149,595 | 169,769 |
| Injectable 3-IM | 500 | 167 | 2,275 | - | 927 | | 145% | 927 | 3,202 | 512 | 512 | 433 |
| Depo-Provera | 500 | 167 | 2,275 | - | 927 | 1/08 | 145% | 927 | 3,202 | 512 | 512 | 433 |
| Injectable 3-IM Provided | 6,500 | 3,992 | 41,435 | 34,000 | 32,515 | | 27% | 36,909 | 81,151 | 10,359 | 10,359 | 8,764 |
| Non-PSI Injectable 3 IM Provided | 6,500 | 3,992 | 41,435 | 34,000 | 32,515 | | 27% | 36,909 | 81,151 | 10,359 | 10,359 | 8,764 |
| Injectable 3-SC Provided | 83 | 135 | 711 | - | - | | 0% | - | 711 | 178 | 178 | 150 |
| Non-PSI Injectable 3 SC Provided | 83 | 135 | 711 | - | - | | -% | - | 711 | 178 | 178 | 150 |
| IUD 10 | 2,374 | 1,118 | 13,891 | 7,000 | 5,489 | | 153% | 5,539 | 38,464 | 12,502 | 57,509 | 62,530 |
| Copper-T 380-A with inserter | - | - | - | 7,000 | 112 | | (100)% | 112 | 112 | - | - | - |
| IUD Copper T 380A | 1,624 | 1,084 | 11,641 | - | 5,252 | 12/13 | 122% | 5,302 | 35,977 | 10,477 | 48,194 | 52,402 |
| PPIUD Cu T380A | 750 | 33 | 2,250 | - | 125 | | 1,700% | 125 | 2,375 | 2,025 | 9,315 | 10,128 |
| IUD 10 Insertion | 2,321 | 1,280 | 16,693 | 28,000 | 20,782 | | (20)% | 22,777 | 79,419 | 16,693 | 76,788 | 83,493 |
| Non-PSI IUD 10 Inserted | 2,321 | 1,280 | 16,693 | 28,000 | 20,782 | | (20)% | 22,777 | 79,419 | 16,693 | 76,788 | 83,493 |
| LLIN | 1,931,018 | 315,586 | 3,534,911 | 4,343,735 | 4,911,866 | | (28)% | 4,911,866 | 23,073,148 | 5,726,556 | - | 1,480,704 |
| MILD - (G) | 1,227,548 | 293,264 | 2,107,344 | 4,343,735 | 3,685,706 | 10/14 | (43)% | 3,685,706 | 13,305,496 | 3,413,897 | - | 882,725 |
| MILD - (O) | - | - | 36 | - | 45 | 9/16 | (20)% | 45 | 1,125,719 | 58 | - | 15 |
| MILD - (U) | - | 22,322 | 724,061 | - | 1,226,115 | 12/14 | (41)% | 1,226,115 | 7,938,463 | 1,172,979 | - | 303,295 |
| Yorkool White (Generic Net) | 703,470 | - | 703,470 | - | - | | -% | - | 703,470 | 1,139,621 | - | 294,670 |
| Malaria PPT (ACT) | - | - | - | - | 460,404 | | (100)% | 460,404 | 4,646,729 | - | - | - |
| Coartem 12 tabs | - | - | - | - | 138,127 | 5/10 | (100)% | 138,127 | 1,694,442 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Coartem 6 tabs | - | - | - | - | 322,277 | 5/10 | (100)% | 322,277 | 2,952,287 | - | - | - |
| Manual Vacuum Aspiration for PAC | 354 | 317 | 3,896 | 3,450 | 3,121 | | 25% | 3,528 | 11,606 | 3,896 | - | 2,337 |
| MVA for PAC | 354 | 317 | 3,896 | 3,450 | 3,121 | 7/15 | 25% | 3,528 | 11,606 | 3,896 | - | 2,337 |
| Misoprostol for PAC Provided | 609 | 570 | 6,562 | 11,000 | 5,843 | | 12% | 6,303 | 20,774 | 6,562 | - | 4,499 |
| Non-PSI Misoprostol for PAC Provided | 609 | 570 | 6,562 | 11,000 | 5,843 | | 12% | 6,303 | 20,774 | 6,562 | - | 4,499 |
| Misoprostol for Safe Abortion | - | - | - | 50,000 | - | | 0% | - | 2,400 | - | - | - |
| Misoprostol for Safe Abortion | - | - | - | 50,000 | - | | -% | - | 2,400 | - | - | - |
| OCs Provided | 929 | 426 | 4,764 | 5,500 | 5,086 | | (6)% | 5,695 | 11,647 | 318 | 318 | 283 |
| Non-PSI OCs Provided | 929 | 426 | 4,764 | 5,500 | 5,086 | | (6)% | 5,695 | 11,647 | 318 | 318 | 283 |
| SDM (Cycle Beads) Provided | 3 | 6 | 38 | - | 25 | | 52% | 36 | 84 | 38 | 57 | 69 |
| Non-PSI SDM (Cycle Beads) Provided | 3 | 6 | 38 | - | 25 | | 52% | 36 | 84 | 38 | 57 | 69 |
| Seasonal Malaria Chemoprevention | - | - | - | 5,385,721 | 1,665,225 | | (100)% | 1,665,225 | 4,076,234 | - | - | - |
| SMC for Children ages 12-59 months | - | - | - | 5,385,721 | 1,361,725 | | (100)% | 1,361,725 | 3,333,317 | - | - | - |
| SMC for Infants ages 3-11 months | - | - | - | - | 303,500 | 3/17 | (100)% | 303,500 | 742,917 | - | - | - |
| Toilets Sold | 5 | 2 | 86 | 4,000 | 27 | | 216% | 27 | 6,384 | 493 | - | 19 |
| Toilet Type 1, Direct Sales | 5 | 2 | 86 | 4,000 | 27 | 12/16 | 216% | 27 | 6,384 | 493 | - | 19 |
| Toilets Sold - All | 103 | 59 | 1,781 | - | 1,515 | | 18% | 1,515 | 3,296 | 10,152 | - | - |
| Toilets Sold - All | 103 | 59 | 1,781 | - | 1,515 | | 18% | 1,515 | 3,296 | 10,152 | - | - |
| Water Treatment Tablets | 355,200 | 29,867 | 787,200 | 1,248,000 | 262,400 | | 200% | 262,400 | 44,311,670 | 12,940 | - | 111 |
| Aquatab | 355,200 | 29,867 | 787,200 | 1,248,000 | 262,400 | 2/09 | 200% | 262,400 | 44,311,670 | 12,940 | - | 111 |
| Somaliland | | | | | | | | | | | 4,894 | 141,394 |
| Acute Malnutrition Screening_CU5 | - | - | 389 | - | - | | 0% | - | 389 | 389 | - | - |
| Acute Malnutrition Screening_CU5 | - | - | 389 | - | - | | -% | - | 389 | 389 | - | - |
| Counseling & Tx for Moderate Acute MalnutritionCU! | 3,347 | 1,406 | 18,707 | 20,942 | 9,126 | | 105% | 20,332 | 39,039 | 18,707 | - | 58,514 |
| Counseling & Tx for Moderate Acute MalnutritionCU5 | 3,347 | 1,406 | 18,707 | 20,942 | 9,126 | | 105% | 20,332 | 39,039 | 18,707 | - | 58,514 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Diarrhea Treatment Kit | - | - | 80,000 | 220,416 | 108,358 | | (26)% | 128,358 | 1,175,956 | 72,000 | - | 7,857 |
| SD OFLV-DTK | - | - | 80,000 | - | 108,358 | 9/11 | (26)% | 128,358 | 1,030,435 | 72,000 | - | 7,857 |
| Shuban Daweeye_DTK | - | - | - | 220,416 | - | 6/11 | -% | - | 145,521 | - | - | - |
| HIV Testing Services | 2,256 | 1,012 | 16,573 | 13,720 | 8,430 | | 97% | 12,506 | 29,079 | 16,573 | - | 158 |
| VCT Individual (HIV-Negative) | 2,256 | 1,012 | 16,573 | 13,720 | 8,430 | | 97% | 12,506 | 29,079 | 16,573 | - | 158 |
| Implant 3 | 799 | 68 | 1,065 | 360 | (40) | | 0% | 42 | 1,374 | 959 | 2,396 | 2,442 |
| Nasiye Implant (Implanon) | 799 | 68 | 1,119 | 360 | 126 | 12/15 | 788% | 236 | 1,938 | 1,007 | 2,518 | 2,566 |
| (b)PSI Implant 3 Distributed Inserted | - | - | (54) | - | (166) | | -% | (194) | (564) | (49) | (122) | (124) |
| Implant 3 Insertion | 43 | 34 | 371 | 353 | 454 | | (18)% | 545 | 1,267 | 371 | 928 | 945 |
| Non-PSI Implant 3 Inserted | 43 | 34 | 317 | 353 | 288 | | 10% | 351 | 703 | 317 | 793 | 808 |
| PSI Implant 3 Inserted | - | - | 54 | - | 166 | | (67)% | 194 | 564 | 54 | 135 | 138 |
| Implant 4 | - | - | (85) | - | - | | 0% | - | (85) | (77) | (245) | (246) |
| (b)PSI Implant 4 Distributed Inserted | - | - | (85) | - | - | | -% | - | (85) | (77) | (245) | (246) |
| Implant 4 Insertion | - | - | 170 | - | - | | 0% | - | 170 | 170 | 544 | 546 |
| Non-PSI Implant 4 Inserted | - | - | 85 | - | - | | -% | - | 85 | 85 | 272 | 273 |
| PSI Implant 4 Inserted | - | - | 85 | - | - | | -% | - | 85 | 85 | 272 | 273 |
| Injectable 1 Provided | - | - | 270 | - | - | | 0% | - | 270 | 21 | 21 | 17 |
| Non-PSI Injectable 1 Provided | - | - | 270 | - | - | | -% | - | 270 | 21 | 21 | 17 |
| Injectable 3-IM | - | - | 320 | 3,500 | 4,017 | | (92)% | 4,367 | 27,646 | 72 | 72 | 54 |
| Nasiye - Inj 3 | - | - | 320 | 3,500 | 4,017 | 6/11 | (92)% | 4,367 | 27,646 | 72 | 72 | 54 |
| Injectable 3-IM Provided | 51 | 45 | 655 | 1,040 | 786 | | (17)% | 936 | 1,591 | 164 | 164 | 123 |
| Non-PSI Injectable 3 IM Provided | 51 | 45 | 655 | 1,040 | 786 | | (17)% | 936 | 1,591 | 164 | 164 | 123 |
| IPTp2 | 941 | 439 | 5,713 | 3,870 | 3,199 | | 79% | 3,758 | 9,471 | 5,713 | - | 639 |
| IPTp2 | 941 | 439 | 5,713 | 3,870 | 3,199 | | 79% | 3,758 | 9,471 | 5,713 | - | 639 |
| Iron Folic Acid Tablet | - | - | - | 19,843 | - | | 0% | - | - | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Iron Folic Acid Tablet | - | - | - | 19,843 | - | | -% | - | - | - | - | - |
| IUD 5 Insertion | 26 | 23 | 229 | 311 | 250 | | (8)% | 299 | 528 | 229 | 756 | 770 |
| Non-PSI IUD 5 Inserted | 26 | 23 | 229 | 311 | 250 | | (8)% | 299 | 528 | 229 | 756 | 770 |
| IUS 5 | - | - | (41) | - | - | | 0% | - | (41) | (37) | (122) | (124) |
| (b)PSI IUS 5 Distributed Inserted | - | - | (41) | - | - | | -% | - | (41) | (37) | (122) | (124) |
| IUS 5 Insertion | - | - | 82 | - | - | | 0% | - | 82 | 82 | 271 | 276 |
| Non-PSI IUS 5 Inserted | - | - | 41 | - | - | | -% | - | 41 | 41 | 135 | 138 |
| PSI IUS 5 Inserted | - | - | 41 | - | - | | -% | - | 41 | 41 | 135 | 138 |
| Misoprostol for PPH | 500 | 2,667 | 15,500 | 4,500 | 27,300 | | (43)% | 30,800 | 210,208 | 4,650 | - | 101 |
| Ummul-gargaar | 500 | 2,667 | 15,500 | 4,500 | 27,300 | 3/10 | (43)% | 30,800 | 210,208 | 4,650 | - | 101 |
| Multivitamin | - | - | - | 24,202 | - | | 0% | - | - | - | - | - |
| Multivitamin | - | - | - | 24,202 | - | | -% | - | - | - | - | - |
| OCs | - | - | - | 26,000 | 23,089 | | (100)% | 23,089 | 150,040 | - | - | - |
| Nasiye - OC | - | - | - | 26,000 | 23,089 | 3/12 | (100)% | 23,089 | 150,040 | - | - | - |
| OCs Provided | 119 | 97 | 1,647 | 1,995 | 1,811 | | (9)% | 1,880 | 3,527 | 110 | 110 | 87 |
| Non-PSI OCs Provided | 119 | 97 | 1,647 | 1,995 | 1,811 | | (9)% | 1,880 | 3,527 | 110 | 110 | 87 |
| ORS | 3,000 | - | 3,000 | - | - | | 0% | - | 3,000 | 1,350 | - | 141 |
| Orasel ORS Sachet | 3,000 | - | 3,000 | - | - | | -% | - | 3,000 | 1,350 | - | 141 |
| ORS Provided | 3,568 | 1,264 | 25,557 | 13,914 | 10,942 | | 134% | 13,509 | 39,066 | 25,557 | - | 1,332 |
| Non-PSI ORS Provided | 3,568 | 1,264 | 25,557 | 13,914 | 10,942 | | 134% | 13,509 | 39,066 | 25,557 | - | 1,332 |
| Pneumonia PPT | - | - | - | - | 14,500 | | (100)% | 14,500 | 53,213 | - | - | - |
| Pneumox 125mg tablet (Amoxicillin) x 20's | - | - | - | - | 2,900 | 11/14 | (100)% | 2,900 | 10,716 | - | - | - |
| Pneumox 250mg tablet (Amoxicillin) x 20's | - | - | - | - | 11,600 | 11/14 | (100)% | 11,600 | 42,497 | - | - | - |
| Pneumonia PPT Provided | 2,520 | 664 | 13,706 | - | 9,945 | | 38% | 11,575 | 25,281 | 13,706 | - | 15,836 |
| Non-PSI Pneumonia PPT Provided | 2,520 | 664 | 13,706 | - | 9,945 | | 38% | 11,575 | 25,281 | 13,706 | - | 15,836 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| QAACTs Provided after Confirmatory Diagnosis | 300 | 113 | 1,661 | 1,928 | 1,371 | | 21% | 1,872 | 3,533 | 1,661 | - | 373 |
| Non-PSI QAACTs Provided after Confirmed Diagnosis | 300 | 113 | 1,661 | 1,928 | 1,371 | | 21% | 1,872 | 3,533 | 1,661 | - | 373 |
| Skilled Birth Attendance | 3,111 | 1,108 | 16,909 | 17,196 | 13,771 | | 23% | 16,695 | 33,604 | 16,909 | - | 24,092 |
| Skilled Birth Attendance | 3,111 | 1,108 | 16,909 | 17,196 | 13,771 | | 23% | 16,695 | 33,604 | 16,909 | - | 24,092 |
| STI Screening | 282 | 5 | 940 | 2,588 | 393 | | 139% | 2,302 | 3,242 | 940 | - | - |
| STI Screening | 282 | 5 | 940 | 2,588 | 393 | | 139% | 2,302 | 3,242 | 940 | - | - |
| Treatment for Pre-Eclampsia (with MgSO4) | 63 | 21 | 323 | 353 | 287 | | 13% | 343 | 666 | 323 | - | 1,121 |
| Treatment for Pre-Eclampsia (with MgSO4) | 63 | 21 | 323 | 353 | 287 | | 13% | 343 | 666 | 323 | - | 1,121 |
| Treatment for Severe Acute Malnutrition | 1,282 | 464 | 6,637 | 9,888 | 8,731 | | (24)% | 9,600 | 16,237 | 6,637 | - | 25,299 |
| Treatment for Severe Acute Malnutrition | 1,282 | 464 | 6,637 | 9,888 | 8,731 | | (24)% | 9,600 | 16,237 | 6,637 | - | 25,299 |
| Water Treatment Tablets | 135,000 | - | 1,064,762 | 1,862,250 | 4,153,480 | | (74)% | 4,513,480 | 75,775,704 | 17,503 | - | 325 |
| Aquatab | 135,000 | - | 672,602 | 864,000 | 334,000 | 9/10 | 101% | 334,000 | 36,581,392 | 11,056 | - | 205 |
| Biyosifeeye | - | - | 392,160 | 998,250 | 3,819,480 | 7/08 | (90)% | 4,179,480 | 39,194,312 | 6,446 | - | 120 |
| Zinc | 2,550 | - | 2,550 | - | - | | 0% | - | 2,550 | 2,295 | - | 60 |
| Shuban Daweeye_Zinc | 2,550 | - | 2,550 | - | - | 6/11 | -% | - | 2,550 | 2,295 | - | 60 |
| Zinc Provided | 3,573 | 1,260 | 25,038 | 12,189 | 9,296 | | 169% | 11,834 | 36,872 | 25,038 | - | 656 |
| Non-PSI Zinc Provided | 3,573 | 1,260 | 25,038 | 12,189 | 9,296 | | 169% | 11,834 | 36,872 | 25,038 | - | 656 |
| South Sudan | | | | | | | | | | | - | 752,222 |
| Acute Malnutrition Screening_CU5 | - | - | - | - | 619,055 | | (100)% | 619,055 | 619,055 | - | - | - |
| Acute Malnutrition Screening_CU5 | - | - | - | - | 619,055 | | (100)% | 619,055 | 619,055 | - | - | - |
| LLIN | 283,449 | 2,010 | 829,276 | 4,947,768 | 171,692 | | 383% | 755,027 | 15,284,710 | 1,343,427 | - | 274,563 |
| Free Permanet Mesh | 283,449 | 2,010 | 829,276 | 4,947,768 | 141,399 | 4/08 | 486% | 724,734 | 9,400,003 | 1,343,427 | - | 274,563 |
| Mass LLIN - WES | - | - | - | - | 30,293 | 6/14 | (100)% | 30,293 | 5,884,707 | - | - | - |
| Malaria PPT (ACT) | 221,759 | 291,651 | 1,515,389 | 4,650,120 | 2,740,576 | | (45)% | 3,022,439 | 15,582,870 | 1,363,850 | - | 477,660 |
| ACTs for Adult (14+ years) | 51,000 | 109,300 | 545,083 | 1,257,791 | 435,230 | 2/13 | 25% | 641,055 | 3,596,178 | 490,575 | - | 171,813 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| ACTs for Child (6-14 years) | 40,200 | 78,000 | 393,653 | 918,479 | 440,909 | 2/13 | (11)% | 479,609 | 2,170,323 | 354,288 | - | 124,082 |
| ACTs for Infant (2-12 months) | 39,275 | 18,947 | 118,984 | 882,296 | 681,483 | 2/13 | (83)% | 692,193 | 3,606,368 | 107,086 | - | 37,504 |
| ACTs for Toddler (1-5 years) | 91,200 | 63,164 | 348,187 | 1,232,271 | 1,122,558 | 2/13 | (69)% | 1,139,058 | 6,029,995 | 313,368 | - | 109,751 |
| Artemether Tabs – Adult | 30 | 12,620 | 69,240 | 139,755 | 31,640 | | 119% | 36,350 | 105,590 | 62,316 | - | 21,825 |
| Artemether Tabs - Child | 54 | 6,940 | 31,278 | 102,053 | 22,802 | | 37% | 26,276 | 57,554 | 28,150 | - | 9,859 |
| Artemether Tabs - Infant | - | 900 | 2,964 | 49,016 | 1,128 | | 163% | 2,022 | 4,986 | 2,668 | - | 934 |
| Artemether Tabs - Toddler | - | 1,780 | 6,000 | 68,459 | 4,826 | | 24% | 5,876 | 11,876 | 5,400 | - | 1,891 |
| Malaria RDK | 39,000 | 123,725 | 577,825 | 1,275,396 | 3,161,917 | | (82)% | 3,256,042 | 9,069,720 | 520,043 | - | - |
| Malaria Rapid Diagnostic Kit | 39,000 | 123,725 | 577,825 | 1,275,396 | 3,161,917 | 9/14 | (82)% | 3,256,042 | 9,069,720 | 520,043 | - | - |
| ORS | - | - | - | - | 1,210,375 | | (100)% | 1,210,375 | 5,520,636 | - | - | - |
| ORS | - | - | - | - | 1,210,375 | 9/08 | (100)% | 1,210,375 | 5,520,636 | - | - | - |
| Pneumonia PPT | - | - | - | - | 565,947 | | (100)% | 565,947 | 1,994,485 | - | - | - |
| Amoxicillin for Children (1-5 years) | - | - | - | - | 361,615 | 10/12 | (100)% | 361,615 | 1,358,695 | - | - | - |
| Amoxicillin for Infant (2-12 months) | - | - | - | - | 204,332 | 10/12 | (100)% | 204,332 | 635,790 | - | - | - |
| Treatment for Severe Acute Malnutrition | - | - | - | - | 3,106 | | (100)% | 3,106 | 44,752 | - | - | - |
| Treatment for Severe Acute Malnutrition | - | - | - | - | 3,106 | | (100)% | 3,106 | 44,752 | - | - | - |
| Zinc | - | - | - | - | 499,704 | | (100)% | 499,704 | 1,893,104 | - | - | - |
| Zinc | - | - | - | - | 499,704 | 1/08 | (100)% | 499,704 | 1,893,104 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Social Enterprise Market Group

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 11
 Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE SALES | YTD USERS REACHED ^(a) 2019 | YTD CYP 2019 | YTD DALY 2019 |
|-------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------|-------------------------------|---------------------|---|------------------|------------------|
| Social Enterprise | | | | | | | | | | 1,109,629 | 887,295 |
| Condom | 6,427,960 | 3,953,002 | 83,761,942 | 202,585,322 | 125,111,600 | (33)% | 159,709,190 | 792,574,041 | 628,213 | 628,213 | 709,870 |
| Emergency Contraception | 26,945 | 39,381 | 383,760 | 1,240,030 | 511,805 | (25)% | 553,951 | 3,449,863 | 17,269 | 17,269 | 1,768 |
| Injectable 3-IM | (4,273) | 262 | 29,949 | 20,736 | 114,629 | (74)% | 129,729 | 228,759 | 6,739 | 6,739 | 1,127 |
| IUD 10 | (20) | - | 15 | - | 30,644 | (100)% | 65,510 | 65,525 | 14 | 62 | 13 |
| IUD 3 | - | (20) | 68 | - | 6,853 | (99)% | 6,953 | 7,021 | 61 | 153 | 33 |
| IUD 5 | 20 | 397 | 130,564 | 111,600 | 73,761 | 77% | 79,621 | 310,899 | 117,508 | 387,775 | 87,911 |
| IUS 5 | 1 | (51) | 419 | 5,184 | - | -% | - | 419 | 377 | 1,244 | 282 |
| Lubricant | - | 420 | 25,968 | 93,942 | 33,792 | (23)% | 37,944 | 150,336 | - | - | - |
| Male Vasodilator | 20,000 | 48,133 | 1,686,180 | 3,029,400 | - | -% | - | 1,686,180 | 12,646 | - | - |
| Medical Abortion | 25,064 | 32,190 | 535,604 | 1,656,000 | 947,675 | (43)% | 1,139,134 | 2,189,674 | 482,044 | - | 49,781 |
| Misoprostol for Safe Abortion | - | - | - | 250,000 | - | -% | - | - | - | - | - |
| Multivitamin | 119,790 | 109,820 | 1,289,250 | 2,232,000 | 1,877,340 | (31)% | 1,974,210 | 38,298,810 | 6,446 | - | 220 |
| OCs | 54,949 | 82,720 | 1,136,238 | 7,097,180 | 3,903,333 | (71)% | 4,758,355 | 17,219,638 | 68,174 | 68,174 | 9,139 |
| ORS | (700) | (11,530) | 1,353,076 | 1,320,000 | 1,118,856 | 21% | 1,144,506 | 2,824,010 | 608,884 | - | 27,150 |
| Pregnancy Test | 19,618 | 26,762 | 292,510 | 1,188,000 | 429,045 | (32)% | 575,675 | 868,185 | - | - | - |
| Vaginal Wash | - | 1,005 | 18,664 | 71,280 | - | -% | - | 18,664 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 11
Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|------------------|------------------|
| Social Enterprise | | | | | | | | | | | 1,109,629 | 887,295 |
| India LLC | | | | | | | | | | | 851,216 | 337,902 |
| Condom | 5,714,550 | 2,621,718 | 56,261,135 | 160,842,000 | 90,405,567 | | (38)% | 121,087,377 | 317,560,364 | 421,959 | 421,959 | 165,816 |
| Masti 10's - Banana & Chocolate | 54,000 | 120,080 | 522,240 | - | - | | -% | - | 522,240 | 3,917 | 3,917 | 1,539 |
| Masti 10's - Strawberry & Banana | 16,560 | 67,280 | 1,011,120 | - | - | | -% | - | 1,011,120 | 7,583 | 7,583 | 2,980 |
| Masti Banana Dotted 3's | 54,120 | - | 54,120 | - | - | | -% | - | 54,120 | 406 | 406 | 160 |
| Masti Banana Dotted 4's | - | 85,240 | 1,998,600 | - | - | | -% | - | 1,998,600 | 14,989 | 14,989 | 5,890 |
| Masti Cherry 2's | - | 1,429,130 | 5,012,070 | - | - | | -% | - | 5,012,070 | 37,591 | 37,591 | 14,772 |
| Masti Chocolate 4's | 90,000 | 297,360 | 3,813,840 | - | - | | -% | - | 3,813,840 | 28,604 | 28,604 | 11,240 |
| Masti Chocolate Dotted 3's | 54,120 | - | 54,120 | - | - | | -% | - | 54,120 | 406 | 406 | 160 |
| Masti Classic 10's | - | 264,400 | 4,771,200 | - | 9,866,130 | 10/17 | (52)% | 12,641,730 | 21,845,730 | 35,784 | 35,784 | 14,062 |
| Masti Classic 10's (Flavoured) | - | (115,917) | 7,905,860 | - | 6,850,800 | 6/17 | 15% | 12,638,400 | 29,753,900 | 59,294 | 59,294 | 23,301 |
| Masti Classic 2's Orange | - | 168,507 | 1,668,502 | - | 5,002,350 | 4/18 | (67)% | 7,334,310 | 9,002,812 | 12,514 | 12,514 | 4,917 |
| Masti Classic 3's Cool Mint | (14,160) | (10,813) | (47,028) | - | 1,000,080 | 4/18 | (105)% | 1,000,080 | 953,052 | (353) | (353) | (139) |
| Masti Classic 3's | 403,200 | 496,840 | 13,694,340 | - | 36,084,474 | 12/16 | (62)% | 43,947,594 | 122,807,761 | 102,708 | 102,708 | 40,361 |
| Masti Classic 3's (Flavoured) | - | (332,496) | 4,569,318 | - | 15,397,363 | | (70)% | 22,653,043 | 41,308,721 | 34,270 | 34,270 | 13,467 |
| Masti Classic 6's | - | - | - | - | 960 | 12/16 | (100)% | 960 | 27,094,440 | - | - | - |
| Masti Green Apple 2's | - | (49,260) | (147,780) | - | 1,888,290 | | (108)% | 4,018,980 | 3,871,200 | (1,108) | (1,108) | (436) |
| Masti Lemon 2's | 3,130,320 | 69,500 | 3,385,260 | - | - | | -% | - | 3,385,260 | 25,389 | 25,389 | 9,977 |
| Masti Long Innings 2's | 1,144,980 | 62,660 | 1,613,880 | - | - | | -% | - | 1,613,880 | 12,104 | 12,104 | 4,757 |
| Masti Mix 10's Chocolate & Strawberry | 54,000 | (57,440) | 1,893,360 | - | - | | -% | - | 1,893,360 | 14,200 | 14,200 | 5,580 |
| Masti Night Queen (Raat Ki Rani) 2's | 682,890 | 227,540 | 2,835,390 | - | - | | -% | - | 2,835,390 | 21,265 | 21,265 | 8,357 |
| Masti Premium 10's (Flavoured) | (9,360) | (139,763) | (417,460) | - | 4,003,680 | | (110)% | 6,531,960 | 10,364,420 | (3,131) | (3,131) | (1,230) |
| Masti Premium 2's Chocolate | - | - | - | - | 134,910 | | (100)% | 134,910 | 134,910 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|-------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Masti Premium 2's Strawberry | - | - | - | - | 134,824 | | (100)% | 134,824 | 134,824 | - | - | - |
| Masti Premium 3's | - | - | - | - | 23,656 | 12/16 | (100)% | 23,656 | 8,984,681 | - | - | - |
| Masti Premium 3's Cool Mint | (240) | (80) | (480) | - | 913,200 | 4/18 | (100)% | 913,200 | 912,720 | (4) | (4) | (1) |
| Masti Premium 3's (Flavoured) | - | (170) | 2,463 | - | 9,104,850 | | (100)% | 9,113,730 | 16,128,993 | 18 | 18 | 7 |
| Masti Standard 10's | - | - | - | 85,536,000 | - | | -% | - | - | - | - | - |
| Masti Standard 3's | - | - | - | 49,896,000 | - | | -% | - | - | - | - | - |
| Masti Strawberry Dotted 3's | 54,120 | - | 54,120 | - | - | | -% | - | 54,120 | 406 | 406 | 160 |
| Masti Strawberry Dotted 4's | - | 39,120 | 2,014,080 | - | - | | -% | - | 2,014,080 | 15,106 | 15,106 | 5,936 |
| Premium Condom (ONE) | - | - | - | 25,410,000 | - | | -% | - | - | - | - | - |
| Emergency Contraception | (2) | 2,267 | 38,949 | 594,000 | 195,437 | | (80)% | 212,227 | 251,176 | 1,753 | 1,753 | 223 |
| Pronta | - | - | - | - | 18,500 | | (100)% | 18,500 | 18,500 | - | - | - |
| Pronta1 | (2) | (1,370) | (1,405) | - | 161,779 | 4/18 | (101)% | 178,469 | 177,064 | (63) | (63) | (8) |
| Pronta-72 | - | 3,637 | 40,354 | 594,000 | 15,158 | | 166% | 15,258 | 55,612 | 1,816 | 1,816 | 231 |
| Injectable 3-IM | (4,273) | 262 | 29,949 | 20,736 | 114,629 | | (74)% | 129,729 | 228,759 | 6,739 | 6,739 | 1,127 |
| Freedom Inject (3-month) | (4,273) | 262 | 29,949 | 20,736 | 114,629 | 12/16 | (74)% | 129,729 | 228,759 | 6,739 | 6,739 | 1,127 |
| IUD 10 | (20) | - | 15 | - | 30,644 | | (100)% | 65,510 | 65,525 | 14 | 62 | 13 |
| Freedom 10 | (20) | - | 15 | - | 30,644 | 12/16 | (100)% | 65,510 | 65,525 | 14 | 62 | 13 |
| IUD 3 | - | (20) | 68 | - | 6,853 | | (99)% | 6,953 | 7,021 | 61 | 153 | 33 |
| Freedom 3 | - | (20) | 68 | - | 6,853 | 1/18 | (99)% | 6,953 | 7,021 | 61 | 153 | 33 |
| IUD 5 | 20 | 397 | 130,564 | 111,600 | 73,761 | | 77% | 79,621 | 310,899 | 117,508 | 387,775 | 87,911 |
| Freedom 5 | - | (128) | 125,338 | 64,800 | 64,988 | 12/16 | 93% | 70,638 | 296,690 | 112,804 | 372,254 | 84,392 |
| Freedom 5 – Sleek | - | 574 | 4,924 | - | 6,809 | 1/18 | (28)% | 6,909 | 11,833 | 4,432 | 14,624 | 3,315 |
| Freedom 5 (PPIUCD) Cu 375 | 20 | (48) | 302 | 46,800 | 1,964 | | (85)% | 2,074 | 2,376 | 272 | 897 | 203 |
| IUS 5 | 1 | (51) | 419 | 5,184 | - | | 0% | - | 419 | 377 | 1,244 | 282 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Freedom LNG-IUS | - | - | - | 5,184 | - | 1/18 | -% | - | - | - | - | - |
| Sabatica – LNG IUS | 1 | (51) | 419 | - | - | | -% | - | 419 | 377 | 1,244 | 282 |
| Male Vasodilator | 20,000 | 48,133 | 1,686,180 | 3,029,400 | - | | 0% | - | 1,686,180 | 12,646 | - | - |
| Masti Super 100 - 100 mg Tab | 20,000 | 48,133 | 1,686,180 | 3,029,400 | - | | -% | - | 1,686,180 | 12,646 | - | - |
| Medical Abortion | 25,064 | 32,190 | 535,604 | 1,656,000 | 947,675 | | (43)% | 1,139,134 | 2,189,674 | 482,044 | - | 49,781 |
| Mifeso | - | - | 9,000 | 72,000 | - | | -% | - | 9,000 | 8,100 | - | 836 |
| Safe Abort kit | 25,064 | 32,190 | 526,604 | 1,584,000 | 947,675 | 12/16 | (44)% | 1,139,134 | 2,180,674 | 473,944 | - | 48,945 |
| Misoprostol for Safe Abortion | - | - | - | 250,000 | - | | 0% | - | - | - | - | - |
| Avertiso | - | - | - | 250,000 | - | | -% | - | - | - | - | - |
| OCs | (6,860) | 29,530 | 525,529 | 6,376,560 | 3,257,469 | | (84)% | 4,052,619 | 8,248,108 | 31,532 | 31,532 | 5,565 |
| Freedom 28 | (200) | (300) | (656) | 1,134,000 | 40,886 | | (102)% | 42,146 | 41,490 | (39) | (39) | (7) |
| MEURI | 4,560 | 2,250 | 30,910 | 216,000 | 33,925 | | (9)% | 37,645 | 68,555 | 1,855 | 1,855 | 327 |
| Pearl | (11,220) | 27,580 | 495,275 | 5,026,560 | 3,182,658 | 12/16 | (84)% | 3,972,828 | 8,138,063 | 29,717 | 29,717 | 5,245 |
| ORS | (700) | (11,530) | 1,353,076 | 1,320,000 | 1,118,856 | | 21% | 1,144,506 | 2,824,010 | 608,884 | - | 27,150 |
| Neotral Orange 1000ml | (700) | (11,530) | 1,353,076 | 1,320,000 | 1,118,856 | 12/16 | 21% | 1,144,506 | 2,824,010 | 608,884 | - | 27,150 |
| Pregnancy Test | 19,618 | 26,762 | 292,510 | 1,188,000 | 429,045 | | (32)% | 575,675 | 868,185 | - | - | - |
| Pronta (PTK) | 19,618 | 26,762 | 292,510 | 1,188,000 | 429,045 | 4/18 | (32)% | 575,675 | 868,185 | - | - | - |
| Vaginal Wash | - | 1,005 | 18,664 | 71,280 | - | | 0% | - | 18,664 | - | - | - |
| Pronta Intimate Wash – 100 ml bottle | - | 1,005 | 18,664 | 71,280 | - | | -% | - | 18,664 | - | - | - |
| Paraguay | | | | | | | | | | | 72,759 | 21,794 |
| Condom | 380,050 | 285,509 | 2,964,071 | 3,317,080 | 3,293,439 | | (10)% | 3,450,963 | 46,352,098 | 22,231 | 22,231 | 17,022 |
| Pantera | 178,668 | 130,798 | 1,415,834 | 1,628,902 | 1,574,392 | 8/98 | (10)% | 1,641,868 | 38,196,989 | 10,619 | 10,619 | 8,131 |
| Pantera Banana | 22,396 | 15,399 | 145,335 | 154,498 | 158,428 | 9/16 | (8)% | 168,808 | 547,135 | 1,090 | 1,090 | 835 |
| Pantera Chocolate | 25,361 | 19,416 | 182,533 | 219,757 | 219,906 | 2/14 | (17)% | 231,222 | 1,206,455 | 1,369 | 1,369 | 1,048 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--------------------------|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Pantera Neon | 3 | - | 3 | - | - | | -% | - | 3 | - | - | - |
| Pantera Retardant | 57,563 | 51,251 | 506,679 | 536,632 | 536,934 | 2/14 | (6)% | 562,869 | 2,768,348 | 3,800 | 3,800 | 2,910 |
| Pantera Ribbed | 16,355 | 9,814 | 114,391 | 136,806 | 154,507 | 2/14 | (26)% | 165,502 | 911,097 | 858 | 858 | 657 |
| Pantera Strawberry | 34,412 | 29,331 | 290,219 | 293,511 | 298,491 | 2/14 | (3)% | 313,950 | 1,570,740 | 2,177 | 2,177 | 1,667 |
| Pantera Tachas | 16,694 | 10,074 | 112,939 | 130,508 | 140,432 | 9/16 | (20)% | 147,059 | 469,579 | 847 | 847 | 649 |
| Pantera Tutti Frutti | 28,595 | 19,427 | 196,135 | 216,466 | 210,349 | 9/16 | (7)% | 219,685 | 681,749 | 1,471 | 1,471 | 1,126 |
| Pantera XL | 3 | - | 3 | - | - | | -% | - | 3 | - | - | - |
| Emergency Contraception | 26,947 | 30,417 | 308,571 | 358,605 | 313,368 | | (2)% | 338,724 | 3,159,447 | 13,886 | 13,886 | 978 |
| Pronta | 22,539 | 27,130 | 277,486 | 241,605 | 313,278 | 2/04 | (11)% | 338,634 | 3,128,272 | 12,487 | 12,487 | 880 |
| Pronta1 | 4,408 | 3,287 | 31,085 | 117,000 | 90 | | 34,439% | 90 | 31,175 | 1,399 | 1,399 | 99 |
| Multivitamin | 119,790 | 109,820 | 1,289,250 | 2,232,000 | 1,877,340 | | (31)% | 1,974,210 | 38,298,810 | 6,446 | - | 220 |
| VitalDia | 119,790 | 109,820 | 1,289,250 | 2,232,000 | 1,877,340 | 11/00 | (31)% | 1,974,210 | 38,298,810 | 6,446 | - | 220 |
| OCs | 61,809 | 53,190 | 610,709 | 720,620 | 645,864 | | (5)% | 705,736 | 8,971,530 | 36,643 | 36,643 | 3,574 |
| Segura | 57,360 | 48,919 | 566,367 | 690,020 | 609,563 | 4/01 | (7)% | 667,753 | 8,683,739 | 33,982 | 33,982 | 3,315 |
| Segura Plus | 4,449 | 4,271 | 44,342 | 30,600 | 36,301 | 3/11 | 22% | 37,983 | 287,791 | 2,661 | 2,661 | 259 |
| PSI South Africa | | | | | | | | | | | 185,654 | 527,599 |
| Condom | 333,360 | 1,045,776 | 24,536,736 | 38,426,242 | 31,412,594 | | (22)% | 35,170,850 | 428,661,579 | 184,023 | 184,023 | 527,033 |
| Lovers Plus | 648 | 153,504 | 2,319,552 | 4,207,083 | 3,035,431 | 10/92 | (24)% | 3,350,719 | 50,053,312 | 17,397 | 17,397 | 49,847 |
| Lovers Plus C&F | - | - | 137,016 | 2,785,260 | 2,968,007 | 1/08 | (95)% | 3,238,511 | 38,586,190 | 1,028 | 1,028 | 2,938 |
| Lovers Plus C&S | 24,624 | 81,480 | 1,583,640 | - | - | | -% | - | 1,583,640 | 11,877 | 11,877 | 34,124 |
| Lovers Plus Climax Delay | 22,896 | (37,272) | 209,664 | - | - | | -% | - | 209,664 | 1,572 | 1,572 | 4,624 |
| Lovers Plus Extra Play | - | - | 63,072 | 831,317 | 552,284 | 3/16 | (89)% | 610,748 | 3,790,718 | 473 | 473 | 1,352 |
| Lovers Plus R&S | 46,656 | 110,832 | 1,460,376 | 2,282,405 | 1,990,836 | 11/12 | (27)% | 2,216,556 | 24,236,885 | 10,953 | 10,953 | 31,246 |
| Lovers Plus UltraThin | 33,264 | (63,744) | 186,768 | 429,981 | 594,216 | | (69)% | 634,392 | 821,160 | 1,401 | 1,401 | 4,200 |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|---|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Trust | 43,056 | 211,464 | 7,628,544 | 15,041,017 | 8,520,833 | 5/01 | (10)% | 9,253,073 | 147,992,376 | 57,214 | 57,214 | 163,174 |
| Trust Extra C&S | 32,688 | 26,472 | 558,216 | 865,152 | 591,840 | | (6)% | 705,528 | 1,263,744 | 4,186 | 4,186 | 11,828 |
| Trust Extra Thin | 65,952 | 91,656 | 882,576 | 1,049,252 | 631,728 | | 40% | 692,496 | 1,575,072 | 6,619 | 6,619 | 18,910 |
| Trust Studded | 63,576 | 471,384 | 9,507,312 | 10,934,775 | 12,527,419 | 1/05 | (24)% | 14,468,827 | 158,548,818 | 71,304 | 71,304 | 204,791 |
| Emergency Contraception | - | 6,697 | 36,240 | 287,425 | 3,000 | | 1108% | 3,000 | 39,240 | 1,631 | 1,631 | 566 |
| Pronta1 | - | 6,697 | 36,240 | 287,425 | 3,000 | | 1,108% | 3,000 | 39,240 | 1,631 | 1,631 | 566 |
| Lubricant | - | 420 | 25,968 | 93,942 | 33,792 | | (23)% | 37,944 | 150,336 | - | - | - |
| Lovers Plus Lube Natural (100mL) | - | 428 | 22,056 | 93,942 | 33,792 | 1/13 | (35)% | 37,944 | 146,424 | - | - | - |
| Lovers Plus Lubricant 2-in-1, 100 ml tube | - | 4 | 972 | - | - | | -% | - | 972 | - | - | - |
| Lovers Plus Lubricant Strawberry, 100 ml tube | - | (16) | 1,980 | - | - | | -% | - | 1,980 | - | - | - |
| Lovers Plus Lubricant Warming, 100 ml tube | - | 4 | 960 | - | - | | -% | - | 960 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 11

Year: 2019

| | DISTRIBUTION 11/2019 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION 2019 | DISTRIBUTION TARGET 2019 | YTD DISTRIBUTION 2018 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2018 | CUMULATIVE DISTRIBUTION | (a)YTD USERS REACHED 2019 | YTD CYP 2019 | YTD DALY 2019 |
|--|-------------------------|---------------------------------|-----------------------------|--------------------------------|-----------------------------|----------------|-----------------|-------------------------------|----------------------------|---------------------------------|-----------------|------------------|
| Inactive | | | | | | | | | | | - | - |
| Guinea | | | | | | | | | | | - | - |
| Free Condom | - | - | - | - | 344,316 | | (100)% | 344,316 | 22,621,422 | - | - | - |
| Condom Combo | - | - | - | - | 1,911 | 11/16 | (100)% | 1,911 | 147,197 | - | - | - |
| Generic Condom | - | - | - | - | 342,405 | 11/16 | (100)% | 342,405 | 22,474,225 | - | - | - |
| Free Female Condom | - | - | - | - | 1,190 | | (100)% | 1,190 | 186,850 | - | - | - |
| Condom Feminin | - | - | - | - | 1,190 | 5/16 | (100)% | 1,190 | 186,850 | - | - | - |
| Lubricant | - | - | - | - | 265,698 | | (100)% | 265,698 | 5,662,921 | - | - | - |
| Vanilla Scented Lubricant Sachet, 3.5 ml | - | - | - | - | 265,698 | 10/16 | (100)% | 265,698 | 5,662,921 | - | - | - |

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.